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RHODIUM-CATALYZED CYCLOADDITIONS TO CONSTRUCT NITROGEN HETEROCYCLES 
AND PROGRESS TOWARDS THE SYNTHESIS OF IONOMYCIN 
 The ability to construct molecules in a rapid, atom-economical fashion is a major goal of organic 
chemistry. This work describes four topics; pyridone synthesis, mechanistic understanding in [2+2+2] 
cycloadditions, pyrimidinone synthesis, and progress towards ionomycin. 
 The first chapter describes the synthesis of 4,6-substituted 2-pyridones and 3,5-substituted 4-
pyridones from the rhodium-catalyzed [2+2+2] cycloaddition of two alkynes and an isocyanate.  
 Our group demonstrated that an enantioselective rhodium-catalyzed [2+2+2] cycloaddition of 
alkenyl isocyanates and alkynes generates indolizidinone and quinolizidinone products. Although trends 
for product and regioselectivity were established, the underlying mechanism was unclear. The second 
chapter describes X-ray analysis of rhodium·phosphoramidite complexes in conjunction with other 
mechanistic work to elucidate a theory that explains product and regioselectivity in this reaction. This 
system is amazing in that it illuminates the factors contributing to oxidative cycloadditions in a 
spectacular fashion by delivering two different products.  
 The third chapter describes the enantioselective synthesis of pyrimidinones from a rhodium-
catalyzed [4+2] cycloaddition of α,β-unsaturated imines and isocyanates. 
 The final chapter describes our group's progress toward the synthesis of ionomycin using 
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Metal-Catalyzed [2+2+2] Cycloadditions and Regioselective Rhodium-Catalyzed [2+2+2] Cycloaddition 
of Alkynes and Isocyanates to Form Pyridones 
1.1 Metal Catalyzed [2+2+2] Cycloadditions 
 Organic chemistry has come a long way in the past two centuries and the basic questions have 
shifted from "Is it possible for us to make..." to "How can we efficiently and expediently make...". It can 
be argued that Hendrickson1 initiated this shift, but the concept of efficiency is now being embraced and 
espoused. This concept has been refined in the ideas of atom economy,2 step economy,3 redox economy,4 
and green chemistry.5 The time and material required for synthetic endeavors reminds us that, as a field, 
organic chemistry is still not fully mature and there is room for improvement. Synthesis of natural and 
non-natural targets challenges current methodology and exposes missing synthetic tools. Methods 
development is the arena where new synthetic tools are developed that can reinvent the ways that we 
target molecules. 
 Cycloaddition reactions are powerful synthetic tools. The rapid generation of complexity in a 
single step, the incorporation of all the starting material into the  product, and the ability to control regio- 
and enantioselectivity make cycloadditions an attractive method. In [2+2+2] cycloadditions, three new σ 
bonds are formed, up to three separate π components can be incorporated, and up to six stereocenters can 
be set in a single step (Figure 1.1.1). In addition to carbocycles, the introduction of a heteroatom into the 
π component makes this an excellent approach to heterocycles. Although thermal [2+2+2] cycloadditions 
are possible,6 extreme temperatures (400 °C) are necessary.7 Metal catalysis offers a way to overcome 
                                                            
1 (a) Hendrickson, J. B. J. Am. Chem. Soc. 1971, 93, 6847-6854. (b) Hendrickson, J. B. J. Am. Chem. Soc. 1975, 97, 
5784-5800. 
2 Trost, B. M. Science 1991, 254, 1471-1477. 
3 Wender, P. A.; Verma, V. A.; Paxton, T. J.; Pillow, T. H. Acc. Chem. Res. 2008, 41, 40-49. 
4 Burns, N. Z.; Baran, P. S.; Hoffmann, R. W. Angew. Chem. Int. Ed. 2009, 48, 2854-2867. 
5 Hudlicky, T.; Frey, D. A.; Koroniak, L.; Claeboe, C. D.; Brammer Jr., L. E. Green Chem. 1999, 1, 57-59. 
6 Woodward, R. B.; Hoffmann, R. Angew. Chem. Int. Ed., Eng. 1969, 8, 781-853. 
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these prohibitive conditions. Reppe was the first to demonstrated the promise of metal-catalyzed [2+2+2] 
cycloadditions in the 1940s by his synthesis of benzene from acetylene using a nickel catalyst.8 
 
Figure 1.1.1. [2+2+2] Cycloadditions: Potential and Demonstrated Reactivity. 
 Since Reppe's report, [2+2+2] cycloadditions of alkynes have been greatly expanded.9 This 
approach challenged the conventional aromatic substitution approach to construct aromatic compounds. 
Although cyclizing three different alkynes to make aromatic compounds could render their synthesis 
trivial, this has proven a difficult task. Chemoselectivity is a major issue as the cyclization of just one or 
two components tends to predominate over incorporation of all three components. Even with just one or 
two unsymmetrical π components, regioselectivity is another difficult problem to overcome. These 
problems are compounded when alkenes are used as enantioselectivity becomes an additional issue. The 
use of alkenes and π components containing heteroatoms tends to suffer from chemoselectivity problems 
due to differences in reactivity of the various π components. Ideally, a catalyst could be created that 
overcomes all these difficulties, but to date this has not been achieved. Many solutions have emerged 
including the use of stoichiometric metals,10 tethering strategies,11 and the use of alkyne surrogates.12 
Treatment of π components with stoichiometric metal generates a metallacycle that is sequentially reacted 
with the final π component to generate the desired product. This approach can overcome chemoselectivity 
problems, but regioselectivity can still be problematic and the use of stoichiometric metals is typically 
undesirable. Tethering two of the π components has proven a very effective strategy and typically solves 
                                                                                                                                                                                               
7 Berthelot, M. C. R. Hebd. Seances Acad. Sci.1866, 62, 905. 
8 Reppe, V. W.; Schweckendiek, W. J. Liebigs Ann. 1948, 560, 104-116.  
9 For reviews on [2+2+2] cycloadditions of alkynes see: (a) Saito, S.; Yamamoto, Y. Chem. Rev. 2000, 100, 2901-
2915. (b) Kotha, S.; Brahmachary, E.; Lahiri, K. Eur. J. Org. Chem.  2005, 4741-4767. (c) Agenet, N.; Busine, O.; 
Slowinski, F.; Gandon, V.; Aubert, C.; Malacria, M. Org. React. 2007, 68, 1-302. (d) Galan, B. R.; Rovis, T. Angew. 
Chem. Int. Ed. 2009, 48, 2830-2834. (e) Broere, D. J.; Ruijter, E. Synthesis 2012, 44, 2639-2672. 
10 Suzuki, D.; Urabe, H.; Sato, F. J. Am. Chem. Soc. 2001, 123, 7925-7926. 
11 Use of in-situ tether: Yamamoto, Y.; Ishii, J.-i.; Nishiyama, H.; Itoh, K. J. Am. Chem. Soc. 2004, 126, 3712-3713. 
12 Hara, H.; Hirano, M. Tanaka, K. Org. Lett. 2008, 10, 2537-2540. 
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regioselectivity and chemoselectivity problems for two of the π components. Although effective, it still 
suffers from regio- and chemoselectivity of the untethered π component and generates bicycles that are 
not always desirable. Finally, alkyne surrogates and π components with widely varying sterics and 
electronics have been used to construct carbocycles with three different π components in an 
intermolecular fashion. This is the closest to ideal [2+2+2] cycloadditions, but use of special substrates 
and limited product scope restrict the utility of this approach. In short, cycloadditions are a powerful 
method for carbo- and heterocycle construction, but still suffer from problems in controlling chemo- and 
regioselectivities. 
 
Figure 1.1.2. Difficulties in [2+2+2] cycloadditions and current solutions. 
1.2 Nitrogen Heterocycle Synthesis via Metal-Catalyzed [2+2+2] Cycloadditions 
 Nitrogen containing heterocycles are found in many biologically active compounds, both 
originating from nature and produced by the pharmaceutical industry. [2+2+2] cycloadditions 
incorporating a nitrogen π component offer a rapid synthesis of these heterocycles. In this effort nitriles, 
isocyanates, carbodiimides,13 and imines14 have been used in [2+2+2] cycloadditions with alkynes (Figure 
                                                            
13 (a) Hoberg, H.; Burkhart, G. Synthesis 1979, 525-526. (b) Hong, P.; Yamazaki, H. Tetrahedron Lett. 1977, 1333-
1336. (c) Diversi, P.; Ingrosso, G.; Lucherini, A.; Malquori, S. J. Mol. Catal.1987, 40, 267-280. (d) Young, D. D.; 
Teske, J. A.; Deiters, A. Synthesis 2009, 3785-3790. 
14 (a) Ogoshi, S.; Ikeda, H.; Kurosawa, H. Pure Appl. Chem. 2008, 80, 1115-1125. (b) Adak, L.; Chan, W. C.; 
Yoshikai, N. Chem. Asian J. 2011, 6, 359-362. 
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1.2.1). 15 The use of nitriles to make pyridines is a powerful method and is well reviewed.16 In our work, 













Pyridine Pyridone Pyridinylidene Dihydropyridine
 
Figure 1.2.1. Nitrogen heterocycles synthesis using [2+2+2]. 
 Pyridone can refer to two constitutional isomers, 2-pyridone 1 or 4-pyridone 2 (Figure 1.2.2). 
Pyridones display a variety of biological activities, and typical syntheses utilize condensation reactions 
and transformations from other heterocycles.17  In addition to potential bioactivity, pyridones can serve as 
building blocks for other heterocycles. One of the more well known condensations to make 2-pyridone is 
the Guareschi-Thorpe condensation of a β-diketone 6 and an α-cyanoester 7.18 Pyridones are also 
constructed from other heterocycles. This includes the oxidation of pyridinium salts 9 and condensation 
of pyranones 10 with ammonium.19 4-pyridones are similarly made through condensations20 and 
transformations from other heterocycles as seen in the Gould-Jacobs reaction.21 This is a small sampling 
of ways to make pyridones. Although classical methods for pyridone synthesis exist, the development of 
new methods allows for substitution patterns that are difficult or impossible to attain with older methods. 
                                                            
15 Use of isothiocyanates in these reactions leads to sulfur containing heterocycles. For examples, see: (a) Yamazaki, 
H. J. Synth. Org. Chem., Jpn. 1987, 45, 244-257. (b) Yamamoto, Y.; Kinpara, K.; Saigoku, T.; Takagishi, H.; 
Okuda, S.; Nishiyama, H.; Itoh, K. J. Am. Chem. Soc. 2005, 127, 605-613. (c) Tanaka, K.; Wada, A.; Noguchi, K. 
Org. Lett. 2006, 8, 907-909. 
16 (a) Varela, J. A.; Saá, C. Chem. Rev. 2003, 103, 3787-3801. (b) Chopade, P. R.; Louie, J. Adv. Syn. Catal. 2006, 
348, 2307-2327. (c) Heller, B.; Hapke, M. Chem. Soc. Rev. 2007, 36, 1085-1094. (d) Varela, J. A.; Saá, C. Synlett 
2008,  2571-2578. 
17 (a) Mitscher, L. A. Chem. Rev. 2005, 105, 559-592. (b) Torres, M.; Gil, S.; Parra, M. Curr. Org. Chem. 2005, 9, 
1757-1779. 
18 Li, J. J. Name Reactions: 2nd edition. Springer-Verlag Berlin Heidelberg, New York, 2003. 
19 (a) Katritzky, A. R.; Patel, R. C.; Shanta, M. J. Chem. Soc. Perkin Trans. 1 1980, 1888-1889. (b) Torres, M.; Gil, 
S.; Parra, M. Curr. Org. Chem. 2005, 9, 1757-1779. 
20 Eicher, T.; Hauptmann, S. The Chemistry of Heterocycles: 2nd edition. Wiley-VCH GmbH & Co., Weinheim, 
2003. 
21 Gould, Jr., R. G.; Jacobs, W. A. J. Am. Chem. Soc. 1939, 61, 2890-2895. 
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In addition to [2+2+2] cycloadditions that are discussed below, newer methods, such as C-H activation, 
have been recently been applied to the synthesis of pyridones as well.22  
 
Figure 1.2.2. Pyridone isomers and numbering, biologically active pyridones, and typical pyridone 
syntheses. 
 The first reports of pyridone synthesis using [2+2+2] cycloadditions of two equivalents of alkyne 
and one equivalent of isocyanate were during the 1970s and 1980s. Yamazaki's report of using a 
cobaltacyclopentadiene catalyst to synthesize pyridones was the first (Eq 1).23  This catalysts generates 
two different regioisomers (1aa and 1aa'). Hoberg disclosed that nickel is also a competent catalyst for 
generating pyridones from alkynes and isocyanates (Eq 2).24 Hoberg also described the generation of 
various metallacycles, such as I and II, using stoichiometric nickel. Flynn reported pyridone synthesis 
                                                            
22(a) Su, Y.; Zhao, M.; Han, K.; Song, G.; Li, X. Org. Lett. 2010, 12, 5462-5465. (b) Hyster, T. K.; Rovis, T. Chem. 
Sci. 2011, 2, 1606-1610. 
23 (a) Hong, P.; Yamazaki, H. Synthesis 1977, 1, 50-52. (b) Hong, P.; Yamazaki, H. Tetrahedron Lett. 1977, 15, 
1333-1336. 
24 (a) Hoberg, H.; Oster, B. W. Synthesis 1982, 324-325. (b) Hoberg, H.; Oster, B. W. J. Organomet. Chem. 1983, 
234, C35-C38. (c) Hoberg, H.; Oster, B. W. J. Organomet. Chem. 1983, 252, 359-364. 
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using a rhodacyclopentadiene catalyst, but alkyne trimerization was the main product.25 This 
demonstrated that rhodium is a competent catalyst for this transformation, but also shows the difficulty in 
controlling chemoselectivity. 
 
Vollhardt employed a tethering strategy that overcame some of the problems associated with 
chemo- and regioselectivity by connecting the alkyne to the isocyanate (Eq 3).26 This methodology was 
used in the synthesis of camptothecin 5. Research groups have used similar tethering strategies in 
developing other catalytic systems including ruthenium,27 nickel,28 and rhodium.29 Tanaka has shown that 
the use of a chiral cationic rhodium catalyst can generate pyridones 21 that contain axial chirality with 
high enantioselectivities (Eq 4).30 
                                                            
25 Flynn, S. T.; Hasso-Henderson, S. E.; Parkins, A. W. J. Mol. Catal. 1985, 32, 101-105. 
26 (a) Earl, R. A.; Vollhardt, K. P. C. J. Am. Chem. Soc. 1983, 105, 6991-6993. (b) Earl, R. A.; Vollhardt, K. P. C. J. 
Org. Chem. 1984, 49, 4786-4800. 
27 (a) Yamamoto, Y.; Takagishi, H.; Itoh, K. Org. Lett. 2001, 3, 2117-2119. (b)Yamamoto, Y.; Kinpara, K.; 
Saigoku, T.; Takagishi, H.; Okuda, S.; Nishiyama, H.; Itoh, K. J. Am. Chem. Soc. 2005, 127, 605-613. 
28 (a) Duong, H. A.; Cross, M. J.; Louie, J. J. Am. Chem. Soc. 2004, 126, 11438-11439. (b) Duong, H. A.; Louie, J. 
J. Organomet. Chem. 2005, 690, 5098-5104. (c) Duong, H. A.; Louie, J. Tetrahedron 2006, 62, 7552-7559. 
29 Kondo, T.; Nomura, M.; Ura, Y.; Wada, K.; Mitsudo, T. Tetrahedron Lett. 2006, 47, 7107-7111. 
30 (a) Tanaka, K.; Wada, A.; Noguchi, K. Org. Lett. 2005, 7, 4737-4739. (b) Tanaka, K. Synlett 2007,  1977-1993. 




1.3 [2+2+2] Cycloaddition of Alkenyl Isocycanates and Alkynes 
 Our research group sought to replace one of the alkynes with an alkene to generate a carbon 
stereocenter. With the exception of Tanaka’s example, none of these reports contain chirality. In 2006, Yu 
and Rovis reported using alkenyl isocyanates 22 and alkynes 16 to generate lactam 23 and vinylogous 
amide 24 products (Eq 5).31 This reaction was rendered enantioselective using phosphoramidite ligands 
(Eq 6).32 During our lab's investigation of the rhodium-catalyzed cycloaddition of alkenyl isocyanates and 
alkynes, the errant formation of 2-pyridone 1 was noted. Dr. Robert Yu observed this with longer tether 
lengths.33 Dr. Ernest Lee reported 2-pyridone formation with bulky 1,1-disubstituted alkenyl isocyanates 
and when the reaction is run at higher concentrations using 1,1-disubstituted alkenyl isocyanates (Eq 7).34 
                                                            
31 Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 2782-2783. 
32 Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 12370-12371. 
33 Yu, R. T. Enantioselective rhodium-catalyzed [2+2+2] and [4+2+2] cycloaddition reactions of alkenyl 
heterocumulenes: applications to alkaloid synthesis. Ph.D. Dissertation, Colorado State University, Fort Collins, 
CO, 2009. 
34 (a) Lee, E. E.; Rovis, T. Org. Lett. 2008, 10, 1231-1234. (b) Lee, E. E. Colorado State University, Fort Collins, 




 The proposed mechanism for lactam, vinylogous amide, and pyridone formation is below (Figure 
1.3.1). Initial coordination of the alkyne and isocyanate to rhodium leads to complex III. This complex 
can oxidatively cyclize in two ways: either with C-N bond formation generating rhodacycle IV or C-C 
bond formation generating rhodacycle VI. From rhodacycle IV, the alkene coordinates to rhodium and 
undergoes a 1,2-migratory insertion. Reductive elimination of rhodacycle V leads to lactam 23 and 
regenerates the catalyst. Alternatively, generation of rhodacycle VI leads to a metallacycle where the 
alkene cannot coordinate and instead a CO migration occurs to generate rhodacycle VIII. Now the alkene 
coordinates and undergoes a migratory insertion to make 7-membered rhodacycle IX that reductively 
eliminates forming vinylogous amide 24. With this proposed mechanism, an exogenous alkyne can bind 
to rhodacycle IV or VI.  Migratory insertion of the alkyne and reductive elimination generates 2-pyridone 
1. As mentioned earlier, 2-pyridone is observed in the reaction and this mechanism accounts for its 
formation. From this mechanistic hypothesis, we see that another product could be generated from 
interception of rhodacycle VIII by an alkyne. This would lead to the formation of 4-pyridone 2, which 
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had not been reported from this reaction. The isolation of 4-pyridone would provide indirect evidence for 
rhodacycle VI. 
 
Figure 1.3.1. Proposed mechanism for [2+2+2] cycloaddition of alkyenyl isocyanates and alkynes. 
1.4 Development of a Rhodium·Phosphoramidite-Catalyzed [2+2+2] Pyridone Synthesis35 
 We sought to expand the synthesis of pyridones from alkynes and isocyanates using our 
rhodium·phosphoramidite catalyst system. In addition to developing a useful method for making 
pyridones, we focused on revealing mechanistic insight into the cycloaddition of alkenyl isocyanates and 
alkynes. We chose to investigate terminal alkynes initially as these products were observed in our 
previous work. The use of untethered terminal alkynes presents two problems; metal catalysts are known 
                                                            
35 Reprinted with permission from Tetrahedron, Vol 65, Kevin M. Oberg, Ernest E. Lee, Tomislav Rovis, 
"Regioselective rhodium-catalyzed intermolecular [2+2+2] cycloaddition of alkynes and isocyanates to form 
pyridones", 5056-5061. Copyright (2009) Elsevier. 
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to dimerize terminal alkynes36 and the regiochemistry of pyridone formation can be substrate and catalyst 
dependent. Initial results using rac-MonoPhos L3 as a ligand for rhodium shows pyridone yield depends 
on the electronics of the alkyne (Table 1.4.1). Electron-rich aryl alkynes give higher yields, whereas more 
electron-deficient alkynes produce lower yields. With these initial results, we chose phenylacetylene 16d 
and benzyl isocyanate 17b to look at the effect ligand had on the reaction. Benzyl isocyanate 17b was 
chosen because the reaction was easier to monitor and analyze using 1H NMR, and phenylacetylene 16d 
allowed for changes in yield to be more easily detected. 
Table 1.4.1. Initial Alkyne Scope.a 
 
 The use of triphenylphosphine as a ligand produces an additional product in this reaction (Eq 8). 
NMR analysis identified the product as enynamide 25db.37 This conjecture was confirmed by 1H NMR 




36 (a) Albano, P.; Aresta, M. J. Organomet. Chem. 1980, 190, 243-246. (b) Ohshita, J.; Furumori, K.; Matsuguchi, 
A.; Ishikawa, M. J. Org. Chem. 1990, 55, 3277-3280. 
37 See also: Hoshhino, Y.; Shibata, Y.; Tanaka, K. Angew. Chem. Int. Ed. 2012, 51, 9407-9411. 
38 (a) Cherry, K.; Thibonnet, L.; Duchêne, A.; Parrain, J.; Abarbri, M. Tetrahedron Lett. 2004, 45, 2063-2066. (b) 
Abarbri, M. Faculté des Sciences de Tours, Tours, France. Personal communication, 2008. 
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 Optimization of pyridone yields by varying the ligand is shown in Table 1.4.2. In general, triaryl 
phosphine ligands produce poor yields of both products (entries 1-7). Tricyclohexylphosphine as a ligand 
produces a low yield of the desired pyridone and the highest yield of enynamide (entry 8). The use of an 
amidophosphite or a phosphite ligand does not produce any detectable product (entries 9, 10). The use of 
phosphoramidite ligands provide the highest yield of pyridone 1db with the lowest amount of enynamide 
25db (entries 11-16). The highest yielding is rac-L539 (entry 14). When rhodium bisethylene chloride 
dimer or MonoPhos L3 is removed from the reaction, no product is observed, demonstrating the need for 
both rhodium and ligand to be present for the reaction to proceed. 
Table 1.4.2. Investigation of ligand.a 
 
                                                            
39 Giacomina, F.; Meetsma, A.; Panella, L.; Lefort, L.; de Vries, A. H. M.; de Vries, J. G. Angew. Chem. Int. Ed. 
2007, 46, 1497-1500. 
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 Once we found that GuiPhos L4 was a good ligand for this reaction, we did some initial 
exploration with other isocyanates and alkynes. During these initial investigations, we found that three 
products are produced when hexyl isocyanate 17c and 1-octyne 1g are used as reactants (Eq 9). 2-
Pyridone 1gc is produced in moderate yield and enynamide 25gc is seen in trace yield. The final product 
is 4-pyridone 2gc. This product was predicted by our proposed mechanism, but until this point had yet to 
be isolated. One of the reasons for its elusiveness can be attributed to its high polarity. In order to isolate 
it, 10:1 EtOAc:MeOH is required as the eluent during column chromatography (typically, 2:1 or 1:1 
Hex:EtOAc is used to elute lactam, vinylogous amide, and 2-pyridone). 
 
1.5 Scope and Regiochemistry of Pyridone Synthesis 
 We investigated the scope of terminal alkynes using benzyl isocyanate 17b (Table 1.5.1). As rac-
L5 generates the most 2-pyridone and least enynamide, we chose it as the ligand. As seen previously, 
electron-rich aryl alkynes are higher yielding than electron-deficient alkynes (1db, 1eb, 1fb). Substitution 
is tolerated at the para (1fb), meta (1hb), and ortho (1ib) positions of arylalkynes, but the yield lowers 
with ortho subsitution (1ib).40 Other conjugated alkynes, such as 3-ethynylthiophene (1jb) and 1-
ethynylcyclohexene (1kb), produce high yields of 2-pyridone. Aliphatic alkynes give lower yields than 
conjugated alkynes (1gb, 1lb, 1mb, 1nb). Ethoxyacetylene (1ob) also produces 2-pyridone in moderate 
yield. This reaction proceeds with exquisite catalyst control, and only 4,6-substituted 2-pyridone was 
observed for every alkyne investigated. 
 
                                                            
40 Although a decent probe of steric tolerance, methyl substitution would be better than methoxy; methoxy 




Table 1.5.1. Alkyne Scope.a,b 
R
[Rh(C2H4)2Cl]2 (2.5 mol %)











a Reaction conditions: 16 (3 equiv), 17b (0.24 mmol), [Rh(C2H4)2Cl]2 (2.5 mol %), rac-L5 (5 mol %) in PhMe reflux for 12 h.






























































1db: 68% 1eb: 46% 1fb: 88% 1hb: 73%
1ib: 54% 1jb: 80% 1kb: 92% 1gb: 38%
1lb: ~15% 1mb: 19%c 1nb: 18% 1ob: 38%
 
 We determined the regioisomer to be 4,6-substituted based on comparisons with similar 
compounds in the literature (Figure 1.5.1). Our observed coupling constants around 2 Hz are consistent 
with a 1,3 proton relationship (2641 and 2742). For 2-pyridones, protons in a 1,4 relationship (28)43 are 
singlets and 1,2 coupled protons (29)44 have coupling constants around 7 Hz. Chemical shifts of similar 
compounds in the literature suggest 4,6-substitution, because 3,5-substituted pyridones are more 
                                                            
41 Carles, L.; Narkunam, K.; Penlou, S.; Rousset, L.; Bouchu, D.; Ciufolini, M. A. J. Org. Chem. 2002, 67, 4304-
4308. 
42 Sutherland, A.; Gallagher, T. J. Org. Chem. 2003, 68, 3352-3355. 
43 Yamamoto, K. Yamazaki, S.; Murata, I. J. Org. Chem. 1987, 52, 5239-5243. 
44 Overman, L. E.; Tsuboi, S.; Roos, J. P.; Taylor, G. F. J. Am. Chem. Soc. 1980, 102, 747-754. 
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deshielded (27). This regiochemical assignment was confirmed by X-ray crystallography.45 Our previous 
synthesis of lactam and vinylogous amide always generates products with the proton α to the carbonyl. 
This same trend is seen with pyridone formation and this suggests that pyridones are generated from 
similar rhodacycles. 
 
Figure 1.5.1. Regiochemistry determination of 2-pyridone. 
 Many of the [2+2+2] cycloadditions in the literature for the syntheis of pyridones use internal 
alkynes or tethered alkynes. A listing of the known reactions using terminal alkynes is shown in Table 
1.5.2. The earliest report utilizing terminal alkynes is by Hoberg with a single example using nickel that 
generates 4,5-substituted pyridone.46 Diversi and coworkers report the use of a cobalt catalyst and 
depending on the isocyanate used, either a mixture of regioisomers or a single 3,6-regioisomer is 
                                                            
45 Oberg, K. M.; Rovis T. (2013) Private communication to the Cambridge Structural Database, deposit number 
CCDC 917626. 
46 Hoberg, H.; Oster, B. W. Synthesis 1982, 324-325. 
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generated.47 Tanaka has reported the most expansive scope of terminal alkynes using cationic rhodium 
with a bidentate ligand. The regioselectivity is dependent on the alkyne employed in the reaction and a 
mixture of regioisomers is typically observed.48 Notable exceptions are the use of silylalkynes and 
alkynylethers49 that produce single regioisomers. The rhodium·phosphoramidite catalyst system provides 
remarkable selectivity for a single regioisomer, independent of the alkyne.  

























Report R1 R2 catalyst yield (%)
Ph Ph Ni(cod)2, PCy3 - 15 - -
Diversi (47) n-Bu Cy
n-Bu Ph
CoCp(C2H4)2 15 - - 15



















n-Bu - - - 53







- - - 68
- - - 38
Bn - - - 92
3,6-substituted 4,5-substituted 3,5-substituted 4,6-substituted
 
 We also sought to use internal alkynes with this rhodium·phosphoramidite system, but they are 
surprisingly recalcitrant. Internal alkynes such as diphenyl acetylene, 1-phenyl-1-butyne, 1-propynyl-1-
cyclohexane, and 5-decyne do not produce product with these phosphoramidite ligands. The use of 
                                                            
47 Diversi, P.; Giovanni, I.; Lucherini, A.; Malquori, S. J. Mol. Catal. 1987, 40, 267-280. 
48 Tanaka, K.; Wada, A.; Noguchi, K. Org. Lett. 2005, 7, 4737-4739. 
49 Komine, Y.; Tanaka, K. Org. Lett. 2010, 12, 1312-1315. 
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dimethyl acetylenedicarboxylate generates a low amount (20%) of arene product.50 The lack of reactivity 
with internal alkynes is unexpected because Kondo showed that a RhCl(PPh3)x system catalyzes pyridone 
formation with internal symmetrical alkynes.51 Methyl phenylpropiolate 16a does provide product with 
MonoPhos (rac-L3), but shows no reaction with rac-L5 as a ligand (Eq 10). We assigned the regioisomer 
of pyridone 1ab by comparison to a similar pyridone in the literature.52 Saponification of the ester groups 
and subsequent decarboxylation of the resulting acid produces pyridone 1db confirming our original 
assignment. When a high-yielding alkyne, para-methoxyphenyl acetylene 16f, is added to a solution of 
premixed methyl phenylpropiolate 16a, benzyl isocyanate 17b, and  RhCl·rac-L5, we observe no product 
(Eq 11). This suggests that the catalyst is being tied up, potentially in an unproductive metallacycle.  
Ph
CO2Me
[Rh(C2H4)2Cl]2 (2.5 mol %)






















[Rh(C2H4)2Cl]2 (2.5 mol %)
















We looked at the scope of isocyanates that participate in the reaction (Table 1.5.3). During the 
investigation of isocyanates, we observed more 4-pyridone. Benzyl 17b and para-methoxybenzyl 
isocyanate 17d generate 2-pyridone 1 in good yield with trace amounts of 4-pyridone 2 (entries 1,2). 
Alkyl isocyanates generate moderate yields of 2-pyridone with low amounts of 4-pyridone (entries 3,4). 
Aryl isocyanates produce a good combined yield of pyridone and the ratio of 2- to 4-pyridone is 
dependent on the electronics of the isocyanate (entries 5-8). Generally, more electron-deficient 
                                                            
50 (a) Kotha, S.; Khedkar, P. Eur. J. Org. Chem. 2009, 730-738. (b) Oinen, M. E. The Enantioselective Rhodium 
Catalyzed [2+2+2] Cycloaddition of Alkenyl Isocyanates with Diaryl Acetylenes and 1,2-Disubstituted Alkenyl 
Isocyanates. M.S. Thesis, Colorado State University, Fort Collins, CO, 2010. 
51 Kondo, T.; Nomura, M.; Ura, Y.; Wada, K.; Mitsudo, T. Tetrahedron Lett. 2006, 47, 7107-7111. 
52 Hong, P.; Yamazaki, H. Synthesis 1977, 1, 50-52. 
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arylisocyanates produce more 4-pyridone. Vinyl isocyanates work in the reaction, but the ratio of 2- to 4-
pyridone is potentially skewed in entry 9 with (E)-(2-isocyanatovinyl)benzene 17j.  This isocyanate is 
unstable and decomposed as it was being used. The use of p-toluenesulfonyl isocyanate leads to an 
intractable mixture and chlorosulfonyl isocyanate reacts uncatalyzed with alkynes.53 
Table 1.5.3. Scope of isocyanates.a 
 
 The generation of a single 2-pyridone regioisomer remains the same with a variety of isocyanates. 
Additionally, we only observe 2,6-substituted 4-pyridones. This regiochemical assignment is based on 
NMR analysis and literature comparisons (Figure 1.5.2). The NMRs for the 4-pyridones are striking in 
their simplicity suggesting a C2 symmetric molecule. Chemical shifts of the protons suggests 2,6-
subsituted 4-pyridones when compared to compounds in the literature.54 This assignment was confirmed 
                                                            
53 Moriconi, E. J.; Shimakawa, Y. J. Org. Chem. 1972, 37, 196-207. 
54 For 30, see: Barluenga, J.; Lopez Ortiz, F.; Palacios, F.; Gotor, V. Synth. Commun.1983, 13, 411-417. For 31 and 
33, see: Patonay, T.; Lévai, A.; Rimán, É.; Varma, R. S. ARKIVOC 2004, 7, 183-195. For 32 and 34, see: Beak, P.; 
Bonham, J. J. Am. Chem. Soc. 1965, 87, 3365-3371. 
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by X-ray crystallography.55 Once again, the regiochemistry is the same as the vinylogous amide 
regiochemistry and supports our proposed mechanism. 
 
Figure 1.5.2. Regiochemistry determination of 4-pyridone. 
 Deprotecting the products would make this method more useful as many transformations utilize 
NH pyridones.56 Initially, we attempted to deprotect our benzyl protected pyridone 1db using dissolving 
metal conditions, ethyl chloroformate, and hydrogenation,57 but these conditions left the benzyl group 
intact (Eq 12). Due to the difficulty of removing the benzyl group, we attempted to deprotect the para-
methoxy benzyl protecting group on pyridone 1gd (Eq 13). Once again, hydrogenation did not provide 
any of the desired product. Treatment with ceric ammonium nitrate deprotected some of the pyridone as 
evidence by the aldehyde peak in the crude 1H NMR, but this reaction was messy and difficult to purify. 
                                                            
55 Oberg, K. M.; Rovis T. (2013) Private communication to the Cambridge Structural Database, deposit number 
CCDC 917625. 
56 Kelly, T. R.; Lang, F. J. Org. Chem. 1996, 61, 4623-4633. 




We found that refluxing pyridone 1gd in trifluoroacetic acid provided our deprotected pyridone 35 in 
good yield.58 
 
1.6 Proposed Mechanism 
 We propose the following mechanism for pyridone formation (Figure 1.6.1), which is similar to 
the mechanism proposed for the [2+2+2] cycloaddition of alkenylisocyanates and alkynes (Figure 1.3.1). 
The alkyne and isocyanate coordinate to rhodium generating complex III. This can undergo oxidative 
cyclization to form one of two metallacycles. In Pathway A, rhodacycle X is formed and C-N bond 
formation occurs. Insertion of an alkyne into this rhodacycle and reductive elimination generates 2-
pyridone 1. Rhodacycle X can also undergo a  CO migration to generate rhodacycle XI. Insertion of an 
alkyne into this rhodacycle followed by reductive elimination furnishes 4-pyridone 2. Alternatively, 
complex III can undergo cyclization leading to rhodacycle XII, where C-C bond formation occurs. 
Alkyne insertion followed by reductive elimination generates 2-pyridone 1. These metallacycles are 
similar to the ones we propose for the cyclization of alkenyl isocyanates and alkynes (X:VI, XI:VIII, 
XII:IV). A discussion of regioselective metallacyle formation will be left for the next chapter that 
discusses the mechanism of the [2+2+2] cycloaddition of alkenyl isocyanates and terminal alkynes. 
                                                            




Figure 1.6.1. Proposed mechanism for pyridone formation. 
 Although it is possible that both pathways are operative in this reaction, we believe that pathway 
A, via rhodacycle X, is predominant. From rhodacycle XII, it is not possible to generate 4-pyridone 2. 
Rhodacycle X can generate 2-pyridone 1 or 4-pyridone 2. Indirect evidence for this mechanistic 
hypothesis is seen when the yields of pyridone are compared with product selectivity in the [2+2+2] 
cycloaddition of alkenyl isocyanates and alkynes (Figure 1.6.2). According to our proposed mechanism, 
rhodacycle IV generates lactam and rhodacycle VI generates vinylogous amide. Therefore, a higher ratio 
of vinylogous amide suggests more formation of rhodacycle VI. In the reaction to make pyridones, 
alkynes that generate more vinylogous amide also produce higher yields of pyridone. This suggests these 
alkynes generate more VI and X leading to vinylogous amide and pyridone, respectively. The opposite is 
seen with alkynes that favor lactam. Metallacycles such as rhodacycle XII have been isolated before,59 
but metallacycles with the CO α to the metal, such as rhodacycle X, are unprecedented. The generation of 
4-pyridone in these reactions implicates this type of metallacycle exists in both this reaction and [2+2+2] 
cycloadditions of alkenyl isocyanates and alkynes. 
 
                                                            







Figure 1.6.2. Correlation of pyridone yield to vinylogous amide selectivity. 
 The ratio of 2-pyridone to 4-pyridone appears to be independent of alkyne concentration (Eq 14). 
When the reaction is conducted with high concentration and higher alkyne equivalents, a slightly better 
yield of pyridone is generated, but the ratio is the same as standard reaction conditions. When the alkyne 
is slowly added under more dilute conditions, a lower yield of pyridone is seen, but once again the ratio 
remains the same. This can be explained by two mechanisms that are indistinguishable at this time. One, 
the equilibration between rhodacycle X and XI is rapid and dependent on the alkyne and isocyanate that 
are already bound to the metal via the metallacycle. Two, the exogenous alkyne is bound to the metal and 
the difference in rates between migratory insertion of the alkyne into rhodacycles X or XI determines the 

























 We attempted to incorporate three different π components using the rhodium·phosphoramidite 
system with two electronically different alkynes (Eq 15). As mentioned earlier, the incorporation of three 
different π components in a controlled fashion is a difficult task. A mixture of four products was obtained. 
Although we did not achieve the goal of selective product formation, we see that different alkynes react at 
different rates during oxidative cyclization and alkyne insertion. If pyridone is generated from rhodacycle 
X, we see that 1fb and 36, which derived from oxidative cyclization of the more electron-rich alkyne, 
have a higher combined yield than 37 and 1eb, derived from cyclization of the more electron-deficient 
alkyne. This gives a ratio of 2.6:1 for cyclization of para-methoxyphenyl acytelene 16g over meta-
fluorophenyl acytelene 16f. A ratio of ~1.4:1 of the more electron-rich alkyne 16g to the more electron-
deficient alkyne 16f (1.6:1 and 1.2:1) is observed for the second alkyne insertion. From this, we see that 
electron-rich aryl alkynes undergo oxidative cyclization faster that electron-deficient aryl alkynes and that 
the second alkyne insertion is much less selective than the initial oxidative cyclization. 
[Rh(C2H4)2Cl]2 (2.5 mol %)
















































 The generation of pyridone can also be explained by other mechanisms. It is possible that two 
alkynes undergo oxidative cyclization to form rhodacyclopentadienes such as XIII, XIV, and XV (Figure 
1.6.3). Isocyanate insertion into these metallacycles and reductive elimination furnishes pyridone. This 
mechanism is closely related to the [2+2+2] cyclotrimerization of alkynes and has also been suggested for 
pyridone formation.60 Although possible, a number of observations suggest this is not operative in our 
case. The regiochemistry of metallacyclopentadiene formation tends to be either metallacycle XIII or 
XIV or a mixture of one of these metallacycles with metallacyclopentadiene XV. The selectivity is 
typically dependent on the sterics and electronics of the alkyne. Looking back at Table 1.5.2 of other 
catalyst systems, we see pyridones that would be generated from these types of metallacycles. In our case, 
we see a single regioisomer independent of the size and electronics of the alkyne. Additionally, the 
formation of 4-pyridone 2 from any of these metallacycles would not be possible. Finally, we do not see 
arene formation in our reactions that would be derived from interception of any of these metallacycles 
with an exogenous alkyne. This has been noted with other catalyst systems. The lack of arene formation 
also indirectly suggests that the initial oxidative cyclization occurs between the isocyanate and alkyne. 
 
Figure 1.6.3. Metallacyclopentadiene for pyridone formation. 
 Another mechanistic possibility is that enynamide 25 is an intermediate en route to 2-pyridone 1. 
When enynamide 25db is subjected to the reaction conditions, only enynamide 25db is recovered and 
pyridone 1db is not observed. It would also be impossible to get to 4-pyridone 2 from this intermediate. 
We propose that enynamide 25 is generated from a similar mechanism that has been proposed for 
                                                            
60 For reviews, see: (a) Varela, J. A.; Saá, C. Chem. Rev. 2003, 103, 3787-3801. (b) Chopade, P. R.; Louie, J. Synlett 
2006, 348, 2307-2327. (c) Heller, B.; Hapke, M. Chem. Soc. Rev. 2007, 36, 1085-1094. (d) Varela, J. A.; Saá, C. 
Synlett 2008, 17, 2571-2578. For individual papers, see: (d) Wakatsuki, Y.; Yamazaki, H. J. Organomet. Chem. 
1977, 139, 169-177. (e) Hardesty, J. H.; Koerner, J. B.; Albright, T. A.; Lee, G.-Y. J. Am. Chem. Soc. 1999, 121, 
6055-6067. (f) Kichner, K.; Calhorda, M. J.; Schmid, R.; Veiros, L. F. J. Am. Chem. Soc. 2003, 125, 11721-11729. 
(g) Dachs, A.; Torrent, A.; Pla-Quintane, A.; Roglans, A.; Jutand, A. Organometallics 2009, 28, 6036-6043. 
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terminal alkyne dimerization by metal catalysts.61 A C-H insertion into the terminal alkyne generates 
rhodium hydride XVI. This species undergoes a 1,2 migration across another alkyne generating another 
rhodium hydride XVII. This same process occurs with an isocyanate, and reductive elimination of 
rhodium hydride XVIII generates the enynamide 25 and regenerates the catalyst. 
 
Scheme 1.6.1. Test of enynamide as reaction intermediate and proposed mechanism for enynamide 
formation. 
1.7 Conclusion 
 In conclusion, we have developed a rhodium·phosphoramidite catalyzed [2+2+2] cylcoaddition 
of terminal alkynes and isocyanates to generate pyridones. This reaction proceeds with excellent catalyst 
control generating a single regioisomer of 2-pyridone. Additionally, this reaction works best with terminal 
alkynes, a substrate that is traditionally difficult. From the same reaction, 4-pyridone is also isolated as a 
single regiosomer. The isolation of 4-pyridone is the first example of a CO migration for pyridone 
                                                            
61 Schäfer, H.-A.; Marcy, R.; Rüping, T.; Singer, H. J. Organomet. Chem. 1982, 240, 17-25. 
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synthesis using a [2+2+2] cycloaddition of alkynes and isocyanates. We propose that initial oxidative 
cyclization occurs between an alkyne and isocyanate, an unusual mechanistic feature in [2+2+2] 
cycloadditions to generate pyridones. More importantly, the generation of 4-pyridone suggests the 
existence of rhodacycle X, where the carbonyl of the isocyanate is α to the metal. This metallacycle has 
not been reported, and this observation supports our mechanistic proposals in the [2+2+2] cycloaddition 






Mechanistic Insight into the Enantioselective Rhodium-Catalyzed [2+2+2] Cycloaddition of Terminal 
Alkynes and Alkenyl Isocyanates1 
2.1 Introduction 
 Indolizidines and quinolizidines make up the core of a variety of natural products (Figure 2.1.1).2 
The great variety of approaches to these motifs highlights the difficulty that constructing these cores can 
pose.3 In 2006, Yu and Rovis discovered and developed the [2+2+2] cycloaddition between alkenyl 
isocyanates and alkynes that efficiently constructs these cores.4 Through the use of phosphoramidite 
ligands,5 this reaction was rendered enantioselective (Eq 1).6 
 Isolation of lactam 3 from the [2+2+2] cycloaddition of alkenyl isocyanates and alkynes is 
expected, but generation of vinylogous amide 4 is surprising. Vinylogous amide 4 is derived from a 
fragmentation of the isocyanate. The amount of lactam 3 or vinylogous amide 4 produced is dependent on 
substrate sterics and electronics, as well as the nature of the phosphoramidite ligand. The mechanistic 
factors that determine product selectivity and product regiochemistry remained elusive and posed an 
interesting mechanistic problem. 
                                                            
1 Reprinted with permission from Journal of the American Chemical Society, Vol 131, Derek M. Dalton, Kevin M. 
Oberg, Robert T. Yu, Ernest E. Lee, Stéphane Perreault, Mark Emil Oinen, Melissa L. Pease, Guillaume Malik, 
Tomislav Rovis, "Enantioselective Rhodium-Catalyzed [2 + 2 + 2] Cycloadditions of Terminal Alkynes and Alkenyl 
Isocyanates: Mechanistic Insights Lead to a Unified Model that Rationalizes Product Selectivity", 15717-15728. 
Copyright (2009) American Chemical Society. 
2 (a) Daly, J. W. J. Med. Chem. 2003, 46, 445-452. (b) Daly, J. W.; Spande, T. F.; Garraffo, H. M. J. Nat. Prod. 
2005, 68, 1556-1575. 
3 For reviews of recent syntheses, see: (a) Michael, J. P. Nat. Prod. Rep. 2005, 22, 603-626. (b) Michael, J. P. Nat. 
Prod. Rep. 2007, 24, 191-222. (c) Michael, J. P. Nat. Prod. Rep. 2008, 25, 139-165.  
4 Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 2782-2783. 
5 Teichert, J. F.; Feringa, B. L. Angew. Chem. Int. Ed. 2010, 49, 2486-2528. 




Figure 2.1.1. Indolizidine and quinolizidine structures: natural products and indolizidine synthesis via 
[2+2+2] cycloaddition of alkenyl isocyanates and alkynes.  
 The proposed mechanism, mechanism A, for the formation of lactam 3, vinylogous amide 4, and 
side products, 2-pyridone 5 and 4-pyridone 6 is depicted in Figure 2.1.2. Initially, the alkenyl isocyanate 2 
and alkyne 1 coordinate to rhodium generating coordination complex I. From here, conrotatary 
cyclization can proceed in two ways. Cyclization with C-C bond formation generates rhodacycle II.7 
Coordination of the alkene and 1,2-migratory insertion forms rhodacycle III that reductively eliminates to 
furnish lactam 3 and regenerate the catalyst. Alternatively, cyclization with C-N bond formation generates 
rhodacycle IV. Coordination of the alkene is prohibited in this rhodacycle and a CO migration, via V, 
furnishes rhodacycle VI. At this point, the alkene can coordinate and insert to make rhodacycle VII. 
Reductive elimination makes vinylogous amide 4. Coordination and insertion of an exogenous alkyne to 
rhodacycle II or IV forms 2-pyridone 5. In a similiar fashion, coordination and insertion of an alkyne into 
rhodacycle VI generates 4-pyridone 6. 
                                                            
7 For selected publications with similar metallacycles involving an isocyanate and alkyne see: (a) Hoberg, H. J. 
Organomet. Chem. 1988, 358, 507-517. (b) Duong, H. A.; Louie, J. J. Organomet. Chem. 2005, 690, 5098-5104. (c) 
Louie, J. Curr. Org. Chem. 2005, 9, 605-623 (d) Yamamoto, Y.; Kinpara, K.; Saigoku, T.; Takagishi, H.; Okuda, S.; 
Nishiyama, H.; Itoh, K. J. Am. Chem. Soc. 2005, 127, 605-613. (e) Kondo, T.; Nomura, M.; Ura, Y.; Wada, K.; 
Mitsudo, T. Tetrahedron Lett. 2006, 47, 7107-7111. (f) Duong, H. A.; Louie, J. Tetrahedron 2006, 62, 7552-7559. 






Figure 2.1.2. Proposed mechanism A of [2+2+2] cycloaddition of alkenyl isocyanates and alkynes. 
Coordination of alkyne and isocyanate followed by cyclization generates rhodacycle II or IV that 
eventually makes the observed products. 
 An alternative mechanism, mechanism B, can be proposed wherein the alkene and isocyanate 
cyclize first (Figure 2.1.3). In this mechanism, cyclization of the alkene and isocyanate generates IX and 
sets the sp3 stereocenter. Coordination of the alkyne to rhodacycle IX and insertion generates rhodacycle 
III that reductively eliminates to make lactam 3. Rhodacycle IX is in equilibrium with rhodacycle XI via 
a CO migration. Coordination of an alkyne to rhodacycle XI and insertion generates rhodacycle XII en 
route to vinylogous amide 6. According to this mechanism, the equilibrium between rhodacycles IX and 




Figure 2.1.3. Alternative mechanism B: alkene and isocyanate cyclize to form common rhodacycle IX. 
 Although mechanism B is reasonable, a few pieces of data suggests that it is not operative. 
Mechanism B predicts a dependence of the reaction rate on the alkenyl isocyanate, so different alkenyl 
isocyanates should change the rate. Dr. Ernest Lee tested this hypothesis by performing competition 
experiments between alkenyl isocyanate 2 and 1,1-disubstituted alkenyl isocyanate 7 with different 
alkynes (Eq 2 and 3).8 If the alkenyl isocyanate is involved in the turnover limiting step,9 isocyanates 2 
and 7 are predicted to react at different rates giving an unequal product ratio. Using benzyl acetylene 1b 
(selective for lactam), a 1:1 ratio of lactam 3b to 8b derived from isocyanates 2 and 7 is observed. The 
same result occurs with para-methoxyphenyl acetylene 1c (selective for vinylogous amide), where a 1:1 
ratio of vinylogous amide 4c and 9c is observed. This suggests that the olefin is not involved in the 
turnover limiting step. This also suggests that the initial cyclization between the alkyne and alkenyl 
isocyanate is irreversible and product determining, as depicted in mechanism A. 
 Dr. Lee also found that higher concentrations of alkyne with alkenyl isocyanate 7 generates more 
2-pyridone 5a (Eq 4).10 Lower alkyne concentration lowers the amount of 2-pyridone 5a. This indirectly 
suggests that cyclization occurs between the alkyne and isocyanate, as depicted in mechanism A. If 
cyclization of the alkyne and isocyanate does occur, higher concentrations of alkyne favor intermolecular 
                                                            
8 Lee, E. E. Colorado State University, Fort Collins, CO. Unpublished work, 2007. 
9 For a study of thermodynamic effects of nickel coordination by substituted alkenes, see: Tolman, C. A. J. Am. 
Chem. Soc. 1974, 96, 2780-2789. 
10 Lee, E. E.; Rovis, T. Org. Lett. 2008, 10, 1231-1234. 
30 
 
interception of rhodacycle II/IV by a second equivalent of alkyne over the intramolecular insertion of the 
tethered alkene. Additionally, when even bulkier 1,1-disubstituted alkenyl isocyanates are used (such as 
phenyl), only 2-pyridone 5 is observed.11 If cyclization is not reversible, the formation of pyridone in the 
reaction suggests the isocyanate and alkyne cyclize first. 
 
 Finally, if mechanism B is operative, the enantiodetermining step occurs during formation of 
rhodacycle IX. The formation of common rhodacycle IX predicts that lactam 3 and vinylogous amide 4 
should both have a stereocenter with the same configuration. With the same Taddol phosphoramidite, the 
stereochemistry is opposite for both lactam 3 and vinylogous amide 4. This suggests that mechanism B is 
not operative. With all this indirect evidence, we believe that mechanism A is operative.  
 During our group's work on this transformation, a number of trends in product selectivity have 
been observed. Dr. Yu documented product selectivity based on the electronics and sterics of terminal 
alkynes. Electron-rich aryl alkynes provide more vinylogous amide and electron-deficient aryl alkynes 
                                                            
11 Lee, E. E. Colorado State University, Fort Collins, CO. Unpublished work, 2007. 
31 
 























[Rh(C2H4)2Cl]2 (5 mol %)
T2 (10 mol %)





















Figure 2.1.3. Hammett plot correlating alkyne electronics with product selectivity. 
 Dr. Yu also found that the size of the alkyne influences product selectivity. Smaller alkynes favor 
lactam 3 and larger alkynes favor vinylogous amide 4 (Table 2.1.1).14 
                                                            
12 Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 12370-12371. 
13 Hansch, C.; Leo, A.; Taft, R. W. Chem. Rev. 1991, 91, 165-195. 
14 Yu, R. T.; Lee, E. E.; Malik, G.; Rovis, T. Angew. Chem. Int. Ed. 2009, 48, 2379-2382. 
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 In addition to product selectivity based on the alkyne, the ligand exerts a large influence on 
product selectivity (Figure 2.1.4). In general, we observe that Taddol ligands slightly favor lactam, 
whereas BINOL and BiAryl ligands favor vinylogous amide. 
 
Figure 2.1.4. Phosphoramidite ligands commonly used in the [2+2+2] cycloaddition. 
 Although we had observed these trends in product selectivity and could use them to make 
predictions, questions remained about the mechanism (Figure 2.1.5). We observe remarkable 
regioselectivity in the reaction with terminal alkynes; the hydrogen is α to the carbonyl in the products for 
both lactam 3 and vinylogous amide 4. We have never observed the opposite regioisomer despite using a 
wide range of alkynes and phosphoramidite ligands. In collaboration with my colleague, Derek Dalton, 





Figure 2.1.5. Observed trends in product selectivity and remaining mechanistic questions. 
2.2 Investigation of Phosphoramidite Ligands 
 Due to the impact of ligand structure on product selectivity, we conducted a structure activity 
relationship study. Although numerous ligands had been synthesized and employed in the cycloaddition, a 
systematic comparison was lacking. The effect of ligand structure on product selectivity for both aryl and 
alkyl terminal alkynes is shown in Table 2.2.1. A number of trends emerge from this data. Overall, 
Taddol phosphoramidite ligands are more lactam selective than BINOL and BiAryl phosphoramidites. 
We see that the amine portion of the Taddol phosphoramidite affects product selectivity and 
enantioselectivity (entries 1-4). The smallest amine (pyrrolidyl) is vinylogous amide selective and is the 
most enantioselective. As the amine gets larger (N,N-dimethylamine, piperidyl, and N,N-dicyclohexyl), 
more lactam is generated and lower enantioselectivities is observed. This trend is repeated with various 
aryl substitutions (entries 5-9). With BINOL and biaryl phosphoramidites, the amine has less of an impact 
(entries 10-15). Finally, the electronics of the aryl substituent on the Taddol ligands affects product 
selectivity (entries 2, 5, 7, 8). The most electron-deficient ligand T7 favors vinylogous amide, and product 






Table 2.2.1. Structure activity relationship of phosphoramidites with terminal alkynes. 
B1
B2e
a Reaction conditions: 1 (2 equiv), 2, [Rh(C2H4)2Cl]2 (2.5 mol %), L (5 mol %) in PhMe at 110 °C for 16 h.
b Ratio determined by
1H NMR of crude reaction. c Combined isolated yield. d Determined by HPLC analysis on a chiral stationary phase. e Opposite
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1:12.5 77 37 55e
1:12 82 43 55e








1:3.6 53 32 95e
3d:4db yield (%)c ee (%) 3dd ee (%) 4dd
1:3.6 51 50 95e




















































1:6.5 84 91 95
1:5.6 84 96 97
1:1.6 75 94 949
T8
2.5:1 55 87 76
4.0:1 77 90 74
12.5:1 72 82 51
N
T9
6 1:2.8 68 87 85 8.3:1 68 83 46
























2.3 X-Ray Analysis of Rhodium(cod)Cl·Phosphoramidite Complexes 
 We also obtained crystal structures of some of our phosphoramidites complexed to rhodium. We 
chose to synthesize complexes using [Rh(cod)Cl]2 based on the existence of ligated cyclooctadiene 
rhodium complexes in literature.15 Additionally, we thought that complexes derived from [Rh(cod)Cl]2 
would be more stable than those generated from [Rh(C2H4)2Cl]2 because the bisethylene complex 
decomposes in air. In our first crystallization attempt, we mixed (+)-T9 with [Rh(cod)Cl]2 in 
dichloromethane, and this solution was layered with heptanes. The solution slowly evaporated to yield X-
ray quality crystals. After collecting data, we solved our first rhodium(I)(cod)chloride·phosphoramidite 
crystal structure: Rh(cod)Cl·T916 (Figure 2.3.1). After this initial success, we attempted to crystallize a 
range of phosphoramidite ligands bound to rhodium. This led to five more structures: Rh(cod)Cl·T8,17 
Rh(cod)Cl·T1,18 Rh(cod)Cl·T2,19 Rh(cod)Cl·A1,20 and Rh(cod)Cl·B4.21 Selected bond lengths and 
product selectivity for each ligand is shown in Figure 2.3.1. 
                                                            
15 For publications of rhodium and iridium phosphoramidite crystal structures see: (a) Bartels, B.; García-Yebra, C.; 
Rominger, F.; Helmchen, G. Eur. J. Inorg. Chem. 2002, 2569-2586. (b) Leitner, A.; Shekhar, S.; Pouy, M. J.; 
Hartwig, J. F. J. Am. Chem. Soc. 2005, 127, 15506-15514. (c) Faller, J. W.; Milheiro, S. C.; Parr, J. J. Organomet. 
Chem. 2006, 691, 4945-4955. (d) Giacomina, F.; Meetsma, A.; Panella, L.; Lefort, L.; de Vries, A. H. M.; de Vries, 
J. G. Angew. Chem. Int. Ed. 2007, 46, 1497-1500. (e) Mikhel, I. S.; Ruegger, H.; Butti, P.; Camponovo, F.; Huber, 
D.; Mezzetti, A. Organometallics 2008, 27, 2937-2948. (f) Filipuzzi, S.; Maennel, E.; Pregosin, P. S.; Albinati, A.; 
Rizzato, S.; Veiros, L. F. Organometallics 2008, 27, 4580-4588. 
16 Deposit number CCDC 739239. 
17 Deposit number CCDC 739238. 
18 Deposit number CCDC 739237. 
19 Deposit number CCDC 757562. For an additional structure, see: Oberg, K. M. ; Dalton, D. M.; Oinen, M. E.; 
Rovis, T. Private communication to the Cambridge Structural Database, deposit number CCDC 739236. 
20 Deposit number CCDC 739234. 





Figure 2.3.1. Crystal structures of Rh(cod)Cl·T9 and Rh(cod)Cl·A1, selected bond lengths from 
Rh(cod)Cl·L structures, and product selectivity for phenyl acetylene (1a) and 1-octyne (1d) using these 
ligands. 
 From this data, we see that rhodium-phosphorous bond length correlates with product selectivity. 
Longer Rh-P bonds correlate to more lactam 3 and shorter Rh-P bond lengths correlate to more 
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vinylogous amide 4 (Figure 2.3.2). This is also seen with phosphoramidites B4 and A1, but the trend is 
more clear in the Taddol series and is not complicated by large structural differences between the 
different ligand scaffolds. 
 
Figure 2.3.2. Correlation of Rh-P bond lengths with product selectivity with phenyl acetylene (1a) and 1-
octyne (1d). 
 We tested to see if these ligated rhodium complexes are catalytically competent and compared 
them to in situ generated catalysts (Table 2.3.1). Our general conditions utilize catalyst generated in situ 
by mixing [Rh(C2H4)2Cl]2 and the ligand (entry 1). The same reaction with [Rh(cod)Cl]2 as the precatalyst 
provides similar product selectivity and enantioselectivity but a lower yield (entry 2). This decrease in 
yield has been observed in previous precatalyst screens.22 We believe the improved performance with the 
bisethylene complex is due to the ease in which ethylene dissociates from rhodium and generates the 
active catalyst. When the preformed Rh(cod)Cl·T1 complex (even sitting on the bench under ambient air 
and temperature for a month) is used, the same result is obtained as the in situ generated catalyst from 
mixing [Rh(cod)Cl]2 and T1 (entry 3). 
 
                                                            
22 Yu, R. T. Enantioselective rhodium-catalyzed [2+2+2] and [4+2+2] cycloaddition reactions of alkenyl 




Table 2.3.1. Rh(cod)Cl·T1 exhibits similar reactivity to in situ formed catalyst. 
 
2.4 Model for Regioselectivity 
 The regioselectivity of the [2+2+2] cycloaddition of alkenyl isocyanate 2 and terminal alkynes 1 
is excellent (Eq 5). We observe 7-substituted lactam 3 and 5-substituted vinylogous amide 4, and the 
hydrogen is α to the carbonyl (6-H) (Eq 5). To date, we have never observed 6-substituted lactam 3' or 6-
substituted vinylogous amide 4' using a variety of terminal alkynes and phosphoramidite ligands. A 












































 During our examination of the Rh(cod)Cl·L structures, we noticed that one side of the rhodium 
square planar complex is sterically hindered (Figure 2.4.1). This steric hindrance is imposed by one of the 
Taddol aryl rings and the aryl ring of the BINOL/BiAryl complexes. We propose this hindrance biases the 
coordination of the isocyanate and alkyne23 so that the smaller substituents are facing the more hindered 
face of rhodium (Complex I, Figure 2.4.1). Although it is possible that the alkyne and the isocyanate 
                                                            
23 We believe the alkynes displace the ethylenes in the reaction before the isocyanate binds. This bis alkyne complex 
dissociates the alkyne trans to the phosphoramidite, as it has a larger trans influence than the chloride, and the 
isocyanate coordinates to generate complex I. 
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coordinate to rhodium parallel to the square plane,24 we believe they bind orthogonal to the square plane 
as depicted in Figure 2.4.1. This is based on X-ray structures of other d8 complexes and calculations.25 
This coordination minimizes steric repulsion between the π components and allows them to backbond to 
the metal.26 
 
Figure 2.4.1. Steric hindrance of one rhodium face by phosphoramidite ligand. 
                                                            
24 Imabayashi, T.; Fujiwara, Y.; Nakao, Y.; Sato, H.; Sakaki, S. Organometallics 2005, 24, 2129-2140. 
25 For crystal structures, see: (a) Davies, G. R.; Hewerston, W. H.; Maise, R. H. B.; Owston, P. G.; Patel, C. G. J. 
Chem. Soc. 1970, 1873. (b) Beauchamp, A. L.; Rochon, F. R.; Theophanides, T. Can. J. Chem. 1973, 51, 126. For 
computational analysis of alkyne coordination to Pd, see: (c) de Vaal, P.; Dedieu, A. J. Organomet. Chem. 1994, 
478, 121-129. For computational analysis of alkyne coordination to Co, see: (d) Wakatsuki, Y.; Nomura, I.; Kitaura, 
K.; Morokuma, K.; Yamazaki, H. J. Am. Chem. Soc. 1983, 105, 1907-1912. 
26 Dewar-Chatt-Duncanson model, see: (a) Hartwig, J. Organotransition Metal Chemistry: From Bonding to 
Catalysis; University Science Books: Sausalito, California, 2010. (b) Dewar, M. J. S. Bull. Soc. Chim. Fr. 1951, 18, 
79. (c) Chatt, J.; Duncanson, L. A. J. Chem. Soc. 1953, 2939. 
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 From coordination complex I, cyclization can occur in a concerted, conrotatory fashion in one of 
two ways producing either of the two products (Figure 2.4.2). If the smaller substituents of the two π 
components fold away from the metal, via TSI, rhodacycle II is formed. From here, alkene migratory 
insertion and reductive elimination furnishes 7-subsituted lactam 3 with the proton α to the carbonyl. 
Alternatively, if the smaller substituents fold toward the metal, via TSII, rhodacycle IV is generated. 
After the CO shift, rhodacycle VI is made and the proton is now α to the carbonyl. Olefin insertion and 
reductive elimination forms 5-substituted vinylogous amide 4. This model is based on the assumption that 
oxidative cyclization is an irreversible, concerted process.27 
 
Figure 2.4.2. Regioselectivity model. Small substituents face more hindered face in coordination complex 
I due to the large phosphoramidite ligand. Concerted cyclization relays regiochemistry from complex I. 
2.5 Model for Product Selectivity 
 We have seen that product selectivity in this reaction correlates with a number of factors: alkyne 
sterics, alkyne electronics, and phosphorous-rhodium bond lengths. In developing a model to explain 
                                                            
27 (a) For calculations on the concerted nature of oxidative cyclization, see: Wakatsuki, Y.; Nomura, I.; Kitaura, K.; 
Morokuma, K.; Yamazaki, H. J. Am. Chem. Soc. 1983, 105, 1907-1912. (b) For experiments on the irreversibility of 
oxidative cyclization of alkynes and isocyanates, see: Eq 2 and 3  reproduced from  Lee, E. E. Colorado State 
University, Fort Collins, CO. Unpublished work, 2007 and Dalton, D. M.; Oberg, K. M.; Yu, R. T.; Lee, E. E.; 
Perreault, S.; Oinen, M. E.; Pease, M. L.; Malik, G.; Rovis, T. J. Am. Chem. Soc. 2009, 131, 15717-15728.  
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product selectivity, we looked at previous models in the literature that explain product selectivity in 
cycloadditions. The first model explored is an electronic model put forth by Stockis and Hoffmann. The 
second theory is a steric model developed by Wakatsuki and Yamazaki. A strict application of either 
model fails to explain product selectivity in the [2+2+2] cycloaddition of alkenyl isocyanates and alkynes, 
but a model for product selectivity taking into account both electronic and steric contributions does a 
credible job at describing the factors that contribute to product selectivity. 
 Stockis and Hoffmann performed computations on metallacycle formation and concluded that 
orbital overlap between the metal and π components induce the observed regioselectivity.28 The model 
system that they explored was the cyclization of a d8 iron complex with ethylene. They polarized the 
olefins in their computations and determined which bis-olefin metal complex was the most stable during 
metallacycle formation. They found that complex A is lower in energy during and after metallacyle 
formation.29 Complex A is lower in energy because the π* of the bound olefins stabilizes the metal dxy 
orbital during metallacycle formation. This means the largest LUMO coefficient of the π bond prefers to 
be β to the metal and translates to carbons with electron-withdawing groups or more electronegative 
heteroatoms prefering to be α to the metal in the metallacyle. The authors note that this model does not 
apply to metallacycle formation that is reversible, and sterics were not considered in their computations. 
During these calculations, they found that unsymmetrical complex B is intermediate in energy between 
complexes A and C. This suggests that the stabilization effects from the π components during oxidative 




28 Stockis, A.; Hoffmann, R. J. Am. Chem. Soc. 1980, 102, 2952-2962. 
29 Complex C is initially lower in energy, but is higher in energy than complexes A and B during and after 
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Figure 2.5.1. Stockis-Hoffmann model for regioselectivity in metallacycle formation. The largest LUMO 
coefficients of the π components prefer to be β to the metal during oxidative cyclization. 
 Before we apply the Stockis-Hoffmann electronic model to the cyclization of alkenyl isocyanates 
and alkynes, a discussion of the isocyanate LUMO and reactivity is warranted. The largest LUMO 
coefficient of the isocyanate is across the C=O double bond (with a small contribution from the C=N 
double bond), but the largest N-LUMO coefficient is across the C=N double bond (with a small 
contribution from the C=O double bond).30 These two energies are almost degenerate. In metal-catalyzed 
cycloadditions with isocyanates, the C=N bond is typically the reactive bond rather than the C=O bond. 
This is presumably due to bond strength; the bond strength of a C=N double bond is ~60 kcal/mol 
whereas the bond strength of a C=O double bond is ~87 kcal/mol.31 Metal-catalyzed cycloadditions with 
isothiocyanates are opposite in that the C=S double bond typically reacts (bond strength of C=S double 
bond is ~58 kcal/mol). In crystal structures of group VIIIB transition metals with isocyanates or 
                                                            
30 Houk, K. N.; Strozier, R. W.; Hall, J. A. Tetrahedron Lett.1974, 11, 897-900. 
31 BDE were calculated by subtracting the BDE value of a single bond from the BDE of a double bond to give an 
approximate BDE of the double bond. Values from: Luo, Y.-R. Comprehensive Handbook of Chemical Bond 
Energies; CRC Press, Taylor & Francis Group, LLC: Boca Raton, Florida, 2007. O=CH2: 180.6 kcal/mol, HO-C2H5: 
93.5 kcal/mol; •N=CH2: 144 kcal/mol, HN-C2H5: 84.2 kcal/mol; S=CH2: 131.2 kcal/mol, HS-C2H5: 73.6 kcal/mol; 
O=CNCH3: 133 kcal/mol, HN=CO: 122 and 86.6 kcal/mol. Despite the use of an imine radical, this crude 
approximation matches more complex systems (58-66.8 kcal/mol), see; Zhu, X.-Q.; Liu, Q.-Y.; Chen, Q.; Mei, L.-R. 
J. Org. Chem. 2010, 75, 789-808. 
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isothiocycanates bound, C=N binding is more metallacyclopropane-like in isocyanate bound complexes32 
and the C=S binding is more metallacyclopropane-like in isothiocyanate bound structures.33 This binding 
mirrors reactivity in metal-catalyzed cycloadditions with isothiocyanates; typically sulfur-heterocycles are 
generated through reaction of the C=S bond.34 
 
Figure 2.5.2. Reactivity of heterocumulenes with metals: nearly degenerate isocyanate LUMO and N-
LUMO, weakness of N=C bond relative to C=O bond explains chemoselectivity, and metal-
heterocumulene binding mirrors reactivity. 
 A strict application of the Stockis-Hoffmann electronic model to the cyclization of alkenyl 
isocyanates and alkynes does not always predict the correct product (Figure 2.5.2). The largest LUMO 
coefficient is on the carbon of isocyanates, on the internal carbon of alkyl and electron-donating aryl 
alkynes, and on the terminal carbon of electron-withdrawing aryl alkynes. For the cyclization of alkyl 
alkynes with isocyanates, we see that this model predicts 6-subsituted lactam 3'. This is the observed 
product but the incorrect regioisomer. The same product is expected for the reaction of electron-donating 
aryl alkynes and isocyanates. This is both the incorrect product and the incorrect regioisomer. 7-
                                                            
32 For metal-isocyanate crystal structures, see: Cobalt; (a) Klein, H. F.; Helwig, M.; Karnop, M.; Koenig, H.; 
Hammerschmitt, B.; Cordier, G.; Floerke, U.; Haupt, H. J. Z. Naturforsch., B: Chem Sci. 1993, 48, 785. Nickel; (b) 
Mindiola, D. J.; Hillhouse, G. L. Chem. Commun. 2002, 1840-1841. 
33 For metal-isothiocyanate crystal structures, see: Nickel; (a) Bianchini, C.; Masi, D.; Mealli, C.; Meli, A. J. 
Organomet. Chem. 1983, 247, C29-C31. Nickel and cobalt; (b) Bianchini, C.; Masi, D.; Mealli, C.; Meli, A. Inorg. 
Chem. 1984, 23, 2838-2844. Osmium; (c) Flugel, R.; Gevert, O.; Werner, H. Chem. Ber. 1996, 129, 405. 
34 For examples of isothiocyanate cycloadditions, see:  (a) Yamazaki, H. J. Synth. Org. Chem., Jpn. 1987, 45, 244-
257. (b) Yamamoto, Y.; Kinpara, K.; Saigoku, T.; Takagishi, H.; Okuda, S.; Nishiyama, H.; Itoh, K. J. Am. Chem. 
Soc. 2005, 127, 605-613. (c) Tanaka, K.; Wada, A.; Noguchi, K. Org. Lett. 2006, 8, 907-909. 
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Substituted lactam 3 is predicted for the reaction of electron-withdrawing aryl alkynes and isocyanates. 
This is both the observed product and correct regioisomer. Although this model does not predict the 
correct product with every class of alkyne, it predicts the correct product with electron-withdrawing aryl 
alkynes. Most importantly, it suggests that the isocyanate LUMO always selects for a lactam 
metallacycle. 
 
Figure 2.5.2. Strict application of Stockis-Hoffmann model to [2+2+2] cycloaddition of alkenyl 
isocyanates and alkynes does not always predict observed product. 
 As the electronic model of Stockis and Hoffmann does not always predict the correct product and 
regiochemistry, we reasoned that sterics needed to considered. Indeed, we have seen an influence of 
sterics on product selectivity (Table 2.1.1). We are certainly not the first to consider the effect of sterics 
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on cycloadditions; Wakatsuki and Yamazaki also noted that application of the Stockis-Hoffmann model 
to cobaltacyclopentadiene formation did not predict the observed product (Figure 2.5.3). Based on 
computations and comparisons to experimental results, they established a steric model to explain their 
observed product selectivity.35 Based on their computations, they found that cobaltacyclopentadiene 
formation occurs from a coordination complex where the two π components are aligned orthogonal to the 
cobalt square plane. From the more stable coordination complex XIII, where the small and large 
substituents of the π components are opposite to one another, cyclization leads to the major isomer 10 
they observe. This cyclization goes through a transition state, TSIII, where the steric interaction of the 
alkynes is minimized. If coordination of the π components occurs with the two small substituents on the 
same side, higher energy coordination complex XIII' is generated. Cyclization can proceed with the 
smaller substituents folding away from the metal (TSIV) or towards the metal (TSV). Of these two 
transition states, they calculated that TSIV is the lower in energy because there is less alkyne-alkyne 
steric interaction than in TSV. This model based on the sterics of the π components during coordination 
and cyclization successfully explains their experimental results. 
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Small and large substituents opposite
Little steric interaction during cyclization
Corresponds to major isomer
Small substituents on same side
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Small substituents on same side
Large steric interaction during cyclization














Figure 2.5.3. Wakatsuki and Yamazaki steric model for selectivity. Steric interactions during coordination 
(XIII vs XIII') and cyclization (TSIV vs TSV) predicts major and minor isomers. 
 When Wakatsuki and Yamazaki's steric model for selectivity is applied to the cyclization of 
alkenyl isocyanates and alkynes, we see that it does not predict the observed products. In our case, we can 
envision two rhodium coordination complexes. Coordination complex I', where the large groups of the π 
components are opposite one another, corresponds to cobalt complex XIII. From complex I', conrotatory 
cyclization can occur in two ways. Rotation of the isocyanate oxygen and large alkyne substituent away 
from the metal produces metallacycle II' that generates lactam 3'. Cyclization in the other direction leads 
to metallacycle VI' that generates vinylogous amide 4'. Coordination complex I, where the two larger 
substituents are on the same side, corresponds to cobalt complex XIII'. Cyclization of the two smaller 
substiuents away from the metal produces metallacyle II corresponding to lactam 3. Alternatively, 
cyclization the other direction leads to metallacyle VI that produces vinylogous amide 4. According to 
Wakatsuki and Yamazaki's model, we should see three products; lactam 3', vinylogous amide 4', and 
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lactam 3. The major products are predicted to be lactam 3' and vinylogous amide 4', as these are from the 
presumably more stable coordination complex I'. The minor product is predicted to be lactam 3 that is 
derived from minor coordination complex I.  Vinylogous amide 4 should not be observed due to steric 
interactions between the alkyne and isocyanate during cyclization (Figure 2.5.3, TSV). As the observed 
products are lactam 3 and vinylgous amide 4, we see that a strict application of the Wakatsuki-Yamazaki 











































































































Wakatsuki-Yamazaki Steric Model for Selectivity
Coordination complex with large groups opposite




Figure 2.5.4. Strict application of Wakatsuki-Yamazaki does not correctly predict product selectivity for 
[2+2+2] cylcloadditions of alkenyl isocyanates and alkynes. 
 By looking at electronic and steric models in isolation to predict product selectivity, we find that 
neither explains product selectivity alone. However, a combination of both models that accounts for both 
electronics and sterics does a remarkably good job at predicting product selectivity and explaining many 
of the trends observed in the [2+2+2] cycloaddition of alkenyl isocyanates and alkynes (Figure 2.5.5) In 
this revised model, we believe the alkyne and isocyanate bind to generate coordination complex I based 
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on our rhodium·phosphoramidite crystal structures (Figure 2.4.1).  Cyclization of the two smaller 
substituents away from the metal generates rhodacycle II via TSI, whereas cyclization of the smaller 
substituents towards rhodium generates rhodacycle IV via TSII. Based on the previous models, we can 
lay out the factors that stabilize or destabilize each transition state.  
 For lactam 3 formation, initial cyclization goes through TSI. The isocyanate LUMO always 
selects for TSI, because the largest LUMO coefficient of the isocyanate is β to the metal. Without 
opposition, this constant electronic preference by the isocyanate would dictate product selectivity and 
only lactam 3 would be generated. This basal electronic selectivity is reinforced by alkynes that have 
electron-withdrawing groups, such as electron-deficient aryl alkynes, because the largest LUMO 
coefficient of the alkyne is also β to the metal. Due to the large size of phosphoramidite ligands, we 
propose there is steric interaction between the alkyne and ligand during oxidative cyclization that 
destabilizes TSI. 
 Cyclization through TSII leads to vinylogous amide 4 formation. This transition state is 
stabilized by alkynes that have electron-donating groups, such as electron-rich aryl alkynes, because the 
largest LUMO coefficient of the alkyne is β to the metal. This transition state also relieves the 
ligand/alkyne steric interactions that destabilize TSI. These stabilizing effects override the inherent 
selectivity imposed by the isocyanate LUMO, and, as shown by Stockis and Hoffmann (Figure 2.5.1), the 




Figure 2.5.5. Transition states for lactam and vinylogous amide products and the factors favoring and 
destabilizing each. Isocyanate LUMO always selects for TSI that generates lactam. Ligand/alkyne steric 
interactions disfavor TSI and therefore select for TSII that generates vinylogous amide. Alkyne 
electronics can favor either transition state and modulate selectivity. 
 This combined steric and electronic model lays out the factors that control product selectivity and 
takes into account the observed trends in the cycloaddition of alkenyl isocyanates and terminal alkynes. 
We have seen that longer Rh-P bond lengths lead to more lactam 3, whereas shorter Rh-P bond lengths 
generate more vinylogous amide 4 (Figure 2.3.2). We believe that longer Rh-P bond lengths reduce the 
steric interaction between the alkyne and ligand in TSI. This makes the reaction more lactam selective. 
Alternatively, shorter Rh-P bond lengths exacerbate the steric interaction between the alkyne and ligand 
to the point where the electronic selectivity of the isocyanate is overridden, and the reaction goes through 
TSII leading to vinylogous amide. This same steric effect is seen when the size of the alkyne is changed 
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(Figure 2.1.1); smaller alkynes are more lactam selective and larger alkynes are more vinylogous amide 
selective. We have also seen a dependable negative Hammett correlation with alkyne electronics when the 
size of the alkyne remains fairly constant (Figure 2.1.3). Electron-deficient aryl alkynes electronically 
stabilize TSI, electron-rich aryl alkynes electronically stabilize TSII, and the other alkynes fall in 
between these two extremes. This steric and electronic model does a good job of explaining these trends. 
 This steric/electronic model also takes into account the electronics of the metal (Figure 2.5.6). If 
the rhodium HOMO is raised, there is better overlap between the rhodium HOMO and the isocyanate 
LUMO. This stabilizes TSI leading to lactam 3. The rhodium HOMO is raised by electron-rich 
phosphoramidite ligands and more donating counterions. The opposite effect is seen if the rhodium 
HOMO is lowered. There is less overlap between the rhodium HOMO and the isocyanate LUMO; this 
decreases the isocyanate's electronic stabilization of TSI. This decrease in electronic stabilization of TSI 
makes steric interactions more important, and the reaction is more vinylogous amide 4 selective. It is 
difficult to decouple the steric and electronic effects of the phosphoramidite ligand, as more electron-
deficient ligands lower the rhodium HOMO and shorten the Rh-P bond length. Some experiments by Dr. 
Catherine Smyth, where she looked at the effects of counterions, shed some light onto the metal 
electronics.36 We see that iodide and bromide lead to more lactam formation (entries 1, 2), whereas the 
more electron-withdrawing cyanide leads to more vinylogous amide formation (entry 5).37 Although we 
cannot exclude sterics completely, we see that changing the metal electronics changes product selectivity, 
and this is accounted for by this combined steric/electronic model. 
                                                            
36 Dr. Catherine Smyth. Colorado State University, Fort Collins, CO. Unpublished work, 2009. 
37 For review on halide influence on metal catalysis, see: (a) Fagnou, K.; Lautens, M. Angew. Chem. Int. Ed. 2002, 
41, 26-47. For the spectroscopic series, see (b) Tsuchida, R. Bull. Chem. Soc. Jpn. 1938, 13, 388-400. (c) Miessler, 




Figure 2.5.6. Influence of metal electronics on product selectivity. 
 This steric/electronic model has led to the rational design of a new ligand (T10) that supports the 
conclusions of this model (Eq 3).38 Due to its electron-deficient nature, T10 displays a short Rh-P bond 
length and is very selective for vinylogous amide. 
 
 This model provides an excellent framework to rationalize regio- and product selectivity for 
rhodium-catalyzed [2+2+2] cyclizations of alkenyl isocyanates and terminal alkynes. When this model is 
                                                            
38 (a) Dalton, D. M.; Rappé, A. K.; Rovis, T. Chem. Sci. 2013, 4, 2062-2070. (b) Dalton, D. M.; Rovis, T. Org. Lett. 
2013, 15, 2346-2349. 
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applied to similar systems (pyridone formation, internal alkynes, and alkenyl carbodiimides), the results 
are more ambiguous. 
 For pyridone formation, we propose the mechanism shown below (Figure 2.5.7). The facets of the 
mechanism that we hope to address through application of this model is product regioselectiviy (4,6-
substituted 2-pyridones 5 and 2,6-substituted 4-pyridones 6), influence of alkyne electronics on yield, and 
isocyanate electronic influence on yield. We propose that both 2-pyridone 5 and 4-pyridone 6 are 
generated from rhodacycle IV rather than rhodacycle II (Chapter 1.6). Product regioselectivity can be 
explained by coordination complex I and irreversible, conrotatary cyclization. From rhodacycle IV, 
insertion of an alkyne39 and reductive elimination generates 4,6-substituted 2-pyridone 5. Rhodacycle VI 
is generated from a CO migration from rhodacycle IV; insertion of an alkyne and reductive elimination 
furnishes 2,6-substituted 4-pyridone 6. This regioselectivity is the same as lactam 3 and vinylogous amide 
4. Unsurprisingly, the nature of the alkyne influences yield. If products are generated from rhodacycle IV, 
then alkynes that favor TSII (large alkynes and electron-rich aryl alkynes) should generate more product. 
Indeed, we have seen that yields are higher with these alkynes (Table 1.5.1) and yield tracks well with 
vinylogous amide selectivity (Figure 1.6.1). Based on this model, we predict that more electron-deficient 
isocyanates should favor TSI due to better overlap between the isocyanate LUMO and rhodium HOMO. 
This should give lower yields as TSI leads to rhodacycle II, and alkynes that favor lactam are not high 
yielding for pyridones. Contradictory to this prediction, we observe that electron-deficient aryl 
isocyanates are just as high yielding as electron-rich aryl isocyanates (Table 1.5.3). In fact, they are more 
selective for 4-pyridone 6 that is generated from rhodacycle VI (itself derived from rhodacycle IV). 
Although product yields based on isocyanate electronics are not fully explained by this steric/electronic 
model, regioselectivity and yields based on alkyne electronics are what we predict. 
                                                            
39 The second alkyne insertion is difficult to rationalize. First, π component insertions into metal-nitrogen bonds  is 
not well studied, therefore it is difficult to predict where the alkyne inserts in rhodacycle II or VI. The factors 
determining the regiochemistry depend on where the alkyne inserts. For example, insertion into the Rh-N bond of 





Figure 2.5.7. Coordination complex I explains product regioselectivity. Alkyne electronic factors favoring 
TSII give higher yields as expected, but isocyanate electronic factors favoring TSI give unexpectedly 
high yields. 
 Application of this steric/electronic model to internal alkynes is not perfect (Figures 2.5.8 and 
2.5.9). With symmetrical alkynes, we predict that metallacycle formation should be dictated by the 
electronics of the isocyanate alone, as the electronics and sterics of the alkyne are equal (Figure 2.5.8). 
The isocyanate LUMO should always select for lactam 3 via TSI. We see internal alkyl alkynes are 




40 (a) Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 2782-2783. (b) Oinen, M. E.; Yu, R. T.; Rovis, T. Org. Lett. 




Figure 2.5.8. Symmetrical alkynes have no steric or electronic bias so isocyanate should dictate product 
selectivity. Internal alkyl alkynes produce lactam 3 as expected, but internal aryl alkynes produce 
vinylogous amide 4. 
 Internal, unsymmetrical alkynes participate in the [2+2+2] cycloaddition in a regioselective 
fashion.41 The predicted rhodacycle from this model matches the probable rhodacycle in most cases, but 
some substrates give a different regioisomer than predicted (Figure 2.5.9). For methyl phenyl propionate 
1e, we predict rhodacycle IVe will be formed. This is because the smaller substitutents, isocyanate 
carbonyl and alkyne ester, are syn as predicted from coordination complex I and rhodacycle IVe is 
stabilized by the largest alkyne LUMO coefficient β to the metal. This rhodacycle corresponds to 
vinylogous amide 4e as the product and this is the observed product when this substrate is used. For 2-
methoxyethynylbenzene 1f, the predicted regioisomer 4f does not match the observed regioisomer 4f'. 
We predict rhodacycle IVf will formed as the alkyne ethoxy group and isocyanate should be syn in 
coordination complex I based on size.42 This produces vinylogous amide 4f with the smaller ethoxy 
substitution α to the carbonyl group. When alkyne 1f is subjected to the reaction, the observed product is 
vinylogous amide 4f', where the smaller ethoxy substituent is β to the carbonyl. Although not predicted, 
rhodacycle IVf' is stabilized by the electron-donating group β to the metal. This demonstrates that this 
                                                            
41 Friedman, R. K.; Rovis, T. J. Am. Chem. Soc. 2009, 131, 10775-10782. 
42 For A values, see: (a) Anslyn, E. V.; Dougherty, D. A. Modern Physical Organic Chemistry. University Science 
Books, Sausalito, California, 2006. For cone values (°), see: (b) Tolman, C. A. Chem. Rev. 1977, 77, 313-348. (c) 
Wakatsuki, Y.; Nomura, I.; Kitaura, K.; Morokuma, K.; Yamazaki, H. J. Am. Chem. Soc. 1983, 105, 1907-1912. 
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steric/electronic model does not always predict the correct product. In this case electronic factors, as 
described by Stockis and Hoffmann, might be more important. 
 
Figure 2.5.9. A combined steric/electronic model predicts the correct product for some internal, 
unsymmetrical alkynes, but not all. 
 In an extension of this work, Dr. Yu reported the rhodium-catalyzed [2+2+2] cycloaddition of 
alkenyl carbodiimides 12 and terminal alkynes (Figure 2.5.10).43 In this work, alkenyl carbodiimides are 
selective for lactam type products, bicyclic amidines 13. Since the same rhodium·phosphoramidite 
catalyst system is employed, we should be able to apply our model for regio- and product selectivity. If 
we assume that the N-aryl substituent is larger than the N-alkyl substitutent, we expect coordination  
complex I' to predominate over complex I. Contrary to our expectation, exclusive formation of bicyclic 
products, 13b and 14b, is observed, corresponding to products derived from coordination complex I. This 
correlates to the same regiochemistry observed in the cycloaddition of alkyenyl isocyanates and alkynes 
(3b and 4b). If we presume that the carbodiimide binds in the same fashion as the isocyanate and 
generates complex I, a new steric interaction between the N-aryl imine and ligand is introduced. This 
interaction will destabilize TSII, thus TSI will be favored and bicyclic amidines 13 will be generated in 
                                                            
43 Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2008, 130, 3262-3263. 
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higher yields. As this steric component has such a large effect on product selectivity, it is surprising that 
only a single regioisomer of product is formed in the reaction. 
 
Figure 2.5.10. Use of alkenyl carbodiimides 12 is selective for lactam-like bicyclic amidines 13. 
Assuming that N-aryl is larger than N-alkyl, mixtures of regioisomeric products should be observed. 
Alkenyl carbodiimides introduce new N-aryl/ligand interaction that destabilizes TSII leading to more 
amidine 13. 
 Application of this steric/electronic model to pyridone synthesis, internal alkynes, and alkenyl 
carbodiimides demonstrates that this model does not explain similar reactions using the 
rhodium·phosphoramidite catalyst with perfect accuracy. Despite these deficiencies, a logical framework 
to explain product selectivity and regioselectivity has been developed for alkenyl isocyanates and 
terminal alkynes. This has led to the development of a new ligand, T10, that is very selective for 
vinylogous amide 4. It must also be kept in mind that small changes in substrate can cause a change in 
mechanism, and different mechanisms in these other cases have not been ruled out. 
58 
 
2.6 Model for Enantioselectivity 
 We attempted to explain the enantioselectivity of the reaction using the 
rhodium(cod)Cl·phosphoramidite crystal structures and the steric/electronic model (Figure 2.6.1). We 
believe our explanation of lactam 3 stereoinduction is reasonable, but a satisfying explanation for 
vinylogous amide 4 stereoinduction is still elusive. To predict the correct enantiomer, we must keep three 
things in mind: for migratory insertion, the alkene must be syn-coplanar to the Rh-N bond, one face of the 
rhodium is hindered by the ligand, and facial selectivity of the alkene is imposed by the tether. 
 In rhodacycle II leading to lactam 3, alkene coordination in complexes IIa and IIb are disfavored 
because the phosphoramidite ligand blocks this face. Complex IIa is further disfavored because the 
alkenyl isocyanate must adopt a high energy twist-boat conformation to coordinate. If coordination to this 
face is possible, it will be complex IIb, in which the alkenyl isocyanate adopts a chair conformation. 
Complex IIb leads to the minor lactam enantiomer. Based on the facial selectivity imparted by the ligand, 
alkene coordination to rhodium will be favored on the unhindered side and this generates complexes IIc 
and IId. Complex IIc is disfavored due to the twist chair conformation that needs to be adopted for alkene 
coordination. The major coordination complex predicted is complex IId, as it is in a chair conformation, 
and this complex leads to the major enantiomer of lactam.  
 Unlike lactam 3 enantioinduction, a model for vinylogous amide 4 enantioselectivity is much 
more speculative, as there are probably multiple rearrangements of unobservable Rh(III) intermediates. 
From rhodacycle IV, CO migration probably occurs by amide bond cleavage and amine migration to the 
open coordination site to generate complex V.44 If the alkenyl carbon migrates to the CO without further 
rearrangement, complex VIa is generated. Migratory insertion of the alkene from this complex leads to 
the minor enantiomer. Alternatively, from complex V, CO migration onto the alkenyl carbon generates 
complex VIb. Migratory insertion of the alkene in this complex leads to the major enantiomer, but such a 
                                                            
44 For selected CO migration references on rhodium(I) species, see: (a) Cavallo, L.; Sola, M. J. Am. Chem. Soc. 
2001, 123, 12294-12302. (b) Gonsalvi, L.; Adams, H.; Sunley, G. J.; Ditzel, E.; Haynes, A. J. Am. Chem. Soc. 2002, 
124, 13597-13612. (c) Gonsalvi, L. Organometallics 2003, 22, 1047-1054. 
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CO migration is unprecedented. Mark Oinen has demonstrated that additives can influence vinylogous 
amide enantioselectivity in the [2+2+2] cycloaddition of alkenyl isocyanates and symmetrical internal 
alkynes.45 This suggests the rearrangement(s) from complex IV to complex VI, where the alkene can 
coordinate, is not straightforward. Due to the probability of multiple rearrangements, we cannot explain 
the correct vinylogous amide enantiomer. The difficulty of predicting the correct vinylogous amide 
enantiomer is further complicated by the fact that Taddol and Binol ligands provide the opposite major 
enantiomer for vinylogous amide, but both deliver the same major enantiomer for lactam. 
 
Figure 2.6.1. Major lactam 3 enantiomer derived from complex IId, where alkene coordinates to 
unhindered rhodium face in a chair conformation. Major vinylogous amide 4 enantiomer difficult to 
                                                            
45 Oinen, M. E.; Yu, R. T.; Rovis, T. Org. Lett. 2009, 11, 4934-4937. 
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predict due to multiple rearrangements of rhodium (III) complexes and lack of precedent for CO 
migration to alkenyl carbon.  
2.7 Reaction Scalability46 
 In addition to a model that explains the trends in our work on the cycloaddition of alkenyl 
isocyanates and alkynes, we sought to demonstrate the practicality of the reaction on larger scale. This 
was realized through the development of a facile, scalable synthesis of phosphoramidite T2, a large scale 
preparation of alkenyl isocyanate 2, and a [2+2+2] cycloaddition delivering over 5 grams of 
indolizidinone 4g.  
 We have found one of the difficulties in making phosphoramidite ligands is the final conversion 
of the diol to the phosphoramidite (Eq 4), because it will often be contaminated with oxidized 
phosphoramidite. Traditionally, we purified our ligands using column chromatography, but we wanted to 
eliminate this procedure as partially oxidized ligand is occasionally observed. In our efforts to make a 
scalable synthesis of phosphoramidite T2, we initially tried to purify the ligand using an acidic workup, 
but this leads to oxidized ligand.47 This sensitivity to acid explains why purification using silica leads to 
partial oxidation. Our final procedure uses deionized water because the aqueous wash removes most of 
the phosphorous byproducts.48 We sought to use recrystallization as our purification method and settled 
on ethyl acetate as the crystallization solvent (other solvents may be used, such as toluene). This leads to a 
facile preparation of pure ligand T2 from diol 15 (Eq 4). Application of this procedure to other ligands 
generates mixed results. For example, ligands rac-A1 and T9 are reluctant to crystallize, but ligands T1 
and T8 have been successfully synthesized using this procedure. One thing to note is that use of an 
impure diol (indicated by its appearance as a yellow goo or solid instead of a white solid) for ligand 
                                                            
46 Oberg, K. M.; Martin, T. J.; Oinen, M. E.; Dalton, D. M.; Friedman, R. K.; Neely, J. M.; Rovis, T. Org. Synth. 
Submitted. 
47 31P NMR shows only product before a 1M HCl wash and then a 1:1 mixture of ligand:oxidized ligand after 
washing. 
48 31P NMR initially shows desired product with 5-7 minor peaks and only product after washing. 
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preparation makes this procedure less likely to succeed. If impure diol is used, column chromatography 
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 Preparation of  alkenyl isocyanate 2 on large scale is a difficult endeavor. There are many ways to 
make isocyanates,49 but our preferred method employs the Curtius rearrangement.  We have traditionally 
synthesized alkenyl isocyanates in one of two ways: conversion of the acyl azide to the isocyanate under 
reduced pressure50 and column chromatography of the acyl azide followed by neat conversion of the acyl 
azide to the isocyanate.51 These methods work well for small scale, but on larger scale, these approaches 
can potentially be dangerous if proper precautions are not observed. Our original large scale approach is 
based on work by Dr. Ernest Lee. After generation of the acyl azide from the carboxylic acid using 
diphenylphosphoryl azide (DPPA), it can be purified via flash column chromatography and then gently 
converted to the product (Eq 5). Care must be taken during this procedure! The exothermic conversion 
from acyl azide to isocyanate happens with heat, releasing nitrogen gas and is therefore autocatalytic. If 
the acyl azide is purified using column chromatography, the column must be slurry packed and flushed 
with a lot of solvent to prevent warming of the column. If the column warms with solvent addition, 
premature conversion of large amounts of acyl azide to isocyanate can cause an explosion. When less 
than 1.5-2 grams of alkyl azide is isolated, the conversion can be done overnight neat (or overnight with 
gentle heating <35 °C). If larger amounts (up to 10 g) are isolated after chromatography, the acyl azide 
needs to be diluted with solvent before the conversion is attempted. We also developed another approach 
                                                            
49 Ozaki, S. Chem. Rev. 1972, 72, 457-496. 
50 Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 2782-2783. 
51 Lee, E. E.; Rovis, T. Org. Lett. 2008, 10, 6, 1231-1234. 
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that avoids column chromatography and handling of the neat acyl azide altogether (Eq 6). We 
investigated a number of bases in order to make isolation of the alkenyl isocyanate easier. Use of 
inorganic bases leads to insoluble salts that do not completely convert to the acyl azide. Lighter amine 
bases distill over with the target isocyanate, so we chose 1,8-diazabicylcoundec-7-ene (DBU) because it is 
able to convert the acid to the acyl azide but it does not co-distill with the target isocyanate. The hexanes 
extraction removes most of the DPPA salts and dilutes the acyl azide so that conversion can be done in a 
controlled fashion at 50 °C. After conversion, a distillation delivers pure isocyanate without purification 
via flash column chromatography or handling of the neat acyl azide. 















1H: 3.32 (t, 2H)
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 The scale up the [2+2+2] cycloaddition reaction is straightforward, but isolation is more difficult 
(Eq 7). The catalyst loading can be dropped from the typical 5-10 mol % catalyst loading to 1 mol % 
without affecting yield or enantioselectivity, but the reaction takes longer (36 h vs 12 h). We attempted to 
work up the reaction and perform a recrystallization of the product from the crude or worked up reaction. 
Despite numerous washes, such as NH4Cl, NH4OH, Na2SO3, or para-toluenesulfonic acid, we could not 
get a solid that would crystallize. Thus, we purify the reaction via flash column chromatography and 
isolate the vinylogous amide 4g in good yield and enantioselectivity.52 This light brown solid can be 
recrystallized from EtOAc to increase the enantiopurity and remove some of the color.  
                                                            






 We have developed a steric/electronic model that explains regio- and product selectivity for the 
rhodium-catalyzed [2+2+2] cycloaddition of alkenyl isocyanates and terminal alkynes (Figure 2.8.1). This 
model is based on previous models developed by Stockis and Hoffmann (electronics) and Wakatsuki and 
Yamazaki (sterics). This model explains the observed regiochemistry and the product selectivity trends 
based on Rh-P bond lengths, alkyne sterics, and alkyne electronics. In summary, we believe that 
regioselectivity is imposed by the ligand that blocks one face of the rhodium center forcing the π 
components to bind with the smaller substituents facing towards the steric hinderance (coordination 
complex I). Conrotatory cyclization in one direction produces lactam 3, and cyclization in the opposite 
direction produces vinylogous amide 4. In both cases, the original binding in complex I leads to the 
exquisite regiocontrol. Cyclization to either  rhodacycle II or IV depends on the steric and electronic 




Figure 2.8.1. Model for regio- and product selectivity in the rhodium-catalyzed [2+2+2] cycloaddition of 
alkenyl isocyanates and alkynes. Coordination complex I dicatates regioselectivity of lactam 3 and 
vinylogous amide 4 products. Electronic and steric factors determine with transition state is more stable 
and therefore product selectivity. 
 Additionally, we have developed a scalable synthesis of phosphoramidite T2 that avoids column 
chromatography, developed a synthesis of alkenyl isocyanate 2 that avoids column chromatography or 
neat handling of the intermediate acyl azide, and demonstrated the scalability of the [2+2+2] 









Enantioselective Rhodium-Catalyzed [4+2] Cycloaddition of α,β-Unsaturated Imines and Isocyanates1 
3.1 Introduction 
 The Rovis group has a long standing interest in the construction of nitrogen heterocycles, and we 
sought to expand our repertoire of reactions. We were inspired by Hoberg's report, where he demonstrated 
that an imine 1 and isocyanate 2 form a metallacyle (I) in the presence of nickel cyclooctadiene and 
tetramethyl ethylene diamine (TMEDA) (Eq 1).2 We envisioned that replacing the imine with an α,β-
unsaturated imine 3 would result in a formal [4+2] cycloaddition, via I, to make dihydropyrimidinones 4 
(Eq 2). 
 
 Interest in pyrimidinones3 stems from their biological activity and modular synthesis via the 
Biginelli reaction (Figure 3.1.1). Pyrimidinones have structure homology with dihydropyridines, which 
are calcium channel modulators.4 In addition to possessing biological activity similar to dihydropyridines 
(typically antihypertensive), pyrimidinones have been shown to be anticancer agents, antiviral agents, and 
                                                     
1 Reprinted with permission from Journal of the American Chemical Society, Vol 133, Kevin M. Oberg, Tomislav 
Rovis, "Enantioselective Rhodium-Catalyzed [4 + 2] Cycloaddition of α,β-Unsaturated Imines and Isocyanates", 
4785-4787. Copyright (2011) American Chemical Society. 
2 Hoberg, H.; Sümmermann, K. J. Organomet. Chem. 1983, 253, 383-389. 
3 3,4-Dihydropyrimidin-2-one is the proper nomenclature based on the Extended Hantzsch-Widman system, but 
pyrimidinone will be used in its place. 
 
4 Dihydropyridines are typically synthesized using the Hantzsch dihydropyridine synthesis: (a) Hantzsch, A. Liebigs 
Ann. Chem. 1882, 215, 1-82. (b) Stout, D. M.; Meyers, A. I. Chem. Rev. 1982, 82, 223-243. 
67 
 
a benign prostatic hyperplasic treatment.5 Pyrimidinones are typically accessed via the Biginelli reaction.6 
As three components (urea 8, β-ketoester 9, and aldehyde 10) are brought together in a single step, this 
reaction belongs to a class of reactions called multicomponent reactions (MCR).7 The Biginelli reaction 
has been made higher yielding using the Atwal modification8 and rendered enantioselective using chiral 
acids such as phosphoric acid 11 and hexadentate ligated ytterbium 12.9 The use of β-ketoesters 9 as 
starting material generates pyrimidinones with electron-withdrawing groups at the 5-position, but there 
are reports of using non-classical starting materials, such as cyclic ketones.10  
 
Figure 3.1.1. Pyrimidinone structure, biological activities, and classical synthesis. 
 An alternative to the Biginelli reaction would be a [4+2] cycloaddition of an α,β-unsaturated 
imine and an isocyanate. Elliot showed that a thermal reaction of alkenyloxazolines 13 and isocyanates 2 
                                                     
5 (a) Kappe, C. O. Eur. J. Med. Chem. 2000, 35, 1043-1052. (b) Singh, K.; Arora, D.; Singh, K.; Singh, S. Mini-Rev. 
Med. Chem. 2009, 9, 95-106. 
6 Biginelli, P. Gazz. Chim. Ital. 1893, 23, 360-413. 
7 (a) Kappe, C. O. J. Org. Chem. 1997, 62, 7201-7204. (b) Kappe, C. O. Acc. Chem. Res. 2000, 33, 879-888. 
8 O'Reilly, B. C.; Atwal, K. S. Heterocycles 1987, 26, 1185-1188. 
9 (a) Huang, Y.; Yang, F.; Zhu, C. J. Am. Chem. Soc. 2005, 127, 16386-16387. (b) Li, N.; Chen, X.-H.; Song, J.; 
Luo, S.-W.; Fan, W.; Gong, L.-Z. J. Am. Chem. Soc. 2009, 131, 15301-15310. (c) Cai, Y.-F.; Yang, H.-M.; Li, L.; 
Jiang, K.-Z.; Lai, G.-Q.; Jiang, J.-X.; Xu, L.-W. Eur. J. Org. Chem. 2010, 4986-4990. (d) Saha, S.; Moorthy, J. N. J. 
Org. Chem. 2011, 76, 396-402. 
10 (a) Wan, J.-P.; Liu, Y. Synthesis 2010, 23, 3943-3953. (b) He, Z.-Q.; Zhou, Q.; Wu, L.; Chen, Y.-C. Adv. Synth. 
Catal. 2010, 352, 1904-1908. 
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generates oxazolopyrimidinones11 diastereoselectively (Eq 4).12 Orru made α,β-unsaturated imines 3 in 
situ from a Horner-Wadsworth-Emmons reaction of nitriles 14, aldehydes 10, and phosphonates 15 and 
reacted the α,β-unsaturated imines 3 with isocyanates to generate pyrimidinones in a multi-step, one-pot 
reaction (Eq 5).13 We sought to develop a metal-catalyzed [4+2] cycloaddition between α,β-unsaturated 
imines and isocyanates.14 
 
3.2 Initial Studies and Optimization 
 Our initial efforts centered around nickel catalysts based on Hoberg's metallacycle report. When 
we mixed α,β-unsaturated imine 3a and phenyl isocyanate 2a together in the presence of nickel, the 1H 
NMR of the unpurified mixture did not show any target material (Eq 6). We then mixed diphenyl imine 1 
and alkenyl isocyanate 2b in the hopes of observing a product derived from trapping of the nickelacycle 
with the tethered alkene (17 or 18). Instead, we observed that the alkenyl isocyanate had trimerized to 
make isocyanurate 16b (Eq 7). Upon reinvestigation of our original reactions with phenyl isocyanate 2a, 
IR spectroscopy confirmed that isocyanurate 16a was being generated.15 Slow addition of the isocyanate 
did not remedy the problem. 
                                                     
11 The intermediate pyrimidinones reacts with an additional isocyanate to install the amide at the 5 position. 
12 (a) Elliott, M. C.; Kruiswijk, E. J. Chem. Soc., Perkin Trans. 1, 1999, 3157-3166. (b) Elliott, M. C.; Kruiswijk, E.; 
Willock, D. J. Tetrahedron 2001, 57, 10139-10146. 
13 Vugts, D. J.; Koningstein, M. M.; Schmitz, R. F.; de Kanter, F. J. J.; Groen, M. B.; Orru, R. V. A. Chem. Eur. J. 
2006, 12, 7178-7189. 
14 For a similar reaction of α, β-unsaturated imines with ketenes, see; Jian, T.-Y.; Shao, P.-L.; Ye, S. Chem. 
Commun. 2011, 47, 2381-2383. 
15 (a) Zhou, A.; Cao, L.; Li, H.; Liu, Z.; Cho, H.; Henry, W. P.; Pittman, Jr., C. U. Tetrahedron 2006, 62, 4188-4200. 
(b) National Institute of Advanced Industrial Science and Technology. SDBSWeb. http://sdbs.riodb.aist.go.jp 




 With trimerization of the isocyanate plaguing us when we used nickel catalysts, we investigated 
other metal catalyst systems (Table 3.2.1). We also chose to use hexyl isocyanate 2c so trimerization 
would be detectable by 1H NMR. After some screening, we found that the rhodium·Taddol 
phosphoramidite catalyst system provides product in moderate yields and good enantioselectivities 
(entries 3, 4, and 6-8). We found that phosphoramidite scaffolds other than Taddol, such as BINOL, 
BiAryl, and VAPOL provide high yields, but enantioselectivities are lower (entries 10, 11, and 13). Use 
of a bidentate ligand (BINAP, L12) does not provide any product. The importance of phosphoramidite 
ligands is demonstrated by the lack of reactivity when Rh(PPh3)3Cl
16 is used (entry 2). The use of 
[Rh(cod)Cl]2·L3 as a catalyst does not yield any product (entry 17). The difference in reactivity from 
cyclooctadiene to bisethylene is staggering. We have seen lower yields of product when using 
cyclooctadiene as a ligand on rhodium in previous work (Chapter 2), but the complete lack of product in 
this reaction with the cyclooctadiene precatalyst is surprising. We settled on L3 as our optimal ligand as it 




                                                     
16 In situ generation of Rh(C2H2)2Cl·PPh3 from 1 equivalent of [Rh(C2H4)2Cl]2 and 2 equivalents of PPh3 yields <2% 
product. 
17 Solvent and temperature effects with [Rh(C2H4)2Cl]2·L3 as the catalyst; MeCN at 80 °C yields no product, DCE 




Table 3.2.1. Catalyst optimization.a  






entry catalyst yield (%)b ee (%)c,d
1 none 0 -
2 <5
3 [Rh(C2H4)2Cl]2, L2 29 81
4 [Rh(C2H4)2Cl]2, L3 56 90






















entry catalyst yield (%)b ee (%)c,d
8 [Rh(C2H4)2Cl]2, L6 12 68
9 [Rh(C2H4)2Cl]2, L7 <5 nd














































7 [Rh(C2H4)2Cl]2, L5 29 84








































11 [Rh(C2H4)2Cl]2, rac-L9 76 -
12 [Rh(C2H4)2Cl]2, L10 21 -52
13 [Rh(C2H4)2Cl]2, L11 79 74
14 [Rh(C2H4)2Cl]2, L12 0 -
15 0 -
16 Pd(dba)2, TMEDA 0 -
17 [Ir(cod)Cl]2, L3 0 -
18 [Rh(cod)Cl]2, L3 0 -
Pd(P(tBu)3)2
a Conditions: 3a (0.3 mmol), 2c (1.25 equiv), and catalyst in PhMe at 110 °C for 12 h. b Isolated yield. c Enantiomeric excess
determined by HPLC using a chiral stationary phase. d Absolute configuration assigned by analogy to (R)-4ag (established by
X-ray analysis).  
3.3 Scope of Pyrimidinone Synthesis and Product Derivatization 
 We investigated the scope of the reaction using [Rh(C2H4)2Cl]2·L3 as the catalyst. We found that 
primary aliphatic N-substituted imines provide the highest yields and enantioselectivities, but N-aryl 
71 
 
imines18 also work quite well (Table 3.3.1). Electron-deficient aryl N-substituted imines provide slightly 
higher yields and enantioselectivities (4cc) than electron-rich aryl N-substituted imines (4bc). Although 
we see this trend in isolated yields, this could be an artifact of isolation19 because the products are acid 
sensitive.20 Primary aliphatic N-substituted imines (4ec, 4fc, 4gc, and 4hc) provide the highest 
enantioselectivities, whereas secondary aliphatic N-substituted imines (4dc) provide high yields with 
moderate enantioselectivities.21 
Table 3.3.1. Scope of nitrogen substitution on α,β-unsaturated imine.a-d 
 
 A variety of substituents at the β-position were examined (Table 3.3.2). Ortho aryl β-substitution 
is tolerated quite well in the reaction providing the desired product in good yield and enantioselectivity 
(4ic). Electron-rich aromatic β-substitution provides higher yields (4jc), but lower enantioselectivities 
than electron-deficient aromatic β-substitution (4kc). Heterocycles (4lc) and vinyl groups (4mc) provide 
                                                     
18 4-iodoarylimine does not provide any product. 
19 A comparison of yield for 3a, 3b, and 3c, using 1,3,5-trimethoxybenzene as an internal standard, shows the same 
conversion for all three substrates (~73%). Isolated yields may be lower for 4bc as the enamine is more electron-rich 
and more reactive. 
20 If the pyrimidinones are stirred in DCM/SiO2 for extended amounts of time, we see minor decomposition by 
1H 
NMR. After exposure to CDCl3, we observe slight decomposition after a few days. Exposure to 3M HCl causes 
almost complete destruction of the products. 
21 Allyl N-substituted imine yields trace product. α,β-Unsaturated O-methyloxime and α,β-unsaturated N,N-
dimethylhydrazone does not produce any product. 
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product in good yields and enantioselectivities. Aliphatic β-substitution provides products in lower yields 
and moderate enantioselectivities (4nc and 4oc). The β-aliphatic α,β-unsaturated imines are unstable so 
the low yields could be partially due to decomposition of the starting materials. 



























4ic, 67%, 94% ee 4jc, 69%, 92% ee 4kc, 36%, 95% ee











[Rh(C2H4)2Cl]2 (5 mol %)





















4hc, 67%, 93% ee
 
 When we attempted subjecting β-ester 3p to the reaction, we isolated a different product, 
pyrrolone 19p.22 Presumably, this product is derived from rhodium acting as a Lewis acid. Intramolecular 
attack of the imine on the ester releases the alcohol. Quenching of the iminium by the alcohol would 
generate pyrrolone 19.23 This happens with or without isocyanate, but is catalyzed by rhodium (Eq 8). 
This is suggested by the enantioenduction and absence of product when the reaction was run without 
catalyst or with only ligand. The use of electron-rich imines is necessary for the reaction; N-phenyl 
substituted imine 3q does not provide pyrrolone, but N-alkyl substituted imine 3r does.  
                                                     
22 Stereochemistry was arbitrarily assigned based on optical rotation of a similar compound: Cuiper, A. D.; Kellogg, 
R. M.; Feringa, B. L. Chem. Commun. 1998, 655-656. 
23 Similar reactions have been reported: (a) Heaney, H.; Shuhaibar, K. F. Tetrahedron Lett. 1994, 35, 2751-2752. (b) 
Lübbers, T.; Angehrn, P.; Gmünder, H.; Herzig, S. Bioorg. Med. Chem. lett. 2007, 17, 4708-4714. 
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[Rh(C2H4)2Cl]2 (5 mol %)
L3 (10 mol %)
PhMe, 110 °C


















 We explored which isocyanates participate in the reaction and found that primary alkyl 
isocyanates work best in this transformation (Table 3.3.3). Interestingly, alkenyl isocyanate provides 
pyrimidinone 4hb as the only observable product, and no intramolecular trapping by the tethered alkene is 
detected. Benzyl and paramethoxybenzyl isocyanate provide product in good yields and 
enantioselectivities (4hd and 4he). Aromatic isocyanates generate product in lower yields and 
enantioselectivities (4hf). Increasing the size of the isocyanate from primary to secondary causes a sharp 
decrease in yield and enantioselecitivity (4hi), and further increases in size leads to no observable 
product.24 We demonstrated that the reaction is scalable by making pyrimidinone 4hd on a 4.5 mmol 
scale, and the catalyst loading was lowered to 2 mol % without compromising yield or enantioselectivity. 
Table 3.3.3. Isocyanate scope.a-d 
 
 In order to determine the absolute configuration, diphenyl α,β-unsaturated imine 3a and 4-
bromophenyl isocyanate 2g were cyclized to yield 4ag as a solid. After recrystallization to 99% ee, we 
                                                     
24 Tert-butyl isocyanate and trimethylsilyl isocyanate do not produce any observable product. 
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obtained a crystal structure25 to establish the absolute configuration as (R), and the other products were 
assigned by analogy. 
 
 To expand the types of α,β-unsaturated imines that participate in this reaction, we sought to use 
doubly substituted α,β-unsaturated imines. We found that β,β-methyl α,β-unsaturated imine 3s provides a 
small amount of product in the reaction (Eq 10). Other substitutions are not tolerated. For example, β,β-
methyl,phenyl α,β-unsaturated imine (3t) and α-methyl α,β-unsaturated imine (3u) does not yield any 
product. 
 
 In order to optimize the reaction for α,β-unsaturated imine 3sc, we used the High-Throughput 
Experimentation (HTE) 26 platform (Figure 3.3.1) at CSU. We found that [Rh(C2H4)2Cl]2 was the only 
precatalyst of the metals screened that provides any product. We found L8 provides the highest yield of 
pyrimidinone 4sc. This mirrors the earlier results during our initial catalyst screen (Table 3.2.1) and 





                                                     
25 Deposit number CCDC 837910. 
26 Based on the HTE platform developed by Merck and Co. Inc. (a) Dreher, S. D.; Dormer, P. G.; Sandrock, D. L.; 
Molander, G. A. J. Am. Chem. Soc. 2008, 130, 9257-9259. (b) Spencer D. Dreher, Merck and Co. Inc., Rahway, 






[Rh(C2H4)2Cl]2 (5 mol %)
[Rh(cod)2]BF4 (10 mol %)




























(11) [Rh(cod)Cl]2 (5 mol %)
Ni(cod)2 (10 mol %)
 
 
Figure 3.3.1. HTE screen of precatalyst and ligands shows [Rh(C2H4)2Cl]2 and L8 are best of screened 
conditions for α,β-unsaturated imine 3sc. 
 To improve the utility of this reaction, we sought to deprotect the urea and derivatize the 
products. Initially, we attempted to deprotect dibenzyl protected pyrimidinone 4hb via hydrogenation, but 
only saw reduction of the enamine to generate tetrahydropyrimidinone 20hb (Eq 12). We thought that 
making di(para-methoxybenzyl) protected pyrimidinone 4fe would allow for other deprotection strategies 
to be investigated and synthesized pyrimidinone 4fe in good yield and enantioselectivity. Hydrogenation 















(Eq 13). The enantiomer of tetrahydropyrimidinone 21 was synthesized by another group,27 and 
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 With a tempered nucleophilic enamine as a synthetic handle, we thought derivatization using 
electrophilic reagents should be possible. Exposure of pyrimidinone 4hb to meta-chloroperoxybenzoic 
acid provides epoxide 22 in low yield (Eq 13), and treatment with osmium and N-methylmorpholine N-
oxide yields dihydroxydihydropyrimidinone 23 (Eq 15). These products are unstable and decomposition 
is observed. Treatment of pyrimidinone 4hc with N-bromosuccinimide in wet N,N-dimethylformamide 
yields bromohydrin 24hc (Eq 16). In situ generation of  the iminium and trapping with an allyl 
nucleophile yields bromotetrahydropyrimidinone 25. These transformations proceed with excellent 
diastereoselectivity (>20:1) and the relative configuration was established by nOe. 
 
3.4 Proposed Mechanism 
 The proposed mechanism for this reaction is shown in Figure 3.4.1. Coordination of the α,β-
unsaturated imine 3 and isocyanate 2 to rhodium and oxidative cyclization generates rhodacycle II. This 
rhodacycle undergoes an η1-η3-η1 shift, via III, to yield 7-membered rhodacycle IV. Reductive 
elimination furnishes pyrimidinone 4 and regenerates the catalyst. The existence of rhodacycle II is 
                                                     
27 He, Z.-Q.; Zhou, Q.; Wu, L.; Chen, Y.-C. Adv. Synth. Catal. 2010, 352, 1904-1908. 
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supported by the isolation of nickallacycle I by Hoberg.28 An alternative mechanism can be envisioned 
that involves an initial [4+1] between rhodium and the α,β-unsaturated imine 3 to generate V.29 
Coordination and insertion of the isocyanate forms rhodacycle IV that undergoes reductive elimination to 
furnish product 4 and catalyst. We believe this is not the operative mechanism because different 
isocyanates give varying enantioselectivity with the same α,β-unsaturated imine. This suggests that the 
isocyanate is involved in the enantiodetermining step. In the proposed mechanism this is during the 
oxidative cyclization involving both the α,β-unsaturated imine and isocyanate so the isocyanate affects 
the enantioselectivity. In the alternative mechanism, only the α,β-unsaturated imine is involved in the first 
cyclization where the stereocenter is established. As the isocyanate has an effect on the enantioselectivity, 
we believe that the mechanism involving oxidative cyclization of the imine and isocyanate is operative, 
but other mechanisms have not been rigorously ruled out. 
 
Figure 3.4.1. Proposed mechanism. 
 
 
                                                     
28 Hoberg, H.; Sümmermann, K. J. Organomet. Chem. 1983, 253, 383-389. 




 In conclusion, we have developed an enantioselective synthesis of pyrimidinones via a rhodium-
catalyzed [4+2] cycloaddition of α,β-unsaturated imines and isocyanates. The use of a 
[Rh(C2H4)2Cl]2·phopshoramidite catalyst proves important; use of [Rh(cod)Cl]2 or phosphine ligands 
other than phosphoramidite ligands do not provide product. For substrates, primary aliphatic N-
substituted imines deliver product with the highest yields and enantioselectivities, numerous substitutions 
at the β position (aryl, heterocyclic, vinyl, and aliphatic) are tolerated, and primary aliphatic isocyanates 
provide the highest yields and enantioselectivities. Substitution at the α position is not tolerated, and 
disubstitution at the β position is low yielding with only the dimethyl substrate working in our hands. The 
products can be derivatized and deprotected, demonstrating the possibility of these compounds to serve as 
chiral heterocycle building blocks. Finally, we believe the mechanism proceeds through an oxidative 
cyclization of the α,β-unsaturated imine and isocyanate on rhodium, followed by an η1-η3-η1 shift and 




Progress towards the Synthesis of Ionomycin 
4.1 Anhydride Desymmetrization and Previous Syntheses of Ionomycin 
 One of the flagship projects in the Rovis group was the desymmetrization of anhydrides.1 In an 
extension of this work, Dr. Matthew Cook developed the desymmetrization of glutaric anhydrides with 
alkyl zinc reagents using a rhodium·Phox ligand system (Scheme 4.1.1).2 Desymmetrization of dimethyl 
glutaric anhydride 1 offers an efficient route to deoxypolypropionate synthons 2. Since then, the 
desymmetrization of trisubstituted glutaric anhydrides 3 has been achieved by Dr. Brian Cochran and 
offers a synthesis of polypropionate synthons 4.3 The synthesis of these motifs has garnered well deserved 
attention due to its ubiquity in natural products having interesting biological properties.4 Nature uses an 
iterative linear assembly process to create a wide range of motifs found in thousands of natural products 
using hundreds of polyketide synthase enzymes and a few simple building blocks.5 Traditionally, these 
motifs are chemically synthesized using aldol technology6 or synthons from chiral pool.7 In a testament to 
the importance of polypropionate synthesis, a number of methodologies that access these motifs have 
                                                            
1 (a) Bercot, E. A.; Rovis, T. J. Am. Chem. Soc. 2002, 124, 174-175. (b) O'Brien, E. M.; Bercot, E. A.; Rovis, T. J. 
Am. Chem. Soc. 2003, 125, 10498-10499. (c) Bercot, E. A.; Rovis, T. J. Am. Chem. Soc. 2004, 126, 10248-10249. 
(d) Bercot, E. A.; Rovis, T. J. Am. Chem. Soc. 2005, 127, 247-254. (e) Johnson, J. B.; Yu, R. T.; Fink, P.; Bercot, E. 
A.; Rovis, T. Org. Lett. 2006, 8, 4307-4310. (f) Rogers, R. L.; Moore, J. L.; Rovis, T. Angew. Chem. Int. Ed. 2007, 
46, 9301-9304. (f) Johnson, J. B.; Bercot, E. A.; Williams, C. M.; Rovis, T. Angew. Chem. Int. Ed. 2007, 46, 4514-
4518. (g) Johnson, J. B.; Bercot, E. A.; Rowley, J. M.; Coates, G. W.; Rovis, T. J. Am. Chem. Soc. 2007, 129, 2718-
2725. 
2 (a) Cook, M. J.; Rovis, T. J. Am. Chem. Soc. 2007, 129, 9302-9303. (b) Cook, M. J.; Rovis, T. Synthesis 2009, 
335-338. (c) Johnson, J. B.; Cook, M. J.; Rovis, T. Tetrahedron 2009, 65, 3202-3210. (d) Cook, M. J. Colorado 
State University, Fort Collins, CO. Unpublished work, 2008. 
3 Henderson, D. D.; Cochran, B. M.; Filloux, C. M.; Rovis, T. Submitted. 
4 Koskinen, A. M. P.; Karisalmi, K. Chem. Soc. Rev. 2005, 34, 677-690. 
5 For reviews of polypropionate synthesis by nature, see: (a) Staunton, J.; Weissman, K. J. Nat. Prod. Rep. 2001, 18, 
380-416. (b) Fischbach, M. A.; Walsh, C. T. Chem. Rev. 2006, 106, 3468-3496. 
6 (a) Evans, D. A.; Nelson, J. V.; Taber, T. R. Top. in Stereochem. 1982, 13, 1-115. (b) Palomo, C.; Oiarbide, M.; 
García, J. M. Chem. Soc. Rev. 2004, 33, 65-75. 
7 Hanessian, S. J. Org. Chem. 2012, 77, 6657-6688. 
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been developed.8 A number of these methods share an iterative approach with nature in constructing these 
motifs. We believe the strength in our approach, the desymmetrization of anhydrides, is that it forges a 
carbon-carbon bond to deliver enantioenriched (deoxy)polypropionate synthons that are five or more 
carbons in length in a single step. 
 
Scheme 4.1.1. Synthesis of deoxypolypropionates and polypropionates via anhydride desymmetrization 
and gold standard aldol synthesis of polypropionates. 
 In an effort to demonstrate the synthetic utility of anhydride desymmetrization for the synthesis of 
natural compounds containing deoxypolypropionate and polypropionate motifs, Dr. Cook devised a route 
to ionomycin 10 based on anhydride desymmetrization.9 Ionomycin was isolated from Streptomyces 
congoblatus fermentation broths in 1978 (Figure 4.1.1).10 Although it demonstrated some antibiotic 
properties, its affinity for calcium is the more interesting feature and ionomycin is used as a tool in 
                                                            
8 For selected examples, see: (a) Negishi, E.-i.; Kondakov, D. Y. Chem. Soc. Rev. 1996, 25, 417-426. (b) Li, J.; 
Menche, D. Synthesis 2009, 14, 2293-2315. (c) Bower, J. F.; Kim, I. S.; Patman, R. L.; Krische, M. J. Angew. Chem. 
Int. Ed. 2009, 48, 34-46. 
9 Cook, M. J. Colorado State University, Fort Collins, CO. Unpublished work, 2008. 
10 For activity and isolation: (a) Liu, C.-m.; Hermann, T. E. J. Biol. Chem. 1978, 253, 5892-5894. (b) Liu, W.-c.; 
Slusarchyk, D. S.; Astle, G.; Trejo, W. H.; Brown, W. E.; Meyers, E. J. Antibiot. 1978, 31, 815-819. For structure 
elucidation, see: (c) Toeplitz, B. K.; Cohen, A. I.; Funke, P. T.; Parker, W. L.; Gougoutas, J. Z. J. Am. Chem. Soc. 
1979, 101, 3344-3353. 
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neuroscience.11 Since its isolation, there have been four total syntheses of ionomycin by Hanessian, 
Evans, Lautens, and Kocienski. In addition to these completed syntheses, a number of fragment syntheses 




































          
Figure 4.1.1. Structure of ionomycin. 
 Hanessian's synthesis13 of ionomycin was a beautiful demonstration of the chiron approach and 
cyclic strategy for the synthesis of enantiopure, complex natural products (Figure 4.1.2). The butenolide 
                                                            
11 (a) Liu, C.-m.; Hermann, T. E. J. Biol. Chem. 1978, 253, 5892-5894. (b) Kauffman, R. F.; Taylor, R. W.; Pfeiffer, 
D. R. J. Biol. Chem. 1980, 255, 2735-2739. 
12 (a) Wuts, P. G. M.; D’Costa, R.; Butler, W. J. Org. Chem. 1984, 49, 2582-2588. (b) Nicoll-Griffith, D.; Weiler, L. 
J. Chem. Soc., Chem. Commun. 1984, 659-661. (c) Schreiber, S. L.; Wang, S. J. Am. Chem. Soc. 1985, 107, 5303-
5305. (d) Spino, C.; Weiler, L. Tetrahedron Lett. 1987, 28, 731-734. (e) Shelly, K. P.; Weiler, L. Can. J. Chem. 
1988, 66, 1359-1365. (f) Nicoll-Griffith, D. A.; Weiler, L. Tetrahedron 1991, 47, 2733-2750. (g) Taschner, M. J.; 
Chen, Q.-Z. Bioorg. Med. Chem. Lett. 1991, 1, 535-538. (h) Guidon, Y.; Yoakin, C.; Gorys, V.; Ogilvie, W. W.; 
Delorme, D.; Renaud, J.; Robinson, G.; Lavallée, J.-F.; Slassi, A.; Jung, G.; Rancourt, J.; Durkin, K.; Liotta, D. J. 
Org. Chem. 1994, 59, 1166-1178. (i) Hu, T. Q.; Weiler, L. Can. J. Chem. 1994, 72, 1500-1511. (j) von der Emde, 
H.; Langels, A.; Noltemeyer, M.; Brüchner, R. Tetrahedron Lett. 1994, 35, 7609-7612. (k) Montaña, A. M.; García, 
F.; Grima, P. M. Tetrahedron 1999, 55, 5483-5504. (l) Montaña, A. M.; García, F.; Grima, P. M. Tetrahedron Lett. 
1999, 40, 1375-1378. (m) Spino, C.; Allan, M. Can. J. Chem. 2004, 82, 177184. (n) Novak, T.; Tan, Z.; Liang, B.; 




chiron 13 serves as an excellent way to build polypropionate fragments with desired syn or anti 
stereochemistry. Despite its strength, the butenolide building block failed to provide a straightforward 
route to the deoxypolypropionate motif and the synthesis was lengthy. This shortcoming was overcome 
through the deployment of γ-butyrolactones 14. Both of these chirons were derived from L-glutamic acid 
12. The major disconnections in Hannessian's synthesis were a Wittig olefination (C22-C23), Julia-
















































Figure 4.1.2. Outline of Hannessian's approach to ionomycin. 
 Through the use of γ-butyrolactones, Hanessian was able to construct both the C1-C10 fragment 
20 and the C11-C16 fragment 17 (Scheme 4.1.2). Through the synthesis of γ-butyrolactone 14a, the 
installment of the C6 and C8 stereocenters were controlled. The key C8 methyl substituent was installed 
using a sulfur-assisted SN2 cuprate addition (16 to 17). This completed the synthesis of the C11-C16 
fragment 17 and the same material was used to construct the C1-C10 fragment. Once again, stereocontrol 
was enforced through the use of a γ-butyrolactone, 14b. 
                                                                                                                                                                                               
13 Fragment syntheses: (a) Hanessian, S.; Murray, P. J.; Sahoo, S. P. Tetrahedron Lett. 1985, 26, 5627-5630. (b) 
Hanessian, S.; Murray, P. J. Can. J. Chem. 1986, 64, 2231-2234. (c) Hanessian, S.; Murray, P. J. Tetrahedron 1987, 





Scheme 4.1.2. Synthesis of C1-C10 fragment 20 and C11-C16 fragment 17 using γ-butyrolactones. 
 The synthesis of C17-C22 fragment 25 was accomplished through cyclic stereocontrol by 
installing the methyl and hydroxyl substituents on butenolide chirons 13 (Scheme 4.1.3). Starting with 
butenolide 13a, the C19 stereocenter was used to install the C17 and C18 stereocenters. After conversion 
of lactone 21 to another butenolide 13b, the same strategy was used to install the C20 and C21 
stereocenters. In this case, diastereoselectivity was not as good, but the undesired epi-23 compound could 
undergo the same synthetic sequence and be epimerized to generate the more thermodynamically stable 
aldehyde 25. 
 
Scheme 4.1.3. Synthesis of C17-C22 fragment using butenolide chirons 13. 
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 The initial stereoinduction in the synthesis of the C23-C32 fragment 32 came from a Sharpless 
asymmetric epoxidation of racemic alcohol 26 (Scheme 4.1.4). This chirality was transferred using a 
vanadium-catalyzed epoxidation to synthesize tetrahydrofuran 31, setting the both C26 and C27 
stereocenters correctly. Elaboration to coupling partner 32 was done through functional group 
manipulation at C23. 
 
Scheme 4.1.4. Synthesis of northern fragment. 
 With all the fragments in hand, the task of coupling and elaboration to ionomycin remained. The 
C23-C32 fragment 32 was coupled with C17-C22 fragment 25 using a Wittig olefination, and the C23 
stereocenter was established using an oxymercuration of olefin 33. The trans-double bond and connection 
of the C17-C32 fragment with the C11-C16 fragment was done using a Julia-Lythgoe olefination. The 
final C1-C10 fragment was attached through an aldol/Collins oxidation sequence to generate protected 
ionomycin 36. Removal of the protecting groups and conversion to the calcium salt following precedent14 
generated the ionomycin calcium complex 11. 
                                                            




Scheme 4.1.5. Completion of ionomycin calcium salt. 
 It is suiting that Hanessian's and Evans' syntheses were published back to back as they serve as 
excellent foils to one another: Hanessian showcases a cyclic strategy using chiral pool material and Evans 
demonstrates the utility of acyclic control by using recyclable chiral auxiliaries.15 All the stereocenters in 
Evans' synthesis were installed directly or derived from stereocenters installed through the addition of 
oxazolidinone imides 40 or prolinol amides 41 into electrophiles. The key disconnections of ionomycin 
into four large fragments were the same in Hanessian's and Evans' syntheses. 
                                                            
15 Fragment syntheses (a) Evans, D. A.; Morrissey, M. M.; Dow, R. L. Tetrahedron Lett. 1985, 26, 6005-6008. (b) 
Evans, D. A.; Dow, R. L. Tetrahedron Lett. 1986, 27, 1007-1010. Total synthesis: (c) Evans, D. A.; Dow, R. L.; 




Figure 4.1.3. Outline of Evans' approach to ionomycin. 
 Evans' synthesis of the C1-C10 fragment 20 used oxazolidinones 40 to directly install the C8 and 
C4 methyl substituents and indirectly set the C6 stereocenter. An aldol reaction established the C8 methyl 
stereocenter and a C9 alcohol stereocenter that would be used to direct the C6 methyl stereocenter. The 
C4 methyl stereocenter was installed using an alkylation of an oxazolidinone with allylic iodide 44. The 
final methyl stereocenter was installed using a directed hydrogenation of diene 47 using a cationic 
rhodium catalyst. 
 
Scheme 4.1.6. Synthesis of C1-C10 fragment 20. 
 In the synthesis of the C11-C16 fragment 51, both methyl stereocenters were installed using 
alkylation of enolates attached to chiral auxiliaries. The second alkylation in this sequence required the 
more nucleophilic prolinol-derived amide 41 to install the C12 methyl stereocenter. With both methyl 




Scheme 4.1.7. Synthesis of C11-C16 fragment 51 using alkylation of valine derived imide and prolinol 
derived amide to install C12 and C14 stereocenters. 
 In the synthesis of the C17-C22 synthon 59, Evans showcased a synthesis of Roche aldehyde 53 
and utilized his recently developed crotonimide 54. Initial efforts to crotylate Roche aldehyde 53 gave 
disappointing diastereoselectivity, but the aldol reaction of aldehyde 53 and crotonimide 54 yielded aldol 
adduct 55 that could be elaborated to crotylation product 57 with complete control of stereochemistry. 
The terminal alkene was dihydroxylated to generate diol 58 with some of the undesired C21 isomer. Both 
diastereomers were converted to acetonide 59, and the unwanted C21 diastereomer could be epimerized 
to the desired isomer. 
 
Scheme 4.1.8. The synthesis of aldehyde 59 included a synthesis of Roche aldehyde 53 and the use of 
crotonimide 54 aldol reaction. 
 The northern fragment started with an aldol reaction of geraniol derived aldehyde 60 with imide 
40c. An unselective epoxidation/ring closing cascade generated tetrahydrofuran 62 that was lactonized 
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under basic conditions. Ozonolysis of bicyclic enol 63 generated ketone 64 that underwent a 
diastereoselective Grignard addition. Derivatization at C23 delivered tetrahydrofuran 65. 
 
Scheme 4.1.9. An aldol reaction set the initial stereocenter for the C23-C32 fragment 65. 
 Evans' and Hannessian's coupling sequences were very similiar. A Wittig olefination joined the 
C23-C32 fragment 65 and C17-C22 fragment 59 and the C23 stereocenter was established through 
oxymercuration. The C16-C17 bond was formed with a Julia-Lythgoe olefination to install the trans-
double bond. After the aldol/Collins oxidation sequence, protected ionomycin 36 was converted to the 
calcium salt following earlier group precedent.16  
                                                            


















































































































Scheme 4.1.10. Assembling fragments to make ionomycin calcium salt. 
 Over a decade later, Lautens published his synthesis17 of ionomycin highlighting the utility of 
desymmetrization of oxabicyclic alkenes for polypropionate synthesis.18 This methodology does an 
excellent job synthesizing polypropionates. However, this approach requires a deoxygenation sequence 
for deoxypolypropionate generation. The C16-C17 trans-double bond and β-diketone were constructed in 
the same way as Hanessian and Evans. The top two fragments were joined using a sulfone addition and 
the C23 stereocenter was generated from an SN2 displacement of a tosylate. 
                                                            
17 Fragment synthesis: (a) Lautens, M.; Chiu, P.; Colucci, J. T. Angew. Chem. Int. Ed. 1993, 32, 281-283. Total 
synthesis: (b) Lautens, M.; Colucci, J. T.; Hiebert, S.; Smith, N. D.; Bouchain, G. Org. Lett. 2002, 4, 1879-1882. 




Figure 4.1.4. Lautens' employment of oxabicyclic alkene desymmetrization to synthesize ionomycin. 
 The C1-C10 fragment synthesis showcases the palladium-catalyzed dialkylzinc opening of 
oxabicycle alkene 68a.19 This single transformation sets every methyl stereocenter for this fragment; C4, 
C6, and C8. After ozonolysis of the alkene, the alcohols at C5 and C7 were removed through sequential 
Barton-McCombie deoxygenations. 
 
Scheme 4.1.11. C1-C10 fragment synthesis showcasing oxabicyclic alkene desymmetrization. 
 The synthesis of the C11-C16 fragment 78 used dimethyl glutaric anhydride 1 for the installation 
of the syn dimethyl substituents. The anhydride 1 was converted to the diester, which underwent a 
desymmetrization with α-chymotrypsin to deliver carboxylester 76. Conversion of carboxylester 76 to 
sulfone 78 was straightforward. 
                                                            
19 (a) Lautens, M.; Renaud, J.-L.; Hiebert, S. J. Am. Chem. Soc. 2000, 122, 1804-1805. (b) Lautens, M.; Hiebert, S.; 




Scheme 4.1.12. The synthesis of the C11-C16 fragment 78 employed enzymatic desymmetrization. 
 The synthesis of the C17-C23 fragment 80 demonstrated the power of oxabicyclic alkenes 
desymmetrization to synthesize polypropionates.20 Desymmetrization of oxabicycle 68b with 
diisobutylaluminum hydride (DIBAL) generates alkene 69b that contains the correct C18-C20 stereotriad. 
The inversion of the C21 alcohol was necessary before ozonolysis generated diol 79 that now contains the 
correct stereochemistry of the ionomycin polypropionate. The two alcohols were elaborated to generate 
aldehyde 80. 
 
Scheme 4.1.13. The expedient synthesis of the C17-C23 fragment showcases the utility of the oxabicyclic 
alkene desymmetrization for the synthesis of polypropionates. 
 Starting from geranyl acetate 81, the C24-C32 fragment 86 was synthesized. Initial 
stereoinduction was done with a Sharpless asymmetric epoxidation. After an acid-catalyzed epoxide 
opening, this stereochemistry was translated using a vanadium-catalyzed epoxidation and cyclization 
sequence to generate tetrahydrofuran 85. The C32 oxygen was removed and the C26 alcohol protected to 
generate C24-C32 coupling partner 86. 
                                                            
20 (a) Lautens, M.; Chiu, P.; Ma, S.; Rovis, T. J. Am. Chem. Soc. 1995, 117, 532-533. (b) Lautens, M.; Rovis, T. J. 




Scheme 4.1.14. C24-C32 fragment synthesis from geranyl acetate 81 using a Sharpless asymmetric 
epoxidation to install stereochemistry and a vanadium-catalyzed epoxidation to translate the initial 
stereoinduction. 
 At this point, the fragments were completed and ready to be coupled. The top fragments were 
joined by addition of the sulfone anion of 86 into aldehyde 80 and elaboration of the resultant alcohol 
delivered ketone 87. The C23 ketone was diastereoselectively reduced and tosylated; SN2 displacement by 
the C27 alcohol generated bistetrahydrofuran fragment 88 with the correct C23 stereocenter. The coupling 
of the C17-C32 fragment with the C11-C16 fragment 78 was done with a Julia-Kocienski coupling. The 
C1-C10 fragment was installed using an aldol/Collins oxidation sequence. Using a similar deprotection 




Scheme 4.1.15. Lautens' completion of ionomycin calcium complex 11. 
 Kocienski's synthesis21 of ionomycin featured non-classical disconnections of ionomycin that 
highlights the utility of newer chemistry to unite and manipulate larger, late stage material. This includes 
a gold-catalyzed cycloisomerization, the utilization of iron complex 91 to install the C4 methyl 
stereocenter, a platinum-catalyzed hydrosilylation to install the C21 alcohol, and rhodium-catalyzed 
rearrangement to install the β-diketone. 
                                                            
21 Fragment syntheses: (a) Cooksey, J.; Kocienski, P.; Li, Y.-F. Collect. Czech. Chem. Commun. 2005, 70, 1653-
1668. (b) Cooksey, J. P.; Kocienski, P. J.; Li, Y.-f.; Schunk, S.; Snaddon, T. N. Org. Biomol. Chem. 2006, 4, 3325-
3336.  (c) Li, Y.; Cooksey, J. P.; Gao, Z.; Kocienski, P. J.; McAteer, S. M.; Snaddon, T. N. Synthesis, 2011, 104-
108. Total synthesis: (d) Gao, Z.; Li, Y.; Cooksey, J. P.; Snaddon, T. N.; Schunk, S.; Viseux, E. M. E.; McAteer, S. 















































Figure 4.1.5. Kocienski's synthesis that employed newer chemistry to manipulate large fragments. 
 The assembly of the C1-C9 fragment 97 used anhydride 1 to generate the syn-C6 and C8 methyl 
stereocenters and iron complex 91 to install the C4 methyl stereocenter. After methanolysis of anhydride 
1, resolution using (S)-(-)-1-phenylethylamine generated carboxylester ent-76. This was converted to 
cuprate 95 that was added into iron complex 91 generating the C4 methyl substituent stereoselectively. 
Amide 96 was then elaborated to C1-C9 fragment 97. 
 
Scheme 4.1.16. Synthesis of C1-C9 fragment from anhydride 1 and iron complex 91. 
 After methanolysis of anhydride 1, resolution using (R)-(+)-1-phenylethylamine generated 
carboxylester 76. Homologation using the Arndt-Eistert reaction delivered carboxylic acid 98 that was 




Scheme 4.1.17. C11-C16 fragment synthesis. 
 Using the stereocenter in Roche aldehyde 53b, the C19 alcohol and C18 methyl substituent were 
installed diastereoselectively.22 Diol differentiation and elaboration furnished aldehyde 102.  
 
Scheme 4.1.18. C17-C21 fragment synthesis from Roche aldehyde 53b. 
 Although geranyl acetate 81 was the starting material, Kocienski's synthesis of bistetrahydrofuran 
109 is unique from the other syntheses and features a gold-catalyzed cycloisomerization. Reduction of 
ynone 103 using Noyori asymmetric transfer hydrogenation generated propargylic alchol 104 with the 
C27 stereocenter in place. Sharpless asymmetric epoxidation of the allylic alcohol and spontaneous 
cyclization generated tetrahydrofuran 105. After manipulation of the alcohols, the alkyne was added into 
(-)-glyceraldehyde acetal; mesylation of the resultant alcohol generated mesylate 106. A SN2' addition of 
methyl cuprate generated allene 107 that was used in the key gold-catalyzed cycloisomerization to 
generate bistetrahydrofuran 108. Reduction of the alkene and alcohol elaboration generated sulfone 109. 
 
                                                            




Scheme 4.1.19. The synthesis of the C22-C32 fragment 109 featured a gold-catalyzed cycloisomerization 
of allene 107. 
 Kocienski's synthesis is quite different in the coupling of the northern and southern fragments 
from the previous syntheses. A Julia-Kocienski olefination coupled bistetrahydrofuran 109 with aldehyde 
102. The C19 alcohol stereocenter was used in an intramolecular hydrosilylation of the alkene to install 
the C21 alcohol. The C16-C17 bond was installed with another Julia-Kocienski olefination and the C11 
ester was converted to an α-diazoketone (112). Addition of the α-diazoketone into aldehyde 97 was 
followed by a rhodium-catalyzed rearrangement to construct β-diketone 36. This protected ionomycin 




Scheme 4.1.20. The coupling sequence was a departure from the classical disconnections and showcased 
a late stage rhodium-catalyzed rearrangement to install the β-diketone. 
4.2. Previous Work towards Ionomycin in the Rovis Group 
 The route to ionomycin 10 undertaken in our lab was to showcase the desymmetrization 
methodology developed in the group (Figure 4.2.1). We sought to employ this methodology in the 
synthesis of three of the four fragments. The C1-C9 and C10-C16 deoxypolypropionate fragments would 
be derived from ketoacids 2 generated from the desymmetrization of dimethyl glutaric anhydride 1. The 
C17-C22 polypropionate fragment would come from ketoacid 4 by the desymmetrization of trisubstituted 
anhydride 3. This approach mimics previous syntheses in that the molecule is divided into four fragments 
with slightly different disconnects. Our first generation synthesis disconnected the β-diketone using an 
aldol between methyl ketone 116 and aldehyde 115; previous aldol disconnections were between C10 and 
C11, whereas this plan was between C9 and C10. The initial Julia olefination to install the trans-double 
bond initially put the aldehyde on C16 (115) and the sulfone on C17 (114). An enol silane addition (114) 
into an oxocarbenium generated from lactol 113 was to connect C22 and C23 and establish the C23 
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stereocenter. Due to difficulties with the Julia-Kocienski olefination in our first generation approach, the 
coupling partners were switched in our second generation. This placed the sulfone on C16 (119) and the 
aldehyde on C17 (118). Finally, a third generation synthesis was needed due to difficulties in establishing 
the correct C23 stereocenter using the oxocarbenium enol silane addition. We joined the northern 
fragments through a palladium cross coupling of thioester 120 and alkyne 121. The C23 stereocenter was 
installed through two approaches, a reductive cyclization and ketone reduction/SN2 displacement 
sequence. During our initial route exploration towards the synthesis of ionomycin, we used (S)-tBuPhox, 
as this was the cheaper antipode of ligand. Towards the end of the second generation synthesis, we 
switched to (R)-tBuPhox for material that we hoped would be incorporated into our synthetic ionomycin. 
 
Figure 4.2.1. Rovis group's approach to ionomycin 10 utilizing desymmetrization of anhydrides to 
construct polypropionate and deoxypolypropionate fragments. 
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 By employing the desymmetrization methodology, Dr. Cook synthesized the carbon skeleton of 
the C1-C9 fragment. Desymmetrization of anhydride 1 with dialkyl zinc reagent 12223 provides ketoacid 
2a in good yield and enantioselectivity. This installs the syn dimethyl substituents and the carbon 
backbone in a single step. Alkylation of unprotected ketoacid 2a installs the C4 methyl substituent 
diastereoselectively. We believe this alkylation goes through a chelate of the potassium counterion (I) by 
the carboxylate and enolate. When methyl ester 127 is subjected to the reaction conditions, a 1:1 mixture 
of C4 diastereomers of ketoester 128 is generated. The ketone was protected as the dithiolane to make 

















































































Scheme 4.2.1. Synthesis of C1-C9 fragment using desymmetrization chemistry. 
 Using the same starting material, the penultimate piece of the C10-C16 fragment was 
synthesized. Desymmetrization of anhydride 1 with methyl zinc bromide generates ketoacid 2b in good 
yield and enantioselectivity with the requisite syn dimethyl substituents on C12 and C14. Global 
                                                            
23 For organozinc reagents, see; (a) Rozema, M. J.; Sidduri, A.; Knochel, P. J. Org. Chem. 1992, 57, 1956-1958. (b) 
Knochel, P.; Singer, R. D. Chem. Rev. 1993, 93, 2117. 
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reduction, iodination of the primary alcohol, and oxidation of the secondary alcohol generates iodoketone 
129. Displacement of the iodide generates cyanoketone 130 that is poised to be used in the aldol coupling, 
where the cyano group serves as a protected aldehyde. 
 
Scheme 4.2.2. Synthesis of C10-C16 fragment using anhydride desymmetrization methodology. 
 Attempts to make the C17-C22 fragment via anhydride desymmetrization were thwarted by 
difficulties in substrate synthesis. Utilizing the approach devised by Harada and Oku,24 diol 133a was 
synthesized, but direct oxidation was not successful. Instead, an approach based on crotylation of Roche 
ester 134 was utilized.25 Crotylation of aldehyde 135 generates alkene 136. Wacker oxidation of the 
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Scheme 4.2.3. Oxidation of diol 133 was unsuccessful. Synthesis of C17-C22 fragment 137 from Roche 
ester 134 was successful. 
                                                            
24 Harada, T.; Matsuda, Y.; Uchimura, J.; Oku, A. J. Chem. Soc., Chem. Commun. 1990, 21-22. 
25 Roush, W. R.; Palkowitz, A. D.; Palmer, M. A. J. J. Org. Chem. 1987, 52, 316-318. 
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 Using a modified procedure developed by Paterson,26 the synthesis of the C23-C32 fragment 113 
was achieved (Scheme 4.1.3). Allylic oxidation of geranyl acetate 81 generates allylic alcohol 138.27 
Stereoinduction is accomplished using Sharpless asymmetric epoxidation.28 Conversion of the alcohol to 
an alkyl iodide and acetate hydrolysis delivers epoxyalcohol 139. Two carbon homologation using the 
enolate of tert-butyl acetate followed by Sharpless epoxidation generates diepoxide 140. Cyclization of 
the diepoxide was done using camphorsulfonic acid as outlined by Paterson. Conversion of the primary 
alcohol  to the bromide enables its removal via hydrogenolysis.29 Reduction using DIBAL generates the 
lactol that can be converted to acetal 113. 
 
Scheme 4.2.4. Initial synthesis of bistetrahydrofuran fragment. 
 Dr. Cook showed that the coupling of northern fragments and the southern fragments are 
possible. The aldol reaction of cyanoketone 130 with aldehyde 126 generates β-hydroxyketone 142. After 
generation of the oxocarbenium from acetal 113, addition of enol silane 143 generates bistetrahydrofuran 
144 in modest diastereoselectivity. This selectivity was expected to improve with the use of the larger 
enol silane in the real coupling. 
                                                            
26 Paterson, I.; Boddy, I.; Mason, I. Tetrahedron Lett. 1987, 28, 5205-5208.  
27 Umbreit, M. A.; Sharpless, K. B. J. Am. Chem. Soc. 1977, 99, 5526-5528. 
28 Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5974-5976. 




Scheme 4.2.5. Demonstration that initial fragment couplings are possible. 
 At this point, Dr. Cook left and a new postdoctoral associate, Dr. Brian Cochran, picked up the 
project.30 Dr. Cochran's synthesis of the C1-C9 fragment 116 was accomplished with some modifications 
to the original approach. The chemoselective reduction of the carboxylic acid over the ester is done with 
borane and recalcitrant dithiolane is removed with Raney® nickel. 
 
Scheme 4.2.6. Revised route to C1-C9 fragment including removal of the dithiolane protecting group. 
 The first generation Julia coupling partner 147 was synthesized from previously made 
cyanoketone 130. Protection of the ketone as the acetal and reduction of the cyanide using DIBAL 
generates aldehyde 147. 
                                                            




Scheme 4.2.7. Synthesis of C10-C16 fragment with the aldehyde on C16. 
 One of Dr. Cochran's key breakthroughs was the synthesis the trisubstituted anhydride 3. 
Attempts towards a one step oxidation of diol 133 to the diacid produced lactone 148. Through the use of 
a Swern oxidation, dialdehyde 149 is generated.31 Pinnick-Lindgren oxidation makes the desired diacid 
that is cyclized using trifluoroacetic anhydride to generate trisubstituted anhydride 3.  
 
Scheme 4.2.8. Trisubstituted anhydride synthesis: problematic one step oxidation and solution via 
dialdehyde synthesis. 
 After synthesis of trisubstituted anhydride 3, its desymmetrization worked efficiently. Using the 
same catalyst and zinc reagents, a range of protected (methyl, benzoate, acetate, and benzyl) trisubstituted 
anhydrides deliver ketoacids 4 with a trans, trans stereotriad. Benzyl was chosen as the protecting group 
in the total synthesis of ionomycin due to its stability to a range of reaction conditions and its efficiency in 
the desymmetrization reaction. Despite the benefits of the benzyl protecting group in the 
desymmetrization and subsequent reactions, the hydroboration step proceeds in lower diastereoselectivity 
(3.5:1). 
                                                            
31 (a) Harada, T.; Kagamihara, Y.; Tanaka, S.; Sakamoto, K.; Oku, A. J. Org. Chem. 1992, 57, 1637-1639. (b) Kann, 
N.; Rein, T. J. Org. Chem. 1993, 58, 3802-3804. (c) Tullis, J. S.; Vares, L.; Kann, N.; Norrby, P.-O.; Rein, T. J. 




Scheme 4.2.9. Desymmetrization of trisubstituted anhydrides 3 delivering ketoacids with trans, trans 
stereotriads. 
 With the desymmetrization of the trisubstituted fragment established, elaboration to fragments 
used in the synthesis of ionomycin was undertaken. Global reduction of ketoacid 4b, selective tosylation 
of the primary alcohol, and oxidation of the secondary alcohol generates methyl ketone 150. 
Displacement of the tosylate with benzothiazole (BT) or phenyl tetrazole (PT) generates the thioether that 
is oxidized using meta-chloroperbenzoic acid (mCPBA). Conversion of the methyl ketone to the enol 
silane generates the enol silane fragment (114) to be added into the C23 oxocarbenium. 
 
Scheme 4.2.10. C17-C22 fragment synthesis using anhydride desymmetrization methodology. 
 The C23-C32 fragment was synthesized in the same fashion with minor procedural changes. The 
iodination and acetate hydrolysis were telescoped in the synthesis of iodoepoxide 139. Better results are 
achieved when the bromination and epoxide cyclization reaction order are swapped. Finally, a basic wash 





Scheme 4.2.11. Revised synthesis of C23-C32 fragment 117. 
 With the C17-C22 and C23-C32 fragments in hand, the enol silane addition was attempted. 
Addition of enol ether 114a into the oxocarbenium generated from acetal 117 synthesized the entire C17-
C32 carbon framework (153).32 The proposed stereochemical model (II) for the addition suggested that 
steric hinderance of the second tetrahydrofuran would prevent attack of the enol silane from top face of 
the oxocarbenium and favor bottom side attack to provide the desired C23 diastereomer. 
 
Scheme 4.2.12. Enol silane addition into oxocarbenium: reaction and proposed selectivity model. 
 Elaboration of the C17-C32 fragment 153 generated Julia coupling partner 154a. Removal of the 
benzyl protecting group revealed the free C19 alcohol that was used to do a directed reduction of the C21 
ketone.33 Protection of the 1,3-diol as the acetal generated coupling partner 154a. 
 
                                                            
32 This coupling was also done with the tosylalcohol in place of the sulfone (Scheme 4.2.15); 94%, 3.5:1 dr. 




Scheme 4.2.13. Elaboration to Julia coupling partner 154a. 
 With C17-C32 sulfone 154 and C10-C16 aldehyde 147 synthesized, the Julia-Kocienski coupling 
was attempted. Despite the sulfones and conditions tried in the coupling,34 no desired product was 
observed.  
 
Scheme 4.2.14. Attempts to couple C17 sulfone 154 failed. 
 The previous syntheses of ionomycin joined these fragments via a Julia olefination, but the 
coupling partners were reversed: the sulfone was on C16 and the aldehyde was on C17. After these 
unsuccessful coupling attempts, it was decided to switch the coupling partners and a revised second 
generation route was drafted and pursued (Figure 4.2.1). 
 The top fragment was constructed using a modification of the first generation approach. Methyl 
ketone 151 was converted to enol silane 156, which can be coupled in the same fashion to acetal 117. The 
same sequence from ketone 157 generates tosyl protected alcohol 158. A number of conditions were 
                                                            




attempted to remove the tosylate before a light induced deprotection was shown to work.35 After 
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Scheme 4.2.15. Revised route to C17-C32 fragment. 
 The synthesis of  C10-C16 fragment 119 was accomplished with two different approaches using 
common intermediate 129. Starting from iodoketone 129, homologation and elaboration to aldehyde 147 
can be achieved by using either cyanide or dithiane. Reduction of the aldehyde and iodination generates 
alkyl iodide 160. Displacement of the iodide with phenyl tetrazole and oxidation generates the sulfone. 
The ketal was deprotected during workup to generate ketosulfone 119. 
 
Scheme 4.2.16. Revised route to C10-C16 fragment. 
                                                            
35 Nishida, A.; Hamada, T.; Yonemitsu, O. J. Org. Chem. 1988, 53, 3386-3387. 
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 The aldol coupling of the bottom fragment was further optimized. The aldol reaction is 
accomplished using 9-iodo-9-borabicyclo[3.3.1]nonane, a commercially available boron reagent, that 
makes the reaction higher yielding and more consistent. Oxidation of β-hydroxyketone 161 is 
accomplished using 2-iodoxybenzoic acid to generate the β-diketone 162.36 
 
Scheme 4.2.17. Coupling and oxidation of C1-C16 fragment. 
 At this point, the entire northern and southern fragments were ready for coupling. Julia-Kocienski 
coupling of aldehyde 159 and unprotected β-diketone 162 was successful. This reaction generates the 
entire carbon skeleton of ionomycin. Acetal removal is accomplished using trifluoroacetic acid to 
generate diol 164,37 but removal of the benzoate and cleavage of the ethyl ester were sluggish. This 
demonstrated that an aggressive coupling of protected aldehyde 159 with the unprotected β-diketone 162 
was a viable route; the synthesis of the entire skeleton was accomplished in a convergent fashion. 
                                                            
36 Bartlett, S. L.; Beaudry, C. M. J. Org. Chem. 2011, 76, 9852-9855. 




Scheme 4.2.18. Successful Julia-Kocienski coupling and elaboration to acid 165. 
4.3 Synthesis of C1-C16 Fragment 
 When I initially joined the project, I was tasked with synthesizing the C1-C16 fragment. The 
C1-C9 fragment was synthesized as before with some minor optimization. In my hands, the use of 
[Rh(nbd)OAc]2 as the precatalyst
38 in place of [Rh(nbd)Cl]2 provides higher yields
39 in the 
desymmetrization of dimethyl glutaric anhydride 140 with dialkylzinc reagent 122. The conversion of the 
                                                            
38 For the synthesis and chemistry of [Rh(nbd)OAc]2, see: (a) Henderson, D. D.; Cochran, B. M.; Filloux, C. M.; 
Rovis, T. Submitted. For review on halide influence on metal catalysis, see: (b) Fagnou, K.; Lautens, M. Angew. 
Chem. Int. Ed. 2002, 41, 26-47. 
39 In a side by side comparison using the same zinc reagent (122)and trimethoxybenzene as the internal standard, 
[Rh(nbd)Cl]2 showed 60% conversion and [Rh(nbd)OAc]2 showed 80% conversion by 
1H NMR of the unpurified 
reactions. Additionally, the [Rh(nbd)OAc]2 reaction was cleaner as well. 
40 Crystal structure: Oberg, K. M.; Rovis T. (2013) Private communication to the Cambridge Structural Database, 
deposit number CCDC 946678. 
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ketone to the dithiolane can only be run for a short amount of time as epimerization is observed. The 
Raney® nickel reduction is capricious. Yields are variable and sometimes decomposition is observed.41 
 
Scheme 4.3.1. Route to C1-C9 fragment. 
 The route to sulfone 119 is similar to the previously outlined route in Scheme 4.2.16. The 
desymmetrization of dimethyl glutaric anhydride 1 with methyl zinc bromide generates ketoacid 2b 
(Scheme 4.3.2).42 Generation of thiol 168 is done using a two step process, conversion to the iodide and 
displacement with thiophenyl tetrazole. An alternative way to access this compound is through use of the 
Mitsunobu reaction to generate thiol ether 65 in one step.43 Oxidation of thiol ether 168 to sulfone 169a is 
done using meta-chloroperbenzoic acid. Epimerization at C12 is problematic during acetal deprotection. 
Removal the acetal with 1M HCl overnight results in a 4:1 mixture of C12 diastereomers. Increasing the 
                                                            
41  Dihydropyran 166 was isolated as a 1:1 mixture of diastereomers (possibly alkene 
isomers). See; Rainier, J. D.; Allwein, S. P. Tetrahedron Lett. 1998, 39, 9601-9604. 
42 Using alkyl iodide 129 from the desymmetrization using (S)-tBuPhox, triazole 170 was synthesized and a crystal 
structure was obtained that confirmed absolute stereochemistry. Oberg, K. M.; Rovis T. (2014) Private 
communication to the Cambridge Structural Database, deposit number CCDC 991677. 
 
43 Although the Mitsunobu reaction is shorter, the two step process generates slightly cleaner thiol ether 65. 
111 
 
concentration improves reaction times, but results in even more epimerization. Lowering the 
concentration leads to longer reaction times and epimerization still occurs. Working up the mCPBA 
oxidation with sodium metabisulfite (Na2S2O5) to remove excess peracid results in loss of the acetal and a 
10:1 mixture of C12 diastereomers. Finally, we have found treatment with cerium trichloride 
heptahydrate and sodium iodide44 results in complete removal of the ketal without any epimerization. 
 
Scheme 4.3.2. Synthesis C10-C16 fragment. 
 My early attempts performing the desymmetrization reaction were plagued by contamination of 
carboxylester rac-76. As the reaction was scaled up, the amounts of carboxylester decreased. Presumably, 
zinc alkoxides are generated from small amounts of oxygen in the reaction and these open the anhydride 
uncatalyzed to form carboxylesters. Formation of zinc alkoxides from alkyl zincs and oxygen is a known 
and well documented process.45 Larger scale reactions generate more product with less carboxylester 
presumably due to smaller molar ratios of oxygen. 
                                                            
44 (a) Marcantoni, E.; Nobili, F. J. Org. Chem. 1997, 62, 4183-4184. (b) Arjona, O.; Menchaca, R.; Plumet, J. Org. 
Lett. 2001, 3, 107-109. 
45 (a) Lewinski, J.; Marciniak, W.; Lipkowski, J.; Justyniak, I. J. Am. Chem. Soc. 2003, 125, 12698-12699. (b) 
Lewinski, J.; Sliwinski, D.; Dranka, M.; Justyniak, I.; Lipkowski, J. Angew. Chem. Int. Ed. 2006, 45, 4826-4829. (c) 




Scheme 4.3.3. Influence of scale on side product formation and presumable cause. 
 An approach that was investigated to expedite the synthesis of the C10-C16 fragment was 
alkylation of a methyl sulfone 174 with alkyl iodide 173 (Scheme 4.3.4). The inherent problem with this 
approach is that the deprotonated sulfone will do SNAr chemistry to generate "dimer" 175. Despite this 
obstacle, we were inspired by reports that fluororomethyl tert-butyltetrazole sulfones had been alkylated46 
and both phenyltetrazole and benzothiazole sulfones had been added into acid chlorides.47 We also had 
promising results alkylating phenylsulfone 174d with alkyl iodide 173. The deprotection of the acetal 
169d without epimerization proved problematic, but if this could be overcome, then a route utilizing a 
classical Julia-Lythgoe coupling could be done just as Hanessian and Evans did in their synthesis. 
Although "dimerization" was not observed with tert-butyltetrazole methyl sulfone 174c, subjecting it to a 
range of bases and isobutyl methanesulfonate 176 or 1-iodo-2-methylpropane 177 did not provide any of 
the targeted alkylated sulfone 178. Additionally, we attempted to alkylate phenyltetrazole methyl sulfone 
174a and used High Throughput Experimentation (HTE)48 to screen conditions,49 but we only observed 
either starting material or "dimer". Based on a patent report,50 we also envisioned cross coupling 
                                                            
46 Zhu, L.; Ni, C.; Zhao, Y.; Hu, J. Tetrahedron 2010, 66, 5089-5100. 
47 Pospisil, J.; Sato, H. J. Org. Chem. 2011, 76, 2269-2272. 
48 Based on the HTE platform developed by Merck and Co. Inc. (a) Dreher, S. D.; Dormer, P. G.; Sandrock, D. L.; 
Molander, G. A. J. Am. Chem. Soc. 2008, 130, 9257-9259. (b) Spencer D. Dreher, Merck and Co. Inc., Rahway, 
New Jersey, USA. Personal Communication, 2011. 
49 174a was subjected to HTE with following variables: substrate: 176 or 177; base/acid: LiHMDS, cesium 
carbonate, 2,2,6,6-tetramethylpiperidine, imidazole, DBU, Amberlyst® 15, sodium acetate, para-toluenesulfonic acid 
monohydrate; solvent: THF, DMF, PhMe, EtOH, acetone, MeCN. 
50 Ting, P. C.; Aslanian, R. G.; Cao, J.; Kim, D. W.-S.; Kuang, R.; Zhou, G.; Herr, R. J.; Zych, A. J.; Yang, J.; Wu, 




bromomethyl tertbutyltetrazole sulfone51 179 with boron reagents. Sp3-sp3 cross coupling is a difficult 
transformation, but it is not without precedent.52 We screened a number of conditions using HTE, but only 
recovered starting material or debrominated starting material. Although frustrating, debromination implies 
that the oxidative addition step may be working, but the transmetallation is not occurring. The use of 
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Scheme 4.3.4. Attempted alkylation approach to sulfone 169a. 
 The aldol coupling of the C1-C9 and C10-C16 fragments to form β-hydroxyketone 161 and 
oxidation to β-diketone 162 were done as before. 
 
Scheme 4.3.5. Aldol coupling and oxidation to generate C1-C16 fragment. 
                                                            
51 Lebrun, M.-E.; Marquand, P. L.; Berthelette, C. J. Org. Chem. 2006, 71, 2009-2013. 
52 (a) Kirchhoff, J. H.; Netherton, M. R.; Hills, I. D.; Fu, G. C. J. Am. Chem. Soc. 2002, 124, 13662-13663. (b) Saito, 
B.; Fu, G. C. J. Am. Chem. Soc. 2007, 129, 9602-9603. 
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4.4 C17-C32 Fragment Synthesis via Enol Silane Addition into Oxocarbenium 
 The synthesis of the C17-C22 fragment included a change in protecting group but otherwise 
remained the same. Desymmetrization of trisubstituted anhydride 3b53 with methyl zinc bromide 
generates ketoacid 4b.54 This was converted to methyl ketone 182 and then enol silane 183. The switch in 
protecting groups was to avoid the use of the tosylate "protecting" group due to its vestigial use from the 
first generation approach. 
 
Scheme 4.4.1. Synthesis of the enol silane precursor 183. 
 The synthesis of the C23-C32 fragment also included some protecting group changes. With some 
minor procedural changes, diepoxide 140 was synthesized. After bromination, the cyclization should be 
done using dry para-toluenesulfonic acid, as the hydrate leads to inconsistent results. The C31 alcohol 
was protected as the tert-butyldimethylsilyl (TBS) ether because hydrolysis of the benzoyl group at this 
position was problematic in Dr. Cochran's initial studies. Reduction of the lactone and benzoylation 
delivered acetal 185. 
                                                            
53 Oberg, K. M.; Rovis T. (2014) Private communication to the Cambridge Structural Database, deposit number 
CCDC 991874. 
54 Desymmetrization of the trisubstituted anhydride 3a using (S)-tBuPhox and its elaboration to sulfone 137b was 
accomplished by Dr. Cochran. After Dr. Cochran left, this compound was spotted by Darrin Flanigan and brought to 
my attention. This compound had crystallized out and the sulfurs gave enough anomalous dispersion for absolute 
stereochemistry determination. Cochran, B. M.; Oberg, K. M.; Rovis T. (2014) Private communication to the 





Scheme 4.4.2. C23-C32 acetal synthesis. 
 The enol silane addition into the oxocarbenium is a high yielding coupling with good 
diastereoselectivity. After the route was initially devised, a paper on the formal synthesis of ionomycin 
was published by Kocienski.55 In their report, they essentially add the same enol silane (156 vs 188) into 
the same oxocarbenium generated from sulfone 189 through a Ley α-heteroalkylation. They found that 
the major diastereomer 190 corresponded to the undesired stereochemistry at C23 and the minor 
diastereomer 191 was the desired stereochemistry. Comparison of the 1H NMRs showed that we are also 
generating the undesired C23 diastereomer as the major product during this reaction. 
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Scheme 4.4.3. Establishment of diastereomer generated from enol silane oxocarbenium addition through 
comparison to Kocienski and coworkers. 
 The preference for the undesired diastereomer can be explained by two models (Figure 4.1.1). 
Woerpel describes a general model for nucleophilic attack of five-membered-ring oxocarbenium ions 
based on transition state energies.56 Approach of the nucleophile from the "inside" of the envelope 
generates a staggered transition state III leading to cis-tetrahydrofuran 186. Alternatively, approach of the 
nucleophile from the "outside" of the envelope generates an eclipsed transition state IV leading to the 
trans-tetrahydrofuran 187. Due to eclipsing interactions generated during the "outside" envelope attack 
IV, this transition state is disfavored and attack from the "inside" of the envelope III is lower in energy. 
This leads to the preference for the undesired C23 diastereomer 186. An alternative model proposed by 
Reißig is based on Felkin-Ahn attack on an equilibrating mixture of conformers.57 In this model, 
conformer V is  more prevalent in solution due to the pseudoequatorial placement of the larger THF ring. 
Attack of this conformer by the enol silane generates the cis-tetrahydrofuran 186. The generation of trans-
tetrahydrofuran 187 is lower because conformer VI is in lower concentration in solution. This model also 
                                                            
56 Larsen, H. C.; Ridgway, B. H.; Shaw, J. T.; Woerpel, K. A. J. Am. Chem. Soc. 1999, 121, 12208-12209. 




explains the preference for the undesired C23 diastereomer 186. Although both models suggest a 
preference for the undesired diastereomer, alkyl enol silanes are relatively poor nucleophiles58 and a 
weaker nucleophile will lead to a latter transition state so the eclipsing interactions found in transition 
state IV should be more important than an equilibrium between V and VI.59 
 
Figure 4.4.1. Models for diastereoselectivity in oxocarbenium addition. 
 Despite the apparent uphill battle, we attempted to remedy this problem through the use of 
different enol silanes and reaction conditions. Increasing the size of the silyl group on the enol silane does 
provide slightly better diastereoselectivity, but at the expense of yield (Scheme 4.4.4). Other conditions 
using titanium tetrachloride60 or dibutylboron trifluoromethanesulfonate61 to generate the enolate in the 
hopes of having an effect on selectivity through chelation of the benzyl alcohol did not produce any 
desired product. We also considered an epimerization of the C23 carbon through a retro-Michael/Michael 
addition. Kocienski and coworkers attempted the same epimerization after getting poor 
diastereoselectivity in their reaction, but they were unsuccessful. Calculations done by my coworker, Dan 
                                                            
58 Mayr, H.; Bug, T.; Gotta, M. F.; Hering, N.; Irrgang, B.; Janker, B.; Kempf, B.; Loos, R; Ofial, A. R.; 
Remennikov, G.; Schimmel, H. J. Am. Chem. Soc. 2001, 123, 9500-9512. 
59 Anslyn, E. V.; Dougherty, D. A. Modern Physical Organic Chemistry. University Science Books, Sausalito, 
California, 2006. 
60 Jalce, G.; Seckk, M.; Franck, X.; Hocquemiller, R.; Figadère, B. J. Org. Chem. 2004, 69, 3240-3241. 
61 (a) Paterson, I.; Gibson, K. R.; Oballa, R. M. Tetrahedron Lett. 1996, 37, 8585-8588. (b) Evans, D. A.; Coleman, 
P. J.; Côté, B. J. Org. Chem. 1997, 62, 788-789. 
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Henderson, also show that an epimerization approach will be difficult as both of these diastereomers are 
very similar in energy; the undesired cis diastereomer is slightly lower in energy. 
 
Scheme 4.4.4. Influence of silane in fragment coupling. Energy calculations showing difficulty in 
epimerization approach. 
 At this point, we thought use of a chiral counterion might be able to change the 
diastereoselectivity of the enol silane addition (Scheme 4.4.5). List has developed disulfonimide 194 that 
serves as a chiral version of trifluoromethanesulfonimide (HNTf2).
62 The utility of this catalyst was 
demonstrated in Mukaiyama aldol reaction of naphthaldehyde 192 and silyl ketene acetal 193 to furnish 
aldol adduct 195 in good yield and enantioselectivity. Based on this report and reports that HNTf2 has 
generated cyclic oxocarbeniums from methacryloyl and methoxy acetals,63 we attempted to override the 
inherent selectivity in our system. Initial investigations of a model system, using enol silane 143 and 
acetal 196, showed promising reactivity with HNTf2. When we used disulfonimide 194 in our real system, 
                                                            
62 (a) García-García, P.; Lay, F.; García-García, P.; Rabalakos, C.; List, B. Angew. Chem. Int. Ed. 2009, 48, 4363-
4366. (b) Ratjen, L.; García-García, P.; Lay, F.; Beck, M. E.; List, B. Angew. Chem. Int. Ed. 2011, 50, 754-758. 
63 For methacryloyl, see; (a) Zandanel, C.; Dehuyser, L.; Wagner, A.; Baati, R. Tetrahedron 2010, 66, 3365-3369. 
For methoxy, see; (b) Midtkandal, R. R.; Macdonald, S. J. F.; Migaud, M. E. Chem. Commun. 2010, 46, 4538-4540. 
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we only saw hydrolysis of the enol silane.64 List has seen such hydrolysis of silyl ketene acetals, and 
despite our use of solvents from a solvent system and drying the reagents using a benzene azeotrope, we 
could not avoid this hydrolysis. An additional problem with this approach is that silyl ketene acetals are 
much more nucleophilic than enol silanes.65 Despite the initial success using a model system, we chose to 
investigate other approaches to make the C22-C23 bond and set the C23 stereocenter due to a lack of 
reactivity in the real system with both the chiral and achiral catalyst. 
 
Scheme 4.4.5. Sulfonimides did not catalyze the enol silane addition of enol silane 183 into lactol 185. 
4.5 Attempted C17-C32 Fragment Synthesis via HWE/Michael Cascade 
 The first alternative bond disconnection was a Horner-Wadsworth-Emmons/Michael addition 
cascade. This had been used in natural product synthesis before66 and we thought this could work here as 
well. The typical ways that β-keto phosphonates are made is through methyl phosphonate addition into 
                                                            
64 We thank Benjamin List for a sample of (R) and (S)-194 and for helpful discussions. 
65 Mayr, H.; Bug, T.; Gotta, M. F.; Hering, N.; Irrgang, B.; Janker, B.; Kempf, B.; Loos, R; Ofial, A. R.; 
Remennikov, G.; Schimmel, H. J. Am. Chem. Soc. 2001, 123, 9500-9512. 
66 (a) Zhou, X.-T.; Carter, R. G. Angew. Chem. Int. Ed. 2006, 45, 1787-1790. (b) Giannis, A.; Heretsch, P.; Sarli, V.; 
Stößel, A. Angew. Chem. Int. Ed. 2009, 48, 7911-7914. 
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aldehydes followed by oxidation, the Arbuzov reaction, and, less frequently, enolate trapping using an 
electrophilic source of phosphonate. 
 
Figure 4.5.1. HWE/Michael cascade approach to set the C23 stereocenter and typical approaches to β-
keto phosphonates. 
 Due to our desymmetrization, the addition of methyl phosphonate into an aldehyde was not a 
viable route. The desymmetrization of anhydrides with a hydride has not been accomplished in our group. 
Another approach would be the desymmetrization of the anhydride using a Reformatsky reagent, but we 
have not been able to achieve this type of desymmetrization either. Although it is possible to convert a 
methyl ketone into an aldehyde, this is a five to six step process, and the synthesis of such a fragment 
should be done using different methodology so we did not investigate the methylphosphonate addition 
approach. 
 
Scheme 4.5.1. Desymmetrizations with hydride sources or zinc phosphonates have not been accomplished 
in our group. Converting a methyl ketone to a β-keto phosphonate is lengthy. 
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 Our initial efforts focused on the Arbuzov reaction67 of an α-bromoketone. This route suffered 
from two flaws; the Perkow reaction is a competing pathway68 and we observed elimination of benzyl 
alcohol from our substrate. The first flaw can be fixed through the use of different leaving groups69 or 
reaction conditions.  The second problem has been a decomposition problem for some time and is a 
common problem in manipulating aldol adducts. Although there are conditions to facilitate the Arbuzov 
reaction at lower temperatures,70 these failed. In combination with the elimination problems at higher 























Scheme 4.5.2. Attempts at the Arbuzov reaction lead to a messy reaction with some elimination and 
possibly Perkow reaction side products. 
 The other approach that we considered was enolate trapping of an electophilic source of 
phosphonate. The difficulty with this approach is controlling carbon versus oxygen phosphorylation; 
phosphorylation typically occurs on oxygen. The use of cerium enolates71 did not circumvent this 
problem, and attempts to add into a phosphonite and do air oxidation led to a mess.72 
 Rather than waste more precious material, we turned to model systems. We attempted to protect 
the ketone as a hydrazone. With the dimethylhydrazone, we were able to achieve carbon phosphorylation, 
but then deprotection problems precluded this route. We observed starting material with most of the 
                                                            
67 Bhattacharya, A. K.; Thyagarajan, G. Chem. Rev. 1981, 81, 415-430. 
68 Borowitz, I. J.; Firstenberg, S.; Borowitz, G. B.; Schuessler, D. J. Am. Chem. Soc. 1972, 94, 1623-1628. Model 
substrate:  
69 Jacobson, H. I.; Griffin, M. J.; Preis, S.; Jensen, E. V. J. Am. Chem. Soc. 1957, 79,  2608-2612. 
70 Johnson, A.-L.; Slätt, J.; Janosik, T.; Bergman, J. Heterocycles 2006, 68, 2165-2170. 
71 Dalpozzo, R.; De Nino, A.; Miele, D.; Tagarelli, A.; Bartoli, G. Eur. J. Org. Chem. 1999, 2299-2301.  
72 Lee, K.; Wiemer, D. F. J. Org. Chem. 1991, 56, 5556-5560. 
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conditions we tried, but some (methyl iodide and trimethylsilyl chloride) gave hydrazine/phosphine 
adducts by mass. Due to the difficulty in deprotecting the dimethyl hydrazone, we looked at protecting 
groups that were easier to remove. In this case, the phosphorylation was more difficult. 
 
Scheme 4.5.3. Carbon phosphorylation of methyl hydrazones feasible, but deprotection was not 
achievable. 
4.6 C17-C32 Fragment Synthesis via Reduction of Oxocarbenium and Reduction/SN2 Sequence 
 Since the addition of a carbon nucleophile into an oxocarbenium gives the wrong diastereomer, 
we hypothesized that we could switch nucleophile to a hydride and get the correct diastereomer (Figure 
4.6.1). 
 
Figure 4.6.1. Switching the nucleophile from carbon to hydrogen should flip the C23 stereocenter. 
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 Changing the order of carbon-carbon bond formation and reduction to change stereochemistry is 
not without precedence; Kishi and coworkers demonstrated that either diastereomer of C-
glycopyranosides can be synthesized by this approach (Scheme 4.6.1).73 After activating lactol 218, 
addition of allyl silane into the oxocarbenium generated from acetal 219 generates C-glycopyranoside 
220. Alternatively, switching the order by allyl Grignard addition to lactone 221 and subsequent acidic 
reduction, the other diastereomer 223 is generated. They also used the ester enolate from ethyl acetate to 
do the same transformation. 
 
 Scheme 4.6.1. Precedent by Kishi and coworkers that switching the nucleophile from carbon to 
hydrogen switches the major diastereomer. 
 Ideally, we would like to add an enolate into lactone 184 and reduce the resulting lactol to quickly 
access our desired tetrahydrofuran diastereomer 201 (Scheme 4.6.2). Our attempts to get this approach to 
work were thwarted by the inability to make the carbon-carbon bond. Enolates from aliphatic ketones are 
not as nucleophilic as enolates from esters, and we did not see precedence for ketone enolates adding into 
lactones. Therefore, we attempted to increase the electrophilicity of the lactone through the generation of 
                                                            
73 Lewis, M. D.; Cha, J. K.; Kishi, Y. J. Am. Chem. Soc. 1982, 104, 4976-4978. 
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dioxocarbeniums with Meerwein's salt74 or alkylation of a thiolactone,75 but we did not observe our 
desired products. We also tried to increase the nucleophilicity of the enolate through the use of dimethyl 
hydrazone 209, and even the combination of these approaches did not give usable amounts of product. 
Finally, we attempted some model studies to couple Weinreb amide 232 and hydrazone 209,76 but these 
reactions were not reproducible in my hands. 
 
Scheme 4.6.2. Ideal approach to bistetrahydrofuran 201 via an enolate addition and acidic reduction 
sequence. The inability to form the carbon-carbon bond frustrated this route. 
 As carbon-carbon bond formation with enolates and enolate derivatives was stumbling, we turned  
to an alkyne as an alternative nucleophile. This nucleophile has been employed in the synthesis of C-
glycopyranosides, giving this approach precedence.77 Although conditions with the lithium acetylide did 
                                                            
74 (a) Deslongchamps, P.; Lessard, J.; Nadeau, Y. Can. J. Chem. 1985, 63, 2485-2492. (b) Velázquez, F.; Olivo, H. 
F. Org. Lett. 2002, 4, 3175-3178. (c) Chamberland, S.; Ziller, J. W.; Woerpel, K. A. J. Am. Chem. Soc. 2005, 127, 
5322-5323. 
75 Filippi, J.-J.; Fernandez, X.; Lizzani-Cuvelier, L.; Loiseau, A.-M. Flavour Fragr. J. 2006, 21, 175-184. 
76 Evans, D. A.; Kaldor, S. W.; Jones, T. K.; Clardy, J.; Stout, T. J. J. Am. Chem. Soc. 1990, 112, 7001-7031. 
77 Sánchez, M. E. L.; Michelet, V.; Besnier, I.; Genêt, J. P. Synlett 1994, 705-708. 
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not work, the use of boron trifluoride (BF3)
78 or cerium(III) chloride79 facilitated the addition of the 
alkyne 234 into lactone 227. The reduction of model ynone 235 using BF3 and triethylsilane (Et3SiH) 
worked (with deprotection of the primary TBS protecting group). After getting the model system to work 



























Scheme 4.6.3. Synthesis and reduction of model ynone 235. 
 We were able to synthesize our targeted alkyne 239 via elimination of both a vinyl phosphonate 
205 and vinyl triflate 238, but chose the vinyl phosphonate route due to purification reasons. 
Deprotonation of methyl ketone 182 with lithium bis(trimethylsilyl)amide (LiHMDS) and 
phosphorylation generates vinyl phosphonate 205. Traditional elimination conditions using LiHMDS or 
lithium diisopropylamide failed to generate the targeted alkyne, but elimination was achieved by using 
tertbutyl lithium. A similar route through vinyl triflate 238 could deliver alkyne 239, but the polarities of 
the vinyl triflate and alkyne are the same, making the isolation of alkyne 239 more difficult. 
 
                                                            
78 (a) Yamaguchi, M.; Shibato, K.; Fujiwara, S.; Hirao, I. Synthesis 1986, 421-422. (b) Doubský, J.; Streinz, L.; 
Lešetický, L.; Koutek, B. Synlett 2003, 937-942. 




Scheme 4.6.4. Synthesis of alkyne 239. The route through phosphonate 205 is preferred due to isolation 
issues with vinyl triflate substrate. 
 With alkyne 239 and lactone 184 in hand, we attempted the addition. Despite our success in 
making model ynone 235, the synthesis of ynone 240 using this approach eluded us. Some control 
experiments shed some light which substrate is problematic. The addition of dichlorophenylcerium into 
lactone 184 works, but alkyne 239 does not add into simple lactone 227. 
 
Scheme 4.6.5. Synthesis of ynone 240 fails due to alkyne 239 being unable to add to a lactone. 
 At this point, forming the carbon-carbon bond was still preventing us from testing our idea. With 
alkyne 239 in hand, we sought to activate the lactone as a thioester and use a palladium-catalyzed 
coupling to generate our targeted ynone.80 Although thioesters from lactones have been synthesized 
                                                            
80 Tokuyama, H.; Miyazaki, T.; Yokoshima, S.; Fukuyama, T. Synlett 2003, 1512-1545. 
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before, the synthesis and handling of these compounds is difficult. The yields are low and the compounds 
are prone to recyclizing to starting material. After finding conditions to make thioester 243,81 we were 
concerned about the viability of the cross coupling due to the free alcohol γ to the thioester as there was 
no precedence. The reaction is under basic conditions with potentially Lewis acidic metals making 
recyclization of the lactone a concern.82 Additionally, it is known that palladium can catalyze the 
formation of esters from aryl halides with carbon monoxide and alcohols.83 From the reaction of model 
thioester 243 and alkyne 234, we were able to isolate ynone 235 in moderate yield. We were still 
concerned about the use of alkyne 239 as it had failed to react when model systems had worked in the 
past, but it also couples with model thioester 243 in low yield. Excited by this result, we attempted the 
cross coupling of thioester 120 and alkyne 239 and achieved the synthesis of ynone 240. 
 
Scheme 4.6.6. Alternate synthesis of ynone 240 via palladium-catalyzed coupling of thioester 120 and 
alkyne 239. 
                                                            
81 Gierasch, T. M.; Shi, Z.; Verdine, G. L. Org. Lett. 2003, 5, 621-624. 
82 After the reaction, lactone is observed and no thioester remains. 
83 Presumably by alcoholysis of a palladium acyl species, which we seek to form in the reaction. See: (a) Milstein, 
D. Acc. Chem. Res. 1988, 21, 428-434. (b) Moser, W. R.; Wang, A. W.; Kildahl, N. K. J. Am. Chem. Soc. 1988, 110, 
2816-2820. (c) Lindsell, W. E.; Palmer, D. D.; Preston, P. N.; Rosair, G. M. Organometallics 2005, 24, 1119-1133. 
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 After finally forming our targeted carbon-carbon bond, we could investigate reductive cyclization 
of ynone 240. Prototypical conditions using BF3/Et3SiH and trimethylsilyl trifluoromethanesulfonate/ 
Et3SiH
84 did not bring about the desired transformation. We were excited to find that tin tetrachloride and 
Et3SiH
85 induces cyclization, but it also removes the secondary TBS  protecting group. Reduction with 
tetramethylammonium triacetoxyborohydride86 also gives a small amount of product. We found sodium 
cyanoborohdride87 and dichloroacetic acid in trifluoroethanol effects the reductive cyclization in 19:1 dr 
to furnish bistetrahydrofuran 245 in good yield. We were excited to get the reaction to work and 
suspected, based on our own work and Kishi's, that we had made the correct C23 stereocenter, but we 
wanted to confirm our stereochemistry before moving on with the synthesis. 
 
Scheme 4.6.7. Reductive cyclization of ynone 240 proceeds in good yields under surprising conditions. 
 In order to establish the C23 stereocenter that we formed using the acidic reduction condition in 
making bistetrahydrofuran 245, we reduced the ynone and performed an SN2 cyclization. Using Noyori 
transfer hydrogenation conditions88 we made both C23 alcoholic stereocenters. While tosylation failed, 
                                                            
84(a) Nicolaou, K. C.; Hwang, C. K.; Nugiel, D. A. J. Am. Chem. Soc. 1989, 111, 4136-4137. (b) González, I. C.; 
Forsyth, C. J. J. Am. Chem. Soc. 2000, 122, 9099-9108. 
85 Zhang, Z.; Ding, Y.; Xu, J.; Chen, Y.; Forsyth, C. J. Org. Lett. 2013, 15, 2338-2341. 
86 Enders, D.; Hieronymi, A.; Raabe, G. Synthesis 2008, 10, 1545-1558. 
87 Wilcox, C. S.; Cowart, M. D. Carbohydrate Research 1987, 171, 141-160. 
88 (a) Matsumura, K.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1997, 119, 8738-8739. (b) 
Newcomb, E. T.; Ferreira, E. M. Org. Lett. 2013, 15, 1772-1775. 
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mesylation using methanesulfonic anhydride89 generated bistetrahydrofurans 248 and 245 upon workup. 
By comparing the 1H NMRs of these compounds, we found that the reductive cyclization surprisingly 
delivers the wrong C23 stereocenter. Although disappointing, this news was delivered through the 
synthesis of the correct C23 diastereomer. 
Ru(cymene)[(R,R)-Ts-DPEN] Ru(cymene)[(S,S)-Ts-DPEN]

































































Scheme 4.6.8. Ynone reduction and cyclization to synthesize both C23 diastereomers. 1H NMR showed 
that we are making the incorrect C23 stereocenter with reductive cyclization conditions. 
 With bistetrahydrofuran 248 in hand, we attempted to elaborate it to known aldehyde 252. 
Dissolving metal conditions effected the reduction of the alkyne down to the alkene and removed the 
benzyl protecting group as expected, but it also partially reduced the tertbutyldiphenyl silyl (TBDPS) 
                                                            
89 Ogawa, K.; Koyama, Y.; Ohashi, I.; Sato, I.; Hirama, M. Angew. Chem. Int. Ed. 2009, 48, 1110-1113. 
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protecting group. This has been observed before.90 Tetrabutylammonium fluoride deprotection of alcohol 
249 generates diol 250 in good yield. Reconstitution of the TBDPS protecting group91 constitutes a formal 
synthesis of aldehyde 252 via Kocienski's synthesis of ionomycin.92  
 
Scheme 4.6.9. Elaboration of alkyne 248. 
 At this point, we had a route to homoallylic alcohol 251 and knew that aldehyde 252 could be 
made in seven steps using known chemistry, but we sought a more expedient route using oxymercuration 
of in situ formed hemiketals developed by Leighton.93 Although Leighton only reported terminal alkenes, 
Bonini did the same transformation on simple electron-deficient 1,2-substituted alkenes.94 When we tried 
the reaction with homoallylic alcohol 251,95 the transformation takes place, but it looks like there might 
be diastereomers (Scheme 4.6.10). Based on Leighton's work, we suspect that the acetonide is syn and the 
                                                            
90 Observed reduction; (a) Kögl, M.; Brecker, L.; Warrass, R.; Mulzer, J. Eur. J. Org. Chem. 2008, 2714-2730. Did 
not observe reduction; (b) Swindell, C. S.; Patel, B. P. Tetrahedron Lett. 1987, 28, 5275-5278. (c) VanderRoest, J. 
M.; Grieco, P. A. J. Am. Chem. Soc. 1993, 115, 5841-5842. (d) Naidu, S. V.; Kumar, P. Tetrahedron Lett. 2007, 48, 
2279-2282. 
91 Benzylation of the primary alcohol yields 41% monoprotected diol, see Appendix 4 for details. 
92 Gao, Z.; Li, Y.; Cooksey, J. P.; Snaddon, T. N.; Schunk, S.; Viseux, E. M. E.; McAteer, S. M.; Kocienski, P. J. 
Angew. Chem. Int. Ed. 2009, 48, 5022-5025. 
93 Dreher, S. D.; Hornberger, K. R.; Sarraf, S. T.; Leighton, J. L. Org. Lett. 2000, 2, 3197-3199. 
94 (a) Bonini, C.; Campaniello, M.; Chiummiento, L.; Videtta, V. Tetrahedron 2008, 64, 8766-8772. (b) Bonini, C.; 
Chiummiento, L.; Funicello, M.; Lupattelli, P.; Videtta, V. Tetrahedron Lett. 2008, 49, 5455-5457.  
95 This reaction also worked with a benzyl protecting group in 17% yield, see Appendix 4 for details. 
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diastereomers are from the mercury, but this has not been confirmed. If the stereochemistry is what we 
suspect, then removal of the mercury, removal of the protecting group, and oxidation would generate 
targeted aldehyde 252. 
 
Scheme 4.6.10. Oxymercuration of the hemiketal derived from homoallylic alcohol 251 generates acetal 
253. 
4.7 Conclusion 
 In conclusion, we have demonstrated the utility of catalytic desymmetrization of anhydrides with 
zinc nucleophiles by synthesizing large portions of ionomycin 10. Despite the ability of the 
desymmetrizations to make complex synthons with the correct stereocenters, other parts of the synthesis 
prevented us from completing ionomycin in the time we had. 
 We found that the Julia-Kocienski olefination required the sulfone to be on C16 and the 
olefination could be done to make the entire ionomycin skeleton in the presence of an unprotected β-
diketone. We had difficulties in making the desired C23 stereocenter. Initial efforts adding a carbon 
nucleophile into an oxocarbenium generated the undesired stereocenter. Despite switching the carbon-
carbon bond forming and reduction steps, we still generated the undesired stereocenter. We were able to 
generate the targeted stereocenter using a reduction and SN2 displacement sequence. We were able to 
elaborate this material to an intermediate that intercepted Kocienski's synthesis of the top fragment of 
ionomycin and demonstrated that an oxymercuration approach to install the C21 alcohol is possible. 
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General Methods. All reactions were carried out under an atmosphere of argon in oven-dried 
glassware with magnetic stirring. Toluene was degassed with argon and passed through one column of 
neutral alumina and one column of Q5 reactant. Column chromatography was performed on Silicycle Inc. 
silica gel 60 (230-400 mesh). Thin layer chromatography was performed on Silicycle Inc. 0.25 mm silica 
gel 60-F plates. Visualization was accomplished with UV light (254 nm), potassium permanganate, 
and/or cerric ammonium nitrate. 
 1H NMR and 13C NMR spectra were obtained in CDCl3 at ambient temperature and chemical 
shifts are expressed in parts per million (δ, ppm). Proton chemical shifts are referenced to 7.26 ppm 
(CHCl3) and carbon chemical shifts are referenced to 77.0 ppm (CDCl3). Data reporting uses the 
following abbreviations: s, singlet; bs, broad singlet; d, doublet; dd, doublet of doublets; t, triplet; m, 
multiplet; and J, coupling constant in Hz. 
 Alkynes 16a, 16b, 16d - 16o, isocyanates 17a - 17c, 17e - 17i, triphenylphosphine, tris(4-
methoxyphenyl)phosphine, and trifluoroacetic acid were purchased from Aldrich Chemicals Co. and used 
without further purification. [Rh(C2H4)2Cl]2 and tris(4-trifluoromethylphenyl)phosphine were purchased 
from Strem Chemical, Inc. and used without further purification. Isocyanate 17d and 17j were 
synthesized by converting the corresponding acid to the acyl azide with diphenylphosphoryl azide and 
gentle heating of the acyl azide neat to afford the isocyanate as described in previous work.1 rac-L5 was 
synthesized as described in the literature.2 
General procedure for cycloaddition.   To an oven-dried round bottom flask, [Rh(C2H4)2Cl]2 
(2.3 mg, 0.006 mmol, 2.5 mol %) and rac-L5 (5.1 mg, 0.012 mmol, 5 mol %) were added and an oven-
dried reflux condenser was fitted in an inert atmosphere (N2) glove box. After removal from the glove 
box, 1 ml of toluene was added via syringe and allowed to stir for 15 min at 23 °C under Ar. A solution of 
alkyne 16 (0.720 mmol, 3 equiv.) and isocyanate 17 (0.240 mmol) in 1 ml toluene was added via syringe. 
After rinsing the condenser with additional 6 ml toluene, the reaction was heated to 110 °C in an oil bath 
and maintained at reflux for 12 h. The reaction mixture was allowed to cool to 23 °C, concentrated in 
vacuo, and purified by flash chromatography (gradient elution typically 1:1 Hex:EtOAc, difficult 
separations used 95:5 CH2Cl2:EtOAc, and 4-pyridones required elution with 10:1 EtOAc:MeOH). 











1 Lee, E. E.; Rovis, T. Org. Lett. 2008, 10, 1231-1234. 
2 Giacomina, F.; Meetsma, A.; Panella, L.; Lefort, L.; de Vries, A. H. M.; de Vries, J. G. Angew. Chem. Int. Ed. 
2007, 46, 1497-1500. 
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Characterization Data for New Compounds. 
 
1-benzyl-4,6-diphenyl-2-pyridone (1db). General procedure yielded 68.3 mg (68%) 
of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.62 (m, 2H), 7.43 (m, 4H), 7.34 (m, 
2H), 7.19 (m, 5H), 6.94 (m, 3H), 6.40 (d, J = 2.1 Hz, 1H), 5.22 (s, 2H). 13C NMR 
(100 MHz, CDCl3) δ 163.5, 150.6, 149.8, 137.2, 137.1, 135.2, 129.4, 129.1, 128.8, 
128.6, 128.2, 127.0, 126.8, 126.7, 115.6, 107.8, 48.4. Rf = 0.24 (2:1 Hex:EtOAc). IR 
(NaCl, CHCl3) 3053, 3027, 2996, 1650, 1603, 1583, 1532, 1486, 748, 723, 697. 
HRMS (ESI) [C24H20NO]
+ calcd 338.15002, found 338.15438. 
(Z)-N-benzyl-3,5-diphenylpent-2-en-4-ynamide (25db). General procedure 
yielded 6.2 mg (6%) of enynamide from reaction above. 1H NMR (400 MHz, 
CDCl3) δ 7.73 (m, 2H), 7.64 (s, 1H), 7.44 - 7.24 (m, 11H), 7.13 (m, 2H), 6.69 (s, 
1H), 4.64 (d, J = 5.3 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.0, 137.8, 137.0, 
131.6, 129.5, 129.0, 128.8, 128.7, 128.5, 128.3, 128.1, 127.6, 126.9, 121.2, 101.6, 
85.8, 44.1. Rf = 0.31 (95:5 CH2Cl2:EtOAc). IR (NaCl, CHCl3) 3247, 3058, 3022, 
2914, 1639, 1526, 1230, 989. HRMS (ESI) [C24H20NO]
+ calcd 338.15002, found 338.15405. 
1-benzyl-4,6-bis(3-fluorophenyl)-2-pyridone (1eb). General procedure yielded 
41.5 mg (46%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.41 (m, 2H), 7.31 
(m, 2H), 7.21 (m, 3H), 7.13 (m, 2H), 6.96 (m, 1H), 6.91 (m, 3H), 6.86 (m, 1H), 
6.33 (d, J = 2.1 Hz, 1H), 5.20 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 164.2, 
163.4, 163.3, 161.8, 160.9, 149.4, 148.7, 139.4, 139.4, 136.9, 136.8, 130.6, 130.5, 
130.1, 130.0, 128.4, 127.2, 126.8, 124.5, 122.4, 116.5, 116.3, 116.2, 116.0, 113.9, 
113.6, 107.5, 48.5. Rf = 0.24 (2:1 Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3027, 3001, 2955, 1660, 1588, 
1537, 1475, 1265, 784, 692. HRMS (ESI) [C24H18F2NO]
+ calcd 374.13118, found 374.13546. 
1-benzyl-4,6-bis(4-methoxyphenyl)-2-pyridone (1fb). General procedure 
yielded 84.8 mg (88%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.58 
(m, 2H), 7.21 (m, 3H), 7.10 (m, 2H), 6.96 (m, 4H), 6.87 (d, J = 2.1 Hz, 1H), 
6.85 (m, 2H), 6.38 (d, J = 2.1 Hz, 1H), 5.21 (s, 2H), 3.84 (s, 3H), 3.82 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 163.7, 160.7, 160.0, 150.0, 149.6, 137.3, 
130.0, 129.4, 128.2, 128.0, 127.7, 126.9, 126.7, 114.2, 114.1, 113.6, 107.8, 
55.2, 48.4. Rf = 0.23 (1:1 Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3032, 2960, 2838, 1650, 1608, 1511, 
1250, 1030, 830, 728. HRMS (ESI) [C26H24NO3]
+ calcd 398.17115, found 398.17577. 
1-benzyl-2,6-bis(4-methoxyphenyl)-4-pyridone (2fb). General procedure 
yielded 3.4 mg (4%) of 4-pyridone from reaction above. 1H NMR (400 MHz, 
CDCl3) δ 7.17 (m, 4H), 7.11 (m, 3H), 6.85 (m, 4H), 6.49 (m, 2H), 6.41 (s, 
2H), 4.93 (s, 2H), 3.81 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 179.0, 160.3, 
153.7, 137.0, 130.0, 128.4, 127.5, 125.7, 120.6, 113.9, 55.3, 53.8. Rf = 0.12 
(10:1 EtOAc:MeOH). IR (NaCl, CHCl3) 3068, 3001, 2925, 2838, 1619, 
1496, 1250, 1173, 1020, 830. HRMS (ESI) [C26H24NO3]
+ calcd 398.17115, found 398.17478. 
 
1,4,6-trihexyl-2-pyridone (1gc). General procedure yielded 26.6 mg (32%) of 2-
pyridone. 1H NMR (300 MHz, CDCl3) δ 6.22 (d, J = 1.6 Hz, 1H), 5.83 (d, J = 1.9 Hz, 
1H), 3.93 (t, J = 7.9 Hz, 2H), 2.54 (t, J = 7.6 Hz, 2H), 2.34 (t, J = 7.3 Hz, 2H), 1.69-1.47 
(m, 6H), 1.40-1.26 (m, 18H), 0.91-0.84 (m, 9H). 13C NMR (75 MHz, CDCl3) δ 163.8, 
135 
 
154.2, 148.5, 115.5, 107.4, 43.6, 35.2, 32.9, 31.6, 31.5, 31.4, 29.2, 29.0, 29.0, 28.9, 28.8, 26.7, 22.5, 22.5, 
14.0, 14.0, 14.0. Rf = 0.38 (2:1 Hex:EtOAc). IR (NaCl, CHCl3) 2956, 2928, 2858, 1665, 1590, 1546, 
1459. LRMS (ESI) [C23H42NO]
+ calcd 348.3, found 348.3. 
 
1,2,6-trihexyl-4-pyridone (2gc). General procedure yielded 6.7 mg (8%) of 4-pyridone 
from reaction above. 1H NMR (400 MHz, CDCl3) δ 6.24 (s, 2H), 3.76 (t, J = 8.3 Hz, 2H), 
2.53 (t, J = 7.6 Hz, 4H), 1.65-1.57 (m, 6H), 1.43-1.29 (m, 18H), 0.92-0.87 (m, 9H). 13C 
NMR (100 MHz, CDCl3) δ 178.9,  152.4, 117.6, 46.6, 32.8, 31.4, 31.2, 31.0, 29.0, 28.9, 
26.7, 22.5, 14.0, 13.9. Rf = 0.11 (4:1 EtOAc:MeOH). IR (NaCl, CHCl3) 2956, 2929, 
2858, 1632, 1568, 1459, 1182. LRMS (ESI) [C23H42NO]
+ calcd 348.3, found 348.3. 
1-benzyl-4,6-bis(3-methoxyphenyl)-2-pyridone (1hb). General procedure 
yielded 71.4 mg (73%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.36 (t, 
J = 8.0 Hz, 1H), 7.29 - 7.14 (m, 6H), 6.96 (m, 4H), 6.92 (d, J = 2.1 Hz, 1H), 
6.81 (m, 1H), 6.60 (m, 1H), 6.40 (d, J = 2.1 Hz, 1H), 5.20 (s, 2H), 3.85 (s, 
3H), 3.56 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 163.6, 160.0, 159.1, 150.6, 
149.8, 138.8, 137.4, 136.4, 130.0, 129.5, 128.4, 127.0, 126.8, 120.8, 119.1, 
115.8, 115.7, 115.1, 113.6, 112.1, 107.6, 55.3, 55.0, 48.7. Rf = 0.26 (95:5 CH2Cl2:EtOAc). IR (NaCl, 
CHCl3) 3063, 3027, 3001, 2955, 2827, 1654, 1588, 1532, 1491, 1286, 1030, 733, 702. HRMS (ESI) 
[C26H24NO3]
+ calcd 398.17115, found 398.17625. 
1-benzyl-4,6-bis(2-methoxyphenyl)-2-pyridone (1ib). General procedure yielded 
55.0 mg (54%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.33 (m, 3H), 7.10 (m, 
3H), 6.95 (m, 3H), 6.86 (m, 5H), 6.29 (d, J = 2.0 Hz, 1H), 5.44 (d, J = 14.8 Hz, 1H), 
4.71 (d, J = 14.8 Hz, 1H), 3.78 (s, 3H), 3.60 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
163.7, 156.6, 156.4, 149.0, 145.5, 137.4, 131.0, 130.8, 130.2, 130.1, 127.9, 127.5, 
127.0, 126.7, 124.5, 120.7, 120.3, 118.7, 111.2, 110.5, 55.5, 55.1, 48.2. Rf = 0.28 (1:1 
Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3006, 2966, 2827, 1650, 1603, 1573, 1245, 1020. HRMS (ESI) 
[C26H24NO3]
+ calcd 398.17115, found 398.17582. 
1-benzyl-4,6-di(thiophen-3-yl)-2-pyridone (1jb). General procedure yielded 68.2 mg 
(80%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.61 (dd, J = 2.7, 1.6 Hz, 1H), 
7.39 (m, 2H), 7.32 (dd, J = 5.0, 3.0 Hz, 1H), 7.22 (m, 3H), 7.16 (dd, J = 3.0, 1.3 Hz, 
1H), 6.98 (m, 2H), 6.91 (dd, J = 5.0, 1.3 Hz, 1H), 6.89 (d, J = 2.0 Hz, 1H), 6.45 (d, J = 
2.1 Hz, 1H), 5.22 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 163.7, 145.1, 144.6, 138.6, 
137.2, 135.4, 128.4, 127.8, 127.0, 126.9, 126.5, 126.2, 125.9, 125.6, 123.9, 114.6, 
107.6, 48.5. Rf = 0.13 (2:1 Hex:EtOAc). IR (NaCl, CHCl3) 3104, 3083, 3022, 3001, 2950, 1660, 1578, 
1552, 851, 789, 728. HRMS (ESI) [C20H15NOS2]
+ calcd 350.06286, found 350.06775. 
1-benzyl-4,6-dicyclohexenyl-2-pyridone (1kb). General procedure yielded 79.9 mg 
(92%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.21 (m, 2H), 7.14 (m, 1H), 7.07 
(m, 2H), 6.44 (d, J = 2.0 Hz, 1H), 6.33 (m, 1H), 6.07 (d, J = 2.1 Hz, 1H), 5.54 (m, 1H), 
5.15 (s, 2H), 2.26 (m, 2H), 2.16 (m, 2H), 1.98 (m, 2H), 1.89 (m, 2H), 1.69 (m, 2H), 
1.57 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 164.1, 151.4, 150.8, 137.9, 133.9, 133.6, 
130.5, 129.4, 128.2, 126.8, 126.6, 112.6, 103.7, 47.9, 29.6, 26.0, 25.9, 24.9, 22.6, 22.3, 
21.8, 21.4. Rf = 0.17 (2:1 Hex:EtOAc). IR (NaCl, CHCl3) 3068, 3022, 2930, 2853, 2827, 1644, 1568, 
1521, 1429. 748, 687. HRMS (ESI) [C24H28NO]








1-benzyl-4,6-dihexyl-2-pyridone (1gb). General procedure yielded 39.8 mg (38%) of 2-
pyridone. 1H NMR (400 MHz, CDCl3) δ 7.28 (m, 2H), 7.21 (m, 1H), 7.10 (m, 2H), 6.38 
(s, 1H), 5.91 (d, J = 1.7 Hz, 1H), 5.32 (s, 2H), 2.47 (t, J = 7.8 Hz, 2H), 2.41 (t, J = 7.6 
Hz, 2H), 1.58 (m, 2H), 1.51 (m, 2H), 1.27 (m, 12H), 0.88 (t, J = 6.8 Hz, 3H), 0.86 (t, J = 
6.9 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 164.0, 155.0, 149.3, 136.9, 128.6, 127.1, 
126.2, 115.4, 107.8, 46.2, 35.3, 32.8, 31.5, 31.4, 29.1, 28.8, 28.5, 22.5, 22.4, 14.0, 13.9. Rf = 0.22 (4:1 
Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3027, 2960, 2930, 2853, 1665, 1588, 1547, 1450, 728. HRMS 
(ESI) [C24H36NO]
+ calcd 354.27522, found 354.27904. 
1-benzyl-4,6-dicyclohexyl-2-pyridone (1lb). General procedure yielded 12.6 mg 
(15%) of 2-pyridone. 1H NMR (300 MHz, CDCl3) δ 7.31-7.19  (m, 3H), 7.13-7.10 
(m, 2H), 6.35 (d, J = 1.3 Hz, 1H), 5.96 (d, J = 1.7 Hz, 1H), 5.37 (s, 2H), 2.54 (m, 
1H), 2.29 (m, 1H), 1.86- 1.67 (m, 10H), 1.42-1.15 (m, 10H). 13C NMR (75 MHz, 
CDCl3) δ 164.3, 159.3, 154.4, 137.5, 128.6, 127.0, 126.3, 113.5, 104.4, 45.8, 43.9, 
40.6, 33.5, 32.6, 26.5, 26.4, 25.9, 25.8. Rf = 0.12 (2:1 Hex:EtOAc). IR (NaCl, 
CHCl3) 2927, 2853, 1661, 1583, 1544, 1496, 1450. LRMS (ESI) [C24H32NO]
+ calcd 
350.2, found 350.3. 
1,4,6-tribenzyl-2-pyridone (1mb). General procedure yielded 17.3 mg (19%) of 
2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.20 (m, 11H), 7.11 (m, 2H), 
7.04 (m, 2H), 6.42 (s, 1H), 5.87 (d, J = 1.8 Hz, 1H), 5.18 (s, 2H), 3.78 (s, 2H), 
3.77 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 164.1, 153.0, 147.1, 137.9, 136.7, 
136.2, 129.1, 129.0, 128.8, 128.7, 128.1, 127.2, 127.1, 126.7, 126.1, 117.1, 110.1, 
46.2, 41.3, 39.2. Rf = 0.12 (95:5 CH2Cl2:EtOAc). IR (NaCl, CHCl3) 3058, 3022, 2996, 1660, 1588, 1542, 
1486, 723, 692. HRMS (ESI) [C26H24NO]
+ calcd 366.18132, found 366.18559. 
(Z)-N,3-dibenzyl-6-phenylhex-2-en-4-ynamide (25mb). General procedure 
yielded 14.8 mg (16%) of enynamide from reaction above.  1H NMR (400 
MHz, CDCl3) δ 7.40 (s, 1H), 7.37 - 7.14 (m, 13H), 7.05 (m, 2H), 6.09 (s, 1H), 
4.42 (d, J = 5.5 Hz, 2H), 3.57 (s, 2H), 3.53 (s, 2H). 13C NMR (100 MHz, 
CDCl3) δ 164.8, 138.0, 137.0, 135.2, 130.4, 129.6, 129.2, 128.7, 128.6, 128.5, 
127.8, 127.4, 126.9, 100.5, 80.3, 44.9, 43.6, 25.7. Rf = 0.28 (95:5 
CH2Cl2:EtOAc). IR (NaCl, CHCl3) 3283, 3058, 3022, 2996, 2914, 1644, 1485, 1450, 697. HRMS (ESI) 
[C26H24NO]
+ calcd 366.18132, found 366.18552. 
1-benzyl-4,6-bis(2-(tert-butyldimethylsilyloxy)ethyl)-2-pyridone (1nb). 
General procedure yielded 22.3 mg (18%) of 2-pyridone. 1H NMR (400 MHz, 
CDCl3) δ 7.28 (m, 2H), 7.21 (m, 1H), 7.09 (m, 2H), 6.40 (s, 1H), 6.00 (s, 1H), 
5.43 (s, 2H), 3.82 (t, J = 6.7 Hz, 2H), 3.76 (d, J = 6.3 Hz, 2H), 2.71 (t, J = 6.3 
Hz, 2H), 2.62 (t, J = 6.7 Hz, 2H), 0.87 (d, J = 0.8 Hz, 9H), 0.84 (d, J = 0.8 Hz, 
9H), 0.03 (d, J = 0.8 Hz, 6H), -0.04 (d, J = 0.8 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 163.8, 151.5, 
146.8, 136.9, 128.7, 127.1, 126.2, 116.9, 109.3, 62.6, 62.3, 46.5, 38.8, 36.0, 25.9, 25.8, 18.3, 18.2, -5.4, -
5.6. Rf = 0.22 (95:5 CH2Cl2:EtOAc). IR (NaCl, CHCl3) 3063, 3027, 2955, 2925, 2883, 2853, 1660, 1588, 
1542, 1255, 1096, 835, 723. HRMS (ESI) [C28H48NO3Si2]
+ calcd 502.31280, found 502.31729. 
 
1-benzyl-4,6-diethoxy-2-pyridone (1ob). General procedure yielded 24.2 mg (38%) of 2-
pyridone. 1H NMR (400 MHz, CDCl3) δ 7.26 (m, 5H), 5.69 (d, J = 2.0 Hz, 1H), 5.21 (bs, 
3H), 3.97 (m, 4H), 1.36 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 168.3, 163.6, 156.8, 
137.5, 128.2, 128.0, 127.1, 89.9, 79.6, 65.3, 63.9, 43.8, 14.3, 14.0. Rf = 0.24 (1:1 
Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3032, 2976, 2935, 2894, 1660, 1593, 1547, 1255, 
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1189, 1112, 738. HRMS (ESI) [C16H20NO3]
+ calcd 274.13985, found 274.14439. 
Dimethyl 1-benzyl-2-oxo-4,6-diphenyl-1,2-dihydropyridine-3,5-dicarboxylate 
(1ab). General procedure using rac-L1 yielded 60.3 mg (42%) of 2-pyridone. 1H 
NMR (400 MHz, CDCl3) δ 7.44 - 7.31 (m, 8H), 7.21 (m, 3H), 7.11 (m, 2H), 6.90 (m, 
2H), 5.15 (s, 2H), 3.64 (s, 3H), 3.05 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 166.1, 
165.9, 159.3, 149.4, 148.4, 136.0, 135.5, 132.0, 129.8, 128.8, 128.8, 128.3, 128.2, 
128.1, 127.4, 127.3, 127.2, 124.3, 116.0, 52.3, 51.8, 49.3. Rf = 0.38 (2:1 Hex:EtOAc). 
IR (NaCl, CHCl3) 3063, 3032, 2950, 1736, 1644, 1532, 1486, 1429, 1250, 1214, 1132, 764, 697. HRMS 
(ESI) [C28H24NO5]
+ calcd 454.16098, found 454.16491. 
1-(4-methoxybenzyl)-4,6-(4-methoxyphenyl)-2-pyridone (1fd). General 
procedure yielded 80.8 mg (79%) of 2-pyridone. 1H NMR (400 MHz, 
CDCl3) δ 7.57 (m, 2H), 7.11 (m, 2H), 6.96 (m, 2H), 6.88 (m, 4H), 6.83 (d, J 
= 2.1 Hz, 1H), 6.74 (m, 2H), 6.34 (d, J = 2.1 Hz, 1H), 5.14 (s, 2H), 3.84 (s, 
6H), 3.75 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 163.7, 160.6, 160.0, 158.4, 
149.8, 149.5, 130.0, 129.5, 128.3, 127.9, 127.8, 114.2, 113.5, 107.6, 55.2, 
55.0, 47.7. Rf = 0.18 (1:1 Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3001, 2955, 
2832, 1650, 1608, 1506, 1245, 1030, 820, 748. HRMS (ESI) [C27H26NO4]
+ calcd 428.18171, found 
428.18407. 
1-(4-methoxybenzyl)-2,6-bis(4-methoxyphenyl)-4-pyridone (2fd). General 
procedure yielded 4.0 mg (4%) of 4-pyridone from reaction above. 1H NMR 
(400 MHz, CDCl3) δ 7.18 (m, 4H), 6.86 (m, 4H), 6.62 (m, 2H), 6.41 (s, 2H), 
6.38 (m, 2H), 4.87 (s, 2H), 3.81 (s, 6H), 3.72 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ 178.9, 160.3, 158.8, 153.8, 130.0, 128.8, 127.5, 127.0, 120.5, 
113.9, 113.8, 55.3, 55.2, 53.4. Rf = 0.33 (10:1 EtOAc:MeOH). IR (NaCl, 
CHCl3) 3006, 2925, 2832, 1619, 1496, 1245, 1173, 1020, 835. HRMS (ESI) 
[C27H26NO4]
+ calcd 428.18171, found 428.18501. 
 
1-hexyl-4,6-bis(4-methoxyphenyl)-2-pyridone (1fc). General procedure 
yielded 49.9 mg (52%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.53 
(m, 2H), 7.29 (m, 2H), 6.95 (m, 4H), 6.74 (d, J = 2.0 Hz, 1H), 6.29 (d, J = 
2.0 Hz, 1H), 3.88 (t, J = 7.9 Hz, 2H), 3.86 (s, 3H), 3.82 (s, 3H), 1.56 (m, 
2H), 1.14 (m, 6H), 0.79 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) 
δ 163.5, 160.6, 160.0, 149.5, 149.2, 129.9, 129.7, 128.1, 127.9, 114.2, 113.8, 107.4, 55.3, 55.2, 45.4, 31.0, 
28.6, 26.3, 22.3, 13.9. Rf = 0.12 (2:1 Hex:EtOAc). IR (NaCl, CHCl3) 3037, 3001, 2955, 2925, 2853, 2827, 
1660, 1614, 1592, 1511, 1301, 1245, 1178, 1030, 825, 723. HRMS (ESI) [C25H30NO3]
+ calcd 392.21810, 
found 392.22287. 
 
1-hexyl-2,6-bis(4-methoxyphenyl)-4-pyridone (2fc). General procedure 
yielded 16.8 mg (18%) of 4-pyridone from reaction above. 1H NMR (400 
MHz, CDCl3) δ 7.33 (m, 4H), 6.98 (m, 4H), 6.34 (s, 2H), 3.86 (s, 6H), 
3.70 (t, J = 7.8 Hz, 2H), 1.13 (m, 2H), 0.98 (m, 2H), 0.77 (m, 4H), 0.68 (t, 
J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 178.7, 160.3, 153.0, 
130.0, 127.8, 120.5, 114.0, 55.4, 50.2, 30.6, 29.8, 25.5, 22.0, 13.7. Rf = 0.16 (10:1 EtOAc:MeOH). IR 
(NaCl, CHCl3) 3001, 2955, 2935, 2853, 1619, 1552, 1501, 1250, 1178, 1035, 830. HRMS (ESI) 
[C25H30NO3]
+ calcd 392.21810, found 392.22238. 
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1-cyclohexyl-4,6-bis(4-methoxyphenyl)-2-pyridone (1fe). General 
procedure yielded 53.5 mg (55%) of 2-pyridone. 1H NMR (400 MHz, 
CDCl3) δ 7.52 (m, 2H), 7.27 (m, 2H), 6.97 (m, 2H), 6.93 (m, 2H), 6.65 (d, J 
= 2.2 Hz, 1H), 6.23 (d, J = 2.2 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 3H), 3.80 (m, 
1H), 2.79 (m, 2H), 1.74 (m, 2H), 1.61 (m, 2H), 1.50 (m, 1H), 1.22 (m, 1H), 
0.96 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 164.4, 160.5, 159.9, 149.8, 148.8, 129.6, 129.4, 129.2, 
127.9, 116.1, 114.2, 113.8, 107.6, 61.8, 55.3, 28.6, 26.1, 24.9. Rf = 0.22 (2:1 Hex:EtOAc). IR (NaCl, 
CHCl3) 3042, 2996, 2925, 2848, 1650, 1603, 1511, 1245, 1168, 1025, 820, 743. HRMS (ESI) 
[C25H28NO3]
+ calcd 390.20245, found 390.20656. 
1-cyclohexyl-2,6-bis(4-methoxyphenyl)-4-pyridone (2fe). General 
procedure yielded 11.5 mg (12%) of 4-pyridone from reaction above. 1H 
NMR (400 MHz, CDCl3) δ 7.33 (m, 4H), 6.95 (m, 4H), 6.27 (s, 2H), 3.87 (s, 
6H), 3.85 (m, 1H), 1.67 (m, 2H), 1.50 (m, 2H), 1.29 (m, 3H), 0.74 (m, 2H), 
0.58 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 178.4, 160.2, 154.2, 130.4, 
129.1, 121.6, 113.6, 66.1, 55.3, 33.9, 26.6, 24.8. Rf = 0.09 (10:1 
EtOAc:MeOH). IR (NaCl, CHCl3) 3001, 2930, 2858, 1624, 1501, 1245, 1025, 830, 733. HRMS (ESI) 
[C25H28NO3]
+ calcd 390.20245, found 390.20633. 
1,4,6-tris(4-methoxyphenyl)-2-pyridone (1ff). General procedure yielded 
42.1 mg (43%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.62 (m, 2H), 
7.07 (m, 2H), 7.02 (m, 2H), 6.98 (m, 2H), 6.84 (d, J = 2.0 Hz, 1H), 6.79 (m, 
2H), 6.71 (m, 2H), 6.48 (d, J = 2.0 Hz, 1H), 3.86 (s, 3H), 3.75 (s, 3H), 3.74 
(s, 3H). 13C NMR (100 MHz, CDCl3) δ 164.0, 160.7, 159.3, 158.6, 150.5, 
149.4, 131.3, 130.3, 129.9, 129.7, 128.3, 128.0, 114.4, 114.3, 114.0, 113.3, 107.1, 55.3, 55.2, 55.1. Rf = 
0.40 (EtOAc). IR (NaCl, CHCl3) 3037, 2996, 2960, 2838, 1650, 1608, 1506, 1250, 1030, 825, 723. 
HRMS (ESI) [C26H24NO4]
+ calcd 414.16606, found 414.17046. 
1,2,6-tris(4-methoxyphenyl)-4-pyridone (2ff). General procedure yielded 
18.6 mg (19%) of 4-pyridone from reaction above. 1H NMR (400 MHz, 
CDCl3) δ 6.98 (m, 4H), 6.68 (m, 6H), 6.51 (m, 2H), 6.48 (s, 2H), 3.74 (s, 
6H), 3.65 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 178.9, 169.7, 159.4, 158.5, 
152.7, 132.7, 130.6, 130.5, 127.9, 119.5, 113.4, 113.3, 55.2, 55.2. Rf = 0.11 
(10:1 EtOAc:MeOH). IR (NaCl, CHCl3) 3053, 3001, 2930, 2832, 1624, 
1501, 1557, 1434, 1255, 1030, 825, 733. HRMS (ESI) [C26H24NO4]
+ calcd 
414.16606, found 414.17067. 
4,6-bis(4-methoxyphenyl)-1-phenyl-2-pyridone (1fg). General procedure 
yielded 34.7 mg (37%) of 2-pyridone. 1H NMR (400 MHz, CDCl3) δ 7.62 
(m, 2H), 7.26 (m, 3H), 7.11 (m, 2H), 7.05 (m, 2H), 6.99 (m, 2H), 6.85 (d, J = 
2.0 Hz, 1H), 6.69 (m, 2H), 6.50 (d, J = 2.0 Hz, 1H), 3.86 (s, 3H), 3.73 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 163.8, 160.8, 159.4, 150.7, 149.1, 138.7, 
130.3, 129.7, 129.0, 128.7, 128.2, 128.1, 127.8, 114.6, 114.4, 113.3, 107.2, 55.4, 55.1. Rf = 0.68 (2:1 
Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3037, 2960, 2935, 2838, 1655, 1603, 1506, 1250, 1025, 820, 728. 
HRMS (ESI) [C25H22NO3]
+ calcd 384.15550, found 384.16035. 
2,6-bis(4-methoxyphenyl)-1-phenyl-4-pyridone (2fg). General procedure 
yielded 18.2 mg (20%) of 4-pyridone from reaction above. 1H NMR (400 
MHz, CDCl3) δ 7.03 (m, 3H), 6.98 (m, 4H), 6.80 (m, 2H), 6.66 (m, 4H), 6.49 
(s, 2H), 3.72 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 179.0, 159.4, 152.4, 
139.9, 130.5, 129.8, 128.4, 127.9, 127.7, 119.6, 113.3, 55.1. Rf = 0.14 (10:1 
EtOAc:MeOH). IR (NaCl, CHCl3) 3058, 3001, 2925, 2832, 1629, 1501, 
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1296, 1250, 1173, 1025, 830, 728. HRMS (ESI) [C25H22NO3]
+ calcd 384.15550, found 384.16090. 
1-(4-fluorophenyl)-4,6-bis(4-methoxyphenyl)-2-pyridone (1fh). General 
procedure yielded 44.7 mg (48%) of 2-pyridone. 1H NMR (400 MHz, 
CDCl3) δ 7.62 (m, 2H), 7.07 (m, 4H), 6.97 (m, 4H), 6.84 (d, J = 1.8 Hz, 1H), 
6.72 (m, 2H), 6.50 (d, J = 1.8 Hz, 1H), 3.86 (s, 3H), 3.75 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ 163.8, 162.8, 160.9, 160.4, 159.5, 150.8, 149.0, 134.6, 
130.7, 130.6, 130.3, 129.5, 128.0, 127.9, 115.9, 115.6, 114.4, 114.3, 113.4, 107.3, 55.3, 55.2. Rf = 0.21 
(1:1 Hex:EtOAc). IR (NaCl, CHCl3) 3068, 3006, 2930, 2838, 1660, 1608, 1506, 1250, 1030, 820, 728. 
HRMS (ESI) [C25H21FNO3]
+ calcd 402.14608, found 402.15125. 
1-(4-fluorophenyl)-2,6-bis(4-methoxyphenyl)-4-pyridone (2fh). General 
procedure yielded 21.6 mg (23%) of 4-pyridone from reaction above. 1H 
NMR (400 MHz, CDCl3) δ 6.97 (m, 4H), 6.77 (m, 2H), 6.72 (m, 2H), 6.68 
(m, 4H), 6.47 (s, 2H), 3.73 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 178.9, 
162.5, 160.0, 159.5, 152.4, 136.0, 131.4, 131.3, 130.5, 127.4, 119.6, 115.6, 
115.3, 113.4, 55.1. Rf = 0.19 (10:1 EtOAc:MeOH). IR (NaCl, CHCl3) 3063, 
3001, 2930, 2832, 1624, 1573, 1506, 1255, 1178, 835, 728. HRMS (ESI) 
[C25H21FNO3]
+ calcd 402.14608, found 402.15103. 
4,6-bis(4-methoxyphenyl)-1-(4-(trifluoromethyl) phenyl)-2-pyridone 
(1fi). General procedure yielded 35.8 mg (34%) of 2-pyridone. 1H NMR (400 
MHz, CDCl3) δ 7.62 (m, 2H), 7.55 (m, 2H), 7.25 (m, 2H), 7.01 (m, 4H), 6.84 
(d, J = 1.9 Hz, 1H), 6.71 (m, 2H), 6.54 (d, J = 1.9 Hz, 1H), 3.86 (s, 3H), 3.75 
(s, 3H). 13C NMR (100 MHz, CDCl3) δ 163.8, 161.2, 159.9, 151.4, 148.8, 
142.1, 130.5, 130.2, 129.9, 129.6, 128.4, 127.8, 126.1, 126.0, 114.7, 114.6, 113.8, 108.0, 55.6, 55.4. Rf = 
0.19 (2:1 Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3001, 2955, 2832, 1660, 1598, 1501, 1250, 1117, 825, 
723. HRMS (ESI) [C26H21F3NO3]
+ calcd 452.14288, found 452.14608. 
2,6-bis(4-methoxyphenyl)-1-(4-(trifluoromethyl) phenyl)-4-pyridone 
(2fi). General procedure yielded 31.7 mg (30%) of 4-pyridone from reaction 
above. 1H NMR (400 MHz, CDCl3) δ 7.30 (m, 2H), 6.94 (m, 6H), 6.67 (m, 
4H), 6.52 (s, 2H), 3.72 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 179.1, 160.0, 
152.3, 143.2, 130.7, 130.5, 127.2, 125.8, 125.7, 120.0, 113.8, 55.4. Rf = 0.28 
(10:1 EtOAc:MeOH). IR (NaCl, CHCl3) 3058, 3001, 2935, 2832, 1629, 
1501, 1245, 1178, 1020, 835, 723. HRMS (ESI) [C26H21F3NO3]
+ calcd 
452.14288, found 452.14620. 
(E)-4,6-bis(4-methoxyphenyl)-1-styryl-2-pyridone (1fj). General 
procedure yielded 12.8 mg (13%) of 2-pyridone. 1H NMR (400 MHz, 
CDCl3) δ 7.61 (m, 2H), 7.37 (m, 2H), 7.24 (m, 5H), 7.06 (d, J = 14.7 Hz, 
1H), 6.98 (m, 2H), 6.92 (m, 2H), 6.85 (d, J = 1.9 Hz, 1H), 6.66 (d, J = 14.7 
Hz, 1H), 6.50 (d, J = 2.0 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ 163.9, 161.0, 160.0, 150.3, 148.2, 134.9, 130.8, 130.4, 129.3, 128.5, 128.1, 128.0, 126.5, 
125.4, 114.4, 113.9, 108.4, 55.4, 55.3. Rf = 0.31 (1:1 Hex:EtOAc). IR (NaCl, CHCl3) 3063, 3022, 2955, 
2930, 2832, 1655, 1603, 1506, 1250, 1168, 1035, 825, 748. HRMS (ESI) [C27H24NO3]






(E)-2,6-bis(4-methoxyphenyl)-1-styryl-4-pyridone (2fj). General procedure 
yielded 16.8 mg (17%) of 4-pyridone from reaction above. 1H NMR (400 
MHz, CDCl3) δ 7.39 (m, 4H), 7.19 (m, 3H), 6.90 (m, 6H), 6.80 (s, 2H), 6.75 
(d, J = 14.5 Hz, 1H), 6.01 (d, J = 14.5 Hz, 1H), 3.80 (s, 6H). 13C NMR (100 
MHz, CDCl3) δ 176.6, 160.4, 153.8, 134.4, 133.2, 130.8, 128.8, 128.7, 127.7, 
126.6, 126.4, 118.2, 114.0, 55.3. Rf = 0.24 (10:1 EtOAc:MeOH). IR (NaCl, 
CHCl3) 3058, 3007, 2960, 2930, 1619, 1496, 1250, 1178, 1025, 835, 748. 
HRMS (ESI) [C27H24NO3]
+ calcd 410.17115, found 410.17575. 
4,6-bis(4-methoxyphenyl)-2-pyridone (35). 2-pyridone 1fd (19.6 mg, 0.046 
mmol) was dissolved in neat trifluoroacetic acid and added to an oven-dried 
pressure tube. The reaction vessel was sealed and heated to 110 °C for 12 h. 
The resulting solution was allowed to cool to 23 °C, concentrated in vacuo, 
and purified with flash chromatography (gradient elution 10:1 
EtOAc:MeOH). The isolated solid was dissolved in concentrated aq NaOH solution and extracted 3x with 
EtOAc. The resulting solution was dried and concentrated in vacuo to afford11.1 mg of pyridone 35 
(78%). 1H NMR (400 MHz, CDCl3) δ 7.69 (m, 2H), 7.60 (m, 2H), 7.01 (m, 4H), 6.66 (m, 2H), 3.88 (s, 
3H), 3.87 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 165.1, 161.1, 160.8, 153.2, 146.1, 130.4, 128.2, 127.9, 
126.2, 114.6, 114.4, 103.6, 55.5, 55.4. Rf = 0.51 (10:1 EtOAc:MeOH). IR (NaCl, CHCl3) 3078, 2955, 
2904, 1639, 1603, 1234, 1024, 809. HRMS (ESI) [C19H18NO3]





























Crystal Structure Tables and Figures.  
 
Table A.1.1.  Crystal data and structure refinement for 1db. 
Identification code  rovis122 
Empirical formula  C24H19NO 
Formula weight  337.40 
Temperature  120 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 18.0500(9) Å = 90°. 
 b = 6.2286(3) Å = 114.967(3)°. 
 c = 17.2636(9) Å  = 90°. 
Volume 1759.51(15) Å3 
Z 4 
Density (calculated) 1.274 Mg/m3 
Absorption coefficient 0.077 mm-1 
F(000) 712 
Crystal size 0.19 x 0.19 x 0.09 mm3 
Theta range for data collection 2.36 to 31.03°. 
Index ranges -26<=h<=25, -9<=k<=9, -25<=l<=25 
Reflections collected 42377 
Independent reflections 5592 [R(int) = 0.0813] 
Completeness to theta = 31.03° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9929 and 0.9857 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5592 / 0 / 235 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0522, wR2 = 0.1342 
R indices (all data) R1 = 0.1074, wR2 = 0.1814 
Largest diff. peak and hole 0.301 and -0.400 e.Å-3 
 
Table A.1.2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 1db.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1148(1) 7103(3) 747(1) 21(1) 
C(2) 2411(1) 7560(2) 2038(1) 19(1) 
C(3) 2212(1) 5896(3) 2420(1) 20(1) 
C(4) 1459(1) 4766(2) 1990(1) 19(1) 
C(5) 960(1) 5356(3) 1175(1) 20(1) 
C(6) 2072(1) 10067(3) 819(1) 22(1) 
C(7) 2700(1) 9593(3) 477(1) 22(1) 
C(8) 2704(1) 7642(3) 95(1) 26(1) 
C(9) 3253(1) 7244(3) -257(1) 32(1) 
C(10) 3809(1) 8805(3) -230(1) 35(1) 
150 
 
C(11) 3811(1) 10756(3) 148(1) 36(1) 
C(12) 3260(1) 11146(3) 504(1) 29(1) 
C(13) 3214(1) 8662(3) 2481(1) 19(1) 
C(14) 3921(1) 7617(3) 2552(1) 25(1) 
C(15) 4679(1) 8546(3) 3001(1) 31(1) 
C(16) 4743(1) 10521(3) 3387(1) 32(1) 
C(17) 4046(1) 11581(3) 3316(1) 31(1) 
C(18) 3282(1) 10659(3) 2870(1) 27(1) 
C(19) 1252(1) 3007(2) 2442(1) 19(1) 
C(20) 1514(1) 3096(3) 3326(1) 22(1) 
C(21) 1329(1) 1453(3) 3757(1) 24(1) 
C(22) 884(1) -316(3) 3315(1) 24(1) 
C(23) 615(1) -408(3) 2436(1) 23(1) 
C(24) 789(1) 1236(3) 1999(1) 21(1) 
N(1) 1883(1) 8209(2) 1227(1) 19(1) 
O(1) 719(1) 7671(2) 6(1) 31(1) 
________________________________________________________________________________ 
 
Table A.1.3.   Bond lengths [Å] and angles [°] for 1db. 
_____________________________________________________ 
C(1)-O(1)  1.2348(19) 
C(1)-N(1)  1.411(2) 
C(1)-C(5)  1.435(2) 
C(2)-C(3)  1.356(2) 
C(2)-N(1)  1.381(2) 
C(2)-C(13)  1.491(2) 
C(3)-C(4)  1.428(2) 
C(4)-C(5)  1.363(2) 
C(4)-C(19)  1.481(2) 
C(6)-N(1)  1.467(2) 
C(6)-C(7)  1.511(2) 
C(7)-C(8)  1.384(2) 
C(7)-C(12)  1.387(2) 
C(8)-C(9)  1.387(2) 
C(9)-C(10)  1.383(3) 
C(10)-C(11)  1.379(3) 
C(11)-C(12)  1.393(3) 
C(13)-C(14)  1.392(2) 
C(13)-C(18)  1.394(2) 
C(14)-C(15)  1.383(2) 
C(15)-C(16)  1.380(3) 
C(16)-C(17)  1.380(3) 
C(17)-C(18)  1.387(2) 
C(19)-C(20)  1.396(2) 
C(19)-C(24)  1.400(2) 
C(20)-C(21)  1.386(2) 
C(21)-C(22)  1.387(2) 
C(22)-C(23)  1.386(2) 












































Symmetry transformations used to generate equivalent atoms:  
  
Table A.1.4.   Anisotropic displacement parameters (Å2x 103)for 1db.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 18(1)  26(1) 18(1)  -1(1) 7(1)  -1(1) 
C(2) 17(1)  19(1) 20(1)  -1(1) 7(1)  1(1) 
C(3) 17(1)  23(1) 19(1)  1(1) 5(1)  0(1) 
C(4) 16(1)  19(1) 20(1)  -2(1) 8(1)  -1(1) 
C(5) 17(1)  23(1) 20(1)  -2(1) 7(1)  -3(1) 
C(6) 23(1)  22(1) 20(1)  2(1) 8(1)  0(1) 
C(7) 20(1)  26(1) 16(1)  4(1) 6(1)  1(1) 
C(8) 29(1)  26(1) 25(1)  0(1) 13(1)  -3(1) 
C(9) 38(1)  34(1) 27(1)  2(1) 16(1)  6(1) 
C(10) 29(1)  53(1) 26(1)  9(1) 15(1)  7(1) 
C(11) 29(1)  48(1) 33(1)  3(1) 15(1)  -10(1) 
C(12) 29(1)  30(1) 27(1)  -1(1) 11(1)  -7(1) 
C(13) 18(1)  21(1) 19(1)  1(1) 7(1)  -2(1) 
C(14) 22(1)  27(1) 26(1)  -5(1) 10(1)  0(1) 
C(15) 17(1)  43(1) 30(1)  -3(1) 8(1)  1(1) 
C(16) 24(1)  43(1) 25(1)  -5(1) 8(1)  -13(1) 
C(17) 36(1)  28(1) 31(1)  -9(1) 14(1)  -11(1) 
C(18) 24(1)  24(1) 32(1)  -4(1) 12(1)  -1(1) 
C(19) 15(1)  20(1) 22(1)  1(1) 8(1)  1(1) 
C(20) 21(1)  21(1) 21(1)  -1(1) 6(1)  -3(1) 
C(21) 24(1)  26(1) 20(1)  2(1) 7(1)  2(1) 
C(22) 21(1)  22(1) 28(1)  5(1) 11(1)  0(1) 
C(23) 18(1)  21(1) 29(1)  -5(1) 10(1)  -2(1) 
C(24) 17(1)  23(1) 21(1)  -2(1) 7(1)  0(1) 
N(1) 19(1)  20(1) 18(1)  1(1) 7(1)  -1(1) 
O(1) 28(1)  39(1) 19(1)  5(1) 3(1)  -6(1) 
______________________________________________________________________________ 
 
Table A.1.5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for 1db. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(3) 2570 5485 2969 24 
H(5) 477 4596 885 24 
H(6A) 2273 11224 1232 26 
H(6B) 1573 10557 353 26 
152 
 
H(8) 2333 6583 73 32 
H(9) 3248 5926 -512 38 
H(10) 4179 8540 -464 42 
H(11) 4181 11814 166 43 
H(12) 3269 12462 762 35 
H(14) 3884 6283 2296 30 
H(15) 5148 7837 3044 37 
H(16) 5254 11134 3694 38 
H(17) 4087 12922 3568 38 
H(18) 2816 11375 2831 32 
H(20) 1816 4269 3630 26 
H(21) 1503 1538 4345 29 
H(22) 768 -1429 3605 28 
H(23) 314 -1587 2136 27 







Table A.1.6.  Crystal data and structure refinement for 2ff. 
Identification code  rovis121_0m 
Empirical formula  C26H23NO4 
Formula weight  413.45 
Temperature  120 K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 212121 
Unit cell dimensions a = 10.7001(5) Å = 90°. 
 b = 18.9198(9) Å = 90°. 
 c = 20.6478(11) Å  = 90°. 
Volume 4180.0(4) Å3 
Z 8 
Density (calculated) 1.314 Mg/m3 
Absorption coefficient 0.089 mm-1 
F(000) 1744 
Crystal size 0.19 x 0.16 x 0.14 mm3 
Theta range for data collection 1.97 to 30.74°. 
Index ranges -15<=h<=15, -27<=k<=27, -29<=l<=29 
Reflections collected 94030 
Independent reflections 12898 [R(int) = 0.0919] 
Completeness to theta = 30.74° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9876 and 0.9837 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12898 / 0 / 565 
Goodness-of-fit on F2 0.982 
Final R indices [I>2sigma(I)] R1 = 0.0527, wR2 = 0.1240 
R indices (all data) R1 = 0.1033, wR2 = 0.1665 
Absolute structure parameter 0.7(9) 
Largest diff. peak and hole 0.333 and -0.534 e.Å-3 
 
Table A.1.7.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 2ff.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 4574(2) 2811(1) 7635(1) 22(1) 
C(2) 4026(2) 2533(1) 8211(1) 23(1) 
C(3) 3124(2) 2875(1) 8554(1) 21(1) 
C(4) 3258(2) 3854(1) 7822(1) 20(1) 
C(5) 4143(2) 3508(1) 7469(1) 23(1) 
C(6) 2516(2) 2520(1) 9110(1) 20(1) 
C(7) 1207(2) 2445(1) 9149(1) 21(1) 
C(8) 682(2) 2051(1) 9642(1) 23(1) 
C(9) 1422(2) 1745(1) 10121(1) 24(1) 
C(10) 2710(2) 1798(1) 10080(1) 26(1) 
C(11) 3242(2) 2176(1) 9571(1) 23(1) 
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C(12) 1483(3) 1109(2) 11123(1) 33(1) 
C(13) 2057(2) 3978(1) 8843(1) 19(1) 
C(14) 2732(2) 4242(1) 9359(1) 22(1) 
C(15) 2140(2) 4631(1) 9841(1) 23(1) 
C(16) 854(2) 4757(1) 9797(1) 21(1) 
C(17) 185(2) 4501(1) 9269(1) 22(1) 
C(18) 779(2) 4108(1) 8795(1) 22(1) 
C(19) 823(3) 5341(1) 10825(1) 30(1) 
C(20) 2821(2) 4560(1) 7604(1) 21(1) 
C(21) 3672(2) 5109(1) 7523(1) 22(1) 
C(22) 3322(2) 5750(1) 7240(1) 24(1) 
C(23) 2108(2) 5829(1) 7015(1) 23(1) 
C(24) 1233(2) 5286(1) 7107(1) 23(1) 
C(25) 1584(2) 4661(1) 7396(1) 22(1) 
C(26) 2516(3) 6980(2) 6572(2) 40(1) 
C(27) 5497(2) 2353(1) 2601(1) 22(1) 
C(28) 6091(2) 2124(1) 3191(1) 22(1) 
C(29) 6900(2) 2543(1) 3528(1) 21(1) 
C(30) 6662(2) 3466(1) 2742(1) 20(1) 
C(31) 5845(2) 3057(1) 2405(1) 22(1) 
C(32) 7521(2) 2270(1) 4124(1) 20(1) 
C(33) 6796(2) 1991(1) 4618(1) 24(1) 
C(34) 7336(2) 1738(1) 5185(1) 24(1) 
C(35) 8629(2) 1756(1) 5253(1) 23(1) 
C(36) 9364(2) 2000(1) 4745(1) 24(1) 
C(37) 8826(2) 2262(1) 4187(1) 23(1) 
C(38) 8548(3) 1272(2) 6324(1) 34(1) 
C(39) 7899(2) 3684(1) 3732(1) 19(1) 
C(40) 9123(2) 3865(1) 3568(1) 22(1) 
C(41) 9814(2) 4270(1) 3989(1) 22(1) 
C(42) 9306(2) 4480(1) 4579(1) 22(1) 
C(43) 8081(2) 4310(1) 4736(1) 24(1) 
C(44) 7374(2) 3917(1) 4303(1) 21(1) 
C(45) 9615(3) 5093(2) 5574(1) 42(1) 
C(46) 7050(2) 4162(1) 2468(1) 21(1) 
C(47) 7603(2) 4150(1) 1855(1) 25(1) 
C(48) 7916(2) 4762(1) 1533(1) 26(1) 
C(49) 7633(2) 5415(1) 1810(1) 22(1) 
C(50) 7071(2) 5445(1) 2415(1) 24(1) 
C(51) 6807(2) 4818(1) 2744(1) 23(1) 
C(52) 7429(3) 6657(1) 1609(2) 33(1) 
N(1) 2725(2) 3546(1) 8368(1) 19(1) 
N(2) 7177(2) 3221(1) 3318(1) 20(1) 
O(1) 5337(2) 2469(1) 7299(1) 29(1) 
O(2) 784(2) 1401(1) 10598(1) 32(1) 
O(3) 184(2) 5129(1) 10245(1) 26(1) 
O(4) 1664(2) 6408(1) 6692(1) 30(1) 
O(5) 4769(2) 1966(1) 2279(1) 26(1) 
O(6) 9264(2) 1533(1) 5791(1) 31(1) 
O(7) 10100(2) 4850(1) 4969(1) 31(1) 





Table A.1.8.   Bond lengths [Å] and angles [°] for 2ff. 
_____________________________________________________ 
C(1)-O(1)  1.252(3) 
C(1)-C(2)  1.426(4) 
C(1)-C(5)  1.439(3) 
C(2)-C(3)  1.360(3) 
C(3)-N(1)  1.393(3) 
C(3)-C(6)  1.482(3) 
C(4)-C(5)  1.363(3) 
C(4)-N(1)  1.391(3) 
C(4)-C(20)  1.486(3) 
C(6)-C(11)  1.389(3) 
C(6)-C(7)  1.410(3) 
C(7)-C(8)  1.381(3) 
C(8)-C(9)  1.392(3) 
C(9)-O(2)  1.364(3) 
C(9)-C(10)  1.384(4) 
C(10)-C(11)  1.394(3) 
C(12)-O(2)  1.430(3) 
C(13)-C(14)  1.381(3) 
C(13)-C(18)  1.393(3) 
C(13)-N(1)  1.464(3) 
C(14)-C(15)  1.390(3) 
C(15)-C(16)  1.400(3) 
C(16)-O(3)  1.366(3) 
C(16)-C(17)  1.391(3) 
C(17)-C(18)  1.384(3) 
C(19)-O(3)  1.435(3) 
C(20)-C(21)  1.390(3) 
C(20)-C(25)  1.404(3) 
C(21)-C(22)  1.397(3) 
C(22)-C(23)  1.388(3) 
C(23)-O(4)  1.367(3) 
C(23)-C(24)  1.402(3) 
C(24)-C(25)  1.377(3) 
C(26)-O(4)  1.436(3) 
C(27)-O(5)  1.259(3) 
C(27)-C(28)  1.440(3) 
C(27)-C(31)  1.441(3) 
C(28)-C(29)  1.365(3) 
C(29)-N(2)  1.387(3) 
C(29)-C(32)  1.491(3) 
C(30)-C(31)  1.361(3) 
C(30)-N(2)  1.389(3) 
C(30)-C(46)  1.494(3) 
C(32)-C(33)  1.387(3) 
C(32)-C(37)  1.402(3) 
C(33)-C(34)  1.390(3) 
C(34)-C(35)  1.391(3) 
C(35)-O(6)  1.370(3) 
C(35)-C(36)  1.389(3) 
C(36)-C(37)  1.379(3) 
C(38)-O(6)  1.428(3) 
C(39)-C(44)  1.379(3) 
C(39)-C(40)  1.395(3) 
C(39)-N(2)  1.447(3) 
C(40)-C(41)  1.375(3) 
C(41)-C(42)  1.393(3) 
C(42)-O(7)  1.364(3) 
C(42)-C(43)  1.388(3) 
C(43)-C(44)  1.387(3) 
C(45)-O(7)  1.427(3) 
C(46)-C(51)  1.391(3) 
C(46)-C(47)  1.398(3) 
C(47)-C(48)  1.377(3) 
C(48)-C(49)  1.394(3) 
C(49)-O(8)  1.366(3) 
C(49)-C(50)  1.387(3) 
C(50)-C(51)  1.395(3) 



































































































Symmetry transformations used to generate equivalent atoms:  
  
Table A.1.9.   Anisotropic displacement parameters (Å2x 103)for 2ff.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 18(1)  23(1) 26(1)  -2(1) -1(1)  0(1) 
C(2) 22(1)  20(1) 25(1)  1(1) -1(1)  1(1) 
C(3) 20(1)  20(1) 22(1)  0(1) -2(1)  -2(1) 
C(4) 21(1)  22(1) 17(1)  0(1) -1(1)  -4(1) 
C(5) 23(1)  28(1) 18(1)  1(1) 3(1)  -2(1) 
C(6) 23(1)  17(1) 20(1)  -1(1) 1(1)  1(1) 
C(7) 22(1)  19(1) 21(1)  -3(1) 0(1)  0(1) 
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C(8) 18(1)  24(1) 28(1)  -3(1) 3(1)  -1(1) 
C(9) 27(1)  21(1) 23(1)  0(1) 4(1)  -2(1) 
C(10) 26(1)  26(1) 26(1)  2(1) -3(1)  -2(1) 
C(11) 21(1)  25(1) 22(1)  -1(1) 0(1)  -3(1) 
C(12) 37(2)  35(2) 27(1)  7(1) 3(1)  -2(1) 
C(13) 22(1)  16(1) 18(1)  -1(1) 2(1)  -1(1) 
C(14) 21(1)  22(1) 23(1)  -3(1) -2(1)  -1(1) 
C(15) 24(1)  25(1) 20(1)  -5(1) -3(1)  -2(1) 
C(16) 25(1)  17(1) 19(1)  -1(1) 3(1)  0(1) 
C(17) 18(1)  24(1) 23(1)  1(1) 0(1)  0(1) 
C(18) 24(1)  21(1) 19(1)  -1(1) -2(1)  -1(1) 
C(19) 39(1)  30(1) 20(1)  -6(1) 2(1)  2(1) 
C(20) 26(1)  22(1) 15(1)  -2(1) 1(1)  -1(1) 
C(21) 23(1)  25(1) 19(1)  -1(1) -2(1)  0(1) 
C(22) 27(1)  23(1) 22(1)  2(1) 1(1)  -4(1) 
C(23) 29(1)  21(1) 19(1)  1(1) 2(1)  2(1) 
C(24) 23(1)  24(1) 21(1)  0(1) 1(1)  1(1) 
C(25) 23(1)  22(1) 19(1)  -1(1) 0(1)  -1(1) 
C(26) 41(2)  29(1) 51(2)  16(1) -3(1)  -8(1) 
C(27) 20(1)  23(1) 23(1)  -5(1) 2(1)  -1(1) 
C(28) 21(1)  21(1) 24(1)  0(1) 0(1)  -1(1) 
C(29) 20(1)  21(1) 22(1)  1(1) 1(1)  1(1) 
C(30) 21(1)  21(1) 18(1)  -2(1) -1(1)  2(1) 
C(31) 25(1)  23(1) 20(1)  -1(1) -2(1)  2(1) 
C(32) 23(1)  17(1) 21(1)  1(1) -2(1)  -1(1) 
C(33) 22(1)  24(1) 24(1)  1(1) 1(1)  1(1) 
C(34) 23(1)  27(1) 22(1)  3(1) 2(1)  -2(1) 
C(35) 27(1)  23(1) 19(1)  2(1) -4(1)  -1(1) 
C(36) 20(1)  24(1) 27(1)  0(1) -3(1)  -2(1) 
C(37) 23(1)  22(1) 24(1)  0(1) 2(1)  -2(1) 
C(38) 43(2)  37(2) 22(1)  8(1) -1(1)  -1(1) 
C(39) 21(1)  18(1) 19(1)  2(1) -4(1)  -2(1) 
C(40) 22(1)  23(1) 21(1)  2(1) 0(1)  1(1) 
C(41) 20(1)  25(1) 22(1)  4(1) -1(1)  -2(1) 
C(42) 23(1)  23(1) 21(1)  0(1) -5(1)  -6(1) 
C(43) 26(1)  24(1) 21(1)  -1(1) 2(1)  -3(1) 
C(44) 20(1)  23(1) 21(1)  1(1) 1(1)  -1(1) 
C(45) 48(2)  53(2) 24(1)  -11(1) 2(1)  -21(2) 
C(46) 21(1)  23(1) 20(1)  1(1) -3(1)  0(1) 
C(47) 29(1)  21(1) 24(1)  -1(1) 0(1)  5(1) 
C(48) 30(1)  27(1) 22(1)  1(1) 4(1)  4(1) 
C(49) 23(1)  21(1) 23(1)  2(1) -2(1)  0(1) 
C(50) 27(1)  18(1) 26(1)  -4(1) -2(1)  1(1) 
C(51) 27(1)  22(1) 20(1)  -4(1) 0(1)  0(1) 
C(52) 34(1)  20(1) 45(2)  2(1) 5(1)  2(1) 
N(1) 18(1)  18(1) 21(1)  -3(1) 1(1)  -1(1) 
N(2) 19(1)  20(1) 19(1)  -1(1) -1(1)  -3(1) 
O(1) 27(1)  30(1) 30(1)  -3(1) 6(1)  5(1) 
O(2) 30(1)  38(1) 28(1)  9(1) 6(1)  -3(1) 
O(3) 27(1)  30(1) 21(1)  -6(1) 3(1)  4(1) 
O(4) 30(1)  23(1) 37(1)  8(1) 0(1)  1(1) 
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O(5) 26(1)  28(1) 25(1)  -6(1) -1(1)  -4(1) 
O(6) 28(1)  40(1) 24(1)  7(1) -6(1)  -3(1) 
O(7) 31(1)  42(1) 22(1)  -6(1) -1(1)  -13(1) 
O(8) 35(1)  22(1) 37(1)  5(1) 8(1)  4(1) 
______________________________________________________________________________ 
 
Table A.1.10.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for 2ff. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2) 4299 2096 8360 27 
H(5) 4479 3730 7107 27 
H(7) 697 2662 8843 25 
H(8) -180 1989 9654 28 
H(10) 3215 1584 10389 31 
H(11) 4108 2199 9538 27 
H(12A) 2042 753 10962 49 
H(12B) 921 900 11431 49 
H(12C) 1956 1476 11330 49 
H(14) 3588 4160 9384 26 
H(15) 2595 4806 10190 28 
H(17) -666 4594 9234 26 
H(18) 327 3931 8446 26 
H(19A) 1135 4931 11044 44 
H(19B) 253 5589 11103 44 
H(19C) 1507 5647 10714 44 
H(21) 4492 5048 7662 27 
H(22) 3894 6117 7204 29 
H(24) 411 5349 6971 27 
H(25) 999 4304 7454 26 
H(26A) 2912 7115 6971 60 
H(26B) 2065 7376 6399 60 
H(26C) 3139 6831 6267 60 
H(28) 5918 1673 3347 26 
H(31) 5493 3240 2029 27 
H(33) 5932 1972 4569 28 
H(34) 6837 1559 5515 29 
H(36) 10230 1986 4781 28 
H(37) 9327 2432 3854 27 
H(38A) 8004 1638 6480 51 
H(38B) 9102 1127 6666 51 
H(38C) 8059 874 6186 51 
H(40) 9467 3712 3178 26 
H(41) 10622 4405 3879 26 
H(43) 7737 4459 5126 29 
H(44) 6546 3810 4398 25 
H(45A) 8887 5377 5498 62 
H(45B) 10238 5371 5791 62 
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H(45C) 9395 4695 5838 62 
H(47) 7763 3716 1659 30 
H(48) 8315 4741 1133 32 
H(50) 6871 5879 2599 28 
H(51) 6461 4840 3157 28 
H(52A) 6542 6620 1671 50 
H(52B) 7599 6992 1271 50 
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General Methods. All reactions were carried out under an atmosphere of argon in oven-dried 
glassware with magnetic stirring. Toluene was degassed with argon and passed through one column of 
neutral alumina and one column of Q5 reactant. Column chromatography was performed on Silicycle Inc. 
silica gel 60 (230-400 mesh). Thin layer chromatography was performed on Silicycle Inc. 0.25 mm silica 
gel 60-F plates. Visualization was accomplished with UV light (254 nm), potassium permanganate, 
and/or cerric ammonium nitrate. 
 1H NMR and 13C NMR spectra were obtained in CDCl3 at ambient temperature and chemical 
shifts are expressed in parts per million (δ, ppm). Proton chemical shifts are referenced to 7.26 ppm 
(CHCl3) and carbon chemical shifts are referenced to 77.0 ppm (CDCl3). Data reporting uses the 
following abbreviations: s, singlet; bs, broad singlet; d, doublet; dd, doublet of doublets; t, triplet; m, 
multiplet; and J, coupling constant in Hz. 
 Ligands T1-T9,1 B3,2 and A13 were synthesized as previously described in the literature. The 
synthesis of ligands B4 and B5 are described below. Alkynes and ligands B1 and B2 were purchased 
from Aldrich Chemicals Co. and used without further purification. Alkenyl isocyanate 2 was synthesized 
as previously described.4 [Rh(C2H4)2Cl]2 was purchased from Strem Chemical, Inc. and used without 
further purification. 
General Procedure for Synthesis of Phosphoramidite Ligands.  The diol (0.27 mmol) was 
dissolved in THF in an oven-dried round bottom flask with a magnetic stir bar. Et3N (3.5 eq, 0.95 mmol) 
was added and the reaction mixture was cooled to 0 °C before dropwise addition of phosphorous 
trichloride (1.1 eq, 0.30 mmol). The reaction mixture was stirred for 1 h and the amine (10 eq, 2.70 
mmol) was added slowly at 0 °C. The reaction was stirred overnight at 23 °C, diluted with ether, and 
filtered. The filtrate was concentrated in vacuo and the resulting crude material was purified by flash 
column chromatography (98:2 Hex:EtOAc) to afford the desired phosphoramidite. 
 
O,O-(R)-3,3'-bis(trimethylsilyl)-1,1'-binapthyl-2,2'-diyl-
pyrrolidinephosphoramidite (B4). General procedure yielded a white solid (85%). 
[α]20D = -550.4°, c = 0.01 g/ml CHCl3. 
1H NMR (400 MHz, CDCl3) δ 8.07 (m, 2H), 
7.90 (m, 2H), 7.32 (m, 2H), 7.18 (m, 4H), 3.18 (m, 2H), 2.84 (bs, 2H), 1.65 (m, 
4H), 0.45 (s, 9H), 0.44 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 137.8, 136.6, 134.0, 
133.7, 132.5, 132.2, 130.7, 130.1, 128.5, 128.3, 128.1, 127.5, 126.8, 126.7, 126.1, 124.2, 123.9, 123.6, 
45.9, 45.7, 25.9, 25.8, 0.1, 0.0, -0.1, -0.9. 31P NMR (75 MHz, CDCl3) δ 149.82. Rf = 0.62 (98:2 
Hex:EtOAc). IR (NaCl, Thin Film) 3534, 3053, 3032, 2960, 2899, 2858, 1578, 1388, 1255, 1086, 968, 
835, 753 cm-1. HRMS (ESI) m/z [C30H37NO2PSi2]
+ calcd 530.2095, found 530.2104. 
 
 
                                                     
1 (a) Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 12370-12371. (b) Lee, E. E.; Rovis, T. Org. Lett. 2008, 10, 
1231-1234. (c) Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2008, 130, 3262-3263. 
2 Yu, R. T.; Lee, E. E.; Malik, G.; Rovis, T. Angew. Chem. Int. Ed. 2009, 48, 2379-2382. 
3 Giacomina, F.; Meetsma, A.; Panella, L.; Lefort, L.; de Vries, A. H. M.; de Vries, J.G. Angew. Chem. Int. Ed. 
2007, 46, 1497-1500. 










piperidinephosphoramidite (B5). General procedure yielded a white solid 
(89%). [α]D = -505.4°, c = 0.01 g/ml CHCl3. 
1H NMR (400 MHz, CDCl3) δ 8.07 
(m, 2H), 7.91 (m, 2H), 7.39 (m, 3H), 7.17 (m, 3H), 2.92 (m, 2H), 1.53 (m, 4H), 
1.32 (m, 2H), 0.51 (s, 9H), 0.45 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 153.6, 
136.7, 133.9, 133.7, 132.6, 132.1, 130.7, 130.0, 128.3, 128.2, 126.8, 126.7, 126.1, 
126.0, 124.3, 124.1, 30.3, 27.2, 24.8. 31P NMR (75 MHz, CDCl3) δ 146.25. Rf = 0.40 (98:2 Hex:EtOAc). 
IR (NaCl, Thin Film) 3052, 2935, 2853, 1368, 1240, 1091, 1055, 979, 943, 840, 748 cm-1. HRMS (ESI) 
m/z [C31H39NO2PSi2]
+ calcd 544.2251, found 544.2263. 
Synthesis and Crystallography of Rhodium(cod)Cl·Ligand Complexes. 
 A 10 ml vial was charged with [Rh(cod)Cl]2 (28 mg, 0.057 mmol) and ligand (0.114 mmol) in an 
inert atmosphere (N2) glove box. Upon removal from the glove box, 1 ml of CH2Cl2 was added via 
syringe and the resulting yellow solution was layered with heptanes (~2 ml). The cap was loosely sealed 
and the solvent was allowed to evaporated slowly over 1 or 2 weeks yielding X-ray quality crystals. 
 All single crystals were coated in oil, transferred to a goniometer head, and mounted on a 
Bruker Kappa Apex CCD diffractometer under a stream of dinitrogen. All data collections were 
performed with Mo Kα radiation and a graphite monochromator. Data sets were taken with complete 
coverage and fourfold redundancy at 120K. Data was integrated and corrected for absorption effects with 
the Apex 2 software package.5 Structures were solved with the SHELXTL software package.6 All non-
hydrogen atoms were refined with anisotropic thermal parameters and hydrogen atoms placed in idealized 
positions. Rhodium alkene bond distances determined in XP using cent/x, join, and bang commands. 
 
General Procedure for Rhodium-Catalyzed [2+2+2] Cycloadditions. 
 An oven-dried 10 mL round bottom flask was charged with [Rh(C2H4)2Cl]2 (2.3 mg, 0.006 mmol) 
and ligand (0.012 mmol) and fitted with an oven-dried reflux condenser in an inert atmosphere (N2) glove 
box. Upon removal from the glove box, 1 ml of toluene was added via syringe and the resulting yellow 
solution was stirred at ambient temperature for 15 min. To this solution, alkyne 1 (0.48 mmol) and 
isocyanate 2 (0.24 mmol) in 2 ml of toluene was added via syringe. An additional 4 ml of toluene was 
used to wash down the residue and added to the reaction mixture. The reaction mixture was heated to 110 
°C in an oil bath and kept at reflux for 16 h. The reaction mixture was cooled to 23 °C, concentrated in 
vacuo, and purified by flash column chromatography (typically 20:1 EtOAc:MeOH). Evaporation of 
solvent afforded the analytically pure products. Absolute stereochemistry of lactam 3a, vinylogous amide 
4a, lactam 3d, and vinylogous amide 4d were previously assigned and the spectra for these compounds 
are reported.7 Enantioselectivity determination of lactam 3a used previous HPLC conditions (Chiralcel 
ADH column, 90:10 Hex:iPrOH, 1 mL/min, 254nm, 23.6 min and 29.7 min). Enantioselectivity 
determination of vinylogous amide 4a used previous HPLC conditions (Chiralcel ODH column, 85:15 
Hex:iPrOH, 0.3 mL/min, 254nm, 55.4 min and 59.1 min) or Chiralcel IC column, 50:50 Hex:EtOAc, 0.8 
mL/min, 330nm, 59.3 min and 63.0 min. Enantioselectivity determination of lactam 3d used previous 
HPLC conditions (Chiralcel ODH column, 97:3 Hex:iPrOH, 1 mL/min, 230nm, 25.8 min and 27.2 min) 
or Chiralcel IC column, 60:40 Hex:iPrOH, 0.9 mL/min, 254nm, 24.1 min and 25.4 min. 
Enantioselectivity determination of vinylogous amide 4d used previous HPLC conditions (Chiralcel ADH 
                                                     
5 Bruker AXS Inc., 5465 East Chervl Parkway, Madison, WI 53711-5373 USA 
6 Sheldrick, G. (1997) SHELXL-97 Program for Crystal Structure Refinement, Institüt für Anorganische Chemie der 
Universität, Göttingen, Germany. 
7 (a) Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 12370-12371. (b) Yu, R. T.; Lee, E. E.; Malik, G.; Rovis, T. 









column, 95:5 Hex(0.5% DEA):iPrOH, 1 mL/min, 330nm, 24.3 min and 27.8 min) or Chiralcel IA 
column, 88:7:5 Hex(0.5% DEA):EtOAc:iPrOH, 1 mL/min, 330nm, 23.9 min and 28.4 min. 
 
(S)-7-(4-methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-5(1H)-one (3g). An 
oven-dried 50 mL round bottom flask was charged with [Rh(C2H4)2Cl]2 (11.7 mg, 
0.03 mmol) and ligand (0.06 mmol) and fitted with an oven-dried reflux 
condenser in an inert atmosphere (N2) glove box. Upon removal from the glove 
box, 20 mL of toluene was added via syringe and the resulting yellow solution 
was stirred at ambient temperature for 15 min. To this solution, alkyne 1e (635 mg, 4.8 mmol) and 
isocyanate 2 (267 mg, 2.4 mmol) in 5 mL of toluene was added via syringe. An additional 10 mL of 
toluene was used to wash down the residue and added to the reaction mixture. The reaction mixture was 
heated to 110 °C in an oil bath and kept at reflux for 16 h. The reaction mixture was cooled to 23 °C, 
concentrated in vacuo, and purified by flash column chromatography (20:1 EtOAc:MeOH). This resulted 
in 8.4 mg (1 % yield) of (S)-7-(4-methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-5(1H)-one 3g as a brown 
solid and 459 mg (79 % yield) of (R)-5-(4-methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one 4g as 
a light brown solid. Physical characteristics of lactam 3g: ee not determined. 1H NMR (400 MHz, CDCl3) 
δ 7.45 (m, 2H), 6.91 (m, 2H), 6.25 (d, J = 2.6 Hz, 1H), 3.83 (s, 3H), 3.80 (m, 1H), 3.69 (m, 1H), 3.52 (m, 
1H), 2.92 (dd, J = 16.4, 4.7 Hz, 1H), 2.47 (ddd, J = 16.5, 14.0, 2.6 Hz, 1H), 2.28 (m, 1H), 2.07 (m, 1H), 
1.86 (m, 1H), 1.72 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 164.3, 160.6, 148.0, 130.0, 127.2, 118.7, 
114.1, 56.5, 55.3, 43.9, 33.5, 33.1, 23.0. Rf  = 0.30 (20:1 EtOAc:MeOH). IR (ATR-IR) 2925, 2878, 1648, 
1604, 1514, 1444, 1258, 1182, 1031. LRMS (APCI/ESI) m/z [C15H18NO2]
+ (M+H) calcd 244.1, found 








Large Scale Ligand Synthesis and Cycloaddition. 
 
 
A.  Taddol-pyrrolidine phosphoramidite. A 250 mL single-necked round bottom flask 
equipped with a magnetic stir bar is flame dried under vacuum. After cooling to 23 °C, (R,R)-Taddol (2.0 
g, 4.29 mmol) (Note 1) is added to the round bottom, a rubber septum is fitted, the reaction flask is put 
under an atmosphere of Ar, and tetrahydrofuran (75 mL) (Note 2) is added via syringe to the round 
bottom. To this clear, colorless solution, triethylamine (2.4 mL, 17.2 mmol, 4 equiv) (Note 3) is added via 
syringe resulting in a clear solution with a slight yellow color. The reaction mixture is cooled to 0 °C with 
an ice bath and trichlorophosphine (0.39 mL, 4.5 mmol, 1.05 equiv) (Note 4) is added drop wise over 2 
min via syringe resulting in a white suspension. The ice bath is removed, the reaction is allowed to warm 
to 23 °C and stirred for 1 h. The reaction mixture is cooled to 0 °C with an ice bath, and pyrrolidine (1.8 
mL, 21.4 mmol, 5 equiv) (Note 5) is added via syringe. The ice bath is removed, the reaction is allowed to 
warm to 23 °C and stir for 1 h. 50 mL Et2O is then added, and the reaction mixture is filtered through a 
medium fritted funnel into a 250 mL round bottom flask. The solid residue in the reaction flask is washed 
an additional two times with 25 mL Et2O and filtered into the round bottom flask. The filtrate is 
transferred to a 500 mL separatory funnel and washed with 50 mL of deionized water (Note 6). The 
organic layer is dried over MgSO4, filtered through  a course fritted funnel into a 250 mL round bottom, 
and the MgSO4 is rinsed twice with 10 mL Et2O. The filtrate is concentrated in vacuo using a rotovap, and 
the off-white solid put on a high vac for 30 min. A magnetic stir bar and 5 mL EtOAc are added to the 
round bottom and a reflux condenser is attached. Using an oil bath, the mixture is heated to reflux with 
stirring and EtOAc is added dropwise until all the solid dissolves (~20 mL). The stir bar is removed from 
the clear, slightly yellow solution. The round bottom is allowed to cool slowly in the oil bath to 23 °C, 
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placed in a -10 °C fridge for 12 h, and then placed in a -24 °C freezer for 12 h. The solid is collected with 
a Buchner funnel (5 cm) with medium porosity filter paper to yield 1.58 g of Taddol-pyrrolidine 
phosphoramidite as white crystals (65 % yield) (Note 7). 
B1.  Pentenyl isocyanate. A 500 mL single-necked round bottom flask equipped with a 
magnetic stir bar is flame dried under vacuum. After cooling to 23 °C, a rubber septum is fitted to the 
round bottom flask and the flask is put under an atmosphere of Ar. Dichloromethane (50 mL) (Note 8) 
and 5-hexenoic acid (10.4 mL, 87.6 mmol) (Note 9) are added to the round bottom flask and the flask is 
cooled to 0 °C with an ice bath. 1,8-diazobicylo[5.4.0]undec-7-ene (14.2 mL, 94.6 mmol, 1.1 equiv) 
(Note 10) is added to the round bottom via syringe over 5 minutes and the clear solution is stirred for 20 
minutes. Diphenyl phosphoryl azide (20.4 mL, 94.6 mmol, 1.1 equiv) (Note 11) is added over 5 min via 
syringe resulting in a clear, yellow solution. The reaction mixture is stirred for 3 h at 0 °C. The ice bath is 
removed, the septa is removed, and 200 mL hexanes (Note 12) is added. The reaction is stirred for 5 
minutes and transferred to a 500 mL separatory funnel. After the layers separate, the lower (yellow) 
dichloromethane layer is collected in a 250 mL Erlenmeyer flask and the cloudy hexane layer is 
transferred to a 1 L round bottom flask. The dichloromethane layer is returned to the separatory flask and 
the 250 mL Erlenmeyer flask is rinsed with 200 mL hexanes and transferred to the separatory funnel. The 
dichloromethane layer is extracted with hexanes. The lower dichloromethane layer is collected in the 250 
mL Erlenmeyer flask and the cloudy hexane layer is transferred to the 1 L round bottom flask. The 1 L 
round bottom flask (without a septum) is put into a 23 °C oil bath that is heated to 50 °C for 3 h and then 
at 55 °C for 3 h (Note 13). After conversion is complete, the solvent is removed via rotovap using a 23 °C 
bath, resulting in a yellow solution. This oil is transferred to a 25 mL round bottom flask and 1 L flask is 
rinsed with minimal hexanes and transferred to the 25 mL round bottom flask. The 25 mL flask is 
concentrated via rotovap using a 23 °C bath. The resultant yellow oil is purified via vacuum distillation 
and the first clear fraction (Note 14) is collected in a 25 ml round bottom flask cooled to 0 °C. This yields 
5.42 g of pentenyl isocyanate as a clear liquid (56 % yield) (Note 15). 
B2.  Pentenyl isocyanate. A 100 mL single-necked round bottom flask equipped with a 
magnetic stir bar is flame dried under vacuum and is cooled to 23 °C. A rubber septum is fitted to the 
round bottom, and the round bottom is put under an atmosphere of Ar. Dichloromethane (20 mL) (Note 
8), 5-hexenoic acid (9.8 mL, 82.8 mmol) (Note 9), and triethylamine (13 mL, 93.5 mmol, 1.1 equiv) 
(Note 3) are added to the round bottom and the clear solution is stirred for 20 min. The round bottom 
flask is cooled to 0 °C with an ice bath and diphenyl phosphoryl azide (20 mL, 92.5 mmol, 1.1 equiv) 
(Note 11) is added over 1 h via a syringe pump resulting in a clear, yellow solution. The reaction mixture 
is stirred for 4 h at 0 °C. The reaction mixture is purified directly via flash chromatography (Note 16,17). 
The last seven fractions containing acyl azide are collected in a 500 mL round bottom flask and 
concentrated in vacuo via rotovap (Note 18). The remaining fractions containing acyl azide are then 
added to the same round bottom  resulting in a volume of ca 400 mL (Note 19). The flask is fitted with a 
septum containing an Ar inlet and two 18 G needles as outlets, heated to 50 °C for 3 h in an oil bath, and 
then at 55 °C for 3 h (Note 13). After conversion is complete, the solvent is removed via rotovap resulting 
in 5.52 g pentenyl isocyanate as a clear liquid (60 % yield) (Note 15). 
C.  (R)-5-(4-methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one. An oven dried 250mL 
round bottom flask equipped with a magnetic stir bar and an oven dried reflux condenser with septum 
attached are loaded into an inert atmosphere (Ar) glove box (Note 20). Chlorobis(ethylene)rhodium(I) 
dimer (58 mg, 0.15 mmol, 0.005 equiv) (Note 21) and Taddol-pyrrolidine phosphoramidite (170 mg, 0.3 
mmol, 0.01 equiv) are added to the round bottom. The reflux condenser is attached, the apparatus is 
removed from the glove box, and 110 mL PhMe (Note 22) is added via syringe resulting in a clear, gold 
solution. 5 mL PhMe is added to a vial containing pentenyl isocyanate (3.33 g, 30 mmol) and 4-
ethynylanisole (6.0 g, 45 mmol, 1.5 equiv) (Note 23) and this solution is added to the reaction mixture. 
The vial is rinsed with 5 mL PhMe, added to the reaction vessel, and another 50 mL PhMe is added to the 
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reaction mixture resulting in a crimson solution. The reaction mixture is heated to 110 °C in an oil bath 
for 36 h resulting in a dark brown solution. The reaction mixture is concentrated in vacuo, and the crude 
reaction mixture is purified via flash chromatography (Note 24) resulting in 5.11 g (R)-5-(4-
methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one as a light brown solid (70% yield, 90% ee) (Note 
25,26). 
Notes 
1.  (R,R)-Taddol was purchased from AK Scientific, Inc. and used as received. 
2.  Tetrahydrofuran was degassed with Ar and passed through two columns of neutral alumina.   
3.  Triethylamine was purchased from Sigma-Aldrich and distilled over KOH before use.   
4.  Trichlorophosphine was purchased from Sigma-Aldrich and distilled before use.   
5.  Pyrrolidine was purchased from Sigma-Aldrich and distilled over KOH before use.   
6.  Use of deionized water is necessary. Degradation of ligand is observed by P31 NMR if tap or 
acidic water is used. 
7. Physical characteristics of Taddol-pyrrolidine phosphoramidite: [α]20D = -145.5 (conc = 
0.0106 g/mL CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.74 (dm, J = 6.9 Hz, 2H), 7.60 (dm, J = 7.2 Hz, 
2H), 7.48 (dm, J = 7.2 Hz, 2H), 7.41 (dm, J = 7.2 Hz, 2H), 7.34 - 7.15 (m, 12 H), 5.20 (dd, J = 8.4, 3.3 
Hz, 1H), 4.82 (d, J = 8.4 Hz, 1H), 3.44 - 3.34 (m, 2H), 3.26 - 3.17 (m, 2H), 1.87 - 1.73 (m, 4H), 1.26 (s, 
3H), 0.28 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 146.9, 146.6, 142.2, 142.0, 129.0, 128.8, 128.7, 128.0, 
127.6, 127.4, 127.2, 127.1, 127.1, 127.0, 111.7, 82.6, 82.5, 82.4, 82.2, 81.8, 81.2, 45.1, 44.9, 27.5, 26.0, 
25.9, 25.3. 31P NMR (121 MHz, CDCl3) δ 137.7. IR (NaCl, Thin Film) 3060, 2969, 2883, 1492, 1447, 
1035, 737. Mp = 215-217 °C. HRMS (ESI) m/z [C35H37NO4P]
+ calcd 566.2455, found 566.2454. Anal. 
calcd for C35H36NO4P: C, 74.32; H, 6.42; N, 2.48; O, 11.31; P, 5.48, found C, 74.29; H, 6.48; N, 2.57; O, 
11.58; P, 4.94. 
8. Dichloromethane was degassed with Ar and passed through two columns of neutral alumina. 
9. 5-Hexenoic acid was purchased from TCI and used as received. 
10. 1-8-Diazabicyclo[5.4.0]undec-7-ene was purchased from AK Scientific, Inc. and distilled over 
KOH before use. 
11. Diphenyl phosphoryl azide was purchased from AK Scientific, Inc. and used as received. 
12. Hexanes were distilled at ambient pressure over boiling chips. 
13. Conversion can be monitored by NMR (2.35 (t, 2H) shifts to 3.32 (t, 2H)) or IR (1720 shifts 
to 2171) for completion. Physical characteristics for acyl azide: 1H NMR (300 MHz, CDCl3) δ 5.76 (ddt, 
J = 17.1, 10.2, 6.9 Hz, 1H), 5.03 (dm, J = 17.1 Hz, 1H), 5.00 (dm, J = 10.2 Hz, 1H), 2.35 (t, J = 7.5 Hz, 
2H), 2.10 (dt, J = 7.2, 7.2 Hz, 2H), 1.73 (tt, J = 7.5, 7.2 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 180.5, 
137.2, 115.7, 36.0, 32.8, 23.7. Rf  = 0.52 (20:1 Hex:EtOAc). IR (NaCl, Thin Film) 2360, 2138, 1720, 
1369, 1161. 
14. Boiling point: 63 °C at 50 torr. 
15. Physical characteristics of pentenyl isocyanate: 1H NMR (300 MHz, CDCl3) δ 5.77 (ddt, J = 
17.1, 10.2, 6.9 Hz, 1H), 5.07 (dm, J = 17.1 Hz, 1H), 5.03 (dm, J = 10.2 Hz, 1H), 3.32 (t, J = 6.6 Hz, 2H), 
2.16 (dt, J = 6.9, 6.9 Hz, 2H), 1.71 (tt, J = 6.9, 6.9 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 136.7, 121.9, 
115.6, 42.0, 30.4, 30.1. IR (NaCl, Thin Film) 2927, 2171, 1690, 1489, 1183, 966. 
16. Column needs to be slurry packed so the column does not heat up during chromatography and 
should be done behind a hood sash or blast shield. If the column heats up, it will promote the 
decomposition of the acyl azide releasing large amounts of nitrogen and can result in an explosion (this 
has not been observed by the authors with this procedure). 
17. Column diameter: 6cm, silica: 160 g (Silicycle, Inc. silica 60 (230-400 mesh)), eluant: 1 L 
(40:1 Hex:EtOAc), 0.5 L (19:1 Hex:EtOAc), fraction size: 50 mL (25 x 150 mm test tubes), product 
typically in fractions 6-20. 
18. Rotovap cold to prevent acyl azide conversion. 
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19. If all the fractions are collected in a 1 L round bottom flask with ca 700 mL solvent, the 
solution must be heated overnight at 60 °C for full conversion. 
20. The use of a glove box is for simplicity of set up due to the air sensitive nature of 
chlorobis(ethylene)rhodium(I) dimer. Use of standard Schlenk techniques in place of a glove box should 
provide similar results if the chlorobis(ethylene)rhodium(I) dimer is of high quality. 
Chlorobis(cyclooctadiene)rhodium(I) dimer may be used as an air stable alternative, but we observe lower 
yields (15-25% lower) when this catalyst is used on smaller scale. The phosphoramidite ligand is air 
stable and can be stored outside the glovebox, but is stored in the glovebox for ease of reaction setup. 
21. Chlorobis(ethylene)rhodium(I) dimer was purchased from Strem, Inc., stored cold in an inert 
atmosphere glove box (Ar), and used as received.  
22. Toluene was degassed with Ar and passed through one column of neutral alumina and one 
column of Q5 reactant. 
23. 4-Ethynylanisole was purchased from AK Scientific, Inc. and used as received. 
24. Column diameter: 6 cm, silica: 140 g (Silicycle, Inc. silica 60 (230-400 mesh)), eluant: 2.5 L 
(20:1 EtOAc:MeOH), fraction size: 50 mL (25 x 150 mm test tubes), product typically found in fractions 
16-49. 
25. Physical characteristics of (R)-5-(4-methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one: 
90% ee by HPLC: Chiralcel ODH column, 90:10 Hex:iPrOH, 1 mL/min, 330nm, RTmajor = 27.72 min, 
RTminor = 33.82 min. [α]
20
D = +592.9 (conc = 0.0084 g/mL CHCl3). 
1H NMR (300 MHz, CDCl3) δ 7.34 
(dm, J = 8.7 Hz, 2H), 6.92 (dm, J = 8.7 Hz, 2H), 5.08 (s, 1H), 4.05 (dddd, J = 13.5, 6.9, 6.9, 6.9 Hz, 1H), 
3.84 (s, 3H), 3.55 (ddd, J = 11.4, 7.2, 5.7 Hz, 1H), 3.27 (ddd, J = 10.8, 7.2, 7.2 Hz, 1H), 2.53 - 2.25 (m, 
3H), 2.07 - 1.71 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 191.9, 162.7, 160.8, 129.2, 128.4, 113.8, 99.7, 
58.6, 55.3, 49.5, 41.4, 31.6, 24.6. Rf  = 0.16 (20:1 EtOAc:MeOH). IR (NaCl, Thin Film) 2967, 2878, 
1624, 1507, 1245, 1030. HRMS (ESI) m/z [C15H18NO2]
+ calcd 244.1332, found 244.1330. Anal. calcd for 
C15H17NO2: C, 74.05; H, 7.04; N, 5.76; O, 13.15, found C, 73.99; H, 7.10; N, 5.80; O, 13.28. 
 26. (R)-5-(4-methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one can be recrystalized from 
































Crystal Structure Tables and Figures. 
Table A.2.1.  Crystal data and structure refinement for Rh(cod)Cl·T9. 
Identification code  rovis36_0m 
Empirical formula  C52H66ClNO4PRh 
Formula weight  938.39 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 212121 
Unit cell dimensions a = 15.3932(6) Å = 90°. 
 b = 17.5850(7) Å = 90°. 
 c = 18.0197(8) Å  = 90°. 
Volume 4877.7(3) Å3 
Z 4 
Density (calculated) 1.278 Mg/m3 
Absorption coefficient 0.481 mm-1 
F(000) 1976 
Crystal size 0.63 x 0.45 x 0.30 mm3 
Theta range for data collection 2.09 to 33.49°. 
Index ranges -21<=h<=23, -26<=k<=27, -27<=l<=27 
Reflections collected 138707 
Independent reflections 18942 [R(int) = 0.0541] 
Completeness to theta = 33.49° 99.3 %  
Absorption correction None 
Max. and min. transmission 0.8683 and 0.7527 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 18942 / 0 / 568 
Goodness-of-fit on F2 1.029 
Final R indices [I>2sigma(I)] R1 = 0.0333, wR2 = 0.0760 
R indices (all data) R1 = 0.0434, wR2 = 0.0811 
Absolute structure parameter -0.014(12) 
Largest diff. peak and hole 0.709 and -0.589 e.Å-3 
 
Table A.2.2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for Rh(cod)Cl·T9.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 19(1) 5558(1) 5821(1) 16(1) 
C(2) 421(1) 4739(1) 5820(1) 18(1) 
C(3) 21(1) 4233(1) 5219(1) 19(1) 
C(4) 611(1) 4193(1) 4521(1) 18(1) 
C(5) -109(2) 3614(1) 6349(1) 27(1) 
C(6) -1056(2) 3632(1) 6604(1) 35(1) 
C(7) 411(2) 3000(1) 6718(1) 41(1) 
C(8) 618(1) 6146(1) 6179(1) 17(1) 
C(9) 476(1) 6908(1) 6024(1) 18(1) 
C(10) 961(1) 7474(1) 6375(1) 21(1) 
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C(11) 1574(1) 7256(1) 6899(1) 25(1) 
C(12) 1715(1) 6499(1) 7071(1) 27(1) 
C(13) 1238(1) 5939(1) 6703(1) 23(1) 
C(14) 809(1) 8301(1) 6194(1) 28(1) 
C(15) 2356(2) 6278(2) 7672(2) 45(1) 
C(16) -862(1) 5565(1) 6212(1) 19(1) 
C(17) -1641(1) 5510(1) 5821(1) 20(1) 
C(18) -2438(1) 5479(1) 6191(1) 24(1) 
C(19) -2443(1) 5508(1) 6967(1) 28(1) 
C(20) -1677(1) 5578(1) 7366(1) 28(1) 
C(21) -886(1) 5604(1) 6988(1) 24(1) 
C(22) -3277(1) 5440(1) 5767(1) 32(1) 
C(23) -1677(2) 5626(2) 8209(1) 42(1) 
C(24) 132(1) 3957(1) 3823(1) 18(1) 
C(25) 478(1) 4166(1) 3141(1) 21(1) 
C(26) 91(1) 3940(1) 2479(1) 24(1) 
C(27) -642(1) 3476(1) 2513(1) 25(1) 
C(28) -998(1) 3249(1) 3187(1) 24(1) 
C(29) -607(1) 3502(1) 3843(1) 21(1) 
C(30) 461(2) 4190(2) 1744(1) 40(1) 
C(31) -1774(2) 2728(1) 3200(1) 38(1) 
C(32) 1388(1) 3654(1) 4632(1) 21(1) 
C(33) 2222(1) 3923(1) 4747(1) 31(1) 
C(34) 2926(2) 3425(2) 4811(2) 40(1) 
C(35) 2780(2) 2655(1) 4770(1) 39(1) 
C(36) 1953(2) 2366(1) 4665(1) 34(1) 
C(37) 1257(2) 2867(1) 4593(1) 28(1) 
C(38) 3840(2) 3741(2) 4927(3) 74(1) 
C(39) 1795(2) 1517(1) 4634(2) 48(1) 
C(40) 158(1) 6132(1) 2978(1) 23(1) 
C(41) -484(1) 6708(1) 2635(1) 29(1) 
C(42) -1385(1) 6359(1) 2565(1) 30(1) 
C(43) -1684(1) 6058(1) 3313(1) 27(1) 
C(44) -1028(1) 5493(1) 3623(1) 21(1) 
C(45) 2499(1) 5939(1) 3906(1) 22(1) 
C(46) 2610(1) 5999(1) 4683(1) 24(1) 
C(47) 3361(1) 6420(1) 5043(1) 32(1) 
C(48) 3122(1) 7238(1) 5252(1) 32(1) 
C(49) 2502(1) 7599(1) 4709(1) 26(1) 
C(50) 2551(1) 7548(1) 3949(1) 25(1) 
C(51) 3277(1) 7164(1) 3529(1) 31(1) 
C(52) 3057(1) 6337(1) 3336(1) 29(1) 
Cl(1) 456(1) 7628(1) 4288(1) 21(1) 
N(1) -162(1) 5843(1) 3678(1) 18(1) 
O(1) -162(1) 5763(1) 5051(1) 16(1) 
O(2) 981(1) 4949(1) 4424(1) 17(1) 
O(3) 275(1) 4342(1) 6495(1) 23(1) 
O(4) -65(1) 3509(1) 5563(1) 24(1) 
P(1) 527(1) 5784(1) 4376(1) 14(1) 




Table A.2.3.   Bond lengths [Å] and angles [°] for Rh(cod)Cl·T9. 
_____________________________________________________ 
C(1)-O(1)  1.4606(19) 
C(1)-C(8)  1.528(2) 
C(1)-C(16)  1.529(2) 
C(1)-C(2)  1.567(2) 
C(2)-O(3)  1.421(2) 
C(2)-C(3)  1.531(2) 
C(3)-O(4)  1.421(2) 
C(3)-C(4)  1.553(2) 
C(4)-O(2)  1.458(2) 
C(4)-C(24)  1.516(2) 
C(4)-C(32)  1.539(2) 
C(5)-O(4)  1.431(2) 
C(5)-O(3)  1.433(2) 
C(5)-C(7)  1.499(3) 
C(5)-C(6)  1.529(3) 
C(8)-C(9)  1.387(3) 
C(8)-C(13)  1.390(2) 
C(9)-C(10)  1.396(2) 
C(10)-C(11)  1.389(3) 
C(10)-C(14)  1.508(3) 
C(11)-C(12)  1.384(3) 
C(12)-C(13)  1.397(3) 
C(12)-C(15)  1.517(3) 
C(16)-C(17)  1.393(2) 
C(16)-C(21)  1.400(3) 
C(17)-C(18)  1.397(3) 
C(18)-C(19)  1.401(3) 
C(18)-C(22)  1.502(3) 
C(19)-C(20)  1.388(3) 
C(20)-C(21)  1.397(3) 
C(20)-C(23)  1.520(3) 
C(24)-C(25)  1.389(2) 
C(24)-C(29)  1.391(3) 
C(25)-C(26)  1.391(3) 
C(26)-C(27)  1.394(3) 
C(26)-C(30)  1.507(3) 
C(27)-C(28)  1.392(3) 
C(28)-C(29)  1.398(2) 
C(28)-C(31)  1.507(3) 
C(32)-C(33)  1.384(3) 
C(32)-C(37)  1.400(3) 
C(33)-C(34)  1.398(3) 
C(34)-C(35)  1.375(4) 
C(34)-C(38)  1.526(4) 
C(35)-C(36)  1.384(4) 
C(36)-C(37)  1.393(3) 
C(36)-C(39)  1.515(3) 
C(40)-N(1)  1.447(2) 
C(40)-C(41)  1.545(3) 
C(41)-C(42)  1.523(3) 
C(42)-C(43)  1.519(3) 
C(43)-C(44)  1.523(3) 
C(44)-N(1)  1.471(2) 
C(45)-C(46)  1.413(3) 
C(45)-C(52)  1.510(3) 
C(45)-Rh(1)  2.1155(19) 
C(46)-C(47)  1.519(3) 
C(46)-Rh(1)  2.1152(19) 
C(47)-C(48)  1.532(3) 
C(48)-C(49)  1.506(3) 
C(49)-C(50)  1.374(3) 
C(49)-Rh(1)  2.2373(19) 
C(50)-C(51)  1.510(3) 
C(50)-Rh(1)  2.2430(19) 
C(51)-C(52)  1.533(3) 
Cl(1)-Rh(1)  2.3654(4) 
N(1)-P(1)  1.6477(15) 
O(1)-P(1)  1.6149(13) 
O(2)-P(1)  1.6283(12) 



































































































































Table A.2.4.   Anisotropic displacement parameters (Å2x 103)for Rh(cod)Cl·T9.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 18(1)  18(1) 14(1)  -1(1) 0(1)  1(1) 
C(2) 22(1)  17(1) 16(1)  -1(1) 0(1)  1(1) 
C(3) 22(1)  16(1) 18(1)  0(1) 1(1)  -1(1) 
C(4) 20(1)  14(1) 19(1)  -1(1) -1(1)  1(1) 
C(5) 41(1)  20(1) 20(1)  3(1) -4(1)  -2(1) 
C(6) 41(1)  35(1) 29(1)  3(1) 6(1)  -7(1) 
C(7) 58(2)  28(1) 38(1)  4(1) -10(1)  8(1) 
C(8) 16(1)  21(1) 15(1)  -4(1) 1(1)  0(1) 
C(9) 16(1)  21(1) 19(1)  -4(1) 1(1)  -1(1) 
C(10) 19(1)  22(1) 23(1)  -7(1) 2(1)  -3(1) 
C(11) 20(1)  30(1) 26(1)  -13(1) 1(1)  -2(1) 
C(12) 18(1)  40(1) 23(1)  -13(1) -3(1)  1(1) 
C(13) 22(1)  27(1) 20(1)  -4(1) -2(1)  4(1) 
C(14) 29(1)  23(1) 33(1)  -7(1) 0(1)  -4(1) 
C(15) 39(1)  53(2) 43(1)  -16(1) -23(1)  13(1) 
C(16) 20(1)  16(1) 21(1)  -1(1) 4(1)  0(1) 
C(17) 22(1)  17(1) 23(1)  -1(1) 2(1)  0(1) 
C(18) 21(1)  15(1) 36(1)  1(1) 6(1)  1(1) 
C(19) 26(1)  23(1) 35(1)  1(1) 13(1)  0(1) 
C(20) 33(1)  25(1) 26(1)  -2(1) 11(1)  -3(1) 
C(21) 24(1)  26(1) 22(1)  -2(1) 3(1)  -2(1) 
C(22) 20(1)  26(1) 49(1)  0(1) 3(1)  1(1) 
C(23) 49(2)  49(1) 28(1)  -4(1) 16(1)  -5(1) 
C(24) 20(1)  16(1) 17(1)  -3(1) 0(1)  3(1) 
C(25) 21(1)  24(1) 19(1)  -4(1) 2(1)  2(1) 
C(26) 24(1)  28(1) 19(1)  -7(1) 2(1)  3(1) 
C(27) 27(1)  27(1) 22(1)  -7(1) -3(1)  0(1) 
C(28) 26(1)  22(1) 25(1)  -5(1) -2(1)  -2(1) 
C(29) 25(1)  18(1) 21(1)  -2(1) 1(1)  -2(1) 
C(30) 38(1)  61(2) 19(1)  -6(1) 3(1)  -15(1) 
C(31) 42(1)  40(1) 33(1)  -6(1) -2(1)  -16(1) 
C(32) 28(1)  19(1) 18(1)  -1(1) -1(1)  7(1) 
C(33) 25(1)  26(1) 41(1)  -1(1) -5(1)  7(1) 
C(34) 29(1)  40(1) 52(1)  1(1) -8(1)  13(1) 
C(35) 46(1)  36(1) 35(1)  0(1) -6(1)  23(1) 
C(36) 50(1)  23(1) 28(1)  0(1) -3(1)  14(1) 
C(37) 37(1)  19(1) 27(1)  -1(1) -2(1)  7(1) 
C(38) 31(1)  57(2) 134(4)  -2(2) -18(2)  12(1) 
C(39) 71(2)  23(1) 49(1)  1(1) -2(1)  16(1) 
C(40) 18(1)  27(1) 25(1)  -3(1) 0(1)  -3(1) 
C(41) 35(1)  26(1) 26(1)  3(1) -10(1)  -1(1) 
C(42) 29(1)  28(1) 32(1)  -2(1) -13(1)  5(1) 
C(43) 19(1)  29(1) 34(1)  -9(1) -6(1)  5(1) 
C(44) 16(1)  23(1) 23(1)  -4(1) -2(1)  -2(1) 
C(45) 16(1)  21(1) 29(1)  -2(1) 0(1)  1(1) 
180 
 
C(46) 17(1)  26(1) 30(1)  2(1) -4(1)  2(1) 
C(47) 20(1)  41(1) 36(1)  -3(1) -10(1)  1(1) 
C(48) 21(1)  43(1) 31(1)  -8(1) -4(1)  -5(1) 
C(49) 18(1)  23(1) 36(1)  -6(1) 1(1)  -6(1) 
C(50) 21(1)  22(1) 31(1)  1(1) 3(1)  -5(1) 
C(51) 24(1)  32(1) 36(1)  -1(1) 8(1)  -5(1) 
C(52) 23(1)  32(1) 31(1)  -4(1) 9(1)  -1(1) 
Cl(1) 19(1)  19(1) 24(1)  2(1) 0(1)  1(1) 
N(1) 15(1)  22(1) 16(1)  0(1) -3(1)  -2(1) 
O(1) 15(1)  17(1) 15(1)  -1(1) -1(1)  0(1) 
O(2) 17(1)  14(1) 19(1)  0(1) 1(1)  1(1) 
O(3) 31(1)  21(1) 17(1)  1(1) -1(1)  -1(1) 
O(4) 38(1)  16(1) 19(1)  1(1) 4(1)  -3(1) 
P(1) 14(1)  15(1) 14(1)  0(1) -1(1)  0(1) 
Rh(1) 13(1)  18(1) 19(1)  0(1) -1(1)  -1(1) 
______________________________________________________________________________ 
 
Table A.2.5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 
Rh(cod)Cl·T9. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2) 1061 4779 5732 22 
H(3) -566 4431 5079 22 
H(6A) -1370 4028 6331 52 
H(6B) -1080 3741 7136 52 
H(6C) -1326 3137 6507 52 
H(7A) 161 2503 6595 62 
H(7B) 398 3074 7257 62 
H(7C) 1013 3022 6542 62 
H(9) 42 7047 5675 22 
H(11) 1905 7636 7146 30 
H(13) 1336 5417 6810 28 
H(14A) 308 8488 6476 42 
H(14B) 694 8355 5662 42 
H(14C) 1325 8597 6326 42 
H(15A) 2935 6469 7542 68 
H(15B) 2376 5722 7716 68 
H(15C) 2173 6498 8146 68 
H(17) -1629 5494 5294 25 
H(19) -2981 5480 7225 34 
H(21) -359 5649 7259 29 
H(22A) -3582 5927 5809 48 
H(22B) -3641 5034 5971 48 
H(22C) -3155 5334 5243 48 
H(23A) -1384 6095 8365 63 
H(23B) -1369 5186 8414 63 
H(23C) -2277 5629 8390 63 
H(25) 988 4470 3126 25 
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H(27) -905 3311 2064 30 
H(29) -849 3362 4308 26 
H(30A) 88 4585 1529 59 
H(30B) 486 3754 1406 59 
H(30C) 1047 4393 1818 59 
H(31A) -2214 2915 2851 57 
H(31B) -2020 2715 3702 57 
H(31C) -1595 2214 3055 57 
H(33) 2318 4456 4783 37 
H(35) 3256 2315 4814 47 
H(37) 688 2673 4516 33 
H(38A) 4241 3322 5030 111 
H(38B) 3837 4095 5347 111 
H(38C) 4027 4010 4478 111 
H(39A) 1840 1303 5134 71 
H(39B) 2230 1279 4311 71 
H(39C) 1213 1418 4435 71 
H(40A) 246 5704 2629 28 
H(40B) 727 6382 3057 28 
H(41A) -514 7168 2951 35 
H(41B) -274 6864 2138 35 
H(42A) -1800 6748 2385 36 
H(42B) -1372 5939 2200 36 
H(43A) -2255 5806 3257 33 
H(43B) -1754 6487 3664 33 
H(44A) -1218 5322 4121 25 
H(44B) -998 5042 3295 25 
H(47A) 3860 6428 4697 39 
H(47B) 3543 6143 5495 39 
H(48A) 2854 7240 5752 38 
H(48B) 3658 7548 5277 38 
H(51A) 3812 7174 3834 37 
H(51B) 3393 7449 3066 37 
H(52A) 2751 6328 2853 34 
H(52B) 3605 6049 3277 34 
H(49) 2103(17) 8006(15) 4886(14) 31(7) 
H(50) 2203(17) 7873(15) 3659(14) 30(7) 
H(45) 2204(18) 5499(16) 3700(15) 36(7) 











Table A.2.6.  Crystal data and structure refinement for Rh(cod)Cl·A1. 
Identification code  rovis41_0m 
Empirical formula  C34H50ClNO2PRh 
Formula weight  674.08 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.4105(5) Å = 77.003(3)°. 
 b = 10.8685(6) Å = 76.360(2)°. 
 c = 16.5368(10) Å  = 64.354(2)°. 
Volume 1622.99(15) Å3 
Z 2 
Density (calculated) 1.379 Mg/m3 
Absorption coefficient 0.688 mm-1 
F(000) 708 
Crystal size 0.70 x 0.37 x 0.17 mm3 
Theta range for data collection 2.10 to 33.37°. 
Index ranges -16<=h<=13, -16<=k<=15, -25<=l<=25 
Reflections collected 19235 
Independent reflections 12140 [R(int) = 0.0176] 
Completeness to theta = 33.37° 96.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8890 and 0.6455 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12140 / 0 / 389 
Goodness-of-fit on F2 1.104 
Final R indices [I>2sigma(I)] R1 = 0.0336, wR2 = 0.0761 
R indices (all data) R1 = 0.0410, wR2 = 0.0792 
Largest diff. peak and hole 1.056 and -0.844 e.Å-3 
 
Table A.2.7.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for Rh(cod)Cl·A1.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1725(2) 5267(2) 3240(1) 13(1) 
C(2) 3191(2) 4967(2) 3167(1) 12(1) 
C(3) 3711(2) 5600(2) 3586(1) 13(1) 
C(4) 2679(2) 6412(2) 4177(1) 18(1) 
C(5) 1231(2) 6611(2) 4340(1) 19(1) 
C(6) 728(2) 6061(2) 3855(1) 16(1) 
C(7) 5251(2) 5552(2) 3354(1) 17(1) 
C(8) 5462(2) 6175(2) 2427(1) 24(1) 
C(9) 6416(2) 4076(2) 3485(1) 23(1) 
C(10) 5482(2) 6415(2) 3879(1) 23(1) 
C(11) 212(2) 7467(2) 5014(1) 29(1) 
C(12) -842(2) 6305(2) 4004(1) 22(1) 
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C(13) 1241(2) 4796(2) 2630(1) 14(1) 
C(14) 1684(2) 3384(2) 2628(1) 14(1) 
C(15) 1071(2) 2863(2) 2194(1) 18(1) 
C(16) 164(2) 3863(2) 1646(1) 22(1) 
C(17) -161(2) 5260(2) 1545(1) 21(1) 
C(18) 342(2) 5760(2) 2065(1) 17(1) 
C(19) 1264(2) 1357(2) 2277(1) 22(1) 
C(20) 1991(2) 396(2) 3020(1) 27(1) 
C(21) 2139(2) 773(2) 1460(2) 33(1) 
C(22) -240(2) 1330(2) 2412(2) 36(1) 
C(23) -1070(2) 6240(2) 893(1) 28(1) 
C(24) -45(2) 7279(2) 1987(1) 22(1) 
C(25) 4216(2) 1871(2) 4453(1) 25(1) 
C(26) 6577(2) 718(2) 3606(1) 22(1) 
C(27) 6010(2) 3301(2) 932(1) 16(1) 
C(28) 4641(2) 3464(2) 823(1) 16(1) 
C(29) 4271(2) 3234(2) 57(1) 21(1) 
C(30) 5448(2) 2006(2) -359(1) 23(1) 
C(31) 6145(2) 815(2) 289(1) 19(1) 
C(32) 7404(2) 550(2) 552(1) 19(1) 
C(33) 8267(2) 1418(2) 274(1) 24(1) 
C(34) 7346(2) 2971(2) 255(1) 22(1) 
Cl(1) 5896(1) -687(1) 2247(1) 21(1) 
N(1) 5070(2) 1691(2) 3620(1) 16(1) 
O(1) 4135(1) 4065(1) 2599(1) 12(1) 
O(2) 2774(1) 2508(1) 3105(1) 14(1) 
P(1) 4404(1) 2437(1) 2749(1) 12(1) 
Rh(1) 5602(1) 1536(1) 1559(1) 12(1) 
________________________________________________________________________________ 
 
Table A.2.8.   Bond lengths [Å] and angles [°] for Rh(cod)Cl·A1. 
_____________________________________________________ 
C(1)-C(2)  1.397(2) 
C(1)-C(6)  1.407(2) 
C(1)-C(13)  1.492(2) 
C(2)-O(1)  1.3982(18) 
C(2)-C(3)  1.399(2) 
C(3)-C(4)  1.400(2) 
C(3)-C(7)  1.538(2) 
C(4)-C(5)  1.394(2) 
C(5)-C(6)  1.400(2) 
C(5)-C(11)  1.513(2) 
C(6)-C(12)  1.505(2) 
C(7)-C(10)  1.533(2) 
C(7)-C(8)  1.536(3) 
C(7)-C(9)  1.540(3) 
C(13)-C(14)  1.399(2) 
C(13)-C(18)  1.403(2) 
C(14)-C(15)  1.397(2) 
C(14)-O(2)  1.402(2) 
C(15)-C(16)  1.403(3) 
C(15)-C(19)  1.538(3) 
C(16)-C(17)  1.383(3) 
C(17)-C(18)  1.407(2) 
C(17)-C(23)  1.512(3) 
C(18)-C(24)  1.503(3) 
C(19)-C(20)  1.534(3) 
C(19)-C(21)  1.536(3) 
C(19)-C(22)  1.541(3) 
C(25)-N(1)  1.457(2) 
C(26)-N(1)  1.462(2) 
C(27)-C(28)  1.409(2) 
C(27)-C(34)  1.526(2) 
C(27)-Rh(1)  2.1299(17) 
C(28)-C(29)  1.508(2) 
C(28)-Rh(1)  2.1182(17) 
C(29)-C(30)  1.534(3) 
C(30)-C(31)  1.510(3) 
C(31)-C(32)  1.369(3) 
C(31)-Rh(1)  2.2678(17) 
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C(32)-C(33)  1.501(3) 
C(32)-Rh(1)  2.2432(16) 
C(33)-C(34)  1.536(3) 
Cl(1)-Rh(1)  2.3485(4) 
N(1)-P(1)  1.6337(15) 
O(1)-P(1)  1.6359(12) 
O(2)-P(1)  1.6333(12) 





























































































Table A.2.9.   Anisotropic displacement parameters (Å2x 103)for Rh(cod)Cl·A1.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 12(1)  13(1) 14(1)  -3(1) -2(1)  -5(1) 
C(2) 12(1)  11(1) 11(1)  -3(1) 0(1)  -4(1) 
C(3) 14(1)  13(1) 14(1)  -2(1) -3(1)  -5(1) 
C(4) 19(1)  18(1) 17(1)  -7(1) -3(1)  -7(1) 
C(5) 17(1)  18(1) 18(1)  -9(1) 2(1)  -5(1) 
C(6) 12(1)  16(1) 18(1)  -5(1) 0(1)  -4(1) 
C(7) 14(1)  20(1) 18(1)  -6(1) -1(1)  -9(1) 
C(8) 30(1)  29(1) 20(1)  -6(1) 2(1)  -21(1) 
C(9) 15(1)  22(1) 33(1)  -7(1) -6(1)  -5(1) 
C(10) 22(1)  31(1) 25(1)  -10(1) -4(1)  -14(1) 
C(11) 23(1)  35(1) 30(1)  -22(1) 5(1)  -8(1) 
C(12) 12(1)  25(1) 27(1)  -10(1) 2(1)  -5(1) 
C(13) 11(1)  16(1) 14(1)  -4(1) -1(1)  -5(1) 
C(14) 10(1)  17(1) 15(1)  -5(1) 0(1)  -5(1) 
C(15) 14(1)  22(1) 20(1)  -11(1) 2(1)  -8(1) 
C(16) 18(1)  31(1) 21(1)  -12(1) -3(1)  -10(1) 
C(17) 13(1)  31(1) 17(1)  -5(1) -3(1)  -6(1) 
C(18) 11(1)  20(1) 18(1)  -3(1) -2(1)  -4(1) 
C(19) 16(1)  23(1) 33(1)  -16(1) 4(1)  -9(1) 
C(20) 27(1)  20(1) 37(1)  -8(1) 2(1)  -13(1) 
C(21) 29(1)  33(1) 37(1)  -23(1) 5(1)  -10(1) 
C(22) 20(1)  31(1) 65(2)  -22(1) 1(1)  -14(1) 
C(23) 21(1)  40(1) 22(1)  -4(1) -9(1)  -8(1) 
C(24) 19(1)  18(1) 25(1)  1(1) -7(1)  -4(1) 
C(25) 26(1)  28(1) 14(1)  -2(1) -1(1)  -6(1) 
C(26) 16(1)  23(1) 21(1)  0(1) -4(1)  -4(1) 
C(27) 19(1)  12(1) 16(1)  -3(1) 1(1)  -7(1) 
C(28) 18(1)  13(1) 15(1)  -2(1) -2(1)  -3(1) 
C(29) 24(1)  19(1) 18(1)  -2(1) -7(1)  -4(1) 
C(30) 32(1)  20(1) 17(1)  -5(1) -5(1)  -8(1) 
C(31) 27(1)  15(1) 15(1)  -7(1) -1(1)  -7(1) 
C(32) 20(1)  14(1) 18(1)  -5(1) 3(1)  -3(1) 
C(33) 18(1)  20(1) 26(1)  -4(1) 6(1)  -5(1) 
C(34) 20(1)  20(1) 23(1)  -4(1) 5(1)  -9(1) 
Cl(1) 22(1)  12(1) 25(1)  -1(1) 2(1)  -6(1) 
N(1) 14(1)  16(1) 13(1)  -1(1) -2(1)  -4(1) 
O(1) 12(1)  12(1) 13(1)  -4(1) 1(1)  -4(1) 
O(2) 11(1)  14(1) 16(1)  -2(1) 0(1)  -5(1) 
P(1) 11(1)  11(1) 12(1)  -3(1) 0(1)  -4(1) 








Table A.2.10.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 
Rh(cod)Cl·A1. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(4) 2976 6842 4478 21 
H(8A) 6423 6144 2266 36 
H(8B) 4777 7115 2353 36 
H(8C) 5319 5656 2083 36 
H(9A) 6231 3656 4051 35 
H(9B) 7348 4109 3385 35 
H(9C) 6396 3545 3100 35 
H(10A) 5377 6035 4462 35 
H(10B) 4779 7347 3804 35 
H(10C) 6433 6403 3700 35 
H(11A) 739 7761 5279 44 
H(11B) -220 6923 5427 44 
H(11C) -528 8260 4765 44 
H(12A) -977 5748 3683 33 
H(12B) -1408 7260 3834 33 
H(12C) -1141 6061 4591 33 
H(16) -247 3567 1328 26 
H(20A) 1942 -481 3073 41 
H(20B) 1504 796 3527 41 
H(20C) 2983 272 2926 41 
H(21A) 1661 1339 995 49 
H(21B) 2216 -150 1498 49 
H(21C) 3086 765 1378 49 
H(22A) -726 1885 1947 54 
H(22B) -793 1690 2922 54 
H(22C) -138 398 2450 54 
H(23A) -1369 5738 620 43 
H(23B) -513 6671 483 43 
H(23C) -1905 6933 1161 43 
H(24A) 527 7429 2302 34 
H(24B) -1049 7738 2203 34 
H(24C) 140 7640 1406 34 
H(25A) 3942 1106 4667 38 
H(25B) 3365 2711 4419 38 
H(25C) 4777 1913 4823 38 
H(26A) 7027 984 3940 33 
H(26B) 7074 721 3038 33 
H(26C) 6619 -191 3831 33 
H(29A) 4094 4061 -352 26 
H(29B) 3384 3087 216 26 
H(30A) 5027 1709 -702 28 
H(30B) 6177 2291 -724 28 
H(33A) 8802 1246 -283 28 
H(33B) 8961 1138 652 28 
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H(34A) 7932 3417 329 26 
H(34B) 7044 3349 -292 26 
H(32) 7840(20) -300(20) 836(13) 14(5) 
H(28) 3810(20) 4010(20) 1165(14) 17(5) 
H(27) 6040(20) 3770(20) 1363(14) 19(5) 








Table A.2.11.  Crystal data and structure refinement for Rh(cod)Cl·T2 (1). 
Identification code  rovis81 
Empirical formula  C45H52Cl5NO4PRh 
Formula weight  982.01 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 10.8926(7) Å = 90°. 
 b = 18.1189(11) Å = 91.835(3)°. 
 c = 11.2230(7) Å  = 90°. 
Volume 2213.9(2) Å3 
Z 2 
Density (calculated) 1.473 Mg/m3 
Absorption coefficient 0.767 mm-1 
F(000) 1012 
Crystal size 0.32 x 0.30 x 0.26 mm3 
Theta range for data collection 2.14 to 35.63°. 
Index ranges -17<=h<=17, -29<=k<=29, -18<=l<=17 
Reflections collected 77157 
Independent reflections 20295 [R(int) = 0.0257] 
Completeness to theta = 35.63° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8249 and 0.7898 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 20295 / 1 / 517 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0232, wR2 = 0.0575 
R indices (all data) R1 = 0.0246, wR2 = 0.0582 
Absolute structure parameter -0.017(8) 
Largest diff. peak and hole 1.091 and -0.978 e.Å-3 
 
Table A.2.12.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for Rh(cod)Cl·T2 (1).  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) -688(1) 709(1) 7937(1) 13(1) 
C(2) -1052(1) 547(1) 6607(1) 14(1) 
C(3) -697(1) -229(1) 6211(1) 13(1) 
C(4) 541(1) -228(1) 5541(1) 12(1) 
C(5) -2683(1) 64(1) 5503(1) 17(1) 
C(6) -2777(1) 458(1) 4309(1) 21(1) 
C(7) -3867(1) -315(1) 5834(1) 27(1) 
C(8) 348(1) 44(1) 4262(1) 13(1) 
C(9) -213(1) -429(1) 3421(1) 17(1) 
C(10) -484(1) -187(1) 2272(1) 21(1) 
C(11) -179(1) 526(1) 1926(1) 24(1) 
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C(12) 416(1) 990(1) 2737(1) 22(1) 
C(13) 674(1) 752(1) 3905(1) 16(1) 
C(14) 1168(1) -978(1) 5536(1) 13(1) 
C(15) 534(1) -1632(1) 5753(1) 19(1) 
C(16) 1139(1) -2312(1) 5707(1) 24(1) 
C(17) 2373(1) -2343(1) 5436(1) 24(1) 
C(18) 3007(1) -1692(1) 5198(1) 21(1) 
C(19) 2408(1) -1017(1) 5240(1) 16(1) 
C(20) -518(1) 1527(1) 8181(1) 15(1) 
C(21) -1110(1) 2061(1) 7475(1) 19(1) 
C(22) -1039(1) 2806(1) 7778(1) 25(1) 
C(23) -371(1) 3025(1) 8793(1) 28(1) 
C(24) 244(1) 2499(1) 9491(1) 26(1) 
C(25) 178(1) 1753(1) 9187(1) 19(1) 
C(26) -1638(1) 378(1) 8768(1) 15(1) 
C(27) -1592(1) -365(1) 9092(1) 19(1) 
C(28) -2481(1) -667(1) 9816(1) 24(1) 
C(29) -3415(1) -229(1) 10237(1) 28(1) 
C(30) -3469(1) 512(1) 9928(1) 30(1) 
C(31) -2589(1) 817(1) 9192(1) 23(1) 
C(32) 1754(1) -987(1) 8671(1) 19(1) 
C(33) 2784(1) -1552(1) 8873(1) 25(1) 
C(34) 3942(1) -1072(1) 8945(1) 24(1) 
C(35) 3694(1) -502(1) 7975(1) 18(1) 
C(36) 3278(1) 1549(1) 6034(1) 15(1) 
C(37) 2212(1) 1947(1) 6320(1) 15(1) 
C(38) 2140(1) 2771(1) 6521(1) 20(1) 
C(39) 3218(1) 3082(1) 7284(1) 22(1) 
C(40) 3669(1) 2544(1) 8237(1) 19(1) 
C(41) 4626(1) 2057(1) 8100(1) 19(1) 
C(42) 5339(1) 1941(1) 6985(1) 22(1) 
C(43) 4523(1) 1910(1) 5841(1) 20(1) 
C(44) 6900(1) 4752(1) 7696(1) 26(1) 
C(45) 6690(2) 7107(1) 7423(2) 40(1) 
Cl(1) 3102(1) 1038(1) 9901(1) 20(1) 
Cl(2) 5966(1) 5338(1) 6807(1) 46(1) 
Cl(3) 6182(1) 3878(1) 7841(1) 35(1) 
Cl(4) 5091(1) 7280(1) 7392(1) 58(1) 
Cl(5) 7570(1) 7914(1) 7400(1) 78(1) 
N(1) 2348(1) -391(1) 8009(1) 14(1) 
O(1) 445(1) 305(1) 8221(1) 13(1) 
O(2) 1332(1) 314(1) 6140(1) 12(1) 
O(3) -1714(1) -479(1) 5494(1) 16(1) 
O(4) -2352(1) 567(1) 6438(1) 19(1) 
P(1) 1729(1) 384(1) 7545(1) 11(1) 








Table A.2.13.   Bond lengths [Å] and angles [°] for  Rh(cod)Cl·T2 (1). 
_____________________________________________________  
C(1)-O(1)  1.4606(13) 
C(1)-C(20)  1.5187(15) 
C(1)-C(26)  1.5373(15) 
C(1)-C(2)  1.5595(15) 
C(2)-O(4)  1.4229(13) 
C(2)-C(3)  1.5290(16) 
C(3)-O(3)  1.4212(13) 
C(3)-C(4)  1.5656(14) 
C(4)-O(2)  1.4570(12) 
C(4)-C(14)  1.5212(15) 
C(4)-C(8)  1.5260(14) 
C(5)-O(4)  1.4275(15) 
C(5)-O(3)  1.4429(15) 
C(5)-C(7)  1.5173(17) 
C(5)-C(6)  1.5188(18) 
C(8)-C(13)  1.3939(16) 
C(8)-C(9)  1.4002(15) 
C(9)-C(10)  1.3847(17) 
C(10)-C(11)  1.393(2) 
C(11)-C(12)  1.3846(19) 
C(12)-C(13)  1.3989(16) 
C(14)-C(15)  1.3961(16) 
C(14)-C(19)  1.4031(15) 
C(15)-C(16)  1.4003(18) 
C(16)-C(17)  1.389(2) 
C(17)-C(18)  1.396(2) 
C(18)-C(19)  1.3878(17) 
C(20)-C(21)  1.3948(16) 
C(20)-C(25)  1.4006(16) 
C(21)-C(22)  1.3942(18) 
C(22)-C(23)  1.390(2) 
C(23)-C(24)  1.391(2) 
C(24)-C(25)  1.3954(19) 
C(26)-C(27)  1.3948(17) 
C(26)-C(31)  1.3999(17) 
C(27)-C(28)  1.3960(17) 
C(28)-C(29)  1.385(2) 
C(29)-C(30)  1.386(2) 
C(30)-C(31)  1.3994(19) 
C(32)-N(1)  1.4725(15) 
C(32)-C(33)  1.5303(18) 
C(33)-C(34)  1.532(2) 
C(34)-C(35)  1.5176(18) 
C(35)-N(1)  1.4825(14) 
C(36)-C(37)  1.4130(16) 
C(36)-C(43)  1.5272(16) 
C(36)-Rh(1)  2.1254(11) 
C(37)-C(38)  1.5127(17) 
C(37)-Rh(1)  2.1071(11) 
C(38)-C(39)  1.5384(18) 
C(39)-C(40)  1.5171(18) 
C(40)-C(41)  1.3780(18) 
C(40)-Rh(1)  2.2749(12) 
C(41)-C(42)  1.5088(19) 
C(41)-Rh(1)  2.2439(11) 
C(42)-C(43)  1.5389(19) 
C(44)-Cl(2)  1.7589(16) 
C(44)-Cl(3)  1.7755(16) 
C(45)-Cl(5)  1.749(2) 
C(45)-Cl(4)  1.769(2) 
Cl(1)-Rh(1)  2.3842(3) 
N(1)-P(1)  1.6353(10) 
O(1)-P(1)  1.6185(8) 
O(2)-P(1)  1.6263(8) 















































































































Symmetry transformations used to generate equivalent atoms:  
  
Table A.2.14.   Anisotropic displacement parameters  (Å2x 103) for Rh(cod)Cl·T2 (1).  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 11(1)  15(1) 12(1)  1(1) 1(1)  1(1) 
C(2) 12(1)  16(1) 13(1)  0(1) 0(1)  1(1) 
C(3) 11(1)  15(1) 13(1)  0(1) 0(1)  -2(1) 
C(4) 11(1)  12(1) 12(1)  0(1) 0(1)  -2(1) 
C(5) 11(1)  22(1) 18(1)  0(1) -1(1)  0(1) 
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C(6) 18(1)  27(1) 18(1)  0(1) -3(1)  2(1) 
C(7) 12(1)  35(1) 33(1)  5(1) 2(1)  -4(1) 
C(8) 12(1)  14(1) 11(1)  0(1) 0(1)  0(1) 
C(9) 18(1)  18(1) 14(1)  -1(1) -2(1)  -2(1) 
C(10) 22(1)  26(1) 15(1)  -3(1) -4(1)  -1(1) 
C(11) 27(1)  29(1) 14(1)  3(1) -4(1)  -1(1) 
C(12) 26(1)  22(1) 16(1)  6(1) -2(1)  -3(1) 
C(13) 18(1)  17(1) 13(1)  2(1) -1(1)  -2(1) 
C(14) 14(1)  12(1) 13(1)  0(1) -1(1)  0(1) 
C(15) 20(1)  14(1) 24(1)  0(1) 1(1)  -2(1) 
C(16) 30(1)  13(1) 30(1)  0(1) 1(1)  0(1) 
C(17) 30(1)  16(1) 27(1)  -2(1) -3(1)  7(1) 
C(18) 19(1)  22(1) 22(1)  -3(1) 0(1)  6(1) 
C(19) 15(1)  17(1) 18(1)  -1(1) 2(1)  2(1) 
C(20) 14(1)  16(1) 16(1)  0(1) 3(1)  0(1) 
C(21) 19(1)  17(1) 21(1)  2(1) 2(1)  4(1) 
C(22) 26(1)  16(1) 34(1)  2(1) 9(1)  5(1) 
C(23) 33(1)  17(1) 34(1)  -7(1) 12(1)  -1(1) 
C(24) 29(1)  24(1) 25(1)  -9(1) 6(1)  -5(1) 
C(25) 20(1)  20(1) 17(1)  -3(1) 2(1)  -2(1) 
C(26) 12(1)  21(1) 12(1)  2(1) 1(1)  -2(1) 
C(27) 20(1)  21(1) 15(1)  1(1) 2(1)  -6(1) 
C(28) 23(1)  30(1) 18(1)  5(1) 1(1)  -11(1) 
C(29) 14(1)  48(1) 21(1)  10(1) 1(1)  -8(1) 
C(30) 15(1)  47(1) 27(1)  12(1) 7(1)  5(1) 
C(31) 15(1)  32(1) 21(1)  7(1) 5(1)  5(1) 
C(32) 18(1)  17(1) 23(1)  7(1) 2(1)  0(1) 
C(33) 23(1)  18(1) 34(1)  9(1) -1(1)  4(1) 
C(34) 20(1)  24(1) 27(1)  4(1) -6(1)  4(1) 
C(35) 12(1)  21(1) 20(1)  1(1) 0(1)  3(1) 
C(36) 16(1)  16(1) 14(1)  0(1) 2(1)  -2(1) 
C(37) 16(1)  15(1) 14(1)  1(1) -1(1)  0(1) 
C(38) 18(1)  16(1) 24(1)  2(1) -1(1)  2(1) 
C(39) 24(1)  14(1) 27(1)  -1(1) -1(1)  -1(1) 
C(40) 20(1)  15(1) 21(1)  -4(1) -2(1)  -3(1) 
C(41) 15(1)  18(1) 24(1)  0(1) -4(1)  -4(1) 
C(42) 13(1)  24(1) 30(1)  0(1) 2(1)  -2(1) 
C(43) 18(1)  21(1) 23(1)  0(1) 6(1)  -3(1) 
C(44) 20(1)  32(1) 27(1)  -5(1) -2(1)  0(1) 
C(45) 41(1)  33(1) 47(1)  6(1) 0(1)  5(1) 
Cl(1) 22(1)  25(1) 13(1)  1(1) -2(1)  -1(1) 
Cl(2) 44(1)  46(1) 47(1)  -1(1) -12(1)  16(1) 
Cl(3) 35(1)  35(1) 36(1)  -12(1) 11(1)  -8(1) 
Cl(4) 40(1)  77(1) 58(1)  -25(1) -6(1)  24(1) 
Cl(5) 83(1)  40(1) 110(1)  18(1) 11(1)  -15(1) 
N(1) 11(1)  16(1) 16(1)  4(1) 2(1)  1(1) 
O(1) 10(1)  16(1) 13(1)  2(1) 1(1)  0(1) 
O(2) 12(1)  13(1) 11(1)  0(1) 0(1)  -2(1) 
O(3) 11(1)  18(1) 20(1)  -2(1) -2(1)  -2(1) 
O(4) 12(1)  27(1) 17(1)  -3(1) -2(1)  4(1) 
P(1) 10(1)  12(1) 11(1)  1(1) 0(1)  -1(1) 
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Rh(1) 12(1)  13(1) 12(1)  0(1) -1(1)  -2(1) 
______________________________________________________________________________  
 
Table A.2.15.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for 
Rh(cod)Cl·T2 (1). 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) -667 922 6082 16 
H(3) -607 -553 6930 15 
H(6A) -3482 794 4298 31 
H(6B) -2885 94 3669 31 
H(6C) -2024 741 4189 31 
H(7A) -3747 -563 6605 40 
H(7B) -4096 -680 5221 40 
H(7C) -4522 53 5888 40 
H(9) -409 -920 3641 20 
H(10) -882 -510 1716 25 
H(11) -378 693 1141 28 
H(12) 651 1471 2500 26 
H(13) 1074 1076 4458 19 
H(15) -311 -1614 5934 23 
H(16) 704 -2755 5862 29 
H(17) 2784 -2805 5411 29 
H(18) 3850 -1712 5007 25 
H(19) 2842 -578 5067 20 
H(21) -1568 1914 6780 23 
H(22) -1447 3165 7290 30 
H(23) -335 3531 9011 33 
H(24) 712 2649 10177 31 
H(25) 605 1397 9664 22 
H(27) -948 -668 8817 22 
H(28) -2446 -1175 10021 29 
H(29) -4015 -434 10735 33 
H(30) -4108 813 10217 35 
H(31) -2636 1323 8978 27 
H(32A) 1060 -1203 8198 23 
H(32B) 1448 -805 9438 23 
H(33A) 2813 -1905 8202 30 
H(33B) 2679 -1828 9624 30 
H(34A) 4044 -835 9737 29 
H(34B) 4685 -1365 8783 29 
H(35A) 4142 -37 8150 21 
H(35B) 3935 -690 7187 21 
H(36) 3114 1103 5527 18 
H(37) 1436 1729 5976 18 
H(38A) 1362 2886 6916 24 
H(38B) 2117 3023 5737 24 
H(39A) 3904 3204 6760 26 
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H(39B) 2955 3545 7670 26 
H(40) 3570 2720 9073 23 
H(41) 5103 1947 8856 23 
H(42A) 5806 1473 7062 27 
H(42B) 5940 2347 6912 27 
H(43A) 4389 2418 5540 25 
H(43B) 4957 1630 5225 25 
H(44A) 7041 4975 8494 32 
H(44B) 7707 4690 7326 32 
H(45A) 6914 6824 8152 49 









Table A.2.16.  Crystal data and structure refinement for Rh(cod)Cl·T2 (2). 
Identification code  rovis49_0m 
Empirical formula  C93H112Cl2N2O8P2Rh2 
Formula weight  1724.51 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 12.9291(3) Å = 90°. 
 b = 10.9044(3) Å = 91.6130(10)°. 
 c = 29.3915(7) Å  = 90°. 
Volume 4142.09(18) Å3 
Z 2 
Density (calculated) 1.383 Mg/m3 
Absorption coefficient 0.560 mm-1 
F(000) 1804 
Crystal size 0.40 x 0.08 x 0.05 mm3 
Theta range for data collection 1.99 to 32.58°. 
Index ranges -19<=h<=19, -13<=k<=16, -44<=l<=44 
Reflections collected 63557 
Independent reflections 25952 [R(int) = 0.0844] 
Completeness to theta = 32.58° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9731 and 0.8062 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 25952 / 1 / 989 
Goodness-of-fit on F2 0.965 
Final R indices [I>2sigma(I)] R1 = 0.0573, wR2 = 0.0972 
R indices (all data) R1 = 0.1048, wR2 = 0.1205 
Absolute structure parameter -0.04(2) 
Largest diff. peak and hole 0.847 and -0.834 e.Å-3 
 
Table A.2.17.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for Rh(cod)Cl·T2 (2).  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 2659(4) 12878(3) 1905(2) 24(1) 
C(2) 2859(4) 13037(4) 2413(2) 27(1) 
C(3) 3501(4) 11915(4) 2535(2) 30(1) 
C(4) 2995(4) 10897(4) 2249(1) 19(1) 
C(5) 3329(3) 9888(3) 966(1) 16(1) 
C(6) 3043(3) 8637(3) 1181(2) 16(1) 
C(7) 1932(3) 8263(3) 1064(2) 17(1) 
C(8) 1186(3) 8542(3) 1458(1) 16(1) 
C(9) 3026(3) 6646(3) 891(2) 19(1) 
C(10) 3136(4) 6424(4) 382(2) 31(1) 
C(11) 3301(4) 5542(4) 1173(2) 34(1) 
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C(12) 3529(4) 9800(3) 460(2) 18(1) 
C(13) 4451(4) 9288(4) 321(2) 25(1) 
C(14) 4686(4) 9246(4) -137(2) 28(1) 
C(15) 4014(5) 9739(5) -458(2) 34(1) 
C(16) 3093(4) 10236(4) -326(2) 30(1) 
C(17) 2852(4) 10258(4) 131(2) 23(1) 
C(18) 4263(3) 10502(3) 1205(1) 18(1) 
C(19) 4887(4) 9891(4) 1513(2) 24(1) 
C(20) 5758(4) 10449(4) 1708(2) 29(1) 
C(21) 6011(4) 11623(4) 1585(2) 28(1) 
C(22) 5393(4) 12239(5) 1271(2) 41(1) 
C(23) 4521(4) 11688(4) 1085(2) 33(1) 
C(24) 65(3) 8679(3) 1284(1) 17(1) 
C(25) -625(4) 9376(4) 1533(2) 22(1) 
C(26) -1644(4) 9464(4) 1387(2) 29(1) 
C(27) -2005(4) 8852(4) 1001(2) 30(1) 
C(28) -1325(4) 8153(4) 757(2) 27(1) 
C(29) -281(4) 8066(4) 895(2) 21(1) 
C(30) 1295(3) 7581(3) 1837(1) 16(1) 
C(31) 2075(3) 7665(3) 2176(2) 19(1) 
C(32) 2180(4) 6794(4) 2513(1) 22(1) 
C(33) 1504(4) 5801(4) 2521(2) 24(1) 
C(34) 743(4) 5691(4) 2193(2) 26(1) 
C(35) 640(4) 6573(3) 1852(2) 21(1) 
C(36) -1179(4) 12926(4) 1068(2) 27(1) 
C(37) -524(4) 13883(4) 1143(2) 27(1) 
C(38) 12(5) 14634(4) 786(2) 38(1) 
C(39) 532(4) 13873(4) 431(2) 37(1) 
C(40) 909(4) 12636(4) 601(2) 24(1) 
C(41) 298(4) 11581(4) 579(2) 21(1) 
C(42) -798(4) 11519(4) 400(2) 30(1) 
C(43) -1519(4) 12488(4) 594(2) 36(1) 
C(44) 7844(4) 9681(4) 2627(2) 20(1) 
C(45) 7546(4) 11022(4) 2665(2) 25(1) 
C(46) 7921(4) 11351(4) 3146(2) 26(1) 
C(47) 7621(4) 10222(3) 3417(2) 22(1) 
C(48) 6810(3) 6908(4) 3998(1) 19(1) 
C(49) 7912(3) 6376(4) 4099(1) 17(1) 
C(50) 8762(3) 7323(4) 4062(1) 18(1) 
C(51) 9299(3) 7223(4) 3599(1) 16(1) 
C(52) 8956(4) 6323(4) 4758(2) 26(1) 
C(53) 9626(4) 5209(5) 4861(2) 41(2) 
C(54) 8712(4) 7083(6) 5174(2) 42(1) 
C(55) 6418(4) 7556(4) 4420(2) 21(1) 
C(56) 5940(3) 6890(4) 4756(2) 27(1) 
C(57) 5646(4) 7466(5) 5158(2) 32(1) 
C(58) 5816(4) 8702(5) 5221(2) 34(1) 
C(59) 6272(4) 9381(4) 4886(2) 29(1) 
C(60) 6579(4) 8797(4) 4485(2) 23(1) 
C(61) 6056(3) 5928(4) 3818(1) 18(1) 
C(62) 6248(4) 4684(4) 3875(2) 24(1) 
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C(63) 5544(4) 3817(4) 3714(2) 28(1) 
C(64) 4632(4) 4192(5) 3504(2) 35(1) 
C(65) 4431(4) 5424(5) 3452(2) 36(1) 
C(66) 5139(4) 6293(4) 3605(2) 29(1) 
C(67) 9883(3) 8386(3) 3467(1) 14(1) 
C(68) 10127(4) 9299(4) 3783(2) 22(1) 
C(69) 10644(4) 10349(4) 3646(2) 24(1) 
C(70) 10893(4) 10507(4) 3200(2) 24(1) 
C(71) 10678(4) 9595(4) 2887(2) 22(1) 
C(72) 10178(4) 8539(3) 3022(1) 19(1) 
C(73) 10004(4) 6098(4) 3590(1) 16(1) 
C(74) 10984(4) 6155(4) 3794(2) 24(1) 
C(75) 11618(4) 5113(4) 3822(2) 28(1) 
C(76) 11275(4) 4016(4) 3640(2) 28(1) 
C(77) 10310(4) 3957(4) 3425(2) 31(1) 
C(78) 9676(4) 4991(4) 3399(2) 23(1) 
C(79) 7248(4) 5211(4) 2589(2) 27(1) 
C(80) 7780(4) 6061(4) 2325(2) 25(1) 
C(81) 7754(4) 6140(5) 1815(2) 36(1) 
C(82) 6671(4) 5980(4) 1599(2) 33(1) 
C(83) 5835(4) 6505(4) 1887(2) 25(1) 
C(84) 5290(4) 5842(4) 2187(2) 29(1) 
C(85) 5458(4) 4507(4) 2305(2) 33(1) 
C(86) 6592(4) 4173(4) 2383(2) 31(1) 
C(87) 4486(5) 10502(6) 3672(2) 49(2) 
C(88) 3696(5) 9538(5) 3770(2) 43(2) 
C(89) 3598(5) 9317(5) 4279(2) 40(1) 
C(90) 2819(4) 8337(5) 4411(2) 38(1) 
C(91) 2744(4) 8134(4) 4917(2) 37(1) 
C(92) 1935(4) 7221(5) 5050(2) 40(1) 
C(93) 1877(4) 7071(6) 5567(2) 47(1) 
Cl(1) -5(1) 12266(1) 2045(1) 25(1) 
Cl(2) 5210(1) 8484(1) 2682(1) 25(1) 
N(1) 2529(3) 11551(3) 1854(1) 20(1) 
N(2) 7676(3) 9210(3) 3089(1) 17(1) 
O(1) 2420(2) 10672(2) 1006(1) 15(1) 
O(2) 1540(2) 9680(2) 1682(1) 15(1) 
O(3) 3664(2) 7663(2) 1019(1) 21(1) 
O(4) 1979(2) 6986(3) 984(1) 21(1) 
O(5) 8471(2) 7003(3) 3260(1) 17(1) 
O(6) 6905(2) 7875(2) 3657(1) 18(1) 
O(7) 9459(2) 7057(3) 4431(1) 22(1) 
O(8) 8003(2) 5914(3) 4548(1) 24(1) 
P(1) 1755(1) 10994(1) 1452(1) 15(1) 
P(2) 7407(1) 7760(1) 3164(1) 14(1) 
Rh(1) 384(1) 12181(1) 1259(1) 18(1) 







Table A.2.18.   Bond lengths [Å] and angles [°] for Rh(cod)Cl·T2 (2). 
_____________________________________________________ 
C(1)-N(1)  1.464(5) 
C(1)-C(2)  1.517(6) 
C(2)-C(3)  1.517(6) 
C(3)-C(4)  1.529(6) 
C(4)-N(1)  1.476(5) 
C(5)-O(1)  1.461(5) 
C(5)-C(12)  1.518(6) 
C(5)-C(18)  1.534(6) 
C(5)-C(6)  1.553(5) 
C(6)-O(3)  1.422(5) 
C(6)-C(7)  1.523(6) 
C(7)-O(4)  1.414(5) 
C(7)-C(8)  1.559(6) 
C(8)-O(2)  1.471(4) 
C(8)-C(24)  1.532(6) 
C(8)-C(30)  1.533(5) 
C(9)-O(3)  1.426(5) 
C(9)-O(4)  1.437(5) 
C(9)-C(11)  1.499(6) 
C(9)-C(10)  1.524(6) 
C(12)-C(17)  1.379(6) 
C(12)-C(13)  1.389(6) 
C(13)-C(14)  1.387(6) 
C(14)-C(15)  1.373(7) 
C(15)-C(16)  1.374(7) 
C(16)-C(17)  1.389(6) 
C(18)-C(19)  1.368(6) 
C(18)-C(23)  1.385(6) 
C(19)-C(20)  1.389(6) 
C(20)-C(21)  1.373(6) 
C(21)-C(22)  1.378(7) 
C(22)-C(23)  1.377(7) 
C(24)-C(29)  1.387(6) 
C(24)-C(25)  1.394(6) 
C(25)-C(26)  1.378(6) 
C(26)-C(27)  1.384(7) 
C(27)-C(28)  1.381(7) 
C(28)-C(29)  1.401(6) 
C(30)-C(35)  1.389(5) 
C(30)-C(31)  1.401(6) 
C(31)-C(32)  1.375(5) 
C(32)-C(33)  1.391(6) 
C(33)-C(34)  1.365(6) 
C(34)-C(35)  1.391(6) 
C(36)-C(37)  1.358(7) 
C(36)-C(43)  1.525(6) 
C(36)-Rh(1)  2.235(5) 
C(37)-C(38)  1.514(7) 
C(37)-Rh(1)  2.217(4) 
C(38)-C(39)  1.507(7) 
C(39)-C(40)  1.514(6) 
C(40)-C(41)  1.396(6) 
C(40)-Rh(1)  2.128(5) 
C(41)-C(42)  1.498(7) 
C(41)-Rh(1)  2.105(4) 
C(42)-C(43)  1.530(6) 
C(44)-N(2)  1.472(5) 
C(44)-C(45)  1.517(5) 
C(45)-C(46)  1.525(6) 
C(46)-C(47)  1.523(6) 
C(47)-N(2)  1.469(5) 
C(48)-O(6)  1.463(5) 
C(48)-C(55)  1.527(6) 
C(48)-C(61)  1.530(6) 
C(48)-C(49)  1.559(6) 
C(49)-O(8)  1.416(5) 
C(49)-C(50)  1.514(6) 
C(50)-O(7)  1.421(5) 
C(50)-C(51)  1.547(5) 
C(51)-O(5)  1.461(5) 
C(51)-C(73)  1.529(6) 
C(51)-C(67)  1.532(6) 
C(52)-O(7)  1.421(5) 
C(52)-O(8)  1.433(6) 
C(52)-C(54)  1.519(7) 
C(52)-C(53)  1.518(7) 
C(55)-C(60)  1.382(6) 
C(55)-C(56)  1.385(6) 
C(56)-C(57)  1.399(6) 
C(57)-C(58)  1.378(7) 
C(58)-C(59)  1.378(7) 
C(59)-C(60)  1.407(6) 
C(61)-C(66)  1.384(6) 
C(61)-C(62)  1.389(6) 
C(62)-C(63)  1.387(6) 
C(63)-C(64)  1.377(7) 
C(64)-C(65)  1.376(7) 
C(65)-C(66)  1.384(7) 
C(67)-C(72)  1.382(6) 
C(67)-C(68)  1.392(6) 
C(68)-C(69)  1.392(6) 
C(69)-C(70)  1.368(6) 
C(70)-C(71)  1.377(6) 
C(71)-C(72)  1.384(6) 
C(73)-C(74)  1.389(6) 
C(73)-C(78)  1.392(6) 
C(74)-C(75)  1.402(6) 
C(75)-C(76)  1.378(7) 
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C(76)-C(77)  1.384(7) 
C(77)-C(78)  1.395(6) 
C(79)-C(80)  1.402(7) 
C(79)-C(86)  1.529(6) 
C(79)-Rh(2)  2.119(4) 
C(80)-C(81)  1.503(7) 
C(80)-Rh(2)  2.111(5) 
C(81)-C(82)  1.530(7) 
C(82)-C(83)  1.505(7) 
C(83)-C(84)  1.354(7) 
C(83)-Rh(2)  2.244(4) 
C(84)-C(85)  1.510(7) 
C(84)-Rh(2)  2.228(4) 
C(85)-C(86)  1.523(7) 
C(87)-C(88)  1.499(8) 
C(88)-C(89)  1.524(8) 
C(89)-C(90)  1.526(7) 
C(90)-C(91)  1.508(8) 
C(91)-C(92)  1.504(7) 
C(92)-C(93)  1.533(7) 
Cl(1)-Rh(1)  2.3777(11) 
Cl(2)-Rh(2)  2.3745(11) 
N(1)-P(1)  1.643(4) 
N(2)-P(2)  1.636(3) 
O(1)-P(1)  1.626(3) 
O(2)-P(1)  1.612(3) 
O(5)-P(2)  1.623(3) 
O(6)-P(2)  1.608(3) 
P(1)-Rh(1)  2.2545(11) 




























































































































































































































Symmetry transformations used to generate equivalent atoms:  
  
 
Table A.2.19.   Anisotropic displacement parameters (Å2x 103)for Rh(cod)Cl·T2 (2).  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 26(3)  11(2) 34(3)  -1(2) -4(2)  -2(2) 
C(2) 36(3)  19(2) 25(3)  -6(2) -5(2)  -2(2) 
C(3) 37(3)  25(2) 28(2)  -2(2) -10(2)  1(2) 
C(4) 21(3)  21(2) 16(2)  -2(2) -1(2)  -4(2) 
C(5) 13(2)  14(2) 20(2)  5(2) 5(2)  2(2) 
C(6) 14(2)  16(2) 17(2)  1(2) 6(2)  3(2) 
C(7) 18(2)  14(2) 19(2)  -1(2) 0(2)  -2(2) 
C(8) 19(2)  12(2) 16(2)  -2(2) 0(2)  -1(2) 
C(9) 19(2)  18(2) 19(2)  0(2) 0(2)  0(2) 
C(10) 26(3)  42(3) 24(3)  -10(2) 4(2)  0(2) 
C(11) 35(3)  26(2) 39(3)  11(2) -9(3)  -1(2) 
C(12) 21(2)  15(2) 18(2)  0(2) 4(2)  -1(2) 
C(13) 28(3)  26(2) 21(2)  3(2) 1(2)  3(2) 
C(14) 28(3)  36(3) 22(3)  -1(2) 8(2)  2(2) 
C(15) 48(4)  37(3) 17(3)  0(2) 11(2)  -5(2) 
C(16) 35(3)  39(3) 17(3)  5(2) 0(2)  2(2) 
C(17) 24(3)  25(2) 21(2)  -1(2) 3(2)  0(2) 
C(18) 19(2)  16(2) 19(2)  -1(2) 2(2)  -2(2) 
C(19) 18(3)  19(2) 35(3)  1(2) -3(2)  0(2) 
C(20) 22(3)  33(2) 32(3)  4(2) -5(2)  2(2) 
C(21) 25(3)  26(2) 33(3)  -7(2) -1(2)  -10(2) 
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C(22) 49(3)  25(2) 47(3)  8(2) -13(3)  -19(2) 
C(23) 41(3)  25(2) 32(3)  10(2) -10(2)  -8(2) 
C(24) 18(2)  16(2) 16(2)  2(2) 0(2)  0(2) 
C(25) 20(3)  25(2) 20(2)  1(2) 2(2)  -3(2) 
C(26) 18(3)  28(2) 42(3)  -1(2) 5(2)  -1(2) 
C(27) 13(2)  37(3) 39(3)  10(2) -6(2)  -5(2) 
C(28) 26(3)  25(2) 30(3)  4(2) -9(2)  -4(2) 
C(29) 22(3)  17(2) 24(2)  0(2) -1(2)  -2(2) 
C(30) 20(2)  16(2) 13(2)  1(1) 2(2)  4(2) 
C(31) 18(2)  16(2) 22(2)  1(2) 3(2)  0(2) 
C(32) 27(3)  24(2) 16(2)  2(2) -2(2)  5(2) 
C(33) 37(3)  16(2) 20(2)  6(2) 10(2)  5(2) 
C(34) 35(3)  15(2) 28(3)  2(2) 10(2)  -3(2) 
C(35) 24(3)  17(2) 22(2)  -1(2) 2(2)  -4(2) 
C(36) 24(3)  29(2) 28(3)  -7(2) -5(2)  14(2) 
C(37) 31(3)  22(2) 29(3)  -1(2) 2(2)  9(2) 
C(38) 53(4)  19(2) 42(3)  5(2) -4(3)  5(2) 
C(39) 43(4)  23(2) 44(3)  15(2) 0(3)  6(2) 
C(40) 24(3)  23(2) 24(3)  7(2) 3(2)  6(2) 
C(41) 27(3)  19(2) 17(2)  -1(2) 2(2)  1(2) 
C(42) 24(3)  37(3) 27(3)  -6(2) -4(2)  -2(2) 
C(43) 27(3)  37(3) 43(3)  -15(2) -15(2)  10(2) 
C(44) 23(3)  18(2) 18(2)  4(2) 1(2)  5(2) 
C(45) 34(3)  16(2) 26(3)  6(2) 5(2)  0(2) 
C(46) 37(3)  15(2) 25(3)  0(2) -2(2)  -4(2) 
C(47) 31(3)  16(2) 18(2)  -6(2) -1(2)  5(2) 
C(48) 15(2)  21(2) 19(2)  6(2) -4(2)  -1(2) 
C(49) 16(2)  21(2) 15(2)  5(2) 5(2)  0(2) 
C(50) 21(2)  21(2) 11(2)  2(2) -2(2)  -1(2) 
C(51) 17(2)  16(2) 15(2)  -1(2) 0(2)  0(2) 
C(52) 27(3)  32(2) 21(2)  10(2) -1(2)  -4(2) 
C(53) 27(3)  39(3) 57(4)  28(3) -14(3)  -7(2) 
C(54) 45(3)  61(4) 20(2)  -1(3) 1(2)  -12(3) 
C(55) 21(3)  26(2) 15(2)  0(2) 1(2)  3(2) 
C(56) 25(2)  31(2) 26(2)  5(2) 1(2)  1(2) 
C(57) 25(3)  47(3) 26(3)  7(2) 8(2)  5(2) 
C(58) 41(4)  43(3) 19(3)  -5(2) 3(2)  11(2) 
C(59) 30(3)  34(2) 24(3)  -5(2) 7(2)  2(2) 
C(60) 21(3)  28(2) 21(2)  4(2) 7(2)  -2(2) 
C(61) 17(2)  26(2) 12(2)  1(2) -1(2)  -2(2) 
C(62) 23(3)  26(2) 23(3)  3(2) 4(2)  -3(2) 
C(63) 28(3)  34(2) 22(3)  0(2) 5(2)  -4(2) 
C(64) 32(3)  49(3) 25(3)  5(2) -2(2)  -20(2) 
C(65) 25(3)  53(3) 28(3)  15(2) -5(2)  -8(2) 
C(66) 18(3)  33(2) 35(3)  10(2) -1(2)  -2(2) 
C(67) 12(2)  19(2) 13(2)  1(2) -1(2)  1(2) 
C(68) 25(3)  22(2) 18(2)  -2(2) 3(2)  -4(2) 
C(69) 27(3)  20(2) 26(3)  -5(2) -3(2)  -5(2) 
C(70) 21(3)  20(2) 32(3)  2(2) 8(2)  -3(2) 
C(71) 23(3)  25(2) 17(2)  5(2) 5(2)  -2(2) 
C(72) 25(3)  15(2) 16(2)  -6(2) 0(2)  -2(2) 
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C(73) 19(2)  21(2) 9(2)  2(2) 3(2)  0(2) 
C(74) 25(3)  23(2) 23(3)  -2(2) -3(2)  -3(2) 
C(75) 17(3)  34(2) 32(3)  2(2) -6(2)  3(2) 
C(76) 24(3)  22(2) 38(3)  11(2) 0(2)  5(2) 
C(77) 33(3)  16(2) 44(3)  1(2) 3(3)  3(2) 
C(78) 19(3)  19(2) 31(3)  -1(2) 1(2)  0(2) 
C(79) 29(3)  17(2) 36(3)  -5(2) -10(2)  7(2) 
C(80) 23(3)  27(2) 24(3)  -12(2) 1(2)  4(2) 
C(81) 37(3)  41(3) 32(3)  -17(2) 11(3)  -2(2) 
C(82) 47(4)  32(2) 20(3)  -5(2) 5(2)  -9(2) 
C(83) 29(3)  25(2) 21(2)  -1(2) -10(2)  3(2) 
C(84) 22(3)  34(2) 30(3)  -12(2) -8(2)  -2(2) 
C(85) 37(3)  29(2) 32(3)  -6(2) -2(3)  -13(2) 
C(86) 41(3)  17(2) 35(3)  -4(2) -13(2)  0(2) 
C(87) 50(4)  64(4) 33(3)  12(3) 2(3)  -3(3) 
C(88) 47(4)  39(3) 42(4)  -3(3) 2(3)  10(3) 
C(89) 34(4)  51(3) 36(3)  -1(3) -4(3)  -3(3) 
C(90) 33(3)  36(3) 43(4)  -5(2) -12(3)  2(2) 
C(91) 29(3)  30(2) 51(4)  -2(2) -12(3)  4(2) 
C(92) 30(3)  40(3) 50(3)  6(3) -6(2)  0(3) 
C(93) 49(4)  48(3) 44(3)  15(3) -13(3)  -11(3) 
Cl(1) 30(1)  24(1) 22(1)  -2(1) 6(1)  2(1) 
Cl(2) 25(1)  24(1) 26(1)  0(1) 0(1)  8(1) 
N(1) 26(2)  14(2) 18(2)  3(1) -6(2)  -3(1) 
N(2) 22(2)  17(2) 11(2)  2(1) -1(2)  1(1) 
O(1) 16(2)  14(1) 15(2)  2(1) 2(1)  3(1) 
O(2) 19(2)  11(1) 16(2)  1(1) 2(1)  -1(1) 
O(3) 19(2)  19(1) 25(2)  -3(1) 5(1)  2(1) 
O(4) 18(2)  15(1) 31(2)  -5(1) 7(1)  -2(1) 
O(5) 18(2)  18(1) 14(1)  -1(1) -3(1)  2(1) 
O(6) 22(2)  17(1) 13(2)  3(1) 1(1)  2(1) 
O(7) 21(2)  29(2) 16(1)  6(1) -1(1)  -4(1) 
O(8) 18(2)  33(2) 22(2)  14(1) -2(1)  -4(1) 
P(1) 18(1)  12(1) 15(1)  1(1) 0(1)  1(1) 
P(2) 17(1)  13(1) 13(1)  1(1) 0(1)  0(1) 
Rh(1) 20(1)  15(1) 18(1)  -1(1) -1(1)  2(1) 
Rh(2) 17(1)  16(1) 15(1)  -1(1) -2(1)  0(1) 
______________________________________________________________________________ 
 
Table A.2.20.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 
Rh(cod)Cl·T2 (2). 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1A) 2038 13312 1805 28 
H(1B) 3239 13171 1734 28 
H(2A) 3239 13787 2478 32 
H(2B) 2217 13048 2576 32 
H(3A) 3470 11733 2858 36 
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H(3B) 4218 12030 2457 36 
H(4A) 3506 10307 2153 23 
H(4B) 2471 10473 2418 23 
H(6) 3133 8693 1512 19 
H(7) 1690 8685 786 20 
H(10A) 2920 7143 217 46 
H(10B) 2711 5741 290 46 
H(10C) 3846 6248 321 46 
H(11A) 4014 5334 1131 50 
H(11B) 2870 4865 1080 50 
H(11C) 3196 5720 1488 50 
H(13) 4917 8969 537 30 
H(14) 5299 8883 -226 34 
H(15) 4183 9736 -763 41 
H(16) 2631 10557 -543 36 
H(17) 2224 10588 217 28 
H(19) 4726 9090 1593 29 
H(20) 6168 10028 1921 35 
H(21) 6596 12001 1712 34 
H(22) 5565 13031 1184 49 
H(23) 4102 12116 877 40 
H(25) -398 9778 1796 26 
H(26) -2098 9944 1550 35 
H(27) -2697 8911 909 36 
H(28) -1561 7736 498 33 
H(29) 175 7600 728 25 
H(31) 2531 8324 2174 22 
H(32) 2702 6868 2735 27 
H(33) 1571 5215 2750 29 
H(34) 293 5026 2196 31 
H(35) 120 6485 1629 25 
H(36) -1700 12820 1300 33 
H(37) -659 14339 1422 33 
H(38A) -494 15165 636 46 
H(38B) 527 15153 936 46 
H(39A) 48 13745 177 44 
H(39B) 1117 14328 318 44 
H(40) 1648 12488 560 28 
H(41) 693 10830 525 25 
H(42A) -1074 10714 467 35 
H(42B) -799 11608 71 35 
H(43A) -1548 13186 389 43 
H(43B) -2211 12149 607 43 
H(44A) 7407 9261 2403 24 
H(44B) 8562 9593 2545 24 
H(45A) 6804 11130 2629 30 
H(45B) 7890 11515 2440 30 
H(46A) 7577 12079 3255 31 
H(46B) 8664 11481 3160 31 
H(47A) 8100 10091 3673 26 
H(47B) 6927 10304 3531 26 
206 
 
H(49) 8040 5708 3885 21 
H(50) 8475 8148 4097 21 
H(53A) 9717 4748 4586 61 
H(53B) 9296 4702 5081 61 
H(53C) 10288 5470 4980 61 
H(54A) 9344 7306 5332 63 
H(54B) 8289 6613 5373 63 
H(54C) 8348 7812 5080 63 
H(56) 5814 6058 4715 33 
H(57) 5334 7011 5384 39 
H(58) 5623 9078 5490 41 
H(59) 6377 10219 4925 35 
H(60) 6895 9253 4260 28 
H(62) 6856 4429 4023 28 
H(63) 5686 2985 3748 33 
H(64) 4153 3615 3399 42 
H(65) 3813 5675 3311 43 
H(66) 4998 7122 3564 35 
H(68) 9947 9207 4086 26 
H(69) 10821 10950 3858 29 
H(70) 11207 11230 3108 29 
H(71) 10869 9688 2587 26 
H(72) 10038 7923 2810 23 
H(74) 11224 6895 3914 28 
H(75) 12270 5162 3963 33 
H(76) 11689 3320 3662 34 
H(77) 10083 3223 3296 37 
H(78) 9028 4940 3254 28 
H(79) 7599 5004 2879 33 
H(80) 8434 6341 2467 30 
H(81A) 8204 5512 1696 44 
H(81B) 8025 6930 1725 44 
H(82A) 6646 6380 1304 40 
H(82B) 6539 5114 1551 40 
H(83) 5447 7181 1744 30 
H(84) 4577 6124 2222 34 
H(85A) 5084 4316 2578 39 
H(85B) 5171 4005 2060 39 
H(86A) 6879 3935 2095 37 
H(86B) 6637 3468 2584 37 
H(87A) 4251 11281 3781 74 
H(87B) 4582 10548 3350 74 
H(87C) 5130 10294 3823 74 
H(88A) 3889 8778 3624 52 
H(88B) 3030 9791 3642 52 
H(89A) 3405 10083 4421 48 
H(89B) 4272 9086 4404 48 
H(90A) 2141 8568 4290 45 
H(90B) 3008 7568 4270 45 
H(91A) 3412 7857 5036 45 
H(91B) 2595 8913 5061 45 
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H(92A) 2090 6432 4915 48 
H(92B) 1266 7486 4929 48 
H(93A) 2548 6857 5691 71 
H(93B) 1393 6435 5635 71 








Table A.2.21.  Crystal data and structure refinement for Rh(cod)Cl·B4. 
Identification code  rovis45_0m 
Empirical formula  C36H46ClNO2PRhSi2 
Formula weight  750.25 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 212121 
Unit cell dimensions a = 11.2417(5) Å = 90°. 
 b = 14.6792(6) Å = 90°. 
 c = 21.3614(9) Å  = 90°. 
Volume 3525.0(3) Å3 
Z 4 
Density (calculated) 1.414 Mg/m3 
Absorption coefficient 0.706 mm-1 
F(000) 1560 
Crystal size 0.23 x 0.09 x 0.07 mm3 
Theta range for data collection 1.68 to 33.27°. 
Index ranges -17<=h<=9, -22<=k<=13, -32<=l<=32 
Reflections collected 31400 
Independent reflections 12869 [R(int) = 0.0581] 
Completeness to theta = 33.27° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9535 and 0.8516 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12869 / 0 / 422 
Goodness-of-fit on F2 0.995 
Final R indices [I>2sigma(I)] R1 = 0.0453, wR2 = 0.0864 
R indices (all data) R1 = NaN, wR2 = 0.1036 
Absolute structure parameter -0.02(2) 
Largest diff. peak and hole 0.585 and -0.513 e.Å-3 
 
Table A.2.22.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for Rh(cod)Cl·B4.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 7261(3) 9780(2) 1414(1) 13(1) 
C(2) 7332(3) 9520(2) 2037(1) 13(1) 
C(3) 8265(3) 9766(2) 2446(1) 14(1) 
C(4) 9178(3) 10266(2) 2185(1) 16(1) 
C(5) 9221(3) 10498(2) 1541(1) 15(1) 
C(6) 10202(3) 10975(2) 1288(2) 19(1) 
C(7) 10256(3) 11172(2) 663(2) 25(1) 
C(8) 9340(3) 10898(2) 265(2) 22(1) 
C(9) 8356(3) 10454(2) 499(1) 18(1) 
C(10) 8261(3) 10247(2) 1149(1) 13(1) 
C(11) 6898(3) 9395(3) 3709(2) 28(1) 
209 
 
C(12) 9112(4) 8363(2) 3425(2) 31(1) 
C(13) 9281(3) 10386(2) 3681(2) 29(1) 
C(14) 6192(3) 9550(2) 1030(1) 14(1) 
C(15) 5816(3) 8655(2) 976(1) 14(1) 
C(16) 4936(3) 8364(2) 545(1) 18(1) 
C(17) 4324(3) 9047(2) 235(1) 20(1) 
C(18) 4542(3) 9979(2) 333(1) 18(1) 
C(19) 3839(3) 10659(2) 41(2) 25(1) 
C(20) 4062(4) 11560(2) 138(2) 28(1) 
C(21) 4994(3) 11826(2) 536(2) 25(1) 
C(22) 5709(3) 11185(2) 820(1) 21(1) 
C(23) 5509(3) 10242(2) 726(1) 16(1) 
C(24) 4629(4) 7106(3) -556(2) 35(1) 
C(25) 5711(3) 6298(2) 618(2) 29(1) 
C(26) 3052(3) 6855(3) 579(2) 30(1) 
C(27) 8050(3) 7068(3) 2062(2) 31(1) 
C(28) 6643(3) 6739(2) 2912(2) 28(1) 
C(29) 3824(3) 9175(2) 2739(2) 23(1) 
C(30) 3607(3) 9198(2) 2095(2) 22(1) 
C(31) 2417(3) 9197(2) 1773(2) 27(1) 
C(32) 1487(3) 8598(3) 2104(2) 26(1) 
C(33) 2014(3) 7731(2) 2352(2) 22(1) 
C(34) 2421(3) 7587(2) 2946(2) 22(1) 
C(35) 2493(3) 8280(3) 3469(2) 30(1) 
C(36) 2885(3) 9224(3) 3253(2) 28(1) 
Cl(1) 4189(1) 6265(1) 2189(1) 27(1) 
N(1) 6937(2) 7296(2) 2369(1) 19(1) 
O(1) 6370(2) 9053(1) 2292(1) 15(1) 
O(2) 6349(2) 7999(1) 1361(1) 15(1) 
P(1) 5957(1) 8027(1) 2098(1) 14(1) 
Rh(1) 4039(1) 7841(1) 2349(1) 15(1) 
Si(1) 8353(1) 9484(1) 3307(1) 18(1) 
Si(2) 4600(1) 7133(1) 319(1) 20(1) 
________________________________________________________________________________ 
 
Table A.2.23.   Bond lengths [Å] and angles [°] for Rh(cod)Cl·B4. 
_____________________________________________________ 
C(1)-C(2)  1.387(4) 
C(1)-C(10)  1.433(4) 
C(1)-C(14)  1.494(4) 
C(2)-O(1)  1.392(3) 
C(2)-C(3)  1.411(4) 
C(3)-C(4)  1.380(4) 
C(3)-Si(1)  1.888(3) 
C(4)-C(5)  1.418(4) 
C(5)-C(6)  1.414(4) 
C(5)-C(10)  1.415(4) 
C(6)-C(7)  1.367(5) 
C(7)-C(8)  1.394(5) 
C(8)-C(9)  1.377(4) 
C(9)-C(10)  1.424(4) 
C(11)-Si(1)  1.852(4) 
C(12)-Si(1)  1.871(4) 
C(13)-Si(1)  1.866(4) 
C(14)-C(15)  1.385(4) 
C(14)-C(23)  1.430(4) 
C(15)-O(2)  1.402(3) 
C(15)-C(16)  1.417(4) 
C(16)-C(17)  1.385(4) 
C(16)-Si(2)  1.907(3) 
C(17)-C(18)  1.406(4) 
C(18)-C(19)  1.417(4) 
C(18)-C(23)  1.426(4) 
C(19)-C(20)  1.363(5) 
C(20)-C(21)  1.404(5) 
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C(21)-C(22)  1.378(5) 
C(22)-C(23)  1.417(4) 
C(24)-Si(2)  1.870(3) 
C(25)-Si(2)  1.863(4) 
C(26)-Si(2)  1.872(4) 
C(27)-N(1)  1.452(4) 
C(28)-N(1)  1.457(4) 
C(29)-C(30)  1.396(5) 
C(29)-C(36)  1.525(5) 
C(29)-Rh(1)  2.141(3) 
C(30)-C(31)  1.503(5) 
C(30)-Rh(1)  2.120(3) 
C(31)-C(32)  1.539(5) 
C(32)-C(33)  1.500(5) 
C(33)-C(34)  1.365(5) 
C(33)-Rh(1)  2.282(3) 
C(34)-C(35)  1.513(5) 
C(34)-Rh(1)  2.252(3) 
C(35)-C(36)  1.525(5) 
Cl(1)-Rh(1)  2.3455(8) 
N(1)-P(1)  1.643(3) 
O(1)-P(1)  1.630(2) 
O(2)-P(1)  1.634(2) 



































































































Symmetry transformations used to generate equivalent atoms:  
  
Table A.2.24.   Anisotropic displacement parameters (Å2x 103)for Rh(cod)Cl·B4.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 14(1)  12(1) 14(1)  0(1) -1(1)  1(1) 
C(2) 14(1)  11(1) 14(1)  1(1) 3(1)  -1(1) 
C(3) 14(1)  14(1) 14(1)  -1(1) -1(1)  2(1) 
C(4) 15(2)  16(1) 17(1)  0(1) -4(1)  2(1) 
C(5) 14(2)  14(1) 17(1)  0(1) 0(1)  -1(1) 
C(6) 18(2)  18(2) 21(1)  3(1) 0(1)  -6(1) 
C(7) 24(2)  25(2) 26(2)  4(1) 0(1)  -11(2) 
C(8) 24(2)  26(2) 17(1)  3(1) 3(1)  -5(1) 
C(9) 24(2)  15(1) 14(1)  0(1) -1(1)  -2(1) 
C(10) 15(1)  11(1) 14(1)  -1(1) 2(1)  -1(1) 
C(11) 24(2)  43(2) 18(1)  0(2) 0(1)  -1(2) 
C(12) 32(2)  29(2) 32(2)  8(2) -3(2)  3(2) 
C(13) 33(2)  34(2) 21(2)  1(1) -7(2)  -5(2) 
C(14) 14(2)  16(1) 12(1)  -2(1) -1(1)  -2(1) 
C(15) 15(2)  15(1) 12(1)  1(1) 2(1)  0(1) 
C(16) 18(2)  23(2) 14(1)  2(1) -1(1)  -5(1) 
C(17) 20(2)  24(2) 18(1)  3(1) -5(1)  -3(1) 
C(18) 19(2)  20(2) 14(1)  2(1) -3(1)  1(1) 
C(19) 25(2)  27(2) 22(1)  2(1) -8(1)  2(1) 
C(20) 32(2)  25(2) 26(2)  4(1) -10(2)  10(2) 
C(21) 31(2)  18(2) 27(2)  2(1) -6(1)  1(1) 
C(22) 26(2)  17(1) 20(1)  1(1) -2(1)  0(1) 
C(23) 18(2)  18(1) 13(1)  3(1) 0(1)  -3(1) 
C(24) 55(2)  33(2) 19(1)  -3(2) -5(2)  -13(2) 
C(25) 30(2)  22(2) 34(2)  -6(2) -3(2)  -2(2) 
C(26) 24(2)  30(2) 35(2)  3(2) -4(2)  -9(2) 
C(27) 26(2)  41(2) 26(2)  4(2) 4(1)  16(2) 
C(28) 28(2)  28(2) 29(2)  16(2) -5(2)  0(2) 
C(29) 20(2)  17(1) 31(2)  -5(1) -2(1)  -2(1) 
C(30) 19(2)  15(2) 32(2)  3(1) 2(1)  4(1) 
C(31) 25(2)  28(2) 29(2)  6(2) 1(2)  6(2) 
C(32) 19(2)  35(2) 24(2)  2(2) -2(1)  3(2) 
C(33) 19(1)  23(2) 25(1)  -2(2) 0(1)  -1(1) 
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C(34) 15(2)  25(2) 24(2)  6(1) 4(1)  -3(1) 
C(35) 22(2)  47(2) 20(2)  -1(2) 4(1)  2(2) 
C(36) 22(2)  35(2) 29(2)  -10(2) 3(2)  -1(2) 
Cl(1) 26(1)  15(1) 38(1)  2(1) 2(1)  -2(1) 
N(1) 17(1)  21(1) 20(1)  7(1) 3(1)  4(1) 
O(1) 14(1)  17(1) 13(1)  0(1) 2(1)  -5(1) 
O(2) 18(1)  15(1) 13(1)  2(1) 0(1)  -1(1) 
P(1) 14(1)  15(1) 14(1)  2(1) 1(1)  0(1) 
Rh(1) 14(1)  14(1) 19(1)  2(1) 1(1)  -1(1) 
Si(1) 18(1)  23(1) 14(1)  3(1) -2(1)  0(1) 
Si(2) 23(1)  19(1) 18(1)  -1(1) -2(1)  -6(1) 
______________________________________________________________________________ 
 
Table A.2.25.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 
Rh(cod)Cl·B4. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(4) 9794 10460 2443 19 
H(6) 10818 11158 1550 23 
H(7) 10904 11489 503 30 
H(8) 9393 11016 -162 27 
H(9) 7746 10286 229 21 
H(11A) 7024 9304 4149 43 
H(11B) 6461 8888 3541 43 
H(11C) 6454 9946 3645 43 
H(12A) 9258 8272 3864 46 
H(12B) 9854 8360 3203 46 
H(12C) 8614 7882 3270 46 
H(13A) 8994 10975 3558 44 
H(13B) 10093 10318 3550 44 
H(13C) 9235 10328 4128 44 
H(17) 3740 8881 -52 25 
H(19) 3217 10487 -220 30 
H(20) 3597 11999 -59 33 
H(21) 5130 12442 609 30 
H(22) 6331 11374 1076 25 
H(24A) 5400 7290 -701 53 
H(24B) 4038 7516 -717 53 
H(24C) 4463 6499 -698 53 
H(25A) 5583 5718 421 43 
H(25B) 5623 6235 1063 43 
H(25C) 6498 6509 524 43 
H(26A) 2829 6268 421 44 
H(26B) 2512 7308 422 44 
H(26C) 3020 6848 1029 44 
H(27A) 8666 7005 2370 47 
H(27B) 8259 7542 1773 47 
H(27C) 7961 6504 1839 47 
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H(28A) 6626 6109 2792 43 
H(28B) 5876 6913 3069 43 
H(28C) 7231 6827 3232 43 
H(31A) 2519 8982 1347 33 
H(31B) 2122 9818 1753 33 
H(32A) 1140 8938 2448 32 
H(32B) 856 8452 1812 32 
H(35A) 3049 8062 3782 36 
H(35B) 1719 8329 3666 36 
H(36A) 3205 9557 3607 34 
H(36B) 2198 9555 3098 34 
H(29) 4470(30) 9340(30) 2866(17) 20(10) 
H(30) 4210(40) 9430(30) 1837(18) 31(11) 
H(33) 1920(30) 7230(20) 2119(15) 16(8) 








Table A.2.26.  Crystal data and structure refinement for Rh(cod)Cl·T1. 
Identification code  rovis53_0m 
Empirical formula  C43H50Cl5NO4PRh 
Formula weight  955.97 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 10.8877(3) Å = 90°. 
 b = 18.0279(5) Å = 91.9240(10)°. 
 c = 11.1484(3) Å  = 90°. 
Volume 2187.00(10) Å3 
Z 2 
Density (calculated) 1.452 Mg/m3 
Absorption coefficient 0.774 mm-1 
F(000) 984 
Crystal size 0.39 x 0.13 x 0.11 mm3 
Theta range for data collection 1.83 to 34.97°. 
Index ranges -17<=h<=17, -26<=k<=29, -17<=l<=17 
Reflections collected 46802 
Independent reflections 17252 [R(int) = 0.0404] 
Completeness to theta = 34.97° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9197 and 0.7512 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 17252 / 1 / 517 
Goodness-of-fit on F2 1.032 
Final R indices [I>2sigma(I)] R1 = 0.0430, wR2 = 0.0935 
R indices (all data) R1 = 0.0552, wR2 = 0.1010 
Absolute structure parameter -0.015(17) 
Largest diff. peak and hole 1.210 and -0.966 e.Å-3 
 
Table A.2.27.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for Rh(cod)Cl·T1.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 589(2) 483(1) 5512(2) 12(1) 
C(2) -646(2) 474(1) 6178(2) 13(1) 
C(3) -1007(2) 1250(1) 6583(2) 14(1) 
C(4) -655(2) 1408(1) 7923(2) 13(1) 
C(5) -2642(2) 765(2) 5463(2) 17(1) 
C(6) -2745(2) 1161(2) 4260(2) 22(1) 
C(7) -3813(2) 381(2) 5799(3) 27(1) 
C(8) 1227(2) -268(1) 5507(2) 14(1) 
C(9) 2485(2) -301(2) 5292(2) 18(1) 
C(10) 3092(2) -976(2) 5259(3) 23(1) 
C(11) 2441(3) -1632(2) 5424(3) 26(1) 
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C(12) 1197(3) -1608(2) 5619(3) 24(1) 
C(13) 586(2) -929(2) 5654(2) 19(1) 
C(14) 404(2) 764(1) 4225(2) 14(1) 
C(15) -162(2) 292(2) 3374(2) 18(1) 
C(16) -445(3) 539(2) 2218(2) 22(1) 
C(17) -133(3) 1256(2) 1888(2) 28(1) 
C(18) 463(3) 1723(2) 2703(2) 26(1) 
C(19) 727(2) 1475(2) 3876(2) 19(1) 
C(20) -1614(2) 1070(2) 8743(2) 16(1) 
C(21) -1567(3) 322(2) 9054(2) 21(1) 
C(22) -2487(3) 6(2) 9744(3) 28(1) 
C(23) -3436(3) 436(2) 10134(3) 34(1) 
C(24) -3472(3) 1182(2) 9863(3) 38(1) 
C(25) -2564(3) 1498(2) 9161(3) 29(1) 
C(26) -498(2) 2233(2) 8177(2) 16(1) 
C(27) -1119(2) 2762(2) 7478(3) 20(1) 
C(28) -1075(3) 3513(2) 7792(3) 26(1) 
C(29) -412(3) 3732(2) 8816(3) 30(1) 
C(30) 239(3) 3213(2) 9504(3) 27(1) 
C(31) 193(2) 2465(2) 9185(2) 20(1) 
C(32) 1872(3) -340(2) 8435(3) 23(1) 
C(33) 3801(2) 305(2) 8107(3) 22(1) 
C(34) 2225(2) 2687(1) 6316(2) 15(1) 
C(35) 3284(2) 2281(1) 6007(2) 17(1) 
C(36) 4526(2) 2650(2) 5803(3) 23(1) 
C(37) 5355(2) 2684(2) 6934(3) 23(1) 
C(38) 4660(2) 2789(2) 8074(3) 20(1) 
C(39) 3711(2) 3280(2) 8234(2) 19(1) 
C(40) 3247(3) 3825(2) 7280(3) 22(1) 
C(41) 2154(2) 3513(2) 6523(2) 21(1) 
C(42) 6599(4) 7882(3) 7469(5) 57(1) 
C(43) 6926(3) 5445(2) 7837(3) 30(1) 
Cl(1) 3137(1) 1804(1) 9920(1) 21(1) 
Cl(2) 5112(2) 8186(2) 7633(2) 120(1) 
Cl(3) 7633(2) 8570(1) 7149(2) 84(1) 
Cl(4) 5882(1) 5954(1) 6915(1) 47(1) 
Cl(5) 6251(1) 4595(1) 8296(1) 38(1) 
N(1) 2454(2) 344(1) 8050(2) 16(1) 
O(1) 1376(2) 1025(1) 6136(2) 12(1) 
O(2) 492(2) 1009(1) 8220(2) 14(1) 
O(3) -1663(2) 226(1) 5450(2) 17(1) 
O(4) -2308(2) 1273(1) 6403(2) 19(1) 
P(1) 1778(1) 1100(1) 7553(1) 12(1) 
Rh(1) 2923(1) 2136(1) 7860(1) 13(1) 
________________________________________________________________________________ 
 
Table A.2.28.   Bond lengths [Å] and angles [°] for Rh(cod)Cl·T1. 
_____________________________________________________ 
C(1)-O(1)  1.461(3) 
C(1)-C(8)  1.522(3) 
C(1)-C(14)  1.529(3) 
C(1)-C(2)  1.558(3) 
C(2)-O(3)  1.423(3) 
C(2)-C(3)  1.526(4) 
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C(3)-O(4)  1.425(3) 
C(3)-C(4)  1.555(3) 
C(4)-O(2)  1.470(3) 
C(4)-C(26)  1.523(4) 
C(4)-C(20)  1.537(3) 
C(5)-O(4)  1.429(3) 
C(5)-O(3)  1.443(3) 
C(5)-C(7)  1.508(4) 
C(5)-C(6)  1.521(4) 
C(8)-C(13)  1.393(4) 
C(8)-C(9)  1.399(3) 
C(9)-C(10)  1.387(4) 
C(10)-C(11)  1.393(4) 
C(11)-C(12)  1.380(4) 
C(12)-C(13)  1.395(4) 
C(14)-C(19)  1.387(4) 
C(14)-C(15)  1.403(4) 
C(15)-C(16)  1.389(4) 
C(16)-C(17)  1.388(5) 
C(17)-C(18)  1.384(4) 
C(18)-C(19)  1.403(4) 
C(20)-C(25)  1.384(4) 
C(20)-C(21)  1.393(4) 
C(21)-C(22)  1.404(4) 
C(22)-C(23)  1.374(5) 
C(23)-C(24)  1.379(5) 
C(24)-C(25)  1.402(4) 
C(26)-C(27)  1.392(4) 
C(26)-C(31)  1.395(4) 
C(27)-C(28)  1.399(4) 
C(28)-C(29)  1.388(5) 
C(29)-C(30)  1.389(5) 
C(30)-C(31)  1.394(4) 
C(32)-N(1)  1.458(3) 
C(33)-N(1)  1.468(3) 
C(34)-C(35)  1.418(3) 
C(34)-C(41)  1.509(4) 
C(34)-Rh(1)  2.107(2) 
C(35)-C(36)  1.531(4) 
C(35)-Rh(1)  2.131(2) 
C(36)-C(37)  1.528(4) 
C(37)-C(38)  1.513(4) 
C(38)-C(39)  1.376(4) 
C(38)-Rh(1)  2.233(3) 
C(39)-C(40)  1.522(4) 
C(39)-Rh(1)  2.267(3) 
C(40)-C(41)  1.541(4) 
C(42)-Cl(3)  1.722(5) 
C(42)-Cl(2)  1.724(5) 
C(43)-Cl(4)  1.764(3) 
C(43)-Cl(5)  1.783(4) 
Cl(1)-Rh(1)  2.3775(6) 
N(1)-P(1)  1.636(2) 
O(1)-P(1)  1.6301(17) 
O(2)-P(1)  1.6158(17) 











































































































Symmetry transformations used to generate equivalent atoms:  
  
Table A.2.29.   Anisotropic displacement parameters (Å2x 103)for Rh(cod)Cl·T1.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 10(1)  11(1) 14(1)  0(1) 1(1)  -1(1) 
C(2) 12(1)  14(1) 13(1)  0(1) 0(1)  -1(1) 
C(3) 13(1)  15(1) 14(1)  1(1) -1(1)  2(1) 
C(4) 11(1)  16(1) 13(1)  0(1) 1(1)  1(1) 
C(5) 14(1)  20(1) 18(1)  -3(1) -1(1)  1(1) 
C(6) 18(1)  27(2) 19(1)  1(1) -4(1)  2(1) 
C(7) 16(1)  35(2) 31(2)  2(1) 2(1)  -2(1) 
C(8) 15(1)  12(1) 14(1)  -1(1) 1(1)  0(1) 
C(9) 17(1)  19(1) 20(1)  -1(1) 5(1)  -1(1) 
C(10) 17(1)  20(1) 32(1)  -4(1) 3(1)  7(1) 
C(11) 31(1)  17(1) 30(2)  -2(1) -2(1)  6(1) 
C(12) 31(1)  13(1) 27(1)  -1(1) 3(1)  0(1) 
C(13) 20(1)  15(1) 22(1)  0(1) 0(1)  -1(1) 
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C(14) 15(1)  15(1) 12(1)  0(1) 1(1)  3(1) 
C(15) 19(1)  17(1) 18(1)  1(1) 0(1)  -2(1) 
C(16) 25(1)  27(1) 14(1)  -2(1) -3(1)  -2(1) 
C(17) 35(2)  37(2) 13(1)  4(1) -1(1)  -5(1) 
C(18) 34(2)  26(2) 18(1)  7(1) -1(1)  -6(1) 
C(19) 23(1)  16(1) 16(1)  1(1) 1(1)  -3(1) 
C(20) 13(1)  23(1) 14(1)  5(1) 1(1)  -3(1) 
C(21) 24(1)  23(1) 18(1)  0(1) 5(1)  -6(1) 
C(22) 31(2)  29(2) 22(1)  7(1) 1(1)  -14(1) 
C(23) 15(1)  59(2) 28(2)  22(2) 2(1)  -8(1) 
C(24) 20(1)  53(2) 42(2)  16(2) 17(1)  8(1) 
C(25) 17(1)  39(2) 32(2)  16(1) 9(1)  7(1) 
C(26) 15(1)  19(2) 16(1)  -2(1) 6(1)  -1(1) 
C(27) 19(1)  20(1) 21(1)  1(1) 6(1)  3(1) 
C(28) 27(1)  18(1) 34(2)  4(1) 12(1)  5(1) 
C(29) 36(2)  17(1) 39(2)  -10(1) 18(1)  -3(1) 
C(30) 30(1)  23(1) 29(1)  -9(1) 8(1)  -6(1) 
C(31) 20(1)  22(1) 18(1)  -2(1) 4(1)  -4(1) 
C(32) 22(1)  18(1) 28(1)  10(1) -4(1)  -3(1) 
C(33) 15(1)  23(1) 29(1)  2(1) 1(1)  3(1) 
C(34) 16(1)  16(1) 14(1)  0(1) 1(1)  -1(1) 
C(35) 18(1)  18(2) 14(1)  1(1) 3(1)  -4(1) 
C(36) 19(1)  23(1) 28(1)  -2(1) 9(1)  -4(1) 
C(37) 14(1)  23(1) 33(1)  -1(1) 3(1)  -3(1) 
C(38) 15(1)  19(1) 27(1)  3(1) -2(1)  -4(1) 
C(39) 21(1)  14(1) 21(1)  -3(1) 1(1)  -4(1) 
C(40) 26(1)  13(1) 27(1)  0(1) 1(1)  -2(1) 
C(41) 22(1)  17(1) 23(1)  2(1) 0(1)  1(1) 
C(42) 53(3)  54(3) 63(3)  22(2) 0(2)  2(2) 
C(43) 25(1)  34(2) 30(2)  -8(1) -1(1)  1(1) 
Cl(1) 23(1)  25(1) 14(1)  0(1) -1(1)  -3(1) 
Cl(2) 67(1)  161(2) 132(2)  47(2) 11(1)  49(1) 
Cl(3) 118(1)  45(1) 91(1)  13(1) 39(1)  -11(1) 
Cl(4) 43(1)  52(1) 45(1)  -6(1) -12(1)  17(1) 
Cl(5) 29(1)  36(1) 51(1)  -10(1) 12(1)  -1(1) 
N(1) 12(1)  14(1) 20(1)  4(1) -1(1)  0(1) 
O(1) 13(1)  13(1) 12(1)  0(1) -1(1)  -3(1) 
O(2) 12(1)  15(1) 14(1)  3(1) 2(1)  0(1) 
O(3) 12(1)  19(1) 19(1)  -1(1) -3(1)  -1(1) 
O(4) 13(1)  24(1) 18(1)  -5(1) -2(1)  3(1) 
P(1) 11(1)  13(1) 11(1)  1(1) 0(1)  -1(1) 











Table A.2.30.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 
Rh(cod)Cl·T1. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2) -557 151 6884 15 
H(3) -625 1621 6073 17 
H(6A) -3393 1522 4276 33 
H(6B) -2925 806 3636 33 
H(6C) -1982 1405 4107 33 
H(7A) -3697 151 6571 41 
H(7B) -4023 10 5209 41 
H(7C) -4465 739 5830 41 
H(9) 2918 136 5169 22 
H(10) 3930 -992 5127 28 
H(11) 2846 -2086 5402 31 
H(12) 765 -2046 5728 28 
H(13) -255 -917 5777 23 
H(15) -349 -193 3586 22 
H(16) -842 226 1667 26 
H(17) -325 1422 1115 34 
H(18) 688 2199 2474 31 
H(19) 1123 1789 4425 22 
H(21) -921 29 8803 26 
H(22) -2454 -496 9937 33 
H(23) -4053 224 10579 40 
H(24) -4101 1476 10146 46 
H(25) -2600 2001 8976 35 
H(27) -1568 2614 6795 24 
H(28) -1487 3864 7317 31 
H(29) -403 4229 9043 36 
H(30) 703 3363 10176 33 
H(31) 627 2118 9649 24 
H(32A) 2173 -749 7977 34 
H(32B) 997 -301 8308 34 
H(32C) 2061 -421 9272 34 
H(33A) 4078 188 8912 33 
H(33B) 4135 775 7877 33 
H(33C) 4071 -73 7570 33 
H(36A) 4945 2376 5188 28 
H(36B) 4385 3149 5507 28 
H(37A) 5828 2229 6998 28 
H(37B) 5931 3091 6857 28 
H(40A) 3911 3945 6754 26 
H(40B) 2996 4280 7666 26 
H(41A) 1399 3624 6924 25 
H(41B) 2119 3762 5752 25 
H(42A) 6873 7636 8205 68 
H(42B) 6601 7516 6831 68 
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H(43A) 7160 5737 8538 36 
H(43B) 7662 5342 7399 36 
H(39) 3460(30) 3371(18) 9050(30) 12(7) 
H(38) 5010(30) 2555(19) 8900(30) 17(8) 
H(34) 1460(30) 2490(18) 6010(30) 13(7) 










Table A.2.31.  Crystal data and structure refinement for Rh(cod)Cl·T8. 
Identification code  rovis73_0m 
Empirical formula  C51H64ClNO4PRh 
Formula weight  924.36 
Temperature  120 K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 15.3754(4) Å = 90°. 
 b = 17.3853(4) Å = 90°. 
 c = 18.1214(4) Å  = 90°. 
Volume 4844.0(2) Å3 
Z 4 
Density (calculated) 1.268 Mg/m3 
Absorption coefficient 0.483 mm-1 
F(000) 1944 
Crystal size 0.31 x 0.26 x 0.19 mm3 
Theta range for data collection 2.10 to 36.43°. 
Index ranges -25<=h<=25, -28<=k<=25, -30<=l<=28 
Reflections collected 52621 
Independent reflections 23450 [R(int) = 0.0546] 
Completeness to theta = 36.43° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9159 and 0.8658 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 23450 / 0 / 542 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0532, wR2 = 0.1024 
R indices (all data) R1 = 0.0916, wR2 = 0.1182 
Absolute structure parameter -0.029(17) 
Largest diff. peak and hole 1.789 and -0.960 e.Å-3 
 
Table A.2.32.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for Rh(cod)Cl·T8.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 697(1) 10732(1) 4473(1) 16(1) 
C(2) 120(2) 10735(1) 5177(1) 18(1) 
C(3) 526(2) 10250(1) 5800(1) 18(1) 
C(4) 115(2) 9427(1) 5839(1) 17(1) 
C(5) 1486(2) 11269(1) 4544(1) 18(1) 
C(6) 1388(2) 12061(1) 4420(2) 26(1) 
C(7) 2094(2) 12556(2) 4497(2) 34(1) 
C(8) 2903(2) 12264(2) 4690(2) 34(1) 
C(9) 3007(2) 11484(2) 4823(2) 33(1) 
C(10) 2296(2) 10995(2) 4749(2) 26(1) 
C(11) 180(2) 10935(1) 3778(1) 17(1) 
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C(12) 452(2) 10655(1) 3102(1) 19(1) 
C(13) 33(2) 10870(2) 2447(2) 23(1) 
C(14) -654(2) 11389(2) 2492(2) 25(1) 
C(15) -943(2) 11677(2) 3164(2) 24(1) 
C(16) -527(2) 11441(1) 3806(2) 21(1) 
C(17) -768(2) 9458(1) 6231(2) 23(1) 
C(18) -806(2) 9415(2) 6996(2) 30(1) 
C(19) -1596(3) 9474(2) 7368(2) 39(1) 
C(20) -2349(2) 9563(2) 6957(2) 45(1) 
C(21) -2339(2) 9599(2) 6187(2) 35(1) 
C(22) -1532(2) 9550(1) 5837(2) 26(1) 
C(23) 721(2) 8852(1) 6216(1) 19(1) 
C(24) 1323(2) 9082(2) 6741(2) 24(1) 
C(25) 1814(2) 8547(2) 7126(2) 29(1) 
C(26) 1704(2) 7762(2) 6971(2) 26(1) 
C(27) 1104(2) 7519(2) 6444(2) 23(1) 
C(28) 614(2) 8068(1) 6076(1) 20(1) 
C(29) 244(2) 11465(2) 6258(2) 36(1) 
C(30) 2693(2) 8895(2) 4784(2) 29(1) 
C(31) 2612(2) 8972(2) 4020(2) 29(1) 
C(32) 3169(2) 8601(2) 3429(2) 42(1) 
C(33) 3379(2) 7764(2) 3595(2) 37(1) 
C(34) 2644(2) 7352(2) 3981(2) 25(1) 
C(35) 2602(2) 7271(2) 4736(2) 26(1) 
C(36) 3226(2) 7606(2) 5280(2) 32(1) 
C(37) 3434(2) 8456(2) 5151(2) 45(1) 
C(38) 2452(2) 8795(2) 7718(2) 45(1) 
C(39) 992(2) 6675(2) 6273(2) 33(1) 
C(40) -3166(2) 9658(2) 5747(2) 47(1) 
C(41) -1687(2) 12241(2) 3190(2) 37(1) 
C(42) 327(2) 10538(2) 1724(2) 33(1) 
C(43) 1982(3) 13405(2) 4358(3) 60(1) 
C(44) -1015(2) 9237(2) 3724(2) 23(1) 
C(45) 162(2) 8627(2) 3047(2) 26(1) 
C(46) -700(2) 8292(2) 2793(2) 39(1) 
C(47) -1329(2) 8931(2) 2986(2) 39(1) 
C(48) 1122(3) 11886(2) 6364(2) 65(1) 
C(49) -1622(3) 9431(2) 8203(2) 60(1) 
C(50) -492(4) 11773(3) 6691(2) 115(3) 
C(51) 3897(2) 11161(2) 5042(3) 61(1) 
Cl(1) 554(1) 7244(1) 4347(1) 21(1) 
N(1) -78(1) 9020(1) 3742(1) 18(1) 
O(1) -70(1) 9177(1) 5090(1) 16(1) 
O(2) 1061(1) 9964(1) 4404(1) 15(1) 
O(3) 363(1) 10675(1) 6449(1) 23(1) 
O(4) 37(1) 11483(1) 5489(1) 23(1) 
P(1) 618(1) 9115(1) 4417(1) 14(1) 






Table A.2.33.   Bond lengths [Å] and angles [°] for Rh(cod)Cl·T8. 
_____________________________________________________ 
C(1)-O(2)  1.454(3) 
C(1)-C(11)  1.531(3) 
C(1)-C(5)  1.536(3) 
C(1)-C(2)  1.553(3) 
C(2)-O(4)  1.425(3) 
C(2)-C(3)  1.541(3) 
C(3)-O(3)  1.412(3) 
C(3)-C(4)  1.565(3) 
C(4)-O(1)  1.453(3) 
C(4)-C(23)  1.528(3) 
C(4)-C(17)  1.533(3) 
C(5)-C(10)  1.384(4) 
C(5)-C(6)  1.402(3) 
C(6)-C(7)  1.392(4) 
C(7)-C(8)  1.388(5) 
C(7)-C(43)  1.508(4) 
C(8)-C(9)  1.388(4) 
C(9)-C(10)  1.392(4) 
C(9)-C(51)  1.531(5) 
C(11)-C(12)  1.382(3) 
C(11)-C(16)  1.399(3) 
C(12)-C(13)  1.401(4) 
C(13)-C(14)  1.392(4) 
C(13)-C(42)  1.501(4) 
C(14)-C(15)  1.391(4) 
C(15)-C(16)  1.390(4) 
C(15)-C(41)  1.508(4) 
C(17)-C(22)  1.384(4) 
C(17)-C(18)  1.389(4) 
C(18)-C(19)  1.394(4) 
C(19)-C(20)  1.385(5) 
C(19)-C(49)  1.515(5) 
C(20)-C(21)  1.398(5) 
C(21)-C(22)  1.396(4) 
C(21)-C(40)  1.504(5) 
C(23)-C(24)  1.387(4) 
C(23)-C(28)  1.396(3) 
C(24)-C(25)  1.387(4) 
C(25)-C(26)  1.404(4) 
C(25)-C(38)  1.516(4) 
C(26)-C(27)  1.393(4) 
C(27)-C(28)  1.387(4) 
C(27)-C(39)  1.510(4) 
C(29)-O(3)  1.428(3) 
C(29)-O(4)  1.428(3) 
C(29)-C(50)  1.478(5) 
C(29)-C(48)  1.548(5) 
C(30)-C(31)  1.396(4) 
C(30)-C(37)  1.524(4) 
C(30)-Rh(1)  2.108(3) 
C(31)-C(32)  1.515(4) 
C(31)-Rh(1)  2.113(3) 
C(32)-C(33)  1.521(4) 
C(33)-C(34)  1.510(4) 
C(34)-C(35)  1.376(4) 
C(34)-Rh(1)  2.242(3) 
C(35)-C(36)  1.495(4) 
C(35)-Rh(1)  2.236(3) 
C(36)-C(37)  1.530(4) 
C(44)-N(1)  1.490(3) 
C(44)-C(47)  1.518(4) 
C(45)-N(1)  1.479(3) 
C(45)-C(46)  1.520(4) 
C(46)-C(47)  1.513(5) 
Cl(1)-Rh(1)  2.3764(6) 
N(1)-P(1)  1.633(2) 
O(1)-P(1)  1.6188(18) 
O(2)-P(1)  1.6261(15) 


































































































































Table A.2.34.   Anisotropic displacement parameters (Å2x 103)for Rh(cod)Cl·T8.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 19(1)  12(1) 16(1)  1(1) 0(1)  2(1) 
C(2) 21(1)  15(1) 18(1)  0(1) 2(1)  2(1) 
C(3) 20(1)  18(1) 15(1)  1(1) 1(1)  0(1) 
C(4) 19(1)  16(1) 16(1)  2(1) 2(1)  -2(1) 
C(5) 22(1)  18(1) 15(1)  -1(1) 2(1)  -1(1) 
C(6) 30(1)  17(1) 29(1)  2(1) -2(1)  -2(1) 
C(7) 41(2)  20(1) 42(2)  1(1) -8(2)  -8(1) 
C(8) 39(2)  26(1) 38(2)  -4(1) -2(1)  -14(1) 
C(9) 22(1)  31(2) 45(2)  1(1) -5(1)  -8(1) 
C(10) 26(1)  19(1) 34(2)  1(1) -2(1)  -3(1) 
C(11) 17(1)  15(1) 20(1)  4(1) -1(1)  -1(1) 
C(12) 19(1)  19(1) 18(1)  3(1) 0(1)  1(1) 
C(13) 25(1)  26(1) 18(1)  4(1) -1(1)  -1(1) 
C(14) 25(1)  25(1) 24(1)  11(1) -3(1)  0(1) 
C(15) 22(1)  24(1) 27(1)  5(1) -1(1)  3(1) 
C(16) 24(1)  18(1) 21(1)  2(1) 2(1)  3(1) 
C(17) 25(1)  15(1) 28(1)  0(1) 10(1)  -2(1) 
C(18) 36(2)  24(1) 30(2)  -3(1) 14(1)  -2(1) 
C(19) 53(2)  25(1) 39(2)  -7(1) 25(2)  -8(2) 
C(20) 41(2)  22(1) 73(3)  -13(2) 38(2)  -9(1) 
C(21) 25(1)  12(1) 66(2)  -5(1) 16(1)  -3(1) 
C(22) 20(1)  18(1) 39(2)  0(1) 8(1)  1(1) 
C(23) 21(1)  21(1) 15(1)  4(1) 1(1)  -2(1) 
C(24) 27(1)  25(1) 19(1)  5(1) -2(1)  -6(1) 
C(25) 30(2)  35(2) 21(1)  6(1) -8(1)  -5(1) 
C(26) 27(1)  26(1) 26(1)  12(1) -1(1)  0(1) 
C(27) 26(1)  24(1) 20(1)  4(1) 3(1)  0(1) 
C(28) 22(1)  21(1) 15(1)  3(1) 0(1)  -2(1) 
C(29) 62(2)  27(2) 20(1)  -5(1) -5(1)  14(1) 
C(30) 21(1)  18(1) 46(2)  -2(1) -10(1)  -1(1) 
C(31) 20(1)  18(1) 49(2)  4(1) 11(1)  1(1) 
C(32) 35(2)  33(2) 58(2)  6(2) 18(2)  7(1) 
C(33) 36(2)  30(1) 46(2)  4(1) 17(2)  11(1) 
C(34) 24(1)  20(1) 31(2)  -2(1) 2(1)  6(1) 
C(35) 22(1)  16(1) 40(2)  3(1) -6(1)  7(1) 
C(36) 29(2)  30(1) 37(2)  3(1) -9(1)  6(1) 
C(37) 30(2)  32(2) 73(2)  -5(2) -29(2)  2(1) 
C(38) 47(2)  48(2) 39(2)  11(2) -25(2)  -15(2) 
C(39) 44(2)  23(2) 33(2)  7(1) 1(1)  6(1) 
C(40) 22(1)  20(1) 99(3)  1(2) 20(2)  4(1) 
C(41) 34(2)  40(2) 37(2)  9(1) -3(2)  14(2) 
C(42) 38(2)  42(2) 18(1)  3(1) 0(1)  9(1) 
C(43) 62(2)  21(1) 97(3)  7(2) -15(3)  -12(2) 
C(44) 17(1)  20(1) 33(1)  3(1) -4(1)  0(1) 
C(45) 28(1)  28(1) 20(1)  -2(1) -3(1)  3(1) 
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C(46) 42(2)  42(2) 34(2)  -6(2) -12(1)  -4(2) 
C(47) 31(2)  45(2) 39(2)  -7(2) -19(1)  6(1) 
C(48) 111(4)  35(2) 48(2)  8(2) -32(2)  -30(2) 
C(49) 83(3)  55(2) 41(2)  -9(2) 39(2)  -13(2) 
C(50) 175(6)  132(5) 37(2)  35(3) 46(3)  125(5) 
C(51) 28(2)  45(2) 109(4)  1(2) -22(2)  -6(2) 
Cl(1) 21(1)  17(1) 25(1)  -2(1) -1(1)  -2(1) 
N(1) 18(1)  20(1) 17(1)  -2(1) -4(1)  1(1) 
O(1) 16(1)  17(1) 15(1)  0(1) 0(1)  -1(1) 
O(2) 16(1)  12(1) 18(1)  2(1) -1(1)  1(1) 
O(3) 37(1)  17(1) 16(1)  -2(1) 4(1)  -4(1) 
O(4) 34(1)  16(1) 20(1)  -1(1) 5(1)  4(1) 
P(1) 14(1)  13(1) 15(1)  1(1) -1(1)  0(1) 
Rh(1) 15(1)  14(1) 21(1)  0(1) -1(1)  1(1) 
______________________________________________________________________________ 
 
Table A.2.35.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 
Rh(cod)Cl·T8. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2) -457 10533 5057 21 
H(3) 1155 10207 5722 21 
H(6) 848 12256 4286 31 
H(8) 3377 12593 4731 41 
H(10) 2366 10472 4840 32 
H(12) 922 10319 3082 22 
H(14) -927 11547 2060 30 
H(16) -721 11621 4260 25 
H(18) -296 9345 7264 36 
H(20) -2879 9600 7202 55 
H(22) -1507 9579 5325 31 
H(24) 1398 9603 6837 29 
H(26) 2035 7399 7223 32 
H(28) 206 7911 5729 24 
H(30) 2501 9348 5061 34 
H(31) 2368 9469 3870 34 
H(32A) 3708 8887 3383 50 
H(32B) 2868 8631 2960 50 
H(33A) 3508 7501 3136 45 
H(33B) 3895 7741 3902 45 
H(34) 2395 6922 3702 30 
H(35) 2326 6792 4900 31 
H(36A) 3764 7315 5261 38 
H(36B) 2986 7548 5772 38 
H(37A) 3566 8696 5621 54 
H(37B) 3949 8495 4843 54 
H(38A) 2450 9346 7757 68 
H(38B) 3026 8622 7589 68 
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H(38C) 2285 8574 8182 68 
H(39A) 535 6466 6574 50 
H(39B) 1526 6408 6376 50 
H(39C) 846 6613 5762 50 
H(40A) -3467 9175 5762 71 
H(40B) -3030 9785 5245 71 
H(40C) -3529 10053 5954 71 
H(41A) -1467 12755 3136 55 
H(41B) -1984 12196 3654 55 
H(41C) -2086 12133 2795 55 
H(42A) 63 10043 1654 49 
H(42B) 948 10483 1727 49 
H(42C) 159 10875 1330 49 
H(43A) 2428 13685 4615 90 
H(43B) 1422 13567 4533 90 
H(43C) 2026 13505 3839 90 
H(44A) -1086 9790 3752 28 
H(44B) -1329 8999 4129 28 
H(45A) 588 8226 3134 31 
H(45B) 392 8988 2688 31 
H(46A) -698 8189 2267 47 
H(46B) -838 7821 3056 47 
H(47A) -1917 8734 3026 46 
H(47B) -1317 9332 2614 46 
H(48A) 1274 11886 6878 97 
H(48B) 1069 12407 6193 97 
H(48C) 1566 11627 6087 97 
H(49A) -1447 8927 8360 90 
H(49B) -2202 9532 8372 90 
H(49C) -1232 9807 8406 90 
H(50A) -987 11441 6636 172 
H(50B) -636 12279 6516 172 
H(50C) -332 11800 7202 172 
H(51A) 4342 11406 4753 91 
H(51B) 3909 10617 4953 91 
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General Methods. All reactions were carried out under an atmosphere of argon in oven-dried 
glassware with magnetic stirring. Toluene was degassed with argon and passed through one column of 
neutral alumina and one column of Q5 reactant. Column chromatography was performed on Silicycle Inc. 
silica gel 60 (230-400 mesh). Thin layer chromatography was performed on Silicycle Inc. 0.25 mm silica 
gel 60-F plates. Visualization was accomplished with UV light (254 nm), anisaldehyde, and KMnO4. 
 1H NMR and 13C NMR spectra were obtained in CDCl3, C6D6, or D3COD at ambient temperature 
and chemical shifts are expressed in parts per million (δ, ppm). Proton chemical shifts are referenced to 
7.26 ppm (CHCl3), 7.16 ppm (C6D6), and 3.31 ppm (D3COD) and carbon chemical shifts are referenced to 
77.0 ppm (CDCl3) and 49.00 (D3COD). Data reporting uses the following abbreviations: s, singlet; bs, 
broad singlet; d, doublet; t, triplet; m, multiplet; and J, coupling constant in Hz. 
 Unless otherwise indicated, commercially available starting materials were purchased from 
Aldrich Chemicals. [Rh(C2H4)2Cl]2 was purchased from Strem Chemicals. Amines were distilled over 
KOH under reduced pressure before use. Ligands L2 - L4 were synthesized as previously reported.1 
Synthesis and Characterization Data of α,β-Unsaturated Imines. 
 
1,4-diphenyl-1-azabuta-1,3-diene (3a). Trans-cinnamaldehyde (6.3 ml, 50 mmol) and 
aniline (4.6 ml, 50 mmol) were dissolved in toluene and MgSO4 was added. The 
reaction was stirred at 23 °C for 6 h, filtered, and concentrated in vacuo. 
Recrystallization from Et2O resulted in yellow-orange needles  (6.5 g, 62%, mp: 107 - 
109 °C). Spectral data matches literature values.2 1H NMR (300 MHz, CDCl3) δ 8.29 
(m, 1H), 7.55 (m, 2H), 7.44 - 7.37 (m, 5H), 7.24 - 7.16 (m, 5H). 
1-(4-methoxyphenyl)-4-phenyl-1-azabuta-1,3-diene (3b). Trans-
cinnamaldehyde (2.1 ml, 16.5 mmol) and p-anisidine (2.02 g, 16.5 mmol) were 
dissolved in toluene and MgSO4 was added. The reaction mixture was stirred at 
23 °C for 12 h, filtered, and concentrated in vacuo. Recrystallization from Et2O 
resulted in yellow flakes (2.53 g, 65%, mp: 119 - 121 °C). Spectral data matches 
literature values.2 1H NMR (300 MHz, CDCl3) δ 8.29 (m, 1H), 7.53 (m, 2H), 7.42 
- 7.34 (m, 3H), 7.22 (m, 2H), 7.12 (m, 2H), 6.92 (m, 2H), 3.82 (s, 3H). 
 
1-(4-trifluoromethylphenyl)-4-phenyl-1-azabuta-1,3-diene (3c). Trans-
cinnamaldehyde (1.3 ml, 10 mmol) and 4-(trifluoromethyl)aniline (1.2 ml, 10 
mmol) were dissolved in toluene and Na2SO4 was added. The reaction mixture 
was stirred at 23 °C for 2 h, filtered, and concentrated in vacuo. Recrystallization 
from Et2O resulted in a yellow powder (0.77 g, 28%, mp: 106 - 108 °C). Spectral 
data matches literature values.2 1H NMR (300 MHz, CDCl3) δ 8.24 (m, 1H), 7.64 
(m, 2H), 7.56 (m, 2H), 7.46 - 7.38 (m, 3H), 7.23 (m, 3H), 7.15 (m, 1H). 
 
                                                            
1 L2, L4: Yu, R. T.; Rovis, T. J. Am. Chem. Soc. 2006, 128, 12370-12371. L3: Appendix 2. 





1-cyclohexyl-4-phenyl-1-azabuta-1,3-diene (3d). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was added 
under Ar. Trans-cinnamaldehyde (2.5 ml, 20 mmol) and cyclohexyl amine (2.3 ml, 20 
mmol) were added and the reaction mixture was stirred at 23 °C for 24 h. The resulting 
mixture was filtered through MgSO4 and Celite and concentrated in vacuo resulting  in 
a brown oil (2.99 g, 70%). 1H NMR (300 MHz, CDCl3) δ 8.02 (m, 1H), 7.44 (m, 2H), 
7.31 (m, 3H), 6.89 (m, 2H), 3.04 (m, 1H), 1.82 - 1.15 (m, 10H). 13C NMR (75 MHz, 
CDCl3) δ 160.2, 140.9, 135.7, 128.8, 128.6, 128.4, 127.0, 69.5, 34.3, 25.4, 24.6. IR (NaCl, Thin Film) 
3027, 2928, 2852, 1636, 1449, 1166, 981, 749 cm-1. HRMS (ESI) m/z [C15H20N]
+ calcd 214.1590, found 
214.1594. 
 
1-phenethyl-4-phenyl-1-azabuta-1,3-diene (3e). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was 
added under Ar. Trans-cinnamaldehyde (1.9 ml, 15 mmol) and phenethylamine 
(1.9 ml, 15 mmol) were added and the reaction mixture was stirred at 23 °C for 24 
h. The resulting mixture was filtered through MgSO4 and Celite and concentrated 
in vacuo. Recrystallization from Et2O resulted in clear cubic crystals with a slight 
yellow hue (1.00 g, 28%, mp: 52 -53 °C). 1H NMR (300 MHz, CDCl3) δ 7.94 (m, 
1H), 7.51 - 7.22 (m, 10H), 6.92 (m, 2H), 3.81 (t, J = 7.5 Hz, 2H), 3.03 (t, J = 7.5 Hz, 2H). 13C NMR (75 
MHz, CDCl3) δ 162.9, 141.4, 139.7, 135.6, 128.9, 128.8, 128.6, 128.2, 127.9, 127.0, 126.0, 62.9, 37.3. IR 
(NaCl, Thin Film) 3028, 2943, 2826, 1634, 1453, 978, 743 cm-1. HRMS (ESI) m/z [C17H18N]
+ calcd 
236.1434, found 236.1436. 
 
1-(4-methoxybenzyl)-4-phenyl-1-azabuta-1,3-diene (3f). In a round bottom 
flask, 3 Å molecular sieves were activated by flame drying under vacuum and 
toluene was added under Ar. Trans-cinnamaldehyde (2.5 ml, 20 mmol) and 4-
methoxybenzyl amine (2.2 ml, 20 mmol) were added and the reaction mixture 
was stirred at 23 °C for 36 h. The resulting mixture was filtered through 
MgSO4 and Celite and concentrated in vacuo resulted in an amorphous pale brown powder (0.98 g, 26%). 
Spectral data matches literature.3 1H NMR (300 MHz, CDCl3) δ 8.12 (m, 1H), 7.48 (m, 2H), 7.36 (m, 
3H), 7.25 (m, 2H), 6.98 (m, 2H), 6.89 (m, 2H), 4.66 (s, 2H), 3.80 (s, 3H). 
 
 1-(3-methoxyphenyl)-4-phenyl-1-azabuta-1,3-diene (3g). 1H NMR (300 
MHz, CDCl3) δ 8.14 (m, 1H), 7.48 (m, 2H), 7.32 (m, 3H), 6.99 (m, 2H), 6.89 





3 Taubinger, A. A.; Fenske, D.; Podlech, J. Tetrahedron 2008, 64, 8659-8667. 
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1-benzyl-4-phenyl-1-azabuta-1,3-diene (3h). In a round bottom flask, 3 Å molecular sieves were 
activated by flame drying under vacuum and toluene was added under Ar. Trans-cinnamaldehyde (2.5 ml, 
20 mmol) and benzylamine (2.2 ml, 20 mmol) were added and the reaction mixture was stirred at 23 °C 
for 36 h. The resulting mixture was filtered through Celite and concentrated in vacuo resulting  in a brown 
oil (3.77 g, 85%). Spectral data matches literature.4 1H NMR (300 MHz, CDCl3) δ 8.15 (m, 1H), 7.49 (m, 
2H), 7.40 - 7.25 (m, 8H), 7.00 (m, 2H), 4.73 (s, 2H). 
 
1-benzyl-4-(2-methoxyphenyl)-1-azabuta-1,3-diene (3i). In a round bottom flask, 
3 Å molecular sieves were activated by flame drying under vacuum and toluene was 
added under Ar. O-methoxy-trans-cinnamaldehyde (3.2 g, 20 mmol) and 
benzylamine (2.2 ml, 20 mmol) were added and the reaction mixture was stirred at 
23 °C for 24 h. The resulting mixture was filtered through MgSO4 and Celite and 
concentrated in vacuo resulting  in a brown oil (3.78 g, 75%). 1H NMR (300 MHz, 
CDCl3) δ 8.18 (m, 1H), 7.55 (m, 1H), 7.42 - 7.26 (m, 7H), 7.12 - 6.90 (m, 3H), 4.74 (s, 2H), 3.88 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 164.2, 157.2, 139.2, 137.0, 130.2, 128.5, 128.4, 127.9, 127.4, 126.8, 124.4, 
120.6, 110.8, 65.1, 55.2. IR (NaCl, Thin Film) 3028, 2837, 1633, 1488, 1246, 1027, 751 cm-1. HRMS 
(ESI) m/z [C17H18NO]
+ calcd 252.1383, found 252.1387. 
 
1-benzyl-4-(4-methoxyphenyl)-1-azabuta-1,3-diene (3j). In a round bottom 
flask, 3 Å molecular sieves were activated by flame drying under vacuum and 
toluene was added under Ar. P-methoxy-trans-cinnamaldehyde (3.2 g, 20 
mmol) and benzylamine (2.2 ml, 20 mmol) were added and the reaction 
mixture was stirred at 23 °C for 24 h. The resulting mixture was filtered 
through MgSO4 and Celite and concentrated in vacuo. Recrystallization from 
Et2O resulted in off-white prisms (3.78 g, 75%, mp: 73 - 75 °C). 
1H NMR (300 MHz, CDCl3) δ 8.12 (m, 
1H), 7.44 (m, 2H), 7.40 - 7.26 (m, 5H), 6.91 (m, 4H), 4.72 (s, 2H), 3.82 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 163.5, 160.3, 141.6, 139.2, 128.6, 128.4, 128.3, 127.9, 126.8, 125.9, 114.1, 65.0, 55.1. IR 
(NaCl, Thin Film) 3018, 2929, 2837, 1573, 1425, 1207, 1033, 738 cm-1. HRMS (ESI) m/z [C17H18NO]
+ 
calcd 252.1383, found 252.1385. 
 
1-benzyl-4-(4-nitrophenyl)-1-azabuta-1,3-diene (3k). In a round bottom 
flask, 3 Å molecular sieves were activated by flame drying under vacuum and 
toluene was added under Ar. 4-nitrocinnamaldehyde (1.8 g, 10 mmol) and 
benzyl amine (1.1 ml, 10 mmol) were added and the reaction mixture was 
stirred at 23 °C for 24 h. The resulting mixture was filtered through MgSO4 and 
Celite and concentrated in vacuo. Recrystallization from Et2O resulted in pale 
yellow flakes (1.74 g, 65%, 104 - 105 °C). 1H NMR (300 MHz, CDCl3) δ 8.18 (m, 3H), 7.58 (m, 2H), 
7.38-7.27 (m, 5H), 7.04 (m, 2H), 4.75 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 162.2, 147.5, 141.8, 138.6, 
132.1, 128.5, 127.9, 127.6, 127.0, 124.0, 65.2. IR (NaCl, Thin Film) 3058, 3027, 2922, 2814, 1617, 1513, 
1345, 741 cm-1. HRMS (ESI) m/z [C16H15N2O2]
+ calcd 267.1128, found 267.1132. 
 
                                                            
4 Colby, D. A.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2008, 130, 3645-3651. 
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1-benzyl-4-(2-furyl)-1-azabuta-1,3-diene (3l). In a round bottom flask, 3 Å molecular sieves were 
activated by flame drying under vacuum and toluene was added under Ar. Trans-3-(2furyl)-acrolein (1.8 
g, 15 mmol) and benzyl amine (1.6 ml, 15 mmol) were added and the reaction mixture was stirred at 23 
°C for 24 h. The resulting mixture was filtered through MgSO4 and Celite and concentrated in vacuo 
resulting  in a brown oil (2.76 g, 87%). 1H NMR (300 MHz, CDCl3) δ 8.07 (m, 1H), 7.44 - 7.32 (m, 6H), 
6.94 - 6.74 (m, 2H), 6.46 (m, 2H), 4.72 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 162.8, 151.7, 143.6, 139.1, 
128.5, 128.4, 127.9, 126.8, 126.1, 111.8, 111.6,  65.1. IR (NaCl, Thin Film) 3062, 3028, 2842, 1633, 
1453, 1155, 963, 698 cm-1. HRMS (ESI) m/z [C14H14NO]
+ calcd 212.1070, found 212.1072. 
 
1-benzyl-6-methyl-1-azabuta-1,3,5-triene (3m). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was 
added under Ar. 2,4-hexadienal (2.2 ml, 20 mmol) and benzyl amine (2.2 ml, 20 
mmol) were added and the reaction mixture was stirred at 23 °C for 24 h. The 
resulting mixture was filtered through MgSO4 and Celite and concentrated in vacuo 
resulting  in a brown oil (3.22 g, 87%) as a 1:10 mixture of isomers. 1H NMR (300 MHz, CDCl3) δ 7.98 
(m, 1H), 7.28 (m, 5H), 6.60 (m, 1H), 6.27 (m, 2H), 5.98 (m, 1H), 4.65 (s, 2H), 1.83 (d, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 163.4, 142.2, 139.2, 136.6, 135.0, 130.7, 129.1, 128.3, 127.8, 126.8, 65.0, 
18.4. IR (NaCl, Thin Film) 3386, 3028, 2925, 1631, 1452, 1171, 1001, 698, 665 cm-1. HRMS (ESI) m/z 
[C14H16N]
+ calcd 186.1277, found 186.1278. 
 
1-benzyl-4-(n-propyl)-1-azabuta-1,3-diene (3n). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was added 
under Ar. trans-2-hexenal (2.3 ml, 20 mmol) and benzyl amine (2.2 ml, 20 mmol) were 
added and the reaction mixture was stirred at 23 °C for 24 h. The resulting mixture was 
filtered through MgSO4 and Celite and concentrated in vacuo resulting  in a brown oil 
(3.07 g, 82%). 1H NMR (300 MHz, CDCl3) δ 8.00 (m, 1H), 7.35 - 7.22 (m, 6H), 6.31 (m, 1H), 4.66 (s, 
2H), 2.23 (dd, J = 13.2, 7.2 Hz, 2H), 1.53 (dt, J = 7.5, 7.5 Hz, 2H), 0.98 (t, J = 7.5 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 163.6, 145.8, 139.3, 130.6, 128.4, 128.2, 128.1, 127.9, 126.8, 64.9, 34.6, 21.6, 13.6. IR 
(NaCl, Thin Film) 3028, 2958, 2930, 2871, 1655, 1454, 969, 698 cm-1. HRMS (ESI) m/z [C13H18N]
+ calcd 
188.1434, found 188.1431. 
 
1-benzyl-4-(i-propyl)-1-azabuta-1,3-diene (3o). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was added 
under Ar. 4-methyl-2-pentenal (1.7 ml, 15 mmol) and benzyl amine (1.6 ml, 15 mmol) 
were added and the reaction mixture was stirred at 23 °C for 24 h. The resulting 
mixture was filtered through MgSO4 and Celite and concentrated in vacuo resulting  in 
a brown oil (2.49 g, 89%). 1H NMR (300 MHz, CDCl3) δ 7.98 (m, 1H), 7.35 - 7.25 (m, 6H), 6.26 (m, 
1H), 4.65 (s, 2H), 2.50 (m, 1H), 1.09 (d, J = 6.9 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 163.8, 152.5, 
139.2, 128.4, 127.9, 127.7, 126.8, 64.9, 31.0, 21.5. IR (NaCl, Thin Film) 3029, 2961, 2869, 1652, 1454, 
973, 698cm-1. HRMS (ESI) m/z [C13H18N]
+ calcd 188.1434, found 188.1439. 
 
 (E)-ethyl 4-(benzylimino)but-2-enoate (3p). In a round bottom flask, 3 Å molecular 
sieves were activated by flame drying under vacuum and toluene was added under Ar. 
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Ethyl trans-4-oxo-2-butenoate (1.2 ml, 10 mmol) and benzyl amine (1.09 ml, 10 mmol) were added and 
the reaction mixture was stirred at 23 °C for 3 h. The resulting mixture was filtered through MgSO4 and 
Celite and concentrated in vacuo resulting  in a red oil (1.82 g, 84%). 1H NMR (400 MHz, CDCl3) δ 8.11 
(m, 1H), 7.38-7.32 (m, 3H), 7.29-7.25 (m, 2H),6.29 (d, J = 15.9 Hz, 1H), 4.76 (s, 2H), 4.25 (q, J = 7.2 Hz, 
2H), 1.31 (t, J =  7.2 Hz, 3 H). 13C NMR (100 MHz, CDCl3) δ 165.7, 161.0, 142.4, 138.2, 130.5, 128.6, 
128.0, 127.3, 65.6, 60.9, 14.1. IR (NaCl, Thin Film) 3030, 2983, 2875, 1718, 1619, 1257, 1096, 699 cm-1. 
LRMS (ESI/APCI) m/z [C13H16NO2]
+ calcd 218.1, found 218.1. 
 
 (E)-ethyl 4-(phenylimino)but-2-enoate (3q). 1H NMR (300 MHz, CDCl3) δ 8.25 (m, 
1H), 7.53-7.37 (m, 3H), 7.27 (m, 1H), 7.19 (m, 2H), 6.43 (d, J = 15.8 Hz, 1H), 4.28 (q, 
J = 7.2, 2H), 1.34 (t, J = 7.2 Hz, 3H). 
 
 (E)-ethyl 4-(butylimino)but-2-enoate (3r). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was 
added under Ar. Ethyl trans-4-oxo-2-butenoate (1.2 ml, 10 mmol) and n-butyl 
amine (0.99 ml, 10 mmol) were added and the reaction mixture was stirred at 23 °C for 3 h. The resulting 
mixture was filtered through MgSO4 and Celite and concentrated in vacuo resulting  in a red oil (1.57 g, 
86%). 1H NMR (400 MHz, CDCl3) δ 7.98 (m, 1H), 7.28 (dd, J = 15.9, 9.1 Hz, 1H), 6.23 (d, J = 15.9 Hz, 
1H), 4.24 (q, J = 7.2 Hz, 2H), 3.55 (dt, J = 7.0, 1.1 Hz, 2H), 1.63 (m, 2H), 1.34 (m, 2H), 1.30 (t, J = 7.2 
Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 165.9, 160.1, 142.6, 129.8, 61.8, 60.9, 
32.6, 20.4, 14.1, 13.8. IR (NaCl, Thin Film) 2960, 2934, 2874, 1721, 1303, 1256, 1186, 1154 cm-1. LRMS 
(ESI/APCI) m/z [C10H17NO2]
+ calcd 184.1, found 184.1. 
 
 1-benzyl-4,4'-dimethyl-1-azabuta-1,3-diene (3s). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was added 
under Ar. 3-methyl-2-butenal (1.9 ml, 20 mmol) and benzyl amine (2.2 ml, 20 mmol) were 
added and the reaction mixture was stirred at 23 °C for 3 h. The resulting mixture was filtered through 
MgSO4 and Celite and concentrated in vacuo resulting  in a brown oil (2.91 g, 83%). Spectral data 
matches literature values.5 1H NMR (300 MHz, CDCl3) δ 8.31 (m, 1H), 7.36-7.22 (m, 5), 6.08 (m, 1H), 
4.65 (s, 2H), 1.95 (s, 3H), 1.89 (s, 3H).  
 
 1-benzyl-4-methyl-4'-phenyl-1-azabuta-1,(E)-3-diene (3t). Aldehyde was prepared 
according to literature procedure.6 Tetrabutylammonium chloride (13.9 g, 50 mmol), 
sodium acetate (4.29 g, 60 mmol), and palladium acetate (0.10 g, 0.5 mmol) was added to 
100 ml round bottom flask. The reaction vessel was evacuated and filled with Ar. To this iodobenzene 
(5.6 ml, 50 mmol), N-methylpyrolidinone (50 ml), and crotonaldehyde (10.4 ml, 125 mmol) was added. 
The reaction was heated to 90 °C for 2 h, cooled to 23 °C, and poured into 200 ml sat. NaHCO3. The 
mixture was extracted with DCM 3x, dried, and concentrated in vacuo. The N-methylpyrolidinone was 
distilled off and the resulting liquid was purified using flash column chromatography 2x. (Z)-3-phenylbut-
2-enal was isolated as a clear oil (0.10 g, 2%). 1H NMR (300 MHz, CDCl3) δ 9.47 (d, J = 8.2 Hz, 1H), 
                                                            


















7.41 (m, 3H), 7.30 (m, 2H), 6.14 (dd, J = 8.2, 1.2 Hz, 1H), 2.32 (d, J = 1.3 Hz, 3H). (E)-3-phenylbut-2-
enal was isolated as a clear oil (1.34 g, 18%). 1H NMR (300 MHz, CDCl3) δ 10.18 (d, J = 7.9 Hz, 1H), 
7.55 (m, 2H), 7.42 (m, 3H), 6.40 (dd, J = 7.8, 1.1 Hz, 1H), 2.58 (d, J = 1.0 Hz, 3H). In a round bottom 
flask, 3 Å molecular sieves were activated by flame drying under vacuum and toluene was added under 
Ar. (E)-3-phenylbut-2-enal  (0.29 g, 1.97 mmol) and benzyl amine (0.21 ml, 1.97 mmol) were added and 
the reaction mixture was stirred at 23 °C for 3 h. The resulting mixture was filtered through MgSO4 and 
Celite and concentrated in vacuo resulting  in a brown oil. 1H NMR (300 MHz, CDCl3) δ 8.51 (m, 1H), 
7.52 (m, 2H), 7.43-7.16 (m, 8H), 6.68 (d, J = 9.3 Hz, 1H), 4.74 (s, 2H), 2.36 (s, 3H). 
 
 1-benzyl-(E)-2-methyl-3-phenyl-1-azabuta-1,3-diene (3u). In a round bottom flask, 3 Å 
molecular sieves were activated by flame drying under vacuum and toluene was added 
under Ar. α-methyl-trans-cinnamaldehyde (2.1 ml, 15 mmol) and benzyl amine (1.6 ml, 15 
mmol) were added and the reaction mixture was stirred at 23 °C for 3 h. The resulting 
mixture was filtered through MgSO4 and Celite and concentrated in vacuo resulting  in a gold oil (3.0 g, 
86%). 1H NMR (300 MHz, CDCl3) δ 8.10 (s, 1H), 7.42-7.24 (m, 10H), 6.85 (s, 1H), 4.78 (s, 2H), 2.21 (s, 
3H). 
 
General Procedure for Rhodium-Catalyzed [4+2] Cycloaddition.  [Rh(C2H4)2Cl]2 (5.8 mg, 
0.015 mmol) and ligand (L3 unless otherwise mentioned) (0.03 mmol) were added to an oven-dried 10 ml 
round bottom flask and the flask was fitted with an oven-dried reflux condenser in an inert atmosphere 
(Ar) glove box. Upon removal from the glove box, the reaction vessel was put under Ar and 4 ml of 
toluene was added via syringe and the resulting gold solution was stirred at 23 °C for 15 min. To this 
solution, imine (0.3 mmol) and isocyanate (0.375 mmol) in 2 ml of toluene was added via syringe. The 
reaction mixture was heated to 110 °C in an oil bath and kept at reflux for 12 h. The reaction mixture was 
cooled to 23 °C, concentrated in vacuo, and purified by flash column chromatography (typically 2:1 
Hex:CH2Cl2, followed by CH2Cl2). Evaporation of solvent afforded the analytically pure products. 
 
Characterization Data for Pyrimidinones and Pyrrolones. 
 
(R)-3-hexyl-1,4-diphenyl-3,4-dihydropyrimidine-2-one (4ac). General 
procedure yielded brown oil (56%). 90% ee by HPLC: Chiralcel IA column, 
90:10 Hex:iPrOH, 1ml/min, RTmajor = 7.68 min, RTminor = 11.08 min, 210 nm. 
[α]20D = +110.0, c = 0.0118 g/ml CHCl3. 
1H NMR (300 MHz, CDCl3) δ 7.43-
7.23 (m, 10H), 6.30 (d, J = 7.8 Hz, 1H), 5.10 (d, J = 4.5 Hz, 1H), 4.97 (dd, J 
= 7.8, 4.5 Hz, 1H), 3.74 (ddd, J = 15.6, 9.6, 6.0 Hz, 1H), 2.76 (ddd, J = 14.4, 9.3, 5.4 Hz, 1H), 1.61 (m, 
1H), 1.50 (m, 1H), 1.26 (m, 6H), 0.87 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 152.3, 142.6, 141.3, 128.9, 
128.7, 128.0, 127.9, 126.5, 126.2, 103.0, 61.6, 46.2, 31.4, 26.8, 26.5, 22.5, 14.0. Rf = 0.42 (98:2 
CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2957, 2928, 2857, 1665, 1450, 1289, 697 cm
-1. HRMS (ESI) m/z 
[C22H27N2O]





(R)-3-hexyl-1-(4-methoxyphenyl)-4-phenyl-3,4-dihydropyrimidin-2-one (4bc). General procedure 
yielded a brown syrup (49%). 89% ee by HPLC: Chiralcel ODH column, 90:10 Hex:iPrOH, 1ml/min, 
RTmajor = 8.76 min, RTminor = 20.42 min, 230 nm. [α]
20
D = +151.3, c = 0.0099 g/ml CHCl3.  
1H NMR (300 
MHz, CDCl3) δ 7.42 - 7.32 (m, 5H), 7.26 (m, 2H), 6.91 (m, 2H), 6.22 (d, J = 7.8 Hz, 1H), 5.08 (d, J = 4.5 
Hz, 1H), 4.92 (dd, J = 7.8, 4.5 Hz, 1H), 3.80 (s, 3H), 3.72 (ddd, J = 15.6, 9.6, 6.0 Hz, 1H), 2.73 (ddd, J = 
14.4, 9.3, 5.4 Hz, 1H), 1.59  (m, 1H), 1.48 (m, 1H), 1.24 (m, 6H), 0.85 (m, 3H). 13C NMR (75 MHz, 
CDCl3) δ 157.9, 152.6, 142.7, 134.3, 128.8, 128.3, 127.9, 127.6, 126.5, 114.0, 102.5, 61.6, 55.4, 46.2, 
31.4, 26.8, 26.5, 22.5, 14.0. Rf = 0.16 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 3029, 2930, 2857, 
1655, 1512, 1246, 1031, 829, 700 cm-1. HRMS (ESI) m/z [C23H29N2O2]
+ calcd 365.2224, found 365.2229. 
 
(R)-3-hexyl-4-phenyl-1-(4-(trifluoromethyl)phenyl)-3,4-
dihydropyrimidin-2-one (4cc). General procedure yielded a brown 
syrup (65%). 91% ee by HPLC: Chiralcel ODH column, 90:10 
Hex:iPrOH, 1ml/min, RTmajor = 6.40 min, RTminor = 7.11 min, 254 nm. 
[α]20D = +159.3°, c = 0.0145 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 
7.64 (m, 2H), 7.50 (m, 2H), 7.39 - 7.33 (m, 5H), 6.32 (d, J = 7.8 Hz, 1H), 
5.09 (d, J = 4.5 Hz, 1H), 5.04 (dd, J = 7.8, 4.5 Hz, 1H), 3.71 (ddd, J = 15.6, 9.6, 6.0 Hz, 1H), 2.76 (ddd, J 
= 14.4, 9.3, 5.1 Hz, 1H), 1.60 (m, 1H), 1.49 (m, 1H), 1.24 (m, 6H), 0.85 (m, 3H). 13C NMR (75 MHz, 
CDCl3) δ 151.8, 144.2, 142.1, 129.0, 128.2, 127.0, 126.5, 126.0, 125.9, 125.8, 104.4, 61.6, 46.4, 31.4, 
26.8, 26.5, 22.5, 14.0. Rf = 0.32 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2958, 2931, 2859, 1667, 
1326, 1124, 699 cm-1. HRMS (ESI) m/z [C23H26F3N2O]
+ calcd 403.1992, found 403.1991. 
 (R)-1-cyclohexyl-3-hexyl-4-phenyl-3,4-dihydropyrimidin-2-one (4dc). 
General procedure yielded a brown syrup (80%). 80% ee by HPLC: Chiralcel 
ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor = 4.24 min, RTminor = 4.64 
min, 210 nm. [α]20D = +221.0°, c = 0.0090 g/ml CHCl3.  
1H NMR (300 MHz, 
CDCl3) δ 7.35 - 7.22 (m, 5H), 6.09 (d, J = 8.1 Hz, 1H), 4.92 (d, J = 4.8 Hz, 
1H), 4.83 (dd, J = 8.1, 4.8 Hz, 1H), 4.33 (m, 1H), 3.67 (ddd, J = 15.3, 9.6, 6.0 
Hz, 1H), 2.68 (ddd, J = 14.4, 9.3, 5.1 Hz, 1H), 1.82 - 1.64 (m, 5H), 1.39 - 1.08 (m, 16H), 0.84 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ 153.1, 143.2, 128.7, 127.7, 126.4, 123.1, 101.9, 60.8, 52.6, 46.2, 32.0, 31.5, 
31.3, 27.0, 26.5, 25.9, 25.7, 25.5, 22.5, 14.0. Rf = 0.44 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2929, 
2856, 1649, 1460, 1226, 699 cm-1. HRMS (ESI) m/z [C22H33N2O]
+ calcd 341.2587, found 341.2582. 
 
(R)-3-hexyl-1-phenethyl-4-phenyl-3,4-dihydropyrimidin-2-one (4ec). 
General procedure yielded a brown syrup (69%). 94% ee by HPLC: 
Chiralcel ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor = 7.31 min, 
RTminor = 8.52 min, 254 nm. [α]
20
D = +149.6°, c = 0.0147 g/ml CHCl3.  
1H 
NMR (300 MHz, CDCl3) δ 7.36 - 7.19 (m, 10H), 5.82 (d, J = 7.8 Hz, 
1H), 4.97 (d, J = 4.5 Hz, 1H), 4.70 (dd, J = 7.8, 4.5 Hz, 1H), 3.86 (dt, J = 13.8, 7.5 Hz, 1H), 3.72 (ddd, J 
= 15.3, 9.3, 6.3 Hz, 1H), 3.58 (dt, J = 13.8, 7.5 Hz, 1H), 2.95 (t, J = 7.5 Hz, 2H), 2.66 (ddd, J = 14.4, 9.0, 
5.4 Hz, 1H), 1.54 (m, 1H), 1.45 (m, 1H), 1.26 (m, 6H), 0.87 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 
153.0, 142.9, 138.8, 129.0, 128.7, 128.4, 127.7, 127.6, 126.4, 126.2, 101.6, 61.3, 49.3, 45.7, 35.5, 31.5, 
26.9, 26.5, 22.5, 14.0. Rf = 0.50 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 3028, 2929, 2858, 1653, 
1455, 1255, 699 cm-1. HRMS (ESI) m/z [C24H31N2O]
+ calcd 363.2431, found 363.2431. 
(R)-3-hexyl-1-(4-methoxybenzyl)-4-phenyl-3,4-dihydropyrimidin-
2-one (4fc). General procedure yielded a brown oil (75%). 94% ee by 
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HPLC: Chiralcel ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  10.37 min, RTminor = 9.20 min, 230 
nm. [α]20D = +171.3, c = 0.0150 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.35 - 7.21 (m, 7H), 6.74 (m, 
2H), 5.98 (d, J = 7.8 Hz, 1H), 4.98 (d, J = 4.5 Hz, 1H), 4.80 (dd, J = 7.8, 4.5 Hz, 1H), 4.69 (d, J = 15.0 
Hz, 1H), 4.59 (d, J = 15.0 Hz, 1H), 3.80 (s, 3H), 3.74 (ddd, J = 15.3, 9.3, 6.3 Hz, 1H), 2.68 (ddd, J = 14.3, 
9.0, 5.3 Hz, 1H), 1.55 (m, 1H), 1.47 (m, 1H), 1.24 (m, 6H), 0.86 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 
158.8, 153.4, 142.8, 130.3, 128.9, 128.7, 127.8, 126.9, 126.4, 113.9, 102.4, 61.3, 55.2, 49.8, 45.9, 31.5, 
26.9, 26.5, 22.5, 14.0. Rf = 0.48 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2955, 2929, 2858, 1652, 
1248, 1035, 700 cm-1. HRMS (ESI) m/z [C24H31N2O2]
+ calcd 379.2380, found 379.2360. 
 
 (R)-3-hexyl-1-(3-methoxybenzyl)-4-phenyl-3,4-dihydropyrimidin-2-one 
(4gc). General procedure yielded a brown oil (77%). 93% ee by HPLC: 
Chiralcel IC column, 80:20 Hex:iPrOH, 1ml/min, RTmajor =  13.63 min, RTminor 
= 14.57 min, 230 nm. [α]20D = +180.2, c = 0.0101 g/ml CHCl3.  
1H NMR (300 
MHz, CDCl3) δ 7.37-7.23 (m, 6H), 6.91-6.80 (m, 3H), 5.97 (d, J = 7.9 Hz, 1H), 5.02 (d, J = 4.6 Hz, 1H), 
4.82 (dd, J = 7.9, 4.6 Hz, 1H), 4.77 (d, J = 15.4 Hz, 1H), 4.63 (d, J = 15.4 Hz, 1H), 3.79 (m, 1H), 3.78 (s, 
3H), 2.70 (ddd, J = 14.1, 9.1, 5.4 Hz, 1H), 1.57 (m, 1H), 1.49 (m, 1H), 1.26 (m, 6H), 0.87 (m, 3H). 13C 
NMR (75 MHz, CDCl3) δ 159.7, 153.3, 142.7, 139.8, 129.5, 128.7, 127.8, 127.0, 126.3, 119.6, 112.9, 
112.6, 102.4, 61.2, 55.0, 50.1, 45.8, 31.4, 26.9, 26.4, 22.4, 13.9. Rf = 0.32 (98:2 CH2Cl2:EtOAc). IR 
(NaCl, Thin Film) 3028, 2929, 2857, 1653, 1463, 1261, 1051, 757, 699 cm-1. HRMS (ESI) m/z 
[C24H31N2O2]
+ calcd 379.2380, found 379.2370. 
 
(R)-1-benzyl-3-hexyl-4-phenyl-3,4-dihydropyrimidin-2-one (4hc). 
General procedure yielded a brown oil (67%). 93% ee by HPLC: Chiralcel 
ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  8.12 min, RTminor = 
7.56 min, 210 nm. [α]20D = +38.4, c = 0.0076 g/ml CHCl3.  
1H NMR (300 
MHz, CDCl3) δ 7.38 - 7.24 (m, 10H), 5.99 (d, J = 7.8 Hz, 1H), 5.02 (d, J = 
4.5 Hz, 1H), 4.82 (dd, J = 7.8, 4.5 Hz, 1H), 4.82 (d, J = 15.3 Hz, 1H), 4.66 (d, J = 15.3 Hz, 1H), 3.77 
(ddd, J = 15.6, 9.3, 6.3 Hz, 1H), 2.69 (ddd, J = 14.1, 9.0, 5.1 Hz, 1H), 1.56 (m, 1H), 1.48 (m, 1H), 1.26 
(m, 6 H), 0.87 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 153.4, 142.7, 138.2, 128.7, 128.5, 127.8, 127.5, 
127.2, 127.0, 126.4, 102.4, 61.3, 50.3, 45.9, 31.5, 26.9, 26.5, 22.5, 14.0. Rf = 0.33 (98:2 CH2Cl2:EtOAc). 
IR (NaCl, Thin Film) 3030, 2929, 2858, 1655, 1453, 1253, 701 cm-1. HRMS (ESI) m/z [C23H29N2O]
+ 
calcd 349.2274, found 349.2277. 
 
(R)-1-benzyl-3-hexyl-4-(2-methoxyphenyl)-3,4-dihydropyrimidin-2-one 
(4ic). General procedure yielded a brown oil (67%). 94% ee by HPLC: 
Chiralcel ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  9.75 min, 
RTminor = 7.15 min, 230 nm. [α]
20
D = +219.7, c = 0.0081 g/ml CHCl3.  
1H 
NMR (300 MHz, CDCl3) δ 7.35 - 7.20 (m, 7H), 6.97 - 6.86 (m, 2 H), 5.95 
(d, J = 7.8 Hz, 1H), 5.46 (d, J = 4.8 Hz, 1H), 4.96 (dd, J = 7.8, 4.8 Hz, 1H), 4.78 (d, J = 15.3 Hz, 1H), 
4.63 (d, J = 15.3 Hz, 1H), 3.89 (ddd, J = 15.3, 8.7, 6.9 Hz, 1H), 3.82 (s, 3H), 2.62 (ddd, J = 14.1, 8.4, 5.7 
Hz, 1H), 1.66 - 1.49 (m, 2H), 1.28 (m, 6H), 0.88 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 155.8, 154.2, 
138.4, 130.3, 128.5, 128.4,  127.4, 127.3, 127.1, 126.8, 120.9, 110.3, 101.8, 55.2, 54.7, 50.2, 46.0, 31.5, 
27.3, 26.4, 22.5, 14.0. Rf = 0.32 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2954, 2929, 2857, 1654, 
1464, 1239, 1029, 704 cm-1. HRMS (ESI) m/z [C24H31N2O2]





(4jc). General procedure yielded a gold oil (69%). 92% ee by HPLC: 
Chiralcel IA column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  10.55 min, 
RTminor = 9.7 min, 210 nm. [α]
20
D = +177.8, c = 0.0086 g/ml CHCl3.  
1H 
NMR (300 MHz, CDCl3) δ 7.35 - 7.20 (m, 5H), 7.16 (m, 2H), 6.85 (m, 2H), 
5.98 (d, J = 7.8 Hz, 1H), 4.95 (d, J = 4.5 Hz, 1H), 4.78 (dd, J = 7.8, 4.5 Hz, 1H), 4.75 (d, J = 15.3 Hz, 
1H), 4.65 (d, J = 15.3 Hz, 1H), 3.80 (s, 3H), 3.71 (ddd, J = 15.3, 9.3, 6.3 Hz, 1H), 2.69 (ddd, J = 14.1, 
9.0, 5.1 Hz, 1H), 1.55 (m, 1H), 1.46 (m, 1H), 1.24 (m, 6H), 0.86 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 
159.2, 153.3, 138.3, 134.9, 128.6, 127.7, 127.5, 127.3, 126.8, 114.0, 102.7, 60.7, 55.2, 50.3, 45.7, 31.5, 
26.9, 26.5, 22.6, 14.0. Rf = 0.35 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2929, 2857, 1653, 1510, 
1249, 1034, 832, 703 cm-1. HRMS (ESI) m/z [C24H31N2O2]
+ calcd 379.2380, found 379.2376. 
 
(R)-1-benzyl-3-hexyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-2-one 
(4kc). General procedure yielded a brown syrup (36%). 95% ee by HPLC: 
Chiralcel IA column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  16.76 min, 
RTminor = 19.91 min, 210 nm. [α]
20
D = +227.3, c = 0.0077 g/ml CHCl3.  
1H 
NMR (300 MHz, CDCl3) 8.18 (m, 2H), 7.39 - 7.28 (m, 7H), 6.04 (d, J = 7.8 
Hz, 1H), 5.12 (d, J = 4.8 Hz, 1H), 4.80 (dd, J = 7.8, 4.8 Hz, 1H), 4.78 (d, J = 15.0 Hz, 1H), 4.63 (d, J = 
15.0 Hz, 1H), 3.80 (ddd, J = 15.3, 9.3, 6.3 Hz, 1H), 2.62 (ddd, J = 14.4, 9.0, 5.4 Hz, 1H), 1.52 (m, 2H), 
1.25 (m, 6H), 0.86 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 153.2, 149.9, 147.5, 137.9, 128.7, 128.3, 127.6, 
127.1, 124.2, 101.0, 60.8, 50.5, 46.4, 31.5, 27.0, 26.4, 22.5, 14.0. Rf = 0.44 (98:2 CH2Cl2:EtOAc). IR 
(NaCl, Thin Film) 2930, 2858, 1654, 1522, 1348, 700 cm-1. HRMS (ESI) m/z [C23H28N3O3]
+ calcd 
394.2125, found 394.2130. 
 
(R)-1-benzyl-4-(furan-2-yl)-3-hexyl-3,4-dihydropyrimidin-2-one (4lc). 
General procedure yielded a brown syrup (82%). 94% ee by HPLC: 
Chiralcel ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  8.86 min, 
RTminor = 8.00 min, 210 nm. [α]
20
D = +138.7, c = 0.0140 g/ml CHCl3.  
1H 
NMR (300 MHz, CDCl3) 7.36 - 7.22 (m, 6H), 6.32 (dd, J = 3.0, 1.8 Hz, 
1H), 6.18 (d, 3.0 Hz, 1H), 6.08 (d, 7.8 Hz, 1H), 5.05 (d, J = 4.8 Hz, 1H), 4.83 (dd, J = 7.8, 4.8 Hz, 1H), 
4.79 (d, J = 15.3 Hz, 1H), 4.63 (d, J = 15.3 Hz, 1H), 3.72 (ddd, J = 15.0, 9.3, 6.0 Hz, 1H), 2.98 (ddd, J = 
14.1, 9.0, 5.1 Hz, 1H), 1.59 (m, 1H), 1.40 (m, 1H), 1.28 (m, 6H), 0.88 (m, 3H). 13C NMR (75 MHz, 
CDCl3) δ 154.1, 153.2, 142.2, 138.1, 129.1, 128.4, 127.3, 127.1, 110.2, 106.8, 98.9, 54.1, 50.1, 46.1, 31.5, 
27.1, 26.4, 22.5, 14.0. Rf = 0.46 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2957, 2929, 2858, 1654, 
1497, 1254, 737 cm-1. HRMS (ESI) m/z [C21H27N2O2]
+ calcd 339.2067, found 339.2075. 
 
(S,E)-1-benzyl-3-hexyl-4-(prop-1-en-1-yl)-3,4-dihydropyrimidin-2-one 
(4mc). General procedure yielded yellow oil (60%) as a 1:10 mixture of 
cis:trans isomers. 89% ee by HPLC: Chiralcel IA column, 90:10 
Hex:iPrOH, 1ml/min, RTmajor =  6.79 min, RTminor = 6.53 min, 230 nm. 
[α]20D = +121.6, c = 0.0124 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 
7.34 - 7.23 (m, 5H), 5.92 (d, J = 7.8 Hz, 1H), 5.59 - 5.33 (m, 2H), 4.70 (d, J 
= 15.3 Hz, 1H), 4.65 (m, 1H), 4.57 (d, J = 15.3 Hz, 1H), 4.30 (dd, J = 7.8, 4.8 Hz, 1H), 3.72 (ddd, J = 
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15.0, 7.8, 7.2 Hz, 1H), 2.90 (ddd, J = 14.1, 8.1, 6.0 Hz, 1H), 1.69 (d, J = 6.0 Hz, 3H), 1.56 (m, 2H), 1.29 
(m, 6H), 0.88 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 153.5, 138.4, 130.8, 128.4, 127.8, 127.3, 127.1, 
126.4, 101.2, 59.1, 50.0, 45.3, 31.5, 27.3, 26.5, 22.6, 17.4, 14.0. Rf = 0.31 (98:2 CH2Cl2:EtOAc). IR 
(NaCl, Thin Film) 3029, 2929, 2857, 1653, 1456, 1253, 964, 703 cm-1. HRMS (ESI) m/z [C20H29N2O]
+ 
calcd 313.2274, found 313.2277. 
 
 (S)-1-benzyl-3-hexyl-4-propyl-3,4-dihydropyrimidin-2-one (4nc).  
General procedure yielded gold syrup (38%). 77% ee by HPLC: Chiralcel 
ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  5.75 min, RTminor = 
5.16 min, 230 nm. [α]20D = +27.0, c = 0.0117 g/ml CHCl3.  
1H NMR (300 
MHz, CDCl3) δ 7.33 - 7.23 (m, 5H), 5.95 (d, J = 7.8 Hz, 1H), 4.74 (m, 1H), 4.71 (d, J = 15.3 Hz, 1H), 
4.53 (d, J = 15.3 Hz, 1H), 3.93 (m, 1H), 3.78 (ddd, J = 14.4, 8.7, 6.6 Hz, 1H), 2.88 (ddd, J = 14.4, 8.7, 5.7 
Hz, 1H), 1.58 (m, 2H), 1.30 (m, 10H), 0.89 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 154.1, 138.4, 128.4, 
127.4, 127.1, 101.7, 56.2, 50.0, 45.8, 37.1, 31.6, 27.8, 26.5, 22.6, 17.0, 14.0. Rf = 0.42 (98:2 
CH2Cl2:EtOAc). IR (NaCl, Thin Film) 3065, 3032, 2930, 2859, 1653, 1454, 1372, 1259, 700 cm
-1. HRMS 
(ESI) m/z [C20H31N2O]
+ calcd 315.2431, found 315.2431. 
 
(S)-1-benzyl-3-hexyl-4-isopropyl-3,4-dihydropyrimidin-2-one (4oc).  
General procedure yielded gold syrup (53%). 83% ee by HPLC: Chiralcel 
ODH column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  6.19 min, RTminor = 
5.43 min, 210 nm. [α]20D = +59.0, c = 0.0116 g/ml CHCl3.  
1H NMR (300 
MHz, CDCl3) δ 7.33 - 7.23 (m, 5H), 6.02 (d, J = 8.1 Hz, 1H), 4.74 (d, J = 
15.3 Hz, 1H), 4.64 (dd, J = 8.1, 4.5 Hz, 1H), 4.48 (d, J = 15.3 Hz, 1H), 3.85 (dd, J = 4.5, 4.2 Hz, 1H), 3.77 
(ddd, J = 15.3, 9.3, 6.3 Hz, 1H), 2.91 (ddd, J = 14.4, 9.0, 5.4 Hz, 1H), 1.97 (dd, J = 6.6, 4.2 Hz, 1H), 1.59 
(m, 2H), 1.30 (m, 6H), 0.89 (m, 3H), 0.83  (m, 6H). 13C NMR (75 MHz, CDCl3) δ 154.2, 138.2, 129.5, 
128.4, 127.6, 127.1, 97.5, 62.0, 50.0, 46.3, 31.6, 31.4, 27.7, 26.6, 22.6, 17.8, 15.2, 14.0. Rf = 0.43 (98:2 
CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2959, 2929, 2871, 1652, 1455, 1257, 702 cm
-1. HRMS (ESI) m/z 
[C20H31N2O]
+ calcd 315.2431, found 315.2421. 
(R)-1-benzyl-3-(pent-4-en-1-yl)-4-phenyl-3,4-dihydropyrimidin-2-one 
(4hb).  General procedure yielded gold syrup (53%). 91% ee by HPLC: 
Chiralcel IC column, 95:5 Hex:iPrOH, 1ml/min, RTmajor =  20.89 min, RTminor 
= 18.37 min, 210 nm. [α]20D = +120.4, c = 0.0098 g/ml CHCl3.  
1H NMR (300 
MHz, CDCl3) δ 7.38 - 7.23 (m, 10H), 5.99 (d, J = 7.8 Hz, 1H), 5.78 (ddt, J = 
16.8, 10.2, 6.6, 1H), 5.02 - 4.92 (m, 3H), 4.82 (dd, J = 7.8, 4.5 Hz, 1H), 4.78 (d, J = 15.3 Hz, 1H), 4.65 (d, 
J = 15.3 Hz, 1H), 3.74 (ddd, J = 15.3, 9.3, 6.3 Hz, 1H), 2.74 (ddd, J = 14.4, 9.0, 5.4 Hz, 1H), 2.03 (dt, J = 
7.2, 6.6 Hz, 2H), 1.72 - 1.56 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 153.4, 142.7, 138.2, 138.0, 128.8, 
128.6, 127.9, 127.5, 127.3, 127.1, 126.4, 114.8, 102.5, 61.6, 50.3, 45.6, 31.0, 26.2. Rf = 0.24 (4:1 
Hex:EtOAc). IR (NaCl, Thin Film) 3064, 3030, 2930, 1653, 1452, 1246, 913, 700 cm-1. HRMS (ESI) m/z 
[C22H25N2O]
+ calcd 333.1961, found 333.1965. 
 
 (R)-1,3-dibenzyl-4-phenyl-3,4-dihydropyrimidin-2-one (4hd).  General 
procedure yielded gold syrup (65%). 94% ee by HPLC: Chiralcel ODH column, 
90:10 Hex:iPrOH, 1ml/min, RTmajor =  10.53 min, RTminor = 7.97 min, 230 nm. 
[α]20D = +202.5, c = 0.0100 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.43 - 
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7.23 (m, 15H), 6.03 (d, J = 7.8 Hz, 1H), 5.48 (d, J = 15.3 Hz, 1H), 4.89 (d, J = 15.3 Hz, 1H), 4.88 (d, J = 
4.5 Hz, 1H), 4.79 (dd, J = 7.8, 4.5 Hz, 1H), 4.71 (d, J = 15.3 Hz, 1H), 3.56  (d, J = 15.3 Hz, 1H). 13C 
NMR (75 MHz, CDCl3) δ 153.7, 141.8, 138.1, 137.1, 128.8, 128.6, 128.5, 128.0, 127.5, 127.4, 127.3, 
126.9, 126.7, 60.0, 50.6, 47.8. Rf = 0.42 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 3063, 3029, 2926, 
1652, 1449, 1246, 698 cm-1. HRMS (ESI) m/z [C24H23N2O]
+ calcd 355.1805, found 355.1808. 
[Rh(C2H4)2Cl]2 (17.5 mg, 0.045 mmol) and L3 (50.9 mg, 0.09 mmol) were added to an oven-dried 50 ml 
round bottom flask and the flask was fitted with an oven-dried reflux condenser in an inert atmosphere 
(Ar) glove box. Upon removal from the glove box, the reaction vessel was put under Ar and 20 ml of 
toluene was added via syringe and the resulting gold solution was stirred at 23 °C for 15 min. To this 
solution, imine 1d (1.0 g, 4.5 mmol) and isocyanate 2c (0.75 g, 5.6 mmol) in 15 ml of toluene was added 
via syringe. The reaction mixture was heated to 110 °C in an oil bath and kept at reflux for 12 h. The 
reaction mixture was cooled to 23 °C, concentrated in vacuo, and purified by flash column 
chromatography (2:1 Hex:CH2Cl2, followed by CH2Cl2). Evaporation of solvent afforded 1.13g (71%, 
94% ee) of 3gc. 
 
 (R)-1-benzyl-3-(4-methoxybenzyl)-4-phenyl-3,4-dihydropyrimidin-2-one 
(4he).  General procedure yielded gold syrup (75%). 93% ee by HPLC: Chiralcel 
ODH column, 90:10 Hex:iPrOH, 1 ml/min, RTmajor =  14.91 min, RTminor = 11.61 
min, 210 nm. [α]20D = +182.6, c = 0.0113 g/ml CHCl3.  
1H NMR (300 MHz, 
CDCl3) δ 7.42 - 6.88 (m, 12H), 6.89 (m, 2H), 6.00 (d, J = 7.8 Hz, 1H), 5.41 (d, J = 
15.0 Hz, 1H), 4.88 (d, J = 15.3 Hz, 1H), 4.88 (d, J = 4.5 Hz, 1H), 4.77 (dd, J = 7.8, 
4.5 Hz, 1H), 4.70 (d, J = 15.3 Hz, 1H), 3.82 (s, 3H), 3.49 (d, J = 15.0 Hz). 13C 
NMR (75 MHz, CDCl3) δ 158.8, 153.6, 141.9, 138.1, 129.4, 129.0, 128.8, 128.6, 
127.9, 127.5, 127.3, 126.8, 126.6, 113.8, 102.7, 59.7, 55.2, 50.6, 47.1. Rf = 0.42 (98:2 CH2Cl2:EtOAc). IR 
(NaCl, Thin Film) 3028, 2933, 1650, 1511, 1370, 1246, 700 cm-1. HRMS (ESI) m/z [C25H25N2O2]
+ calcd 
385.1911, found 385.1892. 
 
(R)-1-benzyl-3,4-diphenyl-3,4-dihydropyrimidin-2-one (4ha).  General 
procedure yielded brown syrup (42%). 84% ee by HPLC: Chiralcel IA column, 
90:10 Hex:iPrOH, 1 ml/min, RTmajor =  13.74 min, RTminor = 15.11 min, 230 nm. 
[α]20D = +246.5, c = 0.0123 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.39 - 
7.07 (m, 15H), 6.17 (d, J = 7.8 Hz, 1H), 5.29 (d, J = 4.8 Hz, 1H), 5.06 (dd, J = 7.8, 
4.8 Hz, 1H), 4.84 (d, J = 15.0 Hz, 1H), 4.74 (d, J = 15.0 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 153.0, 
142.1, 142.0, 137.8, 128.8, 128.6, 127.9, 127.8, 127.6, 127.5, 127.3, 126.7, 126.5, 64.8, 50.4. Rf = 0.50 
(98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 3062, 3030, 1656, 1416, 1248, 697 cm
-1. HRMS (ESI) m/z 
[C23H21N2O]
+ calcd 341.1648, found 341.1656. 
 
 
 (R)-1-benzyl-3-cyclohexyl-4-phenyl-3,4-dihydropyrimidin-2-one (4hf). General 
procedure yielded brown syrup (4%). 81% ee by HPLC: Chiralcel ODH column, 90:10 
Hex:iPrOH, 1 ml/min, RTmajor =  11.37 min, RTminor = 7.69 min, 210 nm. General 
procedure using L8 as ligand yielded brown syrup (58%). 18% ee by HPLC: Chiralcel 
ODH column, 90:10 Hex:iPrOH, 1 ml/min, RTmajor =  10.24 min, RTminor = 7.028 min, 210 nm. [α]
20
D = 
+28.5, c = 0.0093 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.36-7.21 (m, 10H), 5.95 (d, J = 7.3 Hz, 
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1H), 4.97 (d, J = 5.5 Hz, 1H), 4.92 (dd, J = 7.3, 5.5 Hz, 1H), 4.79 (d, J = 15.2 Hz, 1H), 4.64 (d, J = 15.2 
Hz, 1H), 4.08 (m, 1H), 1.78-1.52 (m, 6H), 1.36-1.13 (m, 2H), 1.06-0.89 (m, 2H). 13C NMR (75 MHz, 
CDCl3) δ 153.8, 145.1, 138.3, 128.6, 128.5, 127.6, 127.4, 127.2, 126.8, 125.7, 103.7, 57.5, 56.8, 50.5, 
31.8, 30.4, 26.2, 26.0, 25.5. Rf = 0.42 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 3029, 2931, 2855, 
1645, 1450, 1270, 1120, 698 cm-1. LRMS (ESI) m/z [C23H26N2O]
+ calcd 346.2, found 347.3. 
 
 (R)-3-(4-bromophenyl)-1,4-diphenyl-3,4-dihydropyrimidin-2-one (4ag). 
General procedure yielded brown solid (37%). 81% ee by HPLC: Chiralcel IA 
column, 90:10 Hex:iPrOH, 1ml/min, RTmajor =  11.44 min, RTminor = 20.74 min, 
210 nm. [α]20D = +161.8, c = 0.0126 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 
7.42 - 6.97 (m, 12H), 6.98 (m, 2H), 6.46 (d, J = 7.8 Hz, 1H), 5.34 (d, J = 4.8 Hz, 
1H), 5.20 (dd, J = 7.8, 4.8 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 151.7, 141.4, 
140.8, 140.6, 131.9, 129.5, 129.4, 128.9, 128.7, 128.5, 128.4, 128.3, 126.8, 126.7, 126.2, 120.3, 104.1, 
65.0. Rf = 0.40 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 3061, 3029, 2924, 1672, 1489, 1264, 697 cm
-
1. HRMS (ESI) m/z [C22H18BrN2O]
+ calcd 405.0597, found 405.0594. Slow crystallization from CH2Cl2 
layered with heptanes yielded clear X-ray quality crystals (<99% ee by HPLC: Chiralcel IA column, 
90:10 Hex:iPrOH, 1ml/min, RTmajor = 11.70 min). 
 
(R)-1-benzyl-3-(4-bromophenyl)-4-phenyl-3,4-dihydropyrimidin-2-one 
(4hg). General procedure yielded brown syrup (58%). ee not determined. [α]20D 
= +174.3, c = 0.0103 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.39-7.32 
(m, 6H), 7.32-7.26 (m, 4H), 7.17-7.14 (m, 2), 6.96 (m, 2H), 6.17 (d, J = 7.8 Hz, 
1H), 5.25 (d, J = 4.8 Hz, 1H), 5.05 (dd, J = 7.8, 4.8 Hz, 1H), 4.81 (d, J = 15.0 
Hz, 1H), 4.73 (d, J = 15.0 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 152.7, 141.6, 141.0 137.6, 131.9, 129.3 
128.8, 128.6, 128.1, 127.9, 127.6, 127.2, 126.7, 120.0, 103.6, 64.8, 50.5. Rf = 0.43 (98:2 CH2Cl2:EtOAc). 
IR (NaCl, Thin Film) 3063, 3030, 2929, 1654, 1491, 1249, 1100, 1029, 823, 699 cm-1. HRMS (ESI) m/z 
[C23H20BrN2O]
+ calcd 419.0750, found 419.0750 and 421.0738. 
 
 1-benzyl-3-hexyl-4,4-dimethyl-3,4-dihydropyrimidin-2-one (4sc). General procedure 
using L8 as ligand yielded brown syrup (25%). 1H NMR (400 MHz, CDCl3) δ 7.34-7.30 
(m, 3H), 7.27-7.21 (m, 2H), 5.87 (d, J = 7.9 Hz, 1H), 4.65 (s, 2H), 4.57 (d, J = 7.9 Hz, 
1H), 3.27 (m, 2H), 1.60 (m, 2H), 1.32 (s, 6H), 1.31 (m, 6H),  0.89 (m, 3H). 13C NMR (100 
MHz, CDCl3) δ 153.9, 138.5, 128.5, 127.4, 127.1, 125.7, 108.7, 57.3, 50.3, 43.1, 31.6, 30.7, 29.1, 27.0, 
22.7, 14.0. Rf = 0.43 (98:2 CH2Cl2:EtOAc). IR (NaCl, Thin Film) 2958, 2929, 2857, 1685, 1649, 1398, 
1362, 723 cm-1. HRMS (ESI) m/z [C19H29N2O]




(4fe).  General procedure yielded gold syrup (78%). 92% ee by HPLC: 
Chiralcel IC column, 80:20 Hex:iPrOH, 1 ml/min, RTmajor =  32.25 min, 
RTminor = 22.60 min, 230 nm. [α]
20
D = +139.5, c = 0.0124 g/ml CHCl3.  
1H 
NMR (300 MHz, CDCl3) δ 7.37 - 7.17 (m, 9H), 6.92 - 6.86 (m, 4H), 5.99 (d, 
J = 7.8 Hz, 1H), 5.38 (d, J = 15.0 Hz, 1H), 4.83 (d, J = 4.5 Hz, 1H), 4.79 (d, 
242 
 
J = 14.7 Hz, 1H), 4.74 (dd, J = 7.8, 4.5 Hz, 1H), 4.62 (d, J = 15.0 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.46 
(d, J = 15.0 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 158.9, 158.8, 153.7, 142.0, 130.2, 129.4, 129.1, 129.0, 
128.8, 127.9, 126.8, 126.7, 114.0, 113.8, 102.7, 59.7, 55.2, 50.1, 47.1. Rf = 0.27 (98:2 CH2Cl2:EtOAc). IR 
(NaCl, Thin Film) 3029, 3002, 2933, 2836, 1651, 1512, 1247, 1034, 828, 665 cm-1. HRMS (ESI) m/z 
[C26H27N2O3]
+ calcd 415.2016, found 415.2018. 
(R)-1-benzyl-5-ethoxy-pyrrol-2-one (19p).7 [Rh(C2H4)2Cl]2 (5.8 mg, 0.015 mmol) and 
ligand L3 (17.0 mg, 0.03 mmol) were added to an oven-dried 10 ml round bottom flask and 
the flask was fitted with an oven-dried reflux condenser in an inert atmosphere (Ar) glove 
box. Upon removal from the glove box, the reaction vessel was put under Ar and 4 ml of 
toluene was added via syringe and the resulting gold solution was stirred at 23 °C for 15 min. 
To this solution, (E)-ethyl 4-(benzylimino)but-2-enoate 3p (69.3 mg, 0.32 mmol) in 2 ml of toluene was 
added via syringe. The reaction mixture was heated to 110 °C in an oil bath and kept at reflux for 12 h. 
The reaction mixture was cooled to 23 °C, concentrated in vacuo, absorbed onto Celite, and purified by 
flash column chromatography (2:1 Hex:EtOAc). Evaporation of solvent afforded the 56.9 mg (82%) of 
(R)-1-benzyl-5-ethoxy-pyrrol-2-one 19p as a brown oil. 20% ee by HPLC: Chiralcel IC column, 80:20 
Hex:iPrOH, 1 ml/min, RTmajor =  14.23 min, RTminor = 15.86 min, 210 nm. [α]
20
D = -38.9, c = 0.0099 g/ml 
CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.36-7.24 (m, 5H), 6.88 (dd, J = 6.0, 1.6 Hz, 1H), 6.26 (dd, J = 
6.1, 0.8 Hz, 1H), 5.27 (bs, 1H), 4.92 (d, J = 14.8 Hz, 1H), 4.16 (d, J = 14.8 Hz,  1H), 3.28 (q, J = 7.0 Hz, 
2H), 1.12 (t, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 169.2, 144.1, 137.1, 129.8, 128.6, 128.4, 
127.5, 87.2, 59.2, 43.1, 15.2. Rf = 0.21 (2:1 Hex:EtOAc). IR (NaCl, Thin Film) 2977, 2928, 1704, 1411, 
1234, 1094, 703 cm-1. LRMS (ESI/APCI) m/z [C13H16NO2]
+ calcd 218.1, found 218.1. 
 
(R)-1-butyl-5-ethoxy-pyrrol-2-one (19r). [Rh(C2H4)2Cl]2 (5.8 mg, 0.015 mmol) and ligand 
L3 (17.0 mg, 0.03 mmol) were added to an oven-dried 10 ml round bottom flask and the flask 
was fitted with an oven-dried reflux condenser in an inert atmosphere (Ar) glove box. Upon 
removal from the glove box, the reaction vessel was put under Ar and 4 ml of toluene was 
added via syringe and the resulting gold solution was stirred at 23 °C for 15 min. To this solution, (E)-
ethyl 4-(butylimino)but-2-enoate 3r (55.5 mg, 0.30 mmol) in 2 ml of toluene was added via syringe. The 
reaction mixture was heated to 110 °C in an oil bath and kept at reflux for 12 h. The reaction mixture was 
cooled to 23 °C, concentrated in vacuo, absorbed onto Celite, and purified by flash column 
chromatography (2:1 Hex:EtOAc). Evaporation of solvent afforded the 33.1 mg (60%) of (R)-1-butyl-5-
ethoxy-pyrrol-2-one 19r as a brown oil. 9% ee by HPLC: Chiralcel IC column, 90:10 Hex:iPrOH, 1 
ml/min, RTmajor =  19.59 min, RTminor = 23.14 min, 210 nm. 
1H NMR (300 MHz, CDCl3) δ 6.88 (dd, J = 
6.0, 1.6 Hz, 1H), 6.21 (d, J = 8.0 Hz, 1H), 5.42 (bs, 1H), 3.57 (ddd, J = 14.8, 7.7, 7.7 Hz, 1H), 3.29 (m, 
2H), 3.10 (ddd, J = 14.1, 7.7, 6.7 Hz, 1H), 1.54 (m, 2H), 1.32 (m, 2H), 1.17 (t, J = 7.0 Hz, 3H), 0.92 (t, J 
= 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 169.5, 143.6, 130.1, 87.7, 58.7, 39.2, 30.5, 20.1, 15.2, 13.7. 
Rf = 0.26 (2:1 Hex:EtOAc). IR (NaCl, Thin Film) 2961, 2932, 2875, 1701, 1414, 1102, 704 cm
-1. LRMS 
(ESI/APCI) m/z [C10H17NO2]
+ calcd 184.1, found 184.1. 
 
Derivitization of Pyrimidinones. 
 
                                                            
7 Stereochemistry was arbitrarily assigned based on optical rotation of a similar compound: Cuiper, A. D.; Kellogg, 






 (R)-1,3-dibenzyl-4-phenyltetrahydropyrimidin-2-one (20hb). In a 10 ml round bottom 
flask, dihydropyrimidinone 4hb (471.3 mg, 1.33 mmol) was dissolved in MeOH and 10% 
Pd/C (25 mg) was added. The reaction flask was evacuated and refilled with H2. After 
stirring at 23 °C for 12 h, the reaction was filtered through Celite, concentrated in vacuo, 
and purified by flash column chromatography to yield 405.6 mg of 20hb (86%) as a clear amorphous 
solid. [α]20D = +2.6, c = 0.0110 g/ml CHCl3.  
1H NMR (400 MHz, CDCl3) δ 7.35-7.24 (m, 13 H), 7.16-
7.13 (m, 2H), 5.59 (d, J = 15.3 Hz, 1H), 4.71 (d, J = 14.9 Hz, 1H), 4.97 (d, J = 14.9 Hz, 1H), 4.47 (m, 
1H), 3.61 (d, J = 15.3 Hz, 1H), 3.03 (m, 1H), 2.20 (m, 1H), 1.82 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 
156.4, 140.9, 138.5, 138.2, 128.6, 128.4, 127.8, 127.7, 127.4, 127.1, 127.0, 126.2, 57.3, 51.6, 49.2, 41.0, 
29.5. Rf = 0.17 (4:1 Hex:EtOAc). IR (NaCl, Thin Film) 3062, 3029, 2928, 1635, 1498, 1449, 1218, 805, 
702 cm-1. HRMS (ESI) m/z [C24H25N2O]
+ calcd 357.1961, found 357.1968. 
 
(R)-1,3-bis(4-methoxybenzyl)-4-phenyltetrahydropyrimidin-2-one (20fe).  
In a 10 ml round bottom flask, dihydropyrimidinone 4fe (127 mg, 0.31 
mmol) was dissolved in MeOH and 10% Pd/C (4 mg) was added. The 
reaction flask was evacuated and refilled with H2. After stirring at 23 °C for 
12 h, the reaction was filtered through Celite, concentrated in vacuo, and 
purified by flash column chromatography to yield 104.5 mg of 20fe (82%) as 
a clear amorphous solid. 92% ee by HPLC: Chiralcel IA column, 85:15 
Hex:iPrOH, 1 ml/min, RTmajor =  18.96 min, RTminor = 16.46 min, 254 nm. 
[α]20D = +11.5, c = 0.0132 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.35 - 7.24 (m, 5H), 7.18 - 7.11 
(m, 4H), 6.88 - 6.83 (m, 4H), 5.50 (d, J = 15.0 Hz, 1H), 4.63 (d, J = 14.8 Hz, 1H), 4.58 (d, J = 14.8 Hz, 
1H), 4.43 (dd, J = 4.8, 3.3 Hz, 1H), 3.80 (s, 6H), 3.51 (d, J = 15.0 Hz, 1H), 3.02 - 2.97 (m, 2H), 2.14 
(dddd, J = 16.8, 12.9, 5.4, 5.4 Hz, 1H), 1.80 (dddd, J = 13.2, 3.3, 3.3, 3.3 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ 158.6, 156.3, 141.0, 130.5, 130.3, 129.1, 129.0, 128.5, 127.3, 126.2, 113.6, 56.9, 55.0, 50.9, 
48.4, 40.7, 29.5. Rf = 0.19 (2:1 Hex:EtOAc). IR (NaCl, Thin Film) 2931, 2835, 1630, 1510, 1245, 1034 
cm-1. HRMS (ESI) m/z [C26H29N2O3]
+ calcd 417.2173, found 417.2162. 
 
(R)-4-phenyltetrahydropyrimidin-2-one (21).8  In a 10 ml round bottom flask, 
dihydropyrimidinone 20fe (91.4 mg, 0.22 mmol) was dissolved in 6 ml TFA and heated 
to 80 °C for 3 h. The reaction was cooled to 23 °C, concentrated in vacuo, and purified by 
flash column chromatography (eluent  10:1 EtOAc:MeOH). The resulting white powder 
was tritrated with EtOAc to yield 25.4 mg of 21 (66%) as a white powder. 94% ee by 
HPLC: Chiralcel IA column, 70:30 Hex:iPrOH, 1 ml/min, RTmajor =  6.80 min, RTminor = 6.33 min, 254 
nm. [α]20D = +41.7, c = 0.0081 g/ml MeOH.  
1H NMR (400 MHz, CDCl3) δ 7.35 - 7.24 (m, 5H), 4.57 (dd, 
J = 6.0, 5.2 Hz, 1H), 3.27 (s, 1H), 3.26 (s, 1H), 3.23 (ddd, J = 12.0, 7.2, 4.8 Hz, 1H), 3.10 (ddd, J = 12.0, 
7.2, 4.8 Hz, 1H), 2.09 (m, 1H), 1.84 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 163.7, 129.7, 128.6, 127.2, 
55.5, 38.4, 30.9. Rf = 0.18 (10:1 EtOAc:MeOH). IR (NaCl, Thin Film) 3222, 3074, 2968, 2917, 1684, 
1515, 13362, 757 cm-1. HRMS (ESI) m/z [C10H13N2O]
+ calcd 177.1022, found 177.1021. 
 
 (1S,5S,6S)-2,4-dibenzyl-5-phenyl-7-oxa-2,4-diazabicyclo[4.1.0]heptan-3-one (22). In a 
10 ml round bottom flask, dihydropyrimidinone 4hb (62.1 mg, 0.18 mmol) was dissolved 
in 6 ml DCM. mCPBA (76.8 mg, 0.34 mmol) was added and the reaction was stirred for 
                                                            
8 He, Z.-Q., Zhou, Q.; Wu, L.; Chen, Y.-C. Adv. Synth. Catal. 2010, 352, 1904-1908. 
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24 h at 23 °C. The reaction was diluted with DCM and washed with 5% NaOH. The organic layer was 
dried and concentrated in vacuo. The resulting residue was purified by flash column chromatography 
(eluent 4:1 Hex:EtOAc) to yield 22.4 mg (34%) of 22 as a clear residue. 1H NMR (300 MHz, CDCl3) δ 
7.43 (m, 2H), 7.33 (m, 6H), 7.22 (m, 3H), 7.06 (m, 2H), 6.97 (m, 2H), 5.28 (d, J = 15.2 Hz, 1H), 5.12 (d, 
J = 14.0 Hz, 1H), 5.06 (d, J = 14.0 Hz, 1H), 4.38 (dd, J = 8.1, 2.1 Hz, 1H), 4.30 (d, J = 8.1 Hz, 1H), 3.76 
(d, J = 15.2 Hz, 1H), 3.37 (d, J = 2.4 Hz, 1H). Rf = 0.42 (2:1 Hex:EtOAc). LRMS (ESI) m/z 
[C24H23N2O2]
+ calcd 371.2, found 371.2. 
 
 (4S,5S,6S)-1,3-dibenzyl-4,5-dihydroxy-6-phenyltetrahydropyrimidin-2-one (23). In a 
10 ml round bottom flask, dihydropyrimidinone 4hb (88.8 mg, 0.25 mmol) was dissolved 
in 5 ml acetone:H2O (1:1). To the reaction mixture, K2OsO2(OH)2 (4.6 mg, 0.0125 mmol) 
and NMO (36.6 mg, 0.31 mmol). The reaction was stirred at 23 °C for 12h. The reaction 
was diluted with EtOAc and H2O. The layers were seperated and the aqueous was 
extracted with EtOAc 2x. The organic layer was dried with MgSO4, filtered, and concentrated. The 
resulting residue was purified by flash column chromatography (eluent 2:1 Hex:EtOAc) to yield 38.3 mg 
(40%) of 23 as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.40-7.20 (m, 11 H), 7.14 (m, 2H), 7.06 (m, 
2H), 5.38 (d, J = 15.3 Hz, 1H), 5.08 (d, J = 14.8 Hz, 1H), 4.62 (d, J = 3.2 Hz, 1H), 4.46 (d, J = 14.9, 1H), 
4.31 (d, J = 6.6 Hz, 1H), 3.84 (dd, J = 6.8, 3.2 Hz, 1H), 3.56 (d, J = 15.3 Hz, 1H), 3.17 (bs, 1H), 2.32 (bs, 
1H). Rf = 0.14 (2:1 Hex:EtOAc). LRMS (ESI) m/z [C24H25N2O3]
+ calcd 389.2, found 371.2 (M-H2O), 
389.2 (M+H), 403.2 (M-OH+MeOH). 
 
(4S,5S,6R)-1-benzyl-5-bromo-3-hexyl-6-hydroxy-4-
phenyltetrahydropyrimidin-2-one (24hc).  In a 10 ml round bottom, 
dihydropyrimidinone 4hc (101.2 mg, 0.29 mmol) was dissolved in 6 ml of wet 
DMF, NBS (52.7 mg, 0.29 mmol) was added, and the reaction was stirred for 3 
h at 23 °C. The reaction was diluted with 50 ml Et2O and the organic layer was 
washed with H2O (3 X 50 ml), concentrated in vacuo, dried with MgSO4, and 
purified by flash column chromatography (eluent 4:1 Hex:EtOAc) to yield 96.7 
mg of 6 (75%) as a clear amorphous solid. 94% ee by HPLC: Chiralcel IC column, 80:20 Hex:iPrOH, 1 
ml/min, RTmajor = 7.14 min, RTminor = 5.23 min, 230 nm. [α]
20
D = -20.6, c = 0.0060 g/ml CHCl3.  
1H NMR 
(300 MHz, CDCl3) δ 7.44 - 7.24 (m, 10H), 5.13 (d, J = 15.3 Hz, 1H), 4.83 (bs, 1H), 4.77 (bd, J = 10.2 Hz, 
1H), 4.59 (dd, J = 2.1, 2.1 Hz, 1H), 4.27 (d, J = 15.3 Hz, 1H), 4.08 (ddd, J = 15.6, 9.3, 6.6 Hz, 1H), 2.70 
(ddd, J = 14.4, 9.3, 5.1 Hz, 1H), 1.62 (m, 3H), 1.28 (m, 6H), 0.87 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 
153.4, 137.9, 137.5, 129.7, 128.7, 128.3, 128.2, 127.2, 126.0, 83.1, 63.4, 48.4, 48.3, 47.7, 31.6, 27.8, 26.6, 
22.6, 14.0. Rf = 0.26 (2:1 Hex:EtOAc). IR (NaCl, Thin Film) 3330, 2955, 2928, 2857, 1616, 1502, 1227, 
1045, 696 cm-1. HRMS (ESI) m/z [C23H30BrN2O2]
+ calcd 445.1485, found 445.1494.  
 
 (4R,5S,6S)-5-bromo-1-hexyl-4-hydroxy-3-(3-methoxybenzyl)-6-
phenyltetrahydropyrimidin-2-one (24gc). In a 10 ml round bottom, 
dihydropyrimidinone 4gc (72.0 mg, 0.19 mmol) was dissolved in 6 ml of wet DMF, 
NBS (36.8 mg, 0.20 mmol) was added, and the reaction was stirred for 3 h at 0 °C. 
The reaction was diluted with 50 ml Et2O and the organic layer was washed with 
H2O (3 X 50 ml), concentrated in vacuo, dried with MgSO4, and purified by flash 
column chromatography (eluent 4:1 Hex:EtOAc) to yield 58.0 mg of 24gc (64%) as 
a clear amorphous solid. [α]20D = -29.6, c = 0.0094 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.45-7.18 
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(m, 6H), 6.93-6.77 (m, 3H), 5.14 (d, J = 15.3 Hz, 1H), 4.84 (bs, 1H), 4.77 (dt, J = 13.7Hz, 1H), 4.61 (t, J 
= 1.9 Hz, 1H), 4.25 (d, J = 15.3 Hz, 1H), 4.10 (ddd, J = 13.9, 9.0, 6.7 Hz, 1H), 3.79 (s, 3H), 2.70 (ddd, J = 
14.1, 9.3, 5.0 Hz, 1H), 1.63 (m, 2H), 1.48 (d, J = 10.7 Hz, 1H), 1.30  (m, 6H), 0.87 (m, 3H). Rf = 0.30 (2:1 
Hex:EtOAc). IR (NaCl, Thin Film) 3320, 2930, 2858, 1616, 1504, 1262, 1045, 727 cm-1. HRMS (ESI) 
m/z [C24H32BrN2O3]
+ calcd 475.1591, found 475.1595 and 477.1576. 
 
(4S,5S,6R)-6-allyl-1-benzyl-5-bromo-3-hexyl-4-
phenyltetrahydropyrimidin-2-one (25).  In a 10 ml round bottom, 
bromohydrin 24hc (54.1 mg, 0.12 mmol) and allyltrimethylsilane (41.4 mg, 
0.36 mmol) was dissolved in DCM and cooled to -78 °C. After cooling, 50 μl 
of boron trifluoride diethyl etherate was added and the reaction vessel was 
removed from the cooling bath and allowed to warm to 23 °C. The reaction 
was concentrated in vacuo, and purified by flash column chromatography 
(eluent  10:1 Hex:EtOAc) to yield 43.1 mg of 7 (72%) as a clear syrup. 94% ee by HPLC: Chiralcel ODH 
column, 90:10 Hex:iPrOH, 1 ml/min, RTmajor = 5.40 min, RTminor = 4.62 min, 254 nm. [α]
20
D = +15.4, c = 
0.0105 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 7.42 - 7.22 (m, 10H), 5.29 (d, J = 15.3 Hz, 1H), 5.25 
(m, 1H), 4.86 (bs, 1H), 4.84 (bd, J = 10.8 Hz, 1H), 4.72 (bs, 1H), 4.21 (bd, J = 16.5 Hz, 1H), 4.16 (m, 
1H), 4.13 (d, J = 15.3 Hz, 1H), 3.49 (dd, J = 11.4, 4.2 Hz, 1H), 2.62 (ddd, J 14.3, 9.9, 4.5 Hz, 1H), 2.14 
(dt, J = 13.8, 5.1 Hz, 1H), 1.72 (m, 1H), 1.57 (m, 1H), 1.41 (m, 2H), 1.29 (m, 5H), 0.87 (m, 3H). 13C 
NMR (75 MHz, CDCl3) δ 154.5, 138.8, 137.7, 132.6, 129.0, 128.3, 128.2, 128.1, 127.2, 126.7, 119.2, 
65.3, 62.3, 49.1, 47.5, 47.2, 37.3, 31.7, 27.7, 26.6, 22.6, 14.0. Rf = 0.38 (4:1 Hex:EtOAc). IR (NaCl, Thin 
Film) 3063, 3028, 2955, 2928, 2857, 1636, 1482, 1230, 923, 818, 702 cm-1. HRMS (ESI) m/z 
[C26H34BrN2O]
+ calcd 469.1849, found 469.1841. 
 
High Throughput Experimentation.9 
 The experimental design was accomplished using ChemDraw and Excel. The reaction set up was 
done in an MBraun duel glovebox. Solvents were purchased from Aldrich (anhydrous, sure-seal) and used 
with no further purification). The reactions were carried out in 1 mL vials (30 mm height x 8 mm 
diameter) (Freeslate, Inc.) in a 24-well plate aluminum reactor block (Analytical Sales & Service, Inc.). 
Chemicals were dosed using an Eppendorf pipettor (20-200 uL). Dosing solvent was removed using a 
custom blow down box with nitrogen inlet and vacuum outlet. The reactions were heated and stirred using 
a tumble stirrer (V&P Scientific, Inc.) using parylene coated tumble stir dowels (1.98 mm diameter, 4.80 
mm length) (V&P Scientific, Inc.). 
 The metals (1 umol and 0.5 umol for dimers) were dosed into the reaction vials as solutions (or 
slurries) (50 uL of an 0.02 M solution in THF). The ligands (1 umol) were dosed into the reaction as 
solutions (50 uL of an 0.02 M solution in THF). The dosing solvent was removed using the blow down 
tool. A stir-bar was added to each reaction vial. The starting materials 1-benzyl-4,4'-dimethyl-1-azabuta-
1,3-diene 3s (10 umol), hexyl isocyanate 2c (15 umol) and trimethoxybenene (internal standard) (1 umol) 
was added to each vial in the desired reaction solvent (0.1 M solutions). The reactions were sealed and 
heated to 110 °C for 14 h. After cooling to 23 °C, the reactions were diluted with 400 uL of MeCN. In a 
seperate 96-1mL-well LC plate, 750 uL of MeCN was added. Aliquots (100 uL) of the diluted reactions 
                                                            
9 This procedure is based on the HTE platform developed by Merck and Co. Inc. (a) Dreher, S. D.; Dormer, P. G.; 
Sandrock, D. L.; Molander, G. A. J. Am. Chem. Soc. 2008, 130, 9257-9259. (b) Spencer D. Dreher, Merck and Co. 
Inc., Rahway, New Jersey, USA. Personal Communication, 2011. 
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were added to the LC plate. The LC plate was sealed and inverted to mix the solution. The reactions were 
analyzed using an Agilent HPLC with a 96-well auto-sampler. HPLC method: Aldrich Ascentis Express 
C-18 column (4.6 diameter, 100 mm length) with mobile phase A (0.1% H3PO4/H2O) and mobile phase B 
(MeCN). Gradient of 10-95% B in 6 minutes, hold 95% B for 2 minutes. Flow rate 1.8 mL/min. 















































































Crystal Structure Tables and Figure for 4ag. 
Table A.3.1.  Crystal data and structure refinement for 4ag. 
Identification code  rovis102 
Empirical formula  C22H17BrN2O 
Formula weight  405.29 
Temperature  120 K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 212121 
Unit cell dimensions a = 5.8881(2) Å α = 90° 
 b = 12.0278(3) Å β = 90° 
 c = 24.8051(7) Å γ = 90° 
Volume 1756.72(9) Å3 
Z 4 
Density (calculated) 1.532 Mg/m3 
Absorption coefficient 2.353 mm-1 
F(000) 824 
Crystal size 0.24 x 0.18 x 0.14 mm3 
Theta range for data collection 1.64 to 30.52°. 
Index ranges -8<=h<=8, -17<=k<=17, -35<=l<=35 
Reflections collected 42873 
Independent reflections 5374 [R(int) = 0.0753] 
Completeness to theta = 30.52° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7387 and 0.5997 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5374 / 0 / 236 
Goodness-of-fit on F2 1.143 
Final R indices [I>2sigma(I)] R1 = 0.0497, wR2 = 0.1249 
R indices (all data) R1 = 0.0869, wR2 = 0.1933 
Absolute structure parameter -0.013(15) 
Largest diff. peak and hole 0.932 and -1.240 e.Å-3 
 
Table A.3.2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 4ag.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Br(1) 13764(1) -2018(1) 447(1) 29(1) 
C(1) 7278(8) 1149(4) 2161(2) 17(1) 
C(2) 6856(9) 3101(4) 2386(2) 23(1) 
C(3) 8429(10) 3419(4) 2029(2) 27(1) 
C(4) 9688(9) 2609(4) 1677(2) 20(1) 
C(5) 4767(9) 1725(4) 2903(2) 19(1) 
C(6) 2777(10) 2333(5) 2945(2) 27(1) 
C(7) 1268(10) 2130(5) 3355(2) 32(1) 
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C(8) 1788(11) 1320(5) 3740(2) 36(2) 
C(9) 3831(12) 722(4) 3715(2) 32(1) 
C(10) 5316(10) 929(4) 3296(2) 24(1) 
C(11) 9860(8) 616(4) 1460(2) 17(1) 
C(12) 8836(10) 167(4) 1004(2) 20(1) 
C(13) 9999(9) -645(4) 708(2) 21(1) 
C(14) 12136(9) -972(4) 877(2) 20(1) 
C(15) 13142(8) -538(4) 1332(2) 20(1) 
C(16) 12003(8) 258(4) 1619(2) 20(1) 
C(17) 9548(8) 3018(4) 1101(2) 19(1) 
C(18) 7535(9) 2892(4) 801(2) 23(1) 
C(19) 7386(10) 3370(4) 293(2) 26(1) 
C(20) 9191(10) 3991(4) 92(2) 30(1) 
C(21) 11140(11) 4138(4) 392(2) 29(1) 
C(22) 11365(10) 3638(4) 897(2) 23(1) 
N(1) 6325(7) 1983(3) 2475(1) 19(1) 
N(2) 8716(8) 1489(3) 1749(1) 19(1) 




Table A.3.3.   Bond lengths [Å] and angles [°] for 4ag. 
_________________________________________________ 
 
Br(1)-C(14)  1.908(5) 
C(1)-O(1)  1.231(6) 
C(1)-N(2)  1.388(6) 
C(1)-N(1)  1.388(6) 
C(2)-C(3)  1.336(7) 
C(2)-N(1)  1.398(6) 
C(3)-C(4)  1.504(7) 
C(4)-N(2)  1.475(6) 
C(4)-C(17)  1.514(6) 
C(5)-C(6)  1.385(8) 
C(5)-C(10)  1.402(7) 
C(5)-N(1)  1.438(6) 
C(6)-C(7)  1.371(8) 
C(7)-C(8)  1.399(9) 
C(8)-C(9)  1.403(9) 
C(9)-C(10)  1.381(7) 
C(11)-C(12)  1.390(6) 
C(11)-C(16)  1.390(7) 
C(11)-N(2)  1.439(6) 
C(12)-C(13)  1.400(7) 
C(13)-C(14)  1.383(7) 
C(14)-C(15)  1.378(7) 
C(15)-C(16)  1.369(7) 
C(17)-C(22)  1.398(7) 
C(17)-C(18)  1.408(7) 
C(18)-C(19)  1.386(7) 
C(19)-C(20)  1.392(8) 
C(20)-C(21)  1.379(9) 













































Symmetry transformations used to generate equivalent atoms:  
 
Table A.3.4.   Anisotropic displacement parameters (Å2x 103)for 4ag.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Br(1) 30(1)  26(1) 30(1)  -7(1) 2(1)  9(1) 
C(1) 18(2)  17(2) 15(2)  -3(2) -2(2)  2(2) 
C(2) 31(3)  16(2) 22(2)  1(2) 3(2)  3(2) 
C(3) 44(3)  14(2) 23(2)  -3(2) 5(2)  0(2) 
C(4) 27(2)  18(2) 15(2)  -1(2) 3(2)  -4(2) 
C(5) 21(2)  21(2) 15(2)  -4(2) 3(2)  -4(2) 
C(6) 28(3)  29(3) 23(2)  -5(2) -3(2)  6(2) 
C(7) 24(2)  42(3) 28(2)  -18(2) 2(2)  6(3) 
C(8) 48(4)  34(3) 27(3)  -13(2) 17(3)  -15(3) 
C(9) 43(3)  25(2) 27(2)  0(2) 14(3)  -6(3) 
C(10) 27(3)  20(2) 26(2)  1(2) 7(2)  -3(2) 
C(11) 22(2)  17(2) 13(2)  0(2) 1(2)  -2(2) 
C(12) 21(2)  21(2) 18(2)  -1(2) -1(2)  2(2) 
C(13) 22(3)  20(2) 21(2)  -1(2) -1(2)  0(2) 
C(14) 22(2)  17(2) 22(2)  -2(2) 6(2)  1(2) 
C(15) 17(2)  25(2) 18(2)  2(2) 0(2)  1(2) 
C(16) 22(2)  24(2) 13(2)  1(2) -3(2)  1(2) 
C(17) 26(2)  15(2) 15(2)  -2(2) 1(2)  3(2) 
C(18) 25(3)  20(2) 25(2)  -3(2) -2(2)  3(2) 
C(19) 28(3)  26(2) 24(2)  2(2) -3(2)  9(2) 
C(20) 45(4)  23(2) 23(2)  7(2) 7(2)  8(2) 
C(21) 34(3)  29(2) 26(2)  7(2) 9(3)  0(2) 
C(22) 28(3)  20(2) 22(2)  1(2) 4(2)  -2(2) 
N(1) 22(2)  17(2) 19(2)  1(1) 3(2)  1(2) 
N(2) 26(2)  16(2) 14(2)  -1(1) 5(2)  1(2) 









Table A.3.5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for 4ag. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2) 6087 3643 2582 28 
H(3) 8758 4173 1998 32 
H(4) 11286 2595 1788 24 
H(6) 2463 2885 2694 32 
H(7) -85 2527 3376 38 
H(8) 765 1175 4017 44 
H(9) 4179 194 3976 38 
H(10) 6680 542 3273 29 
H(12) 7400 402 898 24 
H(13) 9345 -959 403 25 
H(15) 14567 -782 1443 24 
H(16) 12672 565 1924 24 
H(18) 6320 2492 941 28 
H(19) 6080 3276 88 31 
H(20) 9082 4310 -249 36 
H(21) 12314 4574 257 35 
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General Methods. Toluene was degassed with argon and passed through one column of neutral 
alumina and one column of Q5 reactant. Ethyl ether, tetrahydrofuran, and dichloromethane were degassed 
and passed through two columns of neutral alumina. Column chromatography was performed on 
Silicycle, Inc. silica gel 60 (230-400 mesh). Preparative thin layer chromatography was performed on 
Silicycle, Inc. 2.00 mm silica 60-F plates and thin layer chromatography was performed on Silicycle, Inc. 
0.25 mm silica gel 60-F plates. Chemicals were purchased from Aldrich Chemicals, Inc. unless otherwise 
stated. 
 1H NMR and 13C NMR spectra were obtained in CDCl3 at ambient temperature and chemical 
shifts are expressed in parts per million (δ, ppm). Proton chemical shifts are referenced to 7.26 ppm 
(CHCl3) and 7.16 ppm (C6D6) and carbon chemical shifts are referenced to 77.0 ppm (CDCl3) and 128 
(C6D6). Data reporting uses the following abbreviations: s, singlet; bs, broad singlet; d, doublet; dd, 
doublet of doublets; ddd, doublet of doublets of doublets; t, triplet; m, multiplet; and J, coupling constant 
in Hz. 
 Concentrations of alkyl lithium reagents were determined using diphenyl acetic acid titrations.1 
Concentrations of Grignard reagents were determined using LiCl/I2 titrations.
2 
 Spectral data for compounds cis, cis-3-(benzyloxy)-2,4-dimethyl glutaric anhydride (3b), 
(2S,3S,4R)-3-(benzyloxy)-2,4-dimethyl-5-oxohexanoic acid (4b), (E)-5-((2R,3R)-3-(hydroxymethyl)-3-
methyloxiran-2-yl)-3-methylpent-2-en-1-yl acetate (S13), (E)-5-((2R,3S)-3-(iodomethyl)-3-methyloxiran-
2-yl)-3-methylpent-2-en-1-ol (139), tert-butyl 3-((2R,3R)-3-((E)-5-hydroxy-3-methylpent-3-en-1-yl)-2-
methyloxiran-2-yl)propanoate (S14), tert-butyl 3-((2R,3R)-3-(2-((2R,3R)-3-(hydroxymethyl)-2-
methyloxiran-2-yl)ethyl)-2-methyloxiran-2-yl)propanoate (140), (2S,2'R,5'S)-5'-((S)-2-bromo-1-
hydroxyethyl)-2,5'-dimethylhexahydro-[2,2'-bifuran]-5(2H)-one (S15), and (4R,6S,8S,12R,14S,Z)-ethyl 
9-hydroxy-4,6,8,12,14-pentamethyl-11-oxo-16-((1-phenyl-1H-tetrazol-5-yl)sulfonyl)hexadec-9-enoate 
(162) match Dr. Brian Cochran's post doctoral report3 and his data for these compounds are included for 
completeness. 
  
Synthesis of Compounds and Characterization Data. 
C1-C9 Fragment 
 
Triethyl pentane-2,2,4-tricarboxylate (S1). Prepared using modified literature 
procedure.4 Sodium (17.2 g, 0.75 mol) was slowly added to 500 mL EtOH and 
dissolved (~3 h). After heating the solution to reflux, diethyl methylmalonate (127.8 
mL, 750 mmol) and ethyl α-bromoisobutyrate (110.0 mL, 750 mmol) were added quickly. The solution 
turned slight yellow. After 1 h, the solution was bright yellow with a yellow precipitate. The reaction was 
heated for an additional 5 h and cooled to 23 °C. The solution was concentrated in vacuo and 200 mL 
H2O and 200 mL Et2O were added. The layers were separated and the aqueous layer was extracted with 
200 mL Et2O 3x. The organic layers were combined, washed with brine, dried over MgSO4, and 
concentrated to yield 197 g (91%) of triethyl pentane-2,2,4-tricarboxylate as light yellow oil. 
                                                            
1 Kofron, W. G.; Baclawski, L. M. J. Org. Chem. 1976, 41, 1879-1880. 
2 Krasovskiy, A.; Knochel, P. Synthesis 2006, 5, 890-891. 
3 Cochran, B. M. Colorado State University, Fort Collins, CO. Unpublished work, 2012. 








 2,4-dimethylpentanedioic acid (S2). Prepared using modified literature procedure.4 
Triethyl pentane-2,2,4-tricarboxylate S1 (197 g, 683 mmol) was dissolved in 500 mL 
conc. HCl and refluxed for 36 h. Another 100 mL. conc. HCl was added and the 
reaction was refluxed for another 24 h. The reaction was cooled to 23 °C and then put in a -20 °C freezer 
for 12 h. The crystals were filtered off, dissolved in 400 mL Et2O. The layers were separated and the 
organic layer was dried with MgSO4 and concentrated to yield 48 g of 2,4-dimethylpentanedioic acid. The 
aqueous HCl solution was extracted with 200 mL Et2O 4x. The organic layers were combined, dried with 
MgSO4, and concentrated to an amorphous solid. The solid was recrystallized from Hex:EtOAc to yield 
an additional 24 g of 2,4-dimethylpentanedioic acid (72 g total, 66%). 
 
 Cis-2,4-dimethyl glutaric anhydride (1). Prepared using modified literature 
procedures.4,5 2,4-dimethylpentanedioic acid S2 (72 g, 452 mmol) was dissolved in acetic 
anhydride (100 mL) and heated to 130 °C for 6 h. The reaction was concentrated in vacuo 
by azeotroping with PhMe 3x. The resulting solid was dissolved in minimal refluxing EtOAc and 2 mL 
DBU was added. The solution was cooled to 23 °C and then 0 °C and the solid was filtered off to yield 
33.4 g of dimethyl glutaric anhydride as light brown solid (>20:1 cis:trans). The filtrated was 
concentrated and the solid was recrystallized from EtOAc 2x (10.69 g, >20:1 cis:trans; 0.68 g, 19:1 
cis:trans). All the solids were combined and recrystallized from EtOAc to yield 34.4 g (54%) of cis-2,4-
dimethyl glutaric anhydride as clear, cubic crystals. Spectral data matches previous report.4 1H NMR (300 
MHz, CDCl3) δ 2.73 (m, 2H), 2.06 (dt, J = 13.6, 5.3 Hz, 1H), 1.59 (dt, J = 13.3, 13.3 Hz, 1H), 1.38 (d, J = 
6.9 Hz, 6H). X-ray data6 matches previous report.7 
 
 Bis(4-ethoxy-4-oxobutyl)zinc (122). In a 100 ml round bottom flask, ethyl 
4-bromobutyrate (6.0 ml, 40.2 mmol: 1H NMR (300 MHz, CDCl3) δ 4.14 
(q, J = 7.2 Hz, 2H), 3.47 (t, J = 6.5 Hz, 2H), 2.49 (t, J = 7.2 Hz, 2H), 2.17 (m, 2H), 1.26 (t, J = 7.1 Hz, 
3H).) was dissolved in 40 ml acetone. Potassium iodide (13.35 g, 80.4 mmol, 2.0 equiv.) was added, a 
reflux condenser was attached, and the reaction was heated at reflux for 12h. The solution was cooled, 
filtered through a course fritted funnel, and concentrated in vacuo. The resulting yellow oil with fine 
particulates was taken up in ca 50 ml of 1:1 Hex:Et2O and filtered through neutral aluminum to remove 
color. After flushing with an additional 100 ml 1:1 Hex:Et2O, the solution was concentrated to yield 8.44 
g (87%) of ethyl 4-iodobutyrate. 1H NMR (300 MHz, CDCl3) δ 4.14 (q, J = 7.2 Hz, 2H), 3.24 (t, J = 6.8 
Hz, 2H), 2.44 (t, J = 7.1 Hz, 2H), 2.13 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H). A 50 ml Schlenk flask was flame 
dried under vacuum, cooled to 23 °C, and charged with ethyl 4-iodobutyrate (8.4 g, 34.7 mmol) and 
copper(I) iodide (10 mg,  0.05 mmol). After sealing with a greased ground glass stopper, the flask was 
                                                            
5 Saicic, R. N. Synthetic Commun. 2006, 36, 2559-2562. For an alternative procedure using Hünig's base, see: 
Prusov, E.; Röhm, H.; Maier, M. E. Org. Lett. 2006, 8, 1025-1028. 
6 Oberg, K. M.; Rovis T. (2013) Private communication to the Cambridge Structural Database, deposit number 
CCDC 946678. 















evacuated and refilled with Ar. The stopper was replaced with a rubber septum and neat diethyl zinc (14 
ml, 137 mmol, 4 equiv) was added via syringe. The reaction was heated at 40 °C for 12 h. The excess 
diethyl zinc and ethyl iodide were removed under vacuum for 2 h into a trap with methanol cooled to -78 
°C with dry ice and acetone. (CAUTION: A trap cooled with liquid nitrogen easily clogs so dry 
ice/acetone cooling is preferred. Methanol quenches the excess diethyl zinc, but care should be taken 
when cleaning the trap as some diethyl zinc may remain.) After backfilling with Ar, THF (5 ml) was 
added to the reaction vessel and heated at 40 °C for 1 h under Ar. The reaction vessel was evacuated for 1 
h. This step was repeated another two times. After cooling to 23 °C, the generated bis(4-ethoxy-4-
oxobutyl)zinc was diluted with 15 ml of THF and this solution was used directly in the desymmetrization 
reaction. 
 
(2S,4R)-9-ethoxy-2,4-dimethyl-5,9-dioxononanoic acid (2a). A flame 
dried 250 ml round bottom with stirbar was transferred into glove box where 
[Rh(nbd)OAc]2
8 (142.3 mg, 0.28 mmol, 2 mol %) and (R)-tBuPhox9 (217.0 
mg, 0.56 mmol, 4 mol %) were added. The reaction vessel was removed from the glove box, charged with 
15 ml of THF and stirred for 10 min to make a clear, orange solution. The reaction was charged with the 
bis(4-ethoxy-4-oxobutyl)zinc-THF solution from the above reaction and stirred for 10 min resulting in a 
deep red solution. Cis-2,4-dimethyl glutaric anhydride 1 (2.0 g, 14.0 mmol) was added as a solid (septa 
removed, anhydride added in one portion, and reaction flushed after addition of anhydride) and the 
reaction was stirred at 23 °C for 6 days. The reaction was quenched slowly with 1 M HCl and EtOAc was 
added. The layers were separated and the aqueous layer was extracted with EtOAc 3x. The organic phase 
was extracted with sat. NaHCO3 3x and collected into a beaker. With stirring, the aqueous solution was 
acidified using conc. HCl. The acidic solution was extracted with DCM 3x and the organic layer was 
dried with MgSO4, filtered, and concentrated. The resulting oil was absorbed onto Celite and purified via 
flash column chromatography (89:10:1 Hex:EtOAc:AcOH to 78:20:2 Hex:EtOAc:AcOH) to yield 2.10 g 
(58%) of (2S,4R)-9-ethoxy-2,4-dimethyl-5,9-dioxononanoic acid as a pale yellow oil.   [α]20D =  +3.9, c = 
0.0163 g/ml CHCl3.
 1H NMR (400 MHz, CDCl3) δ 9.85 (bs, 1H), 4.11 (q, J = 7.1 Hz, 2H), 2.64-2.45 (m, 
4H), 2.61 (t, J = 7.3 Hz, 2H), 2.07 (ddd, J = 14.0, 8.8, 6.3, 1H), 1.87 (p, J = 7.2 Hz, 2H), 1.36 (ddd, J = 
13.7, 7.7, 5.8 Hz, 1H), 1.24 (t, J = 7.2 Hz, 3H), 1.19 (d, J = 7.0 Hz, 3H), 1.09 (d, J = 7.0 Hz. 3H). 13C 
NMR (100 MHz, CDCl3) δ 212.9, 182.0, 173.3, 60.4, 44.0, 39.6, 37.2, 36.0, 33.3, 18.8, 17.6, 16.4, 14.2. 
Rf = 0.24 (78:20:2 Hex:EtOAc:AcOH; CAM), 0.21 (2:1 Hex:EtOAc). IR (NaCl, Thin Film) 3172, 2977, 
2940, 1717, 1462, 1378, 1192, 1031 cm-1. LRMS (ESI) m/z [C13H21O5]
- (M-H) calcd 257.1, found 257.2. 
 
 (2S,4R)-1-benzyl 9-ethyl 2,4-dimethyl-5-oxononanedioate (S3). 
(2S,4R)-9-ethoxy-2,4-dimethyl-5,9-dioxononanoic acid 2a (212 mg, 0.82 
mmol) was dissolved in 15 ml DCM. Benzyl alcohol (0.1 ml, 1 mmol, 1.2 
equiv), dicyclohexylcarbodiimide (206 mg, 1 mmol, 1.2 equiv), and dimethylaminopyridine (30.5 mg, 
0.25 mmol, 0.3 equiv) were added sequentially. The reaction was stirred at 23 °C for 3 h. The reaction 
                                                            
8 For synthesis of [Rh(nbd)OAc]2, see: Henderson, D. D.; Cochran, B. M.; Filloux, C. M.; Rovis, T. Submitted. 
9 For synthesis of Phox ligands, see: (a) Tani, K.; Behenna, D. C.; McFadden, R. M.; Stoltz, B. M. Org. Lett. 2007, 















was concentrated onto Celite and columned to yield 174.9 mg (61%) of (2S,4R)-1-benzyl 9-ethyl 2,4-
dimethyl-5-oxononanedioate as a clear oil.  1H NMR (300 MHz, CDCl3) δ 7.38-7.32 (m, 5H), 5.14 (d, J = 
12.4, 1H), 5.09 (d, J = 12.3 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 2.28 (t, J = 7.3 Hz, 2H), 2.05 (ddd, J = 
13.9, 9.2, 5.9 Hz, 1H), 1.84 (p, J = 7.1 Hz, 2H), 1.35 (ddd, J = 13.7, 8.1, 5.5 Hz, 1H), 1.25 (t, J = 7.1 Hz, 
3H), 1.17 (d, J = 7.0 Hz, 3H), 1.05 (d, J = 7.0 Hz, 3H). Rf = 0.30 (4:1 Hex:EtOAc; CAM, UV). 89% ee by 
HPLC: Chiralcel IC column, 95:5 Hex:iPrOH, 1 ml/min, RTmajor =  35.59 min, RTminor = 37.13 min, 210 
nm. ent-SX using S-tBuPhox. 92% ee by HPLC: Chiralcel IC column, 95:5 Hex:iPrOH, 1 ml/min, RTmajor 
=  36.60 min, RTminor = 35.35 min, 210 nm. 
 
 (2S,4R,6R)-9-ethoxy-2,4,6-trimethyl-5,9-dioxononanoic acid (123). 
Potassium bis(trimethylsilyl)amide (1.328 g, 6.657 mmol, 2.1 equiv.) was 
added to a flame dried 100 ml round bottom flask in an inert air glove box. 
After removing from the box, 35 ml of freshly pulled PhMe was added to the reaction flask and stirred 
until it was a clear, colorless solution. The reaction was cooled to -78 °C and (2S,4R)-9-ethoxy-2,4-
dimethyl-5,9-dioxononanoic acid 2a (0.820 g, 3.17 mmol) was added in 20 ml THF. The solution turned 
yellow and was stirred for 1 h. Iodomethane (0.79 ml, 12.68 mmol, 4 equiv.) was added neat and the 
reaction was stirred for 16 h at -78 °C. The reaction was quenched at -78 °C with the addiition of 23 ml 
1M HCl and allowed to warm to 23 °C for 1 h. The reaction was extracted with EtOAc 3x and the organic 
layer was washed with sat. Na2S2O3 2x, dried with MgSO4, filtered, and concentrated. The resulting oil 
was loaded onto Celite and purified via flash column chromatography to yield 0.631 g (73%, 5:1 dr) of 
(2S,4R,6R)-9-ethoxy-2,4,6-trimethyl-5,9-dioxononanoic acid as clear liquid. [α]20D =  +2.3, c = 0.0222 
g/ml C6H6. 
1H NMR (400 MHz, CDCl3) δ 8.82 (bs, 1H), 4.11 (q, J = 7.1 Hz, 2H), 2.73 (m, 2H), 2.50 (m, 
1H), 2.26 (m, 2H), 2.06-1.92 (m, 2H), 1.61 (m, 1H), 1.30 (m, 1H), 1.24 (t, J = 7.2 Hz, 3H), 1.20 (d, J = 
7.0 Hz, 3H), 1.08 (d, J = 6.7 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 216.5, 
181.9, 173.2, 60.4, 43.8, 42.7, 37.0, 36.0, 31.8, 27.6, 17.8, 16.5, 16.1, 14.2. Rf = 0.18 (78:20:2 
Hex:EtOAc:AcOH; CAM). IR (ATR) 2974, 2937, 2878, 1732, 1705, 1462, 1377, 1179, 1032 cm-1. 
HRMS (APCI) m/z [C14H25O5]
+ (M+H) calcd 273.1697, found 273.1703. 
 
 (2S,4R)-4-(2-((R)-5-methoxy-5-oxopentan-2-yl)-1,3-dithiolan-2-yl)-2-
methylpentanoic acid (124). In a 20 ml Scintillation vial under Ar, 
(2S,4R,6R)-9-ethoxy-2,4,6-trimethyl-5,9-dioxononanoic acid 123 (570 mg, 
2.09 mmol) was dissolved in 2 ml 1,2-ethanedithiol. Boron trifluoride diethyl etherate (0.33 ml, 2.61 
mmol, 1.25 equiv.) was added via syringe. The reaction was stirred for 15 min (long reaction times lead to 
epimerization) and the entire reaction was immediately subject to flash column chromatography (20:1 
Hex:EtOAc to 9:1 Hex:EtOAc to 4:1 Hex:EtOAc) to yield 640.5 mg (91%) of (2S,4R)-4-(2-((R)-5-
methoxy-5-oxopentan-2-yl)-1,3-dithiolan-2-yl)-2-methylpentanoic acid as a clear oil. [α]20D =  +17.8, c = 
0.0181 g/ml CHCl3.
 1H NMR (400 MHz, CDCl3) δ 9.58 (bs, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.24-3.11 (m, 
4H), 2.62 (m, 1H), 2.43 (m, 1H), 2.32-2.04 (m, 5H), 1.55 (m, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.22 (d, J = 
7.1 Hz, 3H), 1.16 (d, J = 6.4 Hz, 3H), 1.11 (m, 1H), 1.05 (d, J = 6.5 Hz, 3H). 13C NMR (100 MHz, 
















= 0.38 (2:1 Hex:EtOAc; CAM). IR (ATR) 2973, 2924, 2877, 1732, 1703, 1375, 1296, 1178, 958 cm-1. 
HRMS (ESI/APCI) m/z [C16H27O4S2]
+ (M-H) calcd 347.1356, found 347.1337. 
 
 (R)-ethyl 4-(2-((2R,4S)-5-hydroxy-4-methylpentan-2-yl)-1,3-dithiolan-
2-yl)pentanoate (125). In a 25 ml round bottom flask, (2S,4R)-4-(2-((R)-5-
methoxy-5-oxopentan-2-yl)-1,3-dithiolan-2-yl)-2-methylpentanoic acid 124 
(1.52 g, 4.4 mmol) was dissolved in 12 ml THF. Borane·tetrahydrofuran (5.6 ml, 5.63 mmol, 1M in THF, 
1.25 equiv.) was added and the reaction was stirred for 1 h. The reaction was quenched with H2O and 
after bubbling ceased, 1M HCl was added. The reaction was extracted with EtOAc 3x. The organic layer 
was washed with 1M HCl 1x and brine 1x, dried with MgSO4, filtered, and concentrated. The crude 
reaction was loaded onto Celite and purified via flash column chromatography to yield 0.939 g (64%) of 
(R)-ethyl 4-(2-((2R,4S)-5-hydroxy-4-methylpentan-2-yl)-1,3-dithiolan-2-yl)pentanoate as a clear oil. 
[α]20D =  +17.3, c = 0.0169 g/ml CHCl3.
 1H NMR (400 MHz, CDCl3) δ 4.12 (q, J = 7.1 Hz, 2H), 3.57-3.50 
(m, 2H), 3.23-3.16 (m, 4H), 2.43 (m, 1H), 2.27 (m, 1H), 2.17 (m, 1H), 2.06 (m, 1H), 1.78-1.66 (m, 2H), 
1.67 (s, 1H), 1.45 (m, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.12 (d, J = 6.2 Hz, 3H), 1.10 (d, J = 6.2 Hz, 3H), 
1.10 (m, 1H), 0.98 (d, J = 6.5 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 173.6, 83.6, 66.5, 60.3, 41.4, 41.0, 
40.3, 39.7, 37.4, 33.6, 32.7, 28.2, 18.9, 17.4, 15.8, 14.2. Rf = 0.31 (3x 4:1 Hex:EtOAc; anisaldehyde, 
CAM). IR (NaCl, Thin Film) 3448, 2967, 2926, 2874, 1733, 1374, 1179, 1039 cm-1. HRMS (ESI/APCI) 
m/z [C16H30NaO3S2]
+ calcd 357.1529, found 357.1534. Longer reaction times and excess borane lead to 
diol [(2S,4R)-4-(2-((R)-5-hydroxypentan-2-yl)-1,3-dithiolan-2-yl)-2-methylpentan-1-ol]. 1H NMR (400 
MHz, CDCl3) δ3.72-3.45 (m, 2H), 3.65 (m, 1H), 3.54 (m, 1H), 3.24-3.18 (m, 4H), 2.20 (m, 1H), 2.17-
1.71 (m, 8H), 1.50 (m, 1H), 1.24 (m, 1H), 1.13 (d, J = 6.9 Hz, 3H), 1.11 (m, 3H), 0.99 (d,  J = 6.8 Hz, 
3H). Rf = 0.30 (1:1 Hex:EtOAc; anisaldehyde, CAM). IR (ATR) 3320, 2952, 2922, 2871, 1462, 1376, 
1039 cm-1. LRMS (ESI/APCI) m/z [C12H22O2]
+ (M-SCH2CH2SH) calcd 199.2, found 199.2. 
 
 (4R,6S,8S)-methyl 9-hydroxy-4,6,8-trimethylnonanoate (146). (R)-ethyl 
4-(2-((2R,4S)-5-hydroxy-4-methylpentan-2-yl)-1,3-dithiolan-2-
yl)pentanoate 125 (486 mg, 1.45 mmol) was dissolved in 10 ml EtOH in an 
acid washed 100 ml round bottom flask. To this, Raney®-nickel (slurry in H2O: Aldrich 221678) was 
added via pippette (~8) until starting dithiolane gone by TLC (visualization of progress easiest through 
use of anisaldehyde stain). Upon completion, the reaction was filtered through Celite and eluted with 
EtOH (Caution: dry Raney®-nickel is flammable.). The filtrate was concentrated and took up into DCM. 
The organic layer was washed with 1M HCl 2x, dried with MgSO4, concentrated. The crude oil was 
loaded onto Celite and purified via flash column chromatography to yield 192.2 mg (54%) of (4R,6S,8S)-
methyl 9-hydroxy-4,6,8-trimethylnonanoate as a clear oil. [α]20D =  -3.6, c = 0.0106 g/ml CHCl3.
 1H NMR 
(400 MHz, CDCl3) δ 4.12 (q, J = 7.1 Hz, 2H), 3.52 (dd, J = 10.4, 5.0 Hz, 1H), 3.38 (dd, J = 10.4, 6.7 Hz, 
1H), 2.37-2.21 (m, 2H), 1.75-1.45 (m, 5H), 1.49 (bs, 1H), 1.34-1.13 (m, 4H), 1.25 (t, J = 7.2 Hz, 3H), 
0.92 (d, J = 6.7 Hz, 3H), 0.91 (m, 1H), 0.87 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H). 13C NMR (100 
MHz, CDCl3) δ 174.1, 68.1, 60.2, 44.7, 41.2, 33.0, 31.9, 31.3, 29.6, 27.5, 20.8, 20.0, 17.6, 14.2. Rf = 0.20 
(4:1 Hex:EtOAc; CAM, anisaldehyde). IR (ATR) 3444, 2955, 2916, 2872, 1735, 1461, 1377, 1178, 1036 
cm-1. HRMS (ESI/APCI) m/z [C14H28NaO3]













 ethyl 4-(3,5-dimethyl-3,4-dihydro-2H-pyran-6-yl)pentanoate (166). From 
reaction above, this compound was isolated in small amounts. 1H NMR (400 
MHz, CDCl3) δ 3.95 (m, 2H), 3.68 (m, 1H), 3.14 (m, 1H), 2.64 (m, 1H), 2.37-
2.16 (m, 2H), 2.00 (m, 1H), 1.80-1.56 (m, 2H), 1.50 (m, 3H), 1.39-1.30 (m, 2H), 1.13 (d, J = 6.8 Hz, 
1.5H), 1.09 (d, J = 6.8 Hz, 1.5H), 0.94 (t, J = 7.1 Hz, 1.5H), 0.94 (t, J = 7.1 Hz, 1.5H), 0.62 (d, J = 6.6 Hz, 
1.5H), 0.61 (d, J = 6.6 Hz, 1.5H). 13C NMR (100 MHz, CDCl3) δ 173.2/173.2, 149.7/149.4, 101.4/101.2, 
71.0/71.0, 59.9/59.9, 35.9/35.8, 33.3/33.2, 32.7/32.6, 29.8/29.5, 28.0/28.0, 18.8/18.8, 17.6/17.6, 17.2/17.1, 
14.3. Rf = 0.68 (4:1 Hex:EtOAc; CAM). IR (ATR) 2959, 2927, 2871, 1736, 1459, 1374, 1177, 1092 cm
-1. 
HRMS (ESI/APCI) m/z [C14H25O3]
+ (M+H) calcd 241.1798, found 241.1803. 
 
 (4R,6S,8S)-ethyl 4,6,8-trimethyl-9-oxononanoate (116). (4R,6S,8S)-
methyl 9-hydroxy-4,6,8-trimethylnonanoate 146 (192 mg, 0.786 mmol) was 
dissolved in 5 ml DCM in a 20 ml Scintillation vial. To this solution, 4Å 
molecular sieves, 4-methylmorpholine N-oxide (128.9 mg, 1.1 mmol, 1.4 equiv), and 
tetrapropylammonium perruthenate (27.6 mg, 0.08 mmol, 0.10 equiv.) was added. The mixture was 
stirred for 12 h at 23 °C. The reaction was loaded onto Celite and purified via flash column 
chromatography to yield 141.6 mg (74%) of (4R,6S,8S)-ethyl 4,6,8-trimethyl-9-oxononanoate as a clear 
oil. [α]20D = -2.7, c = 0.0077 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 9.57 (d, J = 2.6 Hz, 1H), 4.11 (q, 
J = 7.1 Hz, 2H), 2.48-2.19 (m, 3H), 1.75-1.49 (m, 4H), 1.39-1.25 (m, 1H), 1.24 (t, J = 7.1 Hz, 3H), 1.18-
0.93 (m, 3H), 1.08 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.5 Hz, 3H). 13C NMR (100 
MHz, CDCl3) δ 205.2, 173.9, 60.2, 44.7, 44.0, 38.2, 31.9, 31.5, 29.6, 27.8, 20.3, 19.8, 14.4, 14.2. Rf = 
0.48 (4:1 Hex:EtOAc; CAM). IR (NaCl, Thin Film) 2959, 29926, 2872, 1734, 1459, 1177, 1037 cm-1. 
HRMS (ESI/APCI) m/z [C14H30NO3]
+ (M+NH4) calcd 260.2220, found 260.2226. 
C10-C16 Fragment 
 
 (2S,4R)-2,4-dimethyl-5-oxohexanoic acid (2b). Zinc(II) bromide (14.25 g, 63.3 
mmol, 3 equiv.) was added to a flame dried 250 ml round bottom flask in a glove 
box. The reaction flask was removed from the glove box and the zinc bromide was 
dissolved in 150 ml THF under Ar. The reaction  was cooled to 0 °C and methyl magnesium bromide 
(24.3 ml, 63.3 mmol, 2.6M  in Et2O, 3.0 equiv.) was added slowly. A white precipitate formed and the 
reaction was stirred for 10 min. Stirring was discontinued and the precipitate was allowed to settle for 1 h 
at 0 °C. [Rh(nbd)Cl]2 (48.7 mg, 0.105 mmol, 0.5 mol %) and (R)-tBuPhox (81.8 mg, 0.211 mmol, 1 mol 
%) were added to a separate 300 ml flame dried round bottom flask in glove box. The reaction flask was 
removed from the glove box, charged with 16 ml THF, and stirred for 10 min resulting in an yellow 
solution. The freshly prepared THF solution of methyl zinc bromide was added to the rhodium precatalyst 
via syringe, leaving behind precipitate. The resulting reddish orange solution was stirred for 10 min and  
cis-2,4-dimethyl glutaric anhydride 1 (3.0 g, 21.1 mmol) was added as a solid (septa removed, anhydride 
added in one portion, and reaction flushed after addition of anhydride). The reaction was stirred at 23 °C 

















The layers were separated and the aqueous layer was extracted with EtOAc 3x. The organic phase was 
extracted with sat. NaHCO3 3x and collected into a beaker. With stirring, the aqueous solution was 
acidified using conc. HCl. The acidic solution was extracted with DCM 3x and the organic layer was 
dried with MgSO4, filtered, and concentrated to yield 3.29 g (99%) of (2S,4R)-2,4-dimethyl-5-
oxohexanoic acid as a pale yellow oil. Spectral data matches previous report.10 [α]20D =  +17.5, c = 0.0227 
g/ml CHCl3.
 1H NMR (400 MHz, CDCl3) δ 9.54 (s, 1H), 2.62 (m, 1H), 2.52 (m, 1H), 2.17 (s, 3H), 2.10 
(m, 1H), 1.38 (m, 1H), 1.21 (d, J = 7.0 Hz, 3H), 1.13 (d, J = 7.0 Hz). 13C NMR (100 MHz, CDCl3) δ 
211.8, 181.7, 44.9, 37.1, 36.0, 28.0, 17.6, 16.3. Rf = 0.22 (78:20:2 Hex:EtOAc:AcOH; CAM). IR (ATR) 
2974, 2938, 1734, 1704, 1462, 1357, 1179,1133, 941 cm-1. LRMS (ESI/APCI) m/z [C8H13O3]
- (M-H) 
calcd 157.1, found 157.3. 
 
 (2S,4R)-benzyl 2,4-dimethyl-5-oxohexanoate (S4). (2S,4R)-2,4-dimethyl-5-
oxohexanoic acid 2b (31.6 mg, 0.20 mmol) was dissolved in 3 ml DCM. 
Benzyl alcohol (28.1 mg, 0.26 mmol, 1.3 equiv), dicyclohexylcarbodiimide 
(53.6 mg, 0.20 mmol, 1.3 equiv), and dimethylaminopyridine (7.3 mg, 0.06 mmol, 0.3 equiv.) were added 
sequentially. The reaction was stirred at 23 °C for 2 h. The reaction was concentrated onto Celite and 
columned to yield 30.7 mg (62%) of (2S,4R)-benzyl 2,4-dimethyl-5-oxohexanoate as a clear oil.  1H 
NMR (300 MHz, CDCl3) δ 7.38-7.32 (m, 5H), 5.14 (d, J = 13.4 Hz, 1H), 5.10 (d, J = 13.4 Hz, 1H), 2.61-
2.42 (m, 2H), 2.08 (s, 3H), 2.08 (m, 1H),1.35 (m, 1H), 1.18 (d, J = 7.0 Hz, 3H), 1.08 (d, J = 7.0 Hz, 3H). 
Rf = 0.37 (4:1 Hex:EtOAc; UV, CAM). 87% ee by HPLC: Chiralcel IC column, 95:5 Hex:iPrOH, 1 
ml/min, RTmajor =  11.12 min, RTminor = 11.83 min, 210 nm. 
 
(2S,4R)-2,4-dimethylhexane-1,5-diol (S5). In a flame-dried 50 ml round bottom, 
lithium aluminum hydride (0.67 g, 17.7 mmol,  2 equiv.) was suspended in 10 ml 
THF and cooled to 0 °C. To this suspension, (2S,4R)-2,4-dimethyl-5-oxohexanoic 
acid 2b (1.4 g, 8.85 mmol) dissolved in THF (5 ml) was added slowly. The solution was allowed to warm 
to 23 °C and stirred for 12 h. The reaction was quenched by adding Na2SO4·10H2O portion wise until 
bubbling ceased. The mixture was allowed to stir for 45 minutes and filtered. The supernatant was 
concentrated to yield 1.28 g (99%) of (2S,4R)-2,4-dimethylhexane-1,5-diol as a clear oil of a 1:1.2 
mixture of diastereomers (inseparable by flash column chromotography). Spectral data matches previous 
report.10 1H NMR (300 MHz, CDCl3) δ 3.76 (diastereomer a, dq, J = 9.6, 3.0 Hz, 1 H), 3.56 (diastereomer 
b, dq, J = 6.0, 6.0 Hz, 1.2 H), 3.44 (m, 5.4 H), 2.71 (s, 5.4 H), 1.69 (m, 2.41 H), 1.58 (m, 5.3 H), 1.11 (d, J 
= 6.3 Hz, 7.7 H), 0.89 (m, 19.3 H). 13C NMR (75 MHz, CDCl3) δ 72.0, 69.8, 67.4, 37.7, 36.9, 36.5, 35.7, 
33.3, 32.9, 19.6, 19.5, 18.2, 17.8, 15.7, 15.0. Rf = 0.33 (EtOAc; CAM). IR (NaCl, Thin Film) 3356, 2968, 
2927, 2876, 1460, 1379, 1033 cm-1. HRMS (DART) m/z [C8H22O2N]














 (3R,5S)-6-iodo-3,5-dimethylhexan-2-ol (S6). In a 50 ml round bottom, (2S,4R)-2,4-
dimethylhexane-1,5-diol (0.969 g, 6.60 mmol) was dissolved in 30 ml DCM. Imidazole 
(0.472 g, 6.93 mmol, 1.1 equiv.) and triphenylphosphine (1.82 g, 6.93 mmol, 1.1 
equiv.) were added and the reaction mixture was cooled to 0 °C with an ice bath. To this solution, iodine 
(1.76 g, 6.93 mmol, 1.05 equiv.) was added in 3 portions. The reaction was heated to 45 °C for 1 h in an 
oil bath and cooled to room temperature. The reaction was absorbed onto Celite and purified via flash 
column chromatography to yield 1.15 g (68%) of  (3R,5S)-6-iodo-3,5-dimethylhexan-2-ol as a clear oil of 
a mixture of diastereomers.  1H NMR (300 MHz, CDCl3) δ 3.66 (m, 1H), 3.25 (m 1H), 3.12 (m, 1H), 1.61 
(bs, 1H), 1.45 (m, 3 H), 1.12 (m, 3H), 1.04 (m, 1H), 0.96 (m, 3H), 0.86 (m, 3H). 13C NMR (75 MHz, 
CDCl3) δ 71.4, 70.8, 39.4, 39.2, 37.0, 36.8, 31.5, 31.4, 21.8, 21.7, 20.3, 19.2, 18.0, 17.8, 14.8, 14.1. Rf = 
0.30 (4:1 Hex:EtOAc). IR (NaCl, Thin Film) 3385, 3967, 2927, 1457, 1378, 1195 cm-1. HRMS (DART) 
m/z [C8H21ION]
+ (M+NH4) calcd 274.0668, found 274.0660. 
 
 (3S,5R)-6-iodo-3,5-dimethylhexan-2-one (129). In a 50 ml round bottom, (3S,5R)-6-
iodo-3,5-dimethylhexan-2-ol ent-S6 (0.714g, 2.86 mmol) was dissolved in 10 ml DCM. 
To this solution, 4Å molecular seives, 4-methylmorpholine N-oxide (0.369 g, 3.15 
mmol, 1.1 equiv), and tetrapropylammonium perruthenate (50 mg, 0.14 mmol, 0.05 equiv) was added. 
The mixture was stirred for 12 h at 23 °C. The reaction was loaded onto Celite and purified via flash 
column chromatography to yield 0.665 g (94%) of (3S,5R)-6-iodo-3,5-dimethylhexan-2-one as a clear oil. 
[α]20D = +5.8, c = 0.0100 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 3.21 (dd, J = 9.8, 4.4 Hz, 1H), 3.14 
(dd, J = 9.8 Hz, 5.4 Hz, 1H), 2.56 (ddq, J = 7.2, 7.0, 7.0 Hz, 1H) 2.15 (s, 3H), 1.76 (ddd, J = 13.9, 7.7, 6.2 
Hz, 1H), 1.39 (m, 1H), 1.16 (ddd, J = 13.9, 7.1, 7.1 Hz, 1H), 1.09 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 6.5 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 212.0, 44.6, 39.5, 31.8, 27.9, 20.7, 17.4, 16.6. Rf = 0.31 (4:1 
Hex:EtOAc). IR (NaCl, Thin Film) 2965, 2931, 2875, 1712, 1459, 1237 cm-1. HRMS (DART) m/z 
[C8H19ION]
+ (M+NH4) calcd 272.0511, found 272.0504. 
 
 (3S,5R)-6-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dimethylhexan-2-
one (170). (3S,5R)-6-iodo-3,5-dimethylhexan-2-one 129 (70.0 mg, 0.28 mmol) 
was dissolved in 4 mL DMF and sodium azide (36.4 mg, 0.56 mmol, 2.0 
equiv) was added. The reaction was heated to 50 °C overnight. After cooling to 
23 °C, the reaction was diluted with EtOAc. The organic layer was washed 
with 10 % LiCl 3x, dried with MgSO4, and concentrated to yield 20.9 mg 
(45%) of (3S,5R)-6-azido-3,5-dimethylhexan-2-one (S7). 1H NMR (300 MHz, CDCl3) δ 3.20 (dd, J = 
12.1, 5.8 Hz, 1H), 3.13 (dd, J = 12.0, 6.3 Hz, 1H), 2.63 (m, 1H), 2.15 (s, 3H), 1.85-1.62 (m, 2H), 1.11 (m, 
1H), 1.11 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H). (3S,5R)-6-azido-3,5-dimethylhexan-2-one S7 
(20.9 mg, 0.123 mmol) and 1-bromo-4-ethynyl benzene (22.4 mg, 0.123 mmol, 1.0 equiv) were dissolved 
in 4 mL 1:1 H2O:tBuOH. Copper sulfate (4.0 mg, 0.025 mmol, 0.2 equiv.) and (+)-sodium (L)-ascorbate 
(24.0 mg, 0.123 mmol, 1.0 equiv) were added, resulting in an orange slurry. The reaction was stirred 
overnight and turned green. The reaction was diluted with H2O and EtOAc. The layers were separated and 
the aqueous was extracted with EtOAc 2x, the organic layers were combined and dried with MgSO4. The 

















(3S,5R)-6-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dimethylhexan-2-one as a white powder. [α]20D 
=  -4.2, c = 0.0315 g/ml CHCl3. 
1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.71 (m, 2H), 7.53 (m, 2H), 
4.28 (dd, J = 13.7, 6.3 Hz, 1H), 4.18 (dd, J = 13.7, 7.3 Hz, 1H), 2.67 (m, 1H), 2.11 (s, 3H), 2.08 (m, 1H), 
1.78 (ddd, J = 14.0, 9.2, 5.0 Hz, 1H), 1.14 (m, 1H), 1.12 (d, J = 7.1 Hz, 3H), 0.92 (d, J = 6.7 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 211.9, 146.7, 131.9, 129.6, 127.2, 121.9, 120.0, 56.2, 44.4, 36.9, 32.2, 28.1, 
17.6, 17.5. Rf = 0.16 (2:1 Hex:EtOAc). IR (ATR) 3130, 2966, 2933, 1708, 1457, 1356, 1227, 1069, 1010, 
972, 826 cm-1. LRMS (APCI/ESI) m/z [C16H21Br3O]
+ (M+H) calcd 350.1, found 350.0 and 351.0. Slow 




iodo-3,5-dimethylhexan-2-one 129 (0.665 g, 2.6 mmol) was dissolved in 7 ml benzene 
in a 10 ml round bottom flask. To this solution, p-toluenesulfonic acid monohydrate 
(89 mg, 0.52 mmol, 0.1 equiv) and ethylene glycol (0.7 ml, 13 mmol, 5 equiv) was added. A Dean Stark 
apparatus and reflux condenser were attached and the reaction was placed into a 100 °C oil bath for 1 h 
(longer reaction times lead to epimerization). The reaction was cooled to 23 °C and sat. NaHCO3 and 
EtOAc was added. The layers were separated and the aqueous layer was extracted with EtOAc 3x. The 
organic layer was washed with sat. NaCl, dried with MgSO4, concentrated, and purified via flash column 
chromatography to yield 0.658 g (85%) of 2-((2S,4R)-5-iodo-4-methylpentan-2-yl)-2-methyl-1,3-
dioxolane as a clear oil. [α]20D = -19.7, c = 0.0102 g/ml CHCl3. 
1H NMR (300 MHz, CDCl3) δ 3.92 (m, 
4H), 3.3 (dd, J = 9.7, 3.2 Hz, 1H), 3.1 (dd, J = 9.7, 5.7 Hz, 1H), 1.69 (m, 1H), 1.53 (m, 2H), 1.24 (s, 3H), 
1.05 (m, 1H), 0.99 (d, J = 6.2 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 112.1, 
64.6, 64.5, 38.6, 38.5, 31.9, 22.1, 20.3, 17.4, 14.9. Rf = 0.42 (4:1 Hex:EtOAc). IR (NaCl, Thin Film) 
2960, 2937, 2879, 1380, 1182, 1093, 1047 cm-1. MS (APCI) m/z [C10H20IO2]
+ calcd 299.1, found 299.1. 
 
 2-methyl-2-((2R,4S)-4-methyl-6-(phenylsulfonyl)hexan-2-yl)-1,3-dioxolane 
(169d). Methyl phenyl sulfone (25.9 mg, 1.66 mmol, 1.66 equiv.) was added to 
an oven dried 10 mL round bottom flask. The flask was put under Ar and the 
methyl phenyl sulfone was dissolved in 2 mL THF. The reaction was cooled to -78 °C and nBuLi (0.1 
mL, 1.5M in hexanes, 1.4 equiv.) was added. After stirring for 30 minutes, 2-((2R,4S)-5-iodo-4-
methylpentan-2-yl)-2-methyl-1,3-dioxolane S8 (29.8 mg, 0.1 mmol) was added in 2 mL THF. After 5 
minutes, HMPA was added. The reaction was stirred for 2.5 hours at -78 °C and then quenched with sat. 
NH4Cl. The reaction was extracted with Et2O 2x, dried with MgSO4, filtered, and purified by preparative 
thin layer chromatography to yield 19.4 mg (59%) of 2-methyl-2-((2R,4S)-4-methyl-6-
(phenylsulfonyl)hexan-2-yl)-1,3-dioxolane as a clear oil. 1H NMR (400 MHz, C6D6) δ 7.83-7.81 (m, 2H), 
6.98-6.90 (m, 3H), 3.53-3.45 (m, 4H), 2.95 (ddd, J = 13.4, 11.4, 4.2 Hz, 1H), 2.78 (ddd, J = 13.8, 11.0, 
5.0 Hz, 1H), 1.80 (m, 1H), 1.63 (m, 1H), 1.54-1.27 (m, 3H), 1.14 (s, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.85 
(m, 1H), 0.58 (d, J = 5.9 Hz, 3H). 13C NMR (100 MHz, C6D6) δ 140.7, 133.0, 129.0, 112.3, 64.6, 64.4, 
53.6, 39.0, 38.8, 29.6, 28.1, 20.3, 19.9, 15.6. Rf = 0.56 (1:1 Hex:EtOAc). IR (ATR) 2957, 2919, 2875, 
                                                            














1447, 1305, 1144, 1071, 742 cm-1. HRMS (APCI) m/z [C17H27O4S]




(S9). 1,3-Dithiane (0.94 g, 7.8 mmol, 5 equiv) was dissolved in 16 ml THF:HMPA 
(15:1). The solution was cooled to -30 °C with a dry ice:ethylene glycol:water bath. 
To this solution, n-BuLi (4.9 ml, 7.8 mmol, 5 equiv, 1.6 M in hexanes) was added and the solution went 
from clear to yellow. The mixture was stirred for 30 minutes and 2-((2S,4R)-5-iodo-4-methylpentan-2-
yl)-2-methyl-1,3-dioxolane S8 (0.466 g, 1.56 mmol) was added in 1 ml THF. The reaction was allowed to 
warm to 23 °C and stirred for 1 h. The reaction was quenched with addition of water and then EtOAc was 
added. The layers were separated and the aqueous layer was extracted with EtOAc 3x. The organic layer 
was washed with sat. NaCl, dried with MgSO4, concentrated, and purified via flash column 
chromatography to yield 0.43 g (95%) of 2-((2S,4R)-5-(1,3-dithian-2-yl)-4-methylpentan-2-yl)-2-methyl-
1,3-dioxolane as a clear oil. [α]20D = -31.3, c = 0.0107 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 4.10 
(dd, J = 10.2, 4.6 Hz, 1H), 3.91 (m, 4H), 2.86 (m, 4H), 2.12 (m, 1H), 1.86 (m, 1H), 1.75 (m, 1H), 1.47 (m, 
1H), 1.38 (m, 1H), 1.22 (s, 3H), 1.02 (m, 1H), 0.95 (d, J =  6.5 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 112.4, 64.6, 64.5, 45.6, 41.4, 39.5, 38.5, 30.7, 30.3, 27.5, 26.1, 20.9, 20.2, 
15.0. Rf = 0.26 (9:1 Hex:EtOAc). IR (NaCl, Thin Film) 2932, 2896, 1379, 1145, 1048, 867 cm
-1. HRMS 
(ESI/APCI) m/z [C14H27O2S2]
+ calcd 291.1447, found 291.1448. 
 
 (3R,5S)-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexanal (147). 2-((2S,4R)-5-
(1,3-dithian-2-yl)-4-methylpentan-2-yl)-2-methyl-1,3-dioxolane S9 (0.4 g, 1.38 
mmol) was dissolved in 20 ml MeCN:H2O (1:1). Sodium bicarbonate (1.88 g, 22.4 
mmol, 16 equiv) and iodomethane (1.4 ml, 22.4 mmol, 16 equiv) was added and the reaction was stirred 
for 16 h. The reaction was quenched with addition of water and then EtOAc was added. The layers were 
separated and the aqueous layer was extracted with EtOAc 3x. The organic layer was washed with sat. 
NaCl, dried with MgSO4, concentrated, and purified via flash column chromatography to yield 0.20 g 
(73%) of (3R,5S)-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexanal as a clear oil. [α]20D = -14.6, c = 
0.0105 g/ml CHCl3.  
1H NMR (300 MHz, CDCl3) δ 9.77 (dd, J = 2.0, 1.9 Hz, 1H), 3.92 (m, 4H), 2.43 
(ddd, J = 19.4, 7.9, 1.9 Hz, 1H), 2.16 (m, 2H), 1.68 (m, 1H), 1.53 (ddd, J = 13.5, 8.8, 3.6 Hz, 1H), 1.23 (s, 
3H), 1.09 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 202.8, 
112.1, 64.5, 64.4, 50.0, 39.2, 38.8, 26.1, 21.3, 19.9, 15.2. Rf = 0.27 (4:1 Hex:EtOAc). IR (NaCl, Thin 
Film) 2961, 2880, 1724, 1381, 1167, 1047 cm-1. HRMS (ESI/APCI) m/z [C11H21O3]
+ calcd 201.1485, 
found 201.1489. 
 
 (3S,5R)-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexan-1-ol (167). (3S,5R)-3-
methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexanal 147 (0.337 g, 1.68 mmol) was 
dissolved in 30 ml MeOH in a 100 ml round bottom flask. The reaction was cooled 
to 0 °C and sodium borohydride (0.127 g, 3.36 mmol, 2 equiv.) was added. The reaction was  stirred at 0 
















aqueous layer was extracted with EtOAc 2x. The organic layer was dried with MgSO4, filtered, 
concentrated. The resulting residue was purified by flash column chromotography to yield 0.289 g (85%) 
of (3S,5R)-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexan-1-ol as a clear oil. [α]20D = +4.1, c = 0.0043 
g/ml CHCl3. 
1H NMR (400 MHz, C6D6) δ 3.60-3.46 (m, 6H), 1.84 (m, 1H), 1.72-1.58 (m, 3H), 1.48 (m, 
1H), 1.24 (m, 4H), 1.05 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.3 Hz, 3H). 13C NMR (100 MHz, 
C6D6) δ 113.0, 65.0, 64.9, 61.0, 40.4, 39.7, 39.5, 28.3, 21.7, 20.6, 16.1. Rf = 0.16 (2:1 Hex:EtOAc). IR 
(NaCl, Thin Film) 3422, 2934, 2880, 1380, 1166, 1005, 871 cm-1. HRMS (APCI) m/z [C11H21O3]
- calcd 
201.16, found 201.1122. 
 
 2-((2R,4S)-6-iodo-4-methylhexan-2-yl)-2-methyl-1,3-dioxolane (160). (3S,5R)-3-
methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexan-1-ol 167 (162.4 mg, 0.80 mmol) was 
dissolved in DCM. Triphenyl phosphine (230.8 mg, 0.88 mmol, 1.1 equiv.) and 
imidizole (60.0 mg, 0.88 mmol, 1.1 equiv.) was added and the reaction mixture was cooled to 0 °C. 
Iodine (106.6 mg, 0.42 mmol, 0.52 equiv.) was added in 3 portions, the reaction was stirred for 4 h and 
allowed to warm to 23 °C. The reaction was diluted with DCM and absorbed onto Celite. The reaction 
was purified by flash column chromatography to yield 114.8 mg (46%) of 2-((2R,4S)-6-iodo-4-
methylhexan-2-yl)-2-methyl-1,3-dioxolane as a clear oil. 1H NMR (400 MHz, C6D6) δ 3.54-3.46 (m, 4H), 
2.93 (ddd, J = 9.5, 8.6, 5.0 Hz, 1H), 2.75 (m, 1H),  1.78 (m, 1H), 1.71 (m, 1H), 1.57-1.50 (m, 2H), 1.28 
(m, 1H), 1.19 (s, 3H), 1.01 (d, J = 6.8 Hz, 3H), 0.91 (m, 1H), 0.67 (d, J 6.3 Hz, 3H). 13C NMR (100 MHz, 
C6D6) δ 112.8, 65.0, 64.9, 40.5, 39.7, 39.5, 32.2, 20.6, 20.4, 16.0, 5.2. Rf = 0.23 (20:1 Hex:EtOAc). IR 
(NaCl, Thin Film) 2959, 2933, 2877, 1380, 1160, 1045, 872 cm-1. LRMS (ESI/APCI) m/z [C11H21IO2]
+ 




dioxolane 160 (250 mg, 0.8 mmol), 1-phenyl-tetrazole-5-thiol (214 mg, 1.2 
mmol, 1.5 equiv), and  potassium carbonate (166 mg, 1.2 mmol, 1.5 equiv) 
were added  to 6 ml DMF. The solution was heated to 50 °C for 2 h. After cooling to 23 °C, EtOAc was 
added and the organic solution was washed with 10 % LiCl 3x. The organic layer was dried with MgSO4, 
filtered, concentrated, and purified by flash column chromatography to yield 124.1 mg (92%) of 5-
(((3R,5S)-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexyl)thio)-1-phenyl-1H-tetrazole as a clear oil.  [α]20D 
=  -18.2, c = 0.00103 g/ml CHCl3. 
1H NMR (300 MHz, CDCl3) δ 7.55 (m, 5H), 3.9 (m, 4H), 3.51 (ddd, J 
= 12.3, 9.8, 5.1 Hz, 1H), 3..31 (ddd, J = 12.7, 9.5, 6.7 Hz, 1H), 1.87 (m, 1H), 1.71 (m, 2H), 1.55 (m, 2H), 
1.22 (s, 3H), 1.05 (m, 1H), 0.98 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 154.4, 133.7, 130.0, 129.7, 123.8, 112.3, 64.5, 64.4, 39.0, 38.7, 34.7, 31.0, 30.0, 20.5, 20.0, 15.2. Rf = 
0.42 (2:1 Hex:EtOAc). IR (NaCl, Thin Film) 2959, 2935, 2879, 1500, 1412, 1075,  762 cm-1. HRMS 
(ESI/APCI) m/z [C18H27N4O2S]
+ calcd 363.1849, found 363.1837. 
 (3S,5R)-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexan-1-ol 167 (47.2 mg, 0.23 mmol), triphenyl 
phosphine (73.3 mg, 0.28 mmol, 1.2 equiv.), 1-phenyl-tetrazole-5-thiol (49.9 mg, 0.28 mmol, 1.2 equiv.) 
were dissolved in 5 mL THF and the reaction vessel was cooled to 0 °C under Ar. Diisopropyl 














allowed to warm to 23 °C. The reaction was quenched with sat. NH4Cl and separated. The aqueous layer 
was extracted with EtOAc 2x. The organic layers were combined, washed with brine, and dried with 
MgSO4, filtered, and concentrated. The resulting residue was purified by flash column chromatography to 





2-yl)hexyl)thio)-1-phenyl-1H-tetrazole 168 (107.7 mg, 0.30 mmol) and meta-
chloroperoxybenzoic acid (235 mg, 1.05 mmol, 3.5 equiv.) were dissolved in 
10 ml DCM and stirred for 12 h. The organic solution was diluted with DCM and washed with sat. 
NaHCO3 3x and brine. The organic layer was dried with MgSO4, concentrated, and purified via flash 
column chromatography to yield 99.1 mg (85%) of 5-(((3R,5S )-3-methyl-5-(2-methyl-1,3-dioxolan-2-
yl)hexyl)sulfonyl)-1-phenyl-1H-tetrazole as an amorphous solid. [α]20D =  -11.1, c = 0.00103 g/ml CHCl3.
 
1H NMR (300 MHz, CDCl3) δ 7.68 (m, 2H), 7.60 (m, 3H), 3.91 (m, 4H), 3.81 (m, 1H), 3.66 (m, 1H), 1.98 
(m, 1H), 1.72 (m, 2H), 1.51 (ddd, J = 12.8, 9.0, 3.3 Hz, 1H), 1.21 (s, 3H), 1.06 (m, 1H), 0.98 (d, J = 6.4 
Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 153.4, 133.0, 131.4, 129.6, 125.0, 112.2, 
64.6, 64.5, 53.6, 38.7, 38.4, 29.5, 26.9, 20.3, 19.8, 15.3. Rf = 0.14 (4:1 Hex:EtOAc). IR (NaCl, Thin Film) 
2961, 2938, 2880, 1498, 1342, 1152, 1047 cm-1. HRMS (ESI/APCI) m/z [C18H26N4O4SNa]
+ calcd 
417.1567, found 417.1570. 
(3S,5R)-3,5-dimethyl-7-((1-phenyl-1H-tetrazol-5-yl)sulfonyl)heptan-2-one 
(119a). 5-(((3R,5S)-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)hexyl)sulfonyl)-
1-phenyl-1H-tetrazole 169a (197 mg, 0.5 mmol) was dissolved in MeCN and 
then sodium iodide (12 mg, 0.08 mmol, 0.15 equiv.) and cerium trichloride 
heptahydrate (280 mg, 0.75 mmol, 1.5 equiv.) were added.12  The solution was stirred for 16 h before 
being diluted with Et2O and 0.5M HCl. The layers were separated and the aqueous was extracted with 
Et2O 3x. The organic layer was washed 3x with sat. NaHCO3 and 1x with brine, dried with MgSO4, 
concentrated, and columned to yield 154.3 mg of (3S,5R)-3,5-dimethyl-7-((1-phenyl-1H-tetrazol-5-
yl)sulfonyl)heptan-2-one (88%) as a clear oil. [α]20D =  -1.6, c = 0.0153 g/ml CHCl3.
 1H NMR (300 MHz, 
CDCl3) δ 7.69 (m, 2H), 7.60 (m, 3H), 3.78 (m, 1H), 3.70 (m, 1H), 2.64 (m, 1H), 2.14 (s, 3H), 1.93 (dddd, 
J = 13.6, 11.2, 5.7, 5.7 Hz, 1H), 1.76 (m, 2H), 1.60 (m, 1H), 1.13 (m, 1H), 1.10 (d, J = 7.1 Hz, 3H), 0.96 
(d, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 212.0, 153.4, 133.0, 131.4, 129.7, 125.0, 54.0, 44.5, 
39.1, 30.0, 28.6, 28.3, 19.3, 17.4. Rf = 0.27 (2:1 Hex:EtOAc). IR (NaCl, Thin Film) 2966, 2933, 2877, 
1710, 1342, 1104 cm-1. HRMS (ESI/APCI) m/z [C16H23N4O3S]





12 For use of CeCl3·7H2O/NaI in dioxolane deprotection, see: Marcantoni, E.; Nobili, F.; Bartoli, G.; Bosco, M.; 




















 2,4-dimethylpenta-1,4-dien-3-ol (S10). Magnesium (3 g, 123 mmol, 1.4 equiv.) and stir 
bar were flame dried in a 250 ml round bottom flask. After cooling to 23 °C, a small I2 
crystal and 60 ml THF was added. A reflux condenser was attached and the reaction was 
flushed with Ar. 1 ml of freshly distilled 2-bromopropene (7.5 ml, 84.4 mmol) was added and the reaction 
was stirred until initiation. After initiation, the 2-bromopropene was added to keep the reaction at reflux. 
After addition, the reaction was stirred until it cooled to 23 °C and was then further cooled to 0 °C with an 
ice bath. Freshly distilled methacrolein (10 ml, 121 mmol, 1.4 equiv.) was slowly added. The ice bath was 
removed and the reaction was stirred for 3 h. The reaction was decanted away from the excess magnesium 
into a 500 ml Erlenmeyer and rinsed with 50 mL Et2O. The organic layer was quenched by addition of 1 
M HCl. The reaction was added to a seperatory funnel and the aqueous was extracted 2x with 100 mL 
Et2O. The organic was washed with 100 mL sat. brine, dried with MgSO4, and concentrated to yield 8.0-
8.5 g (85-90%) of 2,4-dimethylpenta-1,4-dien-3-ol as a viscous oil. The crude product was used directly 
in the next reaction. Attempts to purify by flash column chromatography or distillation lead to 
decomposition. 1H NMR (300 MHz, CDCl3) δ 5.06 (m, 2H), 4.94 (m, 2H), 4.48 (bs, 1H), 2.23 (bs, 1H), 
1.64 (bs, 6H). bp: 74 °C at 48 torr. 
 
 (((2,4-dimethylpenta-1,4-dien-3-yl)oxy)methyl)benzene (132b). Sodium hydride (5.3 g, 
133.5 mmol, 1.5 equiv., 60% in mineral oil) was suspended in 100 ml THF under Ar. The 
reaction vessel was cooled to 0 °C with an ice bath. 2,4-dimethylpenta-1,4-dien-3-ol S10 
(9.98 g, 89.0 mmol) was dissolved in 10 ml THF and added slowly to the reaction vessel. The reaction 
was stirred for 45 min and benzyl bromide (12.7 ml, 106.8 mmol, 1.2 equiv.) was added. The reaction 
was stirred at 23 °C for 12 h. The reaction was quenched with H2O and extracted with Et2O 3x. The 
organic layer was dried and concentrated to yield a yellow syrup consisting of a mixture of (((2,4-
dimethylpenta-1,4-dien-3-yl)oxy)methyl)benzene, benzyl bromide, and mineral oil. This mixture can be 
used directly in the hydroboration reaction or purified. Vacuum distillation yields (((2,4-dimethylpenta-
1,4-dien-3-yl)oxy)methyl)benzene as a clear oil with minor benzyl bromide impurities, but free of mineral 
oil. Purification via flash column chromatography yields 9.37 g (52%) of (((2,4-dimethylpenta-1,4-dien-
3-yl)oxy)methyl)benzene as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.38-7.32 (m, 4H), 7.29-7.25 (1H), 
5.10 (m, 2H), 5.00 (m, 2H), 4.47 (s, 2H), 4.12 (s, 1H), 1.65 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 
143.0, 138.8, 128.2, 127.4, 127.2, 112.9, 85.7, 69.7, 18.0. Rf = 0.14 (95:5 Hex:DCM). bp: 55 °C at 4 torr. 
IR (ATR) 3068, 2973, 2856, 1453, 1074, 900, 733, 695 cm-1. HRMS (APCI) m/z [C14H19O]
+ (M+H) calcd 
203.1430, found 203.1433. 
 
 (2R,3s,4S)-3-(benzyloxy)-2,4-dimethylpentane-1,5-diol (133b). A 500 ml pressure 
equalizing addition funnel and 2000 ml round bottom flask were flame dried under 
vacuum. (((2,4-dimethylpenta-1,4-dien-3-yl)oxy)methyl)benzene 132b (7.00 g, 34.6 
mmol) was dissolved in 200 ml THF under Ar in the round bottom flask. The reaction flask was cooled to 












addition funnel. The 9-borabicyclo[3.3.1]nonane solution was added to the reaction over 1 h. The reaction 
was stirred 36 h and allowed to warm to 23 °C.13 The reaction was cooled to 0 °C and aqueous sodium 
hydroxide (140 ml, 42 mmol, 3M, 12.1 equiv.) was added slowly over 1.5 h. While still maintaining 0 °C, 
hydrogen peroxide (56 ml, 554 mmol, 30% wt. in H2O, 16 equiv.) was added slowly over 1.5 h. The 
reaction was stirred for 24 h and allowed to warm to 23 °C. The solution was filtered through Celite to 
remove the formed solids and extracted with Et2O 3x. The organic layer was washed with D.I. H2O 2x (to 
remove some cyclooctane-1,5-diol) and brine 1x. The organic layer was dried with MgSO4, filtered, and 
concentrated to a thick syrup. This syrup was dissolved in minimal Et2O; a seed crystal of cyclooctane-
1,5-diol was added and the flask was cooled to -15 °C for 12h. The mother liquor was decanted away 
from the solid cyclooctane-1,5-diol, concentrated, and purified via flash column chromatography to yield 
4.90 g (58%) of (2R,3s,4S)-3-(benzyloxy)-2,4-dimethylpentane-1,5-diol as a clear oil and a 3.5:1 mixture 
of diastereomers (anti, anti diol: anti, syn diol). 1H NMR (400 MHz, CDCl3) δ 7.36-7.29 (m, 5H), 4.66 (s, 
2H), 3.77 (dd, J = 11.0, 4.1 Hz, 2H), 3.66 (dd, J = 11.0, 5.3 Hz, 2H), 3.45 (t, J = 5.8 Hz, 1H), 2.07 (s, 
2H), 2.00 (m, 2H), 1.08 (d, J = 7.1 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 137.7, 128.6, 128.1, 128.0, 
88.4, 75.8, 65.3, 37.8, 15.4. Rf = 0.22 (1:1 Hex:EtOAc; CAM). IR (ATR) 3345, 2961, 2926, 2876, 1454, 
1066, 1028 cm-1. LRMS (ESI/APCI) m/z [C14H23O3]
+ (M+H) calcd 239.2, found 239.1. 
 
 (2R,3r,4S)-3-(benzyloxy)-2,4-dimethylpentanedial (149b). Dimethyl sulfoxide (2.07 
ml, 29.28 mmol, 3.05 equiv.) was dissolved in 22 ml DCM under Ar and the reaction 
was cooled to -78 °C. Oxalyl chloride (2.43 ml, 28.3 mmol, 2.95 equiv.) was added 
slowly and the reaction was stirred for 20 min. (2R,3s,4S)-3-(benzyloxy)-2,4-dimethylpentane-1,5-diol 
133b (2.29 g, 9.6 mmol) was dissolved in 10 mml DCM and added slowly to the reaction. After stirring 
for 45 min, triethyl amine (13.4 ml, 96 mmol, 10.0 equiv.) and the reaction was placed in an ice bath for 2 
h. At this time, 45 ml PhMe was added and the reaction was filtered through a pad of Celite eluting with 
30 ml Et2O 2x. The filtrate was quickly concentrated to ~1/10 volume via rotovap. The filtrate was diluted 
with E2O and filtered through a pad of Celite. The reaction was concentrated to ~1/10 volume and quickly 
used in the next reaction. If the product is overly concentrated or allowed to sit, the product decomposes 
(light yellow to orange to brown). 1H NMR (300 MHz, CDCl3) δ 9.7 (d, J = 1.9 Hz, 2H), 7.36-7.13 (m, 
5H), 4.59 (s, 2H), 4.08 (t, J = 5.8 Hz, 1H), 2.78 (m, 2H), 1.13 (d, J = 7.2 Hz, 6H). 
 
 (2R,3r,4S)-3-(benzyloxy)-2,4-dimethylpentanedioic acid (S11). (2R,3r,4S)-3-
(benzyloxy)-2,4-dimethylpentanedial 149b (~9.6 mmol) and 2-methyl-2-butene (10.2 
ml, 96 mmol, 10.0 equiv.) were dissolved in 30 ml of a 1:1 THF:tBuOH mixture. The 
reaction was cooled to 0 °C with an ice bath. Sodium chlorite (5.43 g, 48 mmol, 5.0 equiv., technical 
grade, 80%) and sodium phosphate monobasic monohydrate (13.24 g, 96 mmol, 10.0 equiv.) was 
dissolved in 60 ml H2O. This solution was added to the dialdehyde solution via additional funnel over 20 
min. The reaction was allowed to stir overnight. The reaction mixture was made acidic (pH = 1) using 
                                                            
13 If reaction is not stirred at 23 °C for extended time, the second hydroboration does not occur. Early workup of the 
reaction leads to alkenol: 3-(benzyloxy)-2,4-dimethylpent-4-en-1-ol. 1H NMR (300 MHz, CDCl3) δ 7.38-7.29 (m, 
5H), 5.07 (m, 1H), 4.93 (m, 1H), 4.53 (d, J = 11.6 Hz, 1H), 4.25 (d, J = 11.6 Hz, 1H), 3.63-3.59 (m, 2H), 1.98 (m, 
1H), 1.72 (m, 3H), 1.53 (m, 1H), 0.72 (d, J = 7.0 Hz, 3H). Rf = 0.54 (1:1 Hex:EtOAc; CAM). After purification via 











conc. HCl and the reaction was extracted with EtOAc 3x. The organic layer was dried and concentrated to 
yield (2R,3r,4S)-3-(benzyloxy)-2,4-dimethylpentanedioic acid as an impure oil that was used in the next 
reaction. 1H NMR (400 MHz, CDCl3) δ 9.81 (bs, 2H), 7.31-7.23 (m, 5H), 4.63 (s, 2H), 4.06 (t, J = 6.2 Hz, 
1H),  2.91 (m, 2H), 1.22 (d, J = 7.2 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 179.4, 137.4, 128.4, 127.8, 
127.8, 82.1, 74.0, 42.1, 12.8. IR (ATR) 2981, 2943, 2887, 1705, 1218, 1069 cm-1. LRMS (ESI/APCI) m/z 
[C14H18O5]
- (M-H) calcd 265.1, found 265.4. 
 
 Cis, cis-3-(benzyloxy)-2,4-dimethyl glutaric anhydride (3b). (2R,3r,4S)-3-(benzyloxy)-
2,4-dimethylpentanedioic acid S11 (~9.6 mmol) was dissolved in 20 ml DCM and cooled 
to °C. Trifluoroacetic anhydride (2.6 ml, 18.6 mmol, 2.0 equiv.) was added slowly and the 
reaction was stirred for 1 h. The reaction mixture was concentrated en vacuo and the resulting light brown 
paste was tritrated with Et2O to yield 0.644 g (27% over three steps) of cis, cis-3-(benzyloxy)-2,4-
dimethyl glutaric anhydride as a white powder. 1H NMR (400 MHz, CDCl3) δ 7.36-7.25 (m, 5H), 4.68 (s, 
2H), 3.81 (t, J = 2.4 Hz, 1H), 2.84 (dq, J = 6.8, 2.4 Hz, 2H), 1.40 (d, J = 6.8 Hz, 6H). 13C NMR (100 
MHz, CDCl3) δ 168.6, 136.9, 128.5, 128.2, 127.8, 78.5, 76.0, 43.7, 12.9. IR (NaCl, Thin Film) 2979, 
1802, 1773, 1053 cm-1. LRMS (ESI/APCI) m/z [C14H16O4Na]
+ (M+Na) calcd 271.1, found 271.1. Slow 
evaporation of an Et2O solution yielded clear, X-ray quality needles.
14 
 
 (2S,3S,4R)-3-(benzyloxy)-2,4-dimethyl-5-oxohexanoic acid (4b). Zinc(II) bromide 
(5.123 g, 22.75 mmol, 3.5 equiv.) was added to a flame dried 300 ml round bottom 
flask in a glove box. The reaction flask was removed from the glove box and the zinc 
bromide was dissolved in 115 ml THF under Ar. The reaction was cooled to 0 °C and 
methyl magnesium bromide (8.75 ml, 22.75 mmol, 2.6M  in Et2O, 3.5 equiv.) was 
added slowly. A white precipitate formed and the reaction was stirred for 10 min. 
Stirring was discontinued and the precipitate was allowed to settle for 1 h at 0 °C. [Rh(nbd)Cl]2 (59.9 mg, 
0.13 mmol, 2 mol %) and (R)-tBuPhox (100.7 mg, 0.26 mmol, 4 mol %) were added to a separate 250 ml 
flame dried round bottom flask in glove box. The reaction flask was removed from the glove box, charged 
with 16 ml THF, and stirred for 10 min resulting in an yellow solution. The freshly prepared THF 
solution of methyl zinc bromide was added to the rhodium precatalyst via syringe, leaving behind 
precipitate. The resulting reddish orange solution was stirred for 10 min and cis, cis-3-(benzyloxy)-2,4-
dimethyl glutaric anhydride 3b (1.61 g, 6.5 mmol) was added as a solid (septa removed, anhydride added 
in one portion, and reaction flushed after addition of anhydride). The reaction was stirred at 23 °C for 16 
h and precipitate formed. The reaction was quenched slowly with 1 M HCl and EtOAc was added. The 
layers were separated and the aqueous layer was extracted with EtOAc 3x. The organic phase was 
extracted with sat. NaHCO3 3x and collected into a beaker. With stirring and cooled to 0 °C (excessive 
heat causes benzyl alcohol elimination), the aqueous solution was acidified using conc. HCl. The acidic 
solution was extracted with DCM 3x and the organic layer was dried with MgSO4, filtered, and 
concentrated to yield 1.03 g (60%) of (2S,3S,4R)-3-(benzyloxy)-2,4-dimethyl-5-oxohexanoic acid as a 
pale yellow oil. [α]20D = -6.5, c = 0.0110 g/ml CH2Cl2.
 1H NMR (400 MHz, CDCl3) δ 11.12 (br, 1H), 
                                                            












7.24-7.18 (m, 5H), 4.53 (d, J = 11.2 Hz, 1H), 4.45 (d, J = 11.2 Hz, 1H), 3.96 (dd, J = 8.0, 4.0 Hz, 1H), 
2.90 (m, 1H), 2.78 (m, 1H), 2.17 (s, 3H), 1.25 (d, J = 7.2 Hz, 3H), 1.07 (d, J = 7.2 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ 211.2, 179.1, 137.6, 128.4, 127.8, 82.7, 74.2, 49.2, 41.6, 30.3, 12.9, 12.6. Rf = 0.15 
(78:20:2 Hex:EtOAc:AcOH; CAM). IR (ATR) 3090, 3032, 2982, 2886, 1738, 1711, 1497, 1087 cm-1. 
LRMS (ESI/APCI) m/z [C15H20O4Na]
+ (M+Na) calcd 287.1, found 287.1. 
 
 (2R,3R,4S)-3-(benzyloxy)-2,4-dimethylhexane-1,5-diol (S12). Lithium aluminum 
hydride (167 mg, 4.4 mmol, 2.0 equiv.) was suspended in 20 ml THF and cooled to 0 
°C. (2S,3S,4R)-3-(benzyloxy)-2,4-dimethyl-5-oxohexanoic acid 4b (581.5 mg, 2.2 
mmol) was added slowly  in 15 ml THF. The reaction was stirred and allowed to 
warm to 23 °C for 16 h. The reaction was quenched by adding Na2SO4·10H2O portion 
wise until bubbling ceased. The mixture was allowed to stir for 45 minutes and 
filtered. The supernatant was concentrated to yield 410.8 mg (74%) of (2R,3R,4S)-3-(benzyloxy)-2,4-
dimethylhexane-1,5-diol as a clear oil. The crude mixture of diastereomers can be used in the next 
reaction or purified via flash column chromatography. Less polar diastereomer: 1H NMR (400 MHz, 
CDCl3) δ 7.37-7.28 (m, 5H), 4.70 (d, J = 14.8 Hz, 1H), 4.67 (d, J = 14.8 Hz, 1H), 4.24 (dq, J = 6.5, 1.6 
Hz, 1H), 3.76 (dd, J = 10.8, 4.1 Hz, 1H), 3.68 (dd, J = 10.8, 4.7 Hz, 1H), 3.50 (dd, J = 7.6, 4.2 Hz, 1H), 
2.47 (bs, 2H), 2.04 (m, 1H), 1.72 (m, 1H), 1.16 (d, J = 6.5 Hz, 3H), 1.08 (d, J = 7.1 Hz, 3H), 1.01 (d, J = 
7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 137.6, 128.6, 128.1, 127.9, 88.5, 76.2, 66.2, 65.4, 40.0, 37.8, 
20.9, 15.2, 11.2. Rf = 0.30 (1:1 Hex:EtOAc; CAM). IR (NaCl, Thin Film) 3386, 2970, 2932, 2879, 1455, 
1064 cm-1. HRMS (APCI) m/z [C15H23O3]
- (M-H) calcd 251.1653, found 251.1658. More polar 
diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.37-7.29  (m, 5H), 4.65 (d, J = 14.8 Hz, 1H), 4.62 (d, J = 
14.8 Hz, 1H), 3.88 (dd, J = 7.6, 1.2 Hz, 1H), 3.72 (dd, J = 11.1, 4.2 Hz, 1H), 3.64 (dd, J = 11.1, 5.7 Hz, 
1H), 3.44 (m, 1H), 2.02 (m, 1H), 1.90 (m, 1H), 1.18 (d, J = 6.2 Hz, 3H), 1.09 (d, J = 7.1 Hz, 3H), 0.92 (d, 
J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 137.5, 128.6, 128.1, 128.0, 88.9, 75.3, 69.8, 65.4, 43.5, 
38.2, 20.7, 15.7, 14.4. Rf = 0.20 (1:1 Hex:EtOAc; CAM). 
 
(3S,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-
dimethylhexan-2-ol (S13). Procedure adapted from literature procedure.15 
(3S,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexan-
2-ol S12 (122.8 mg, 0.49 mmol) dissolved in 6 mL DMF. Imidazole (73.0 mg, 
1.07 mmol, 2.2 equiv.) and then tert-butyldiphenylsilyl chloride (0.14 mL, 
0.535 mmol, 1.1 equiv.) was added. The reaction was stirred overnight at 23 
°C. The reaction was diluted with EtOAc (100 mL) and washed with 10% LiCl 3x. The organic layer was 
dried with MgSO4, filtered, and concentrated. The resulting residue was loaded onto Celite and purified 
by flash column chromatography to yield 202.3 mg (85%) of (3S,4R,5R)-4-(benzyloxy)-6-((tert-
butyldiphenylsilyl)oxy)-3,5-dimethylhexan-2-ol as a clear oil. Less polar diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.72-7.62 (m, 4H), 7.44-7.31 (m, 6H), 7.24 (m, 3H), 7.09 (m, 2H), 4.54 (d, J = 10.7 Hz, 
1H), 4.50 (d, J = 10.7 Hz, 1H), 4.16 (dd, J = 6.4, 1.1 Hz, 1H), 3.81 (dd, J = 9.9, 5.2 Hz, 1H), 3.74 (dd, J = 
9.9, 3.8 Hz, 1H), 1.10 (d, J = 6.5 Hz, 3H), 1.08 (s, 9H), 1.07 (m, 3H), 0.97 (d, J = 6.9 Hz, 3H). 13C NMR 
                                                            


















(100 MHz, CDCl3) δ 138.0, 135.8, 135.7, 135.2, 134.8, 133.7, 133.6, 129.6, 129.6, 129.6, 128.4, 127.7, 
127.7, 127.7, 127.6, 86.6, 75.6, 66.2, 65.6, 38.8, 38.6, 27.0, 26.6, 20.6, 19.3, 19.0, 14.7, 11.5. Rf = 0.32 
(9:1 Hex:EtOAc). More polar diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.67-7.65 (m, 4H), 7.44-7.21 
(m, 11H), 4.58 (d, J = 11.0 Hz, 1H), 4.54 (d, J = 11.0 Hz, 1H), 3.81 (m, 1H), 3.78 (dd, J = 10.1, 5.4 Hz, 
1H), 3.67 (dd, J = 10.1, 6.6 Hz, 1H), 3.40 (dd, J = 6.8 Hz, 4.9 Hz, 1H), 3.24 (bs, 1H), 2.07 (m, 1H), 1.76 
(m, 1H), 1.12 (d, J = 6.2 Hz, 3H), 1.07 (s, 9H), 1.06 (m, 3H), 0.83 (d, J = 7.0 Hz, 3H). 13C NMR (100 
MHz, CDCl3) δ 138.0, 135.7, 135.6, 133.8, 133.7, 129.6, 129.5, 128.4, 127.7, 127.7, 127.6, 127.6, 87.0, 
74.7, 70.3, 65.4, 42.4, 39.6, 26.9, 20.5, 19.2, 15.2, 14.7. Rf = 0.12 (9:1 Hex:EtOAc). IR (ATR) 3428, 
2962, 2930, 2857, 1427, 1390, 1111, 1062, 700 cm-1. HRMS (APCI) m/z [C31H42NaO3Si]
+ (M+Na) calcd 




butyldiphenylsilyl)oxy)-3,5-dimethylhexan-2-ol S13 (101.7 mg, 0.21 mmol) 
was dissolved in 8 mL DCM and two scoops of 4 A MS was added. 4-
methylmorpholine N-oxide (30.3 mg, 0.26 mmol, 1.25 equiv.) and then tetrapropylammonium 
perruthenate (7.3 mg, 0.21 mmol, 0.1 equiv.) were added. The reaction was stirred for 12 h at 23 °C. The 
entire reaction was loaded onto Celite and purified by flash column chromatography to yield 86.0 mg 
(85%) of (3R,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexan-2-one as a clear 
oil [Caution: this compound decomposes at ambient conditions over time through elimination of benzyl 
alcohol and should be stored frozen in benzene or used soon after making]. [α]20D =  -23.0, c = 0.0078 
g/ml CHCl3.
 1H NMR (400 MHz, CDCl3) δ 7.72-7.69 (m, 4H), 7.46-7.21 (m, 11H), 4.52 (d, J = 11.0 Hz, 
1H), 4.48 (d, J = 11.0 Hz, 1H), 3.82 (dd, J = 10.0, 5.8 Hz, 1H), 3.73 (dd, J = 7.8, 4.4 Hz, 1H), 3.70 (dd, J 
= 10.0, 6.2 Hz, 1H), 3.03 (m, 1H), 2.16 (s, 3H), 2.03 (m, 1H), 1.10 (s, 9H), 1.04 (d, J  = 7.0 Hz, 3H), 1.04 
(d, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 212.3, 138.6, 135.6, 135.6, 134.8, 133.6, 129.6, 128.2, 
127.6, 127.6, 127.5, 127.4, 83.8, 74.4, 65.1, 49.2, 38.1, 30.6, 26.9, 19.2, 14.9, 13.4. Rf = 0.32 (9:1 
Hex:EtOAc). IR (ATR) 3071, 2961, 2930, 2857, 1714, 1428, 1112, 1067, 740, 701 cm-1. HRMS (APCI) 
m/z [C31H44NO3Si]
+ (M+NH4) calcd 506.3090, found 506.3085. 
(3R,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-
dimethylhex-1-en-2-yl diethyl phosphate (205). Lithium 
bis(trimethylsilyl)amide (52.2 mg, 0.312 mmol, 1.05 equiv.) was added to a 
25 mL round bottom flask in an inert air glove box. The reaction vessel was 
sealed and 6 mL of freshly pulled toluene was added. The reaction flask was cooled to -78 °C and 
(3R,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexan-2-one 182 (145.0 mg, 
0.297 mmol) was added in 6 mL THF. The reaction was stirred for 30 min and diethyl chlorophosphate 
(0.05 mL, 0.327 mmol, 1.1 equiv) was added. The reaction was stirred for 12 h and allowed to warm to 23 
°C. The reaction was quenched with sat. NH4Cl and extracted with EtOAc 3x. The organic layers were 
combined, dried with MgSO4, filtered, and dried. The resulting residue was loaded onto Celite and 
purified via flash column chromatography to yield 119.2 mg of (3R,4R,5R)-4-(benzyloxy)-6-((tert-
butyldiphenylsilyl)oxy)-3,5-dimethylhex-1-en-2-yl diethyl phosphate (64%) as an oil. [α]20D =  -1.7, c = 
0.0131 g/ml CHCl3.
 1H NMR (300 MHz, CDCl3) δ 7.68-7.64 (m, 4H), 7.41-7.23 (m, 11), 4.90 (dd, J = 






























(m, 4 H), 3.78 (dd, J = 9.9, 4.9 Hz, 1H), 3.68 (dd, J = 9.9, 6.2 Hz, 1H), 3.49 (t, J = 6.0 Hz, 1H), 2.71 (m, 
1H), 2.01 (m, 1H), 1.30 (m, 6H), 1.11 (d, J = 7.0 Hz, 3H), 1.06 (s, 9H), 1.04 (d, J = 7.0 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 157.2 (d, 
2JCP = 9.5 Hz), 138.9, 135.7, 135.6, 133.8, 133.7, 129.5, 129.5, 128.1, 
127.6, 127.6, 127.2, 97.1, 97.0, 82.6, 74.4, 65.2, 64.2 (d, 2JCP = 6.0 Hz), 64.2 (d, 
2JCP = 5.9 Hz), 41.9 (d, 
3JCP = 6.6 Hz), 37.9, 26.9, 19.2, 16.1 (d, 
3JCP = 6.8 Hz), 15.4, 15.1. 
31P NMR (121 MHz, CDCl3) δ -5.59. 
Rf = 0.34 (2:1 Hex:EtOAc). IR (ATR) 3070, 2961, 2931, 2857, 1472, 1273, 1062, 1029, 998, 702 cm
-1. 
HRMS (APCI) m/z [C35H53NO6PSi]
+ (M+NH4) calcd 642.3380, found 642.3379. 
 
(3R,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-
dimethylhex-1-en-2-yl trifluoromethanesulfonate (238). Potassium 
bis(trimethylsilyl)amide (10.2 mg, 0.051 mmol, 1.1 equiv) was added to an 
oven dried 10 ml round bottom flask in an inert air glovebox. The reaction 
flask was removed and put under Ar. The potassium bis(trimethylsilyl)amide was dissolved in 1.5 mL of 
PhMe and the flask was cooled to -78 °C. (3R,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-
dimethylhexan-2-one 182 (22.4 mg, 0.046 mmol) was dissolved in 1 mL THF and added to the cooled 
reaction flask. After stirring for 30 min, N-phenyl-bis(trifluoromethanesulfonimide) (21.4 mg, 0.060 
mmol, 1.3 equiv) dissolved in 1 mL of THF was added. After stirring for 30 min at -78 °C, the reaction 
was warmed to 0 °C and quenched with brine. The aqueous layers were extracted with Et2O 2x. The 
organic layer was dried with MgSO4, filtered, and concentrated. The resulting residue was purified via 
column chromatography that resulted in 12.3 mg of slightly impure (3R,4R,5R)-4-(benzyloxy)-6-((tert-
butyldiphenylsilyl)oxy)-3,5-dimethylhex-1-en-2-yl trifluoromethanesulfonate (43%) as a clear oil. [α]20D 
=  -8.6, c = 0.0120 g/ml CHCl3.
 1H NMR (400 MHz, CDCl3) δ 7.66-7.63 (m, 4H), 7.42-7.39 (m, 2H), 
7.35-7.32 (m, 4H), 7.29-7.26 (m, 3H), 7.20-7.18 (m, 2H), 5.14 (d, J = 3.8 Hz, 1H), 5.03 (d, J = 3.8 Hz, 
1H), 4.57 (d, J = 11.1 Hz, 1H), 4.53 (d, J = 11.1 Hz, 1H), 3.74 (d, J = 5.1 Hz, 2H), 3.51 (t, J = 5.7 Hz, 
1H), 2.86 (m, 1H), 1.99 (m, 1H), 1.20 (d, J = 7.0 Hz, 3H), 1.07 (s, 9H), 1.02 (d, J = 7.0 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 158.5, 138.4, 135.7, 135.5, 133.6, 133.6, 132.1, 131.0, 130.0, 129.6, 129.6, 
128.2, 127.6, 127.6, 127.5, 127.4, 120.0, 116.8, 104.7, 82.4, 74.7, 65.2, 41.5, 38.1, 26.9, 19.2, 15.5, 15.1. 
Rf = 0.40 (20:1 Hex:EtOAc). IR (ATR) 2961, 2932, 2859, 1418, 1212, 1112, 933, 701 cm
-1. HRMS 
(APCI) m/z [C32H43F3NO5SSi]
+ (M+NH4) calcd 638.2578, found 638.2574. 
  (5R,6R,7R)-6-(benzyloxy)-2,2,5,7,11,11-hexamethyl-4-methylene-10,10-
diphenyl-3,9-dioxa-2,10-disiladodecane (183). (3R,4R,5R)-4-(benzyloxy)-6-
((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexan-2-one 182 (145.0 mg, 0.297 
mmol) was dissolved in 10 mL DCM. After cooling the solution to 0 °C, 
triethyl amine (0.41 mL, 2.97 mmol, 10 equiv.) and trimethylsilyl trifluoromethanesulfonate (0.11 mL, 
0.594 mmol, 2 equiv.) were added sequentially. The reaction was stirred for 1 h and then transferred to a 
separatory funnel. The reaction was diluted with 40 mL DCM and then washed with 0.5 M NH4OH 3x. 
The organic layer was dried with MgSO4 and concentrated to yield 148.0 mg (89%) of mostly pure 
(5R,6R,7R)-6-(benzyloxy)-2,2,5,7,11,11-hexamethyl-4-methylene-10,10-diphenyl-3,9-dioxa-2,10-
disiladodecane as a clear oil. [α]20D =  -3.0, c = 0.0103 g/ml C6H6. 
1H NMR (400 MHz, C6D6) δ 7.83-7.75 
(m, 5H), 7.34 (m, 1H), 7.21-7.18 (m, 8H), 7.09 (m, 1H), 4.74 (d, J = 11.3 Hz, 1H), 4.50 (d, J = 11.3 Hz, 
1H), 4.22 (d, J = 1.0 Hz, 1H), 4.10 (d, J = 1.1 Hz, 1H), 4.00 (dd, J = 9.9, 5.0 Hz, 1H), 3.89 (dd, J = 9.8, 





























3H), 1.10 (d, J = 7.0 Hz, 3H), 0.18 (s, 9H). 13C NMR (100 MHz, C6D6) δ 161.5, 140.0, 136.1, 136.0, 
135.4, 134.3, 129.9, 129.8, 129.7, 127.3, 89.9, 83.3, 74.4, 65.9, 43.4, 38.3, 27.2, 27.1, 27.0,19.5, 15.8, 





(50.0 mg, 0.10 mmol) was dissolved in 5 ml DCM. After cooling the solution 
to 0 °C, triethyl amine (0.14 ml, 1.0 mmol, 10 equiv.) and tert-butyldimethylsilyl 
trifluoromethanesulfonate (0.05 mL, 0.20 mmol, 2 equiv.) were added sequentially. The reaction was 
stirred for 1 h and then transferred to a separatory funnel. The reaction was diluted with 20 ml DCM and 
then washed with 0.5 M NH4OH 3x. The organic layer was dried with MgSO4 and concentrated to yield 
mostly pure (6R,7R,8R)-7-(benzyloxy)-2,2,3,3,6,8,12,12-octamethyl-5-methylene-11,11-diphenyl-4,10-
dioxa-3,11-disilatridecane as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.73-7.63 (m, 6H), 7.42-7.23 (m, 
9H), 4.64 (d, J = 11.0 Hz, 1H), 4.41 (d, J = 11.0 Hz, 1H), 4.07 (d, J = 1.0 Hz, 1H), 3.99 (d, J = 1.0 Hz, 
1H), 3.79 (dd, J = 9.8, 5.2 Hz, 1H), 3.62 (dd, J = 9.9, 7.1 Hz, 1H), 3.50 (m, 1H), 2.51 (m, 1H), 1.98 (m, 




trisilatridecane (S15). Tris(trimethylsilyl)silyl trifluoromethanesulfonate 
was prepared according to a literature procedure.16 
Trifluoromethanesulfonic acid (30.0 mg, 0.20 mmol, 2.0 equiv.) was dissolved in 1 ml DCM in a 10 ml 
round bottom flask. The reaction flask was put under Ar and tri(trimethylsilyl)silane (49.7 mg, 0.20 
mmol, 2.0 equiv.) was added in 1 ml DCM. The reaction was stirred for 30 min and cooled to 0 °C. 
(3R,4R,5R)-4-(benzyloxy)-6-((tert-butyldiphenylsilyl)oxy)-3,5-dimethylhexan-2-one 182 (48.8 mg, 0.10 
mmol) and triethyl amine (0.14 ml, 1.0 mmol, 10 equiv.) were dissolved in 1 ml DCM and added to the 
reaction. The reaction was stirred for 2 h and then transferred to a separatory funnel. The reaction was 
diluted with 20 ml DCM and then washed with 0.5 M NH4OH 3x. The organic layer was dried with 
MgSO4 and concentrated to yield 77.9 mg (53%) of mostly pure (6R,7R,8R)-7-(benzyloxy)-2,2,6,8,12,12-
hexamethyl-5-methylene-11,11-diphenyl-3,3-bis(trimethylsilyl)-4,10-dioxa-2,3,11-trisilatridecane as a 
clear oil. 1H NMR (300 MHz, CDCl3) δ 7.74-7.63 (m, 6H), 7.42-7.22 (m, 9H), 4.62 (d, J = 11.1 Hz, 1H), 
4.65 (d, J = 11.2 Hz, 1H), 4.07 (d, J = 1.4 Hz, 1H), 3.95 (d, J = 1.4 Hz, 1H), 3.80 (dd, J = 9.8, 4.9 Hz, 1H), 
3.58 (dd, J = 9.7, 7.4 Hz, 1H), 3.44 (dd, J = 7.6, 4.2 Hz, 1H), 2.50 (m, 1H), 1.98 (m, 1H), 1.07-1.04 (m, 































butyldiphenylsilyl)oxy)-3,5-dimethylhex-1-en-2-yl diethyl phosphate 205 (119.2 
mg, 0.19 mmol) was dissolved in THF and cooled to -78 °C. tert-butyl lithium 
(0.4 ml, 0.57 mmol, 1.4M in pentanes, 3 equiv.) was added and the reaction was stirred for 30 min. The 
reaction was quenched at -78 °C with sat. NH4Cl and allowed to warm to 23 °C. The reaction was 
extracted with EtOAc 3x, dried with MgSO4, filtered, and concentrated. The resulting residue was loaded 
onto Celite and purified via flash column chromatography to yield 63.4 mg (71%) of (((2R,3S,4S)-3-
(benzyloxy)-2,4-dimethylhex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane as a clear oil. [α]20D =  +5.1, c = 
0.0100 g/ml CHCl3. 
1H NMR (400 MHz, CDCl3) δ 7.69-7.64 (m, 5H), 7.43-7.21 (m, 10H), 4.64 (d, J = 
11.2 Hz, 1H), 4.56 (d, J = 11.2 Hz, 1H), 3.82 (dd, J = 9.9, 5.1 Hz, 1H), 3.72 (dd, J = 9.9, 4.0 Hz, 1H), 
3.38 (dd, J = 7.9, 3.9 Hz, 1H), 2.82 (m, 1H), 2.09 (m, 1H), 2.06 (d, J = 2.5 Hz, 1H), 1.26 (d, J = 7.1 Hz, 
3H), 1.08 (s, 9H), 1.06 (d, J = 6.9 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 138.6, 135.7, 135.7, 133.7, 
133.6, 129.6, 129.5, 128.2, 127.7, 127.6, 127.6, 127.4, 86.2, 82.9, 74.3, 69.8, 65.4, 38.9, 29.0, 27.0, 26.8, 
19.3, 18.1, 14.6. Rf = 0.25 (20:1 Hex:EtOAc). IR (ATR) 3307, 2960, 2931, 2857, 1472, 1428, 1111, 1068, 
823, 739, 701 cm-1. HRMS (APCI) m/z [C31H39O2Si]
+ (M+H) calcd 471.2641, found 471.2714. 
C23-C32 Fragment 
 
 (2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl acetate (138). Procedure 
adapted from literature procedures.17 Selenium dioxide (0.742 g, 6.68 mmol, 14 
mol %) was suspended in 75 ml DCM in a 500 ml round bottom flask. tert-Butyl hydroperoxide (25 ml, 
186.8 mmol, 2 equiv.; Luperox® 70 wt. % in H2O) was added and the reaction was stirred for 30 min 
generating a clear, biphasic solution. Geranial acetate (20 ml, 93.3 mmol; Alfa Aesar) was added via 
syringe. A reflux condenser was attached and the reaction was stirred for 48 h without heating. The 
reaction was diluted with 100 ml MeOH and cooled to 0 °C. Sodium borohydride was added slowly until 
aldehyde not observed by TLC (Rf = 0.52 (2:1 Hex:EtOAc; KMnO4). Solution turned from clear to red to 
yellow to clear during this process. The reaction was diluted with another 100 ml DCM and 100 ml H2O 
and transferred to a separatory funnel rinsing with DCM and H2O. The layers were separated and the 
aqueous layer was extracted with DCM 2x. The organic layer was washed with sat. NaCl, dried with 
MgSO4, filtered, and concentrated. The crude reaction was purified via flash column chromatography to 
yield 12.78 g (59%) of (2E,6E)-8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl acetate as a pale yellow oil. 
Spectral data matches literature.18 1H NMR (300 MHz, CDCl3) δ 5.39-5.32 (m, 2H), 4.58 (d, J = 7.1 Hz, 
2H), 3.99 (s, 2H), 2.21-2.14 (m, 2H), 2.11-2.03 (m, 2H), 2.05 (s, 3H),  1.70 (s, 3H), 1.66 (s, 3H) 1.46 (s, 
1H). Rf = 0.32 (2:1 Hex:EtOAc; KMnO4). 
 
                                                            
17 (a) Umbreit, M. A.; Sharpless, K. B. J. Am. Chem. Soc. 1977, 99, 5526-5528. (b) Cole, K. P.; Hsung, R. P. Org. 
Lett. 2003, 5, 4843-4846. 
















en-1-yl acetate (S16). Procedure adapted from literature procedure.19 In a flame 
dried 500 ml round bottom flask, two scoops of 4 Å molecular sieves was 
suspended in 200 ml DCM under Ar. Titanium(IV) isopropoxide (18.6 ml, 63.2 mmol, 1.05 equiv.) was 
added and the reaction was cooled to -35 °C. (-)-Diethyl D-tartrate (11.3 ml, 66.2 mmol, 1.1 equiv.; 
Chem-Impex International or AK Scientific) and anhydrous tert-butyl hydrogen peroxide20 (40 ml, 120.4 
mmol, ~3.0M in DCM, 2.0 equiv.) was added and the reaction was allowed to stir for 45 min. (2E,6E)-8-
hydroxy-3,7-dimethylocta-2,6-dien-1-yl acetate 138 (12.78 g, 60.2 mmol) in 18 ml DCM was added 
slowly. The reaction was stirred at -30 °C for 6 h. At -20 °C, NaOH (48 ml, 240.8 mmol, aq. 5 M, 4 
equiv.) was added and the reaction was stirred for 1h. The reaction was transferred to a seperatory funnel 
and the lower layer was transferred to an 800 ml beaker. MgSO4 was added until the solution stopped 
bubbling. The solution was filtered through Celite and concentrated to form a milky oil. The crude 
reaction was purified via flash column chromatography to yield 10.09 g (73%) of (E)-5-((2R,3R)-3-
(hydroxymethyl)-3-methyloxiran-2-yl)-3-methylpent-2-en-1-yl acetate as a clear oil (product 
contaminated with diethyl tartrate can be used in the next reaction without a negative impact on yield). 
Spectral data matches literature.21 [α]20D =  +5.4, c = 0.2300 g/ml CH2Cl2. 
1H NMR (400 MHz, CDCl3) δ 
5.38 (dd, J = 7.2, 1.2 Hz, 1H), 4.58 (d, J = 7.2 Hz, 2H), 3.65 (dd, J = 8.0, 4.0 Hz, 1H), 3.56 (dd, J = 12.0, 
8.4 Hz, 1H), 3.00 (t, J = 6.4 Hz, 1H), 2.27-2.12 (m, 2H), 2.04 (s, 3H), 1.82 (dd, J = 8.4, 4.8 Hz, 1H), 1.74-
1.67 (m, 2H), 1.72 (s, 3H), 1.27 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.1, 140.9,119.1, 65.3, 61.2, 
60.9, 59.6, 36.1, 26.3, 21.0, 16.4, 14.2. Rf = 0.25 (1:1 Hex:EtOAc; KMnO4). IR (NaCl, Thin Film) 3353, 
2932, 1739, 1670, 1446, 1383, 1234,1028, 955 cm-1. LRMS (ESI/APCI) m/z [C12H20O4Na]
+ (M+Na) 
calcd 251.1, found 251.2. 
 
 (E)-5-((2R,3S)-3-(iodomethyl)-3-methyloxiran-2-yl)-3-methylpent-2-en-1-ol 
(139). In a 500 ml flask, (E)-5-((2R,3R)-3-(hydroxymethyl)-3-methyloxiran-2-yl)-
3-methylpent-2-en-1-yl acetate S16 (5.33 g, 23.3 mmol) (if contaminated with 
DET, an extra equivalent of PPh3, im, and I2 was added for every mmol of DET) was dissolved in 120 ml 
DCM and the flask was put under Ar. After cooling to 0 °C, imidazole (1.67 g, 24.5 mmol, 1.05 equiv.) 
and triphenyl phosphine (6.43 g, 24.5 mmol, 1.05 equiv.) were added. After dissolution, iodine (6.22 g, 
24.5 mmol, 1.05 equiv.) was added in three portions. After stirring for 2 h, 150 ml methanol and 
potassium carbonate (32.0 g, 233 mmol, 10.0 equiv.) was added sequentially. The reaction flask was 
covered with aluminum foil and stirred for 12 h. The reaction was quenched with sat. Na2S2O3 and 
extracted with Et2O 3x. The organic layer was washed with sat. Na2S2O3 and brine, dried with MgSO4, 
and concentrated. The crude reaction was loaded onto Celite and purified via flash column 
chromatography to yield 5.43 g (78%) of (E)-5-((2R,3S)-3-(iodomethyl)-3-methyloxiran-2-yl)-3-
                                                            
19For procedure, see: Gao, Y.; Hanson, R. M.; Klunder, J. M.; Ko, S. Y.; Masamune, H.; Sharpless, K. B. J. Am. 
Chem. Soc. 1987, 109, 5765-5780. In our hands, this particular workup is excellent for small scale work (>400 mg), 
but becomes cumbersome on larger scale. 
20 3M anhydrous tert-butyl hydrogen peroxide was obtained by swirling 85 mL of commercial TBHP (70 wt. % in 
H2O ) with 140 mL DCM in a separatory funnel. The phases were separated and the lower organic layer was stored 
over 4 Å MS. See: (a) Sharpless, K. B.; Verhoeven, T. R. Aldrichimica Acta 1979, 12, 4, 63-74. (b) Armarego, W. 
L. F.; Chai, C. L. L. Purification of Laboratory Chemicals, 5th ed. Elsevier Science: Burlington, MA., 2003; pg 
148-149. 









methylpent-2-en-1-ol as a pale yellow oil. Spectral data matches literature.22 [α]20D = -6.3, c = 0.1800 g/ml 
CH2Cl2. 
1H NMR (400 MHz, CDCl3) δ 5.46 (m, 1H), 4.15 (d, J = 6.8 Hz, 2H), 3.22 (d, J = 10.0 Hz, 1H), 
3.07 (d, J = 9.6 Hz, 1H), 2.86 (t, J = 6.4 Hz, 1H), 2.24-2.11 (m, 2H), 1.70-1.65 (m, 2H), 1.68 (s, 3H), 1.44 
(s, 3H). 13C NMR (100 MHz, CDCl3) δ 138.0, 124.3, 66.0, 60.1, 59.2, 36.0, 27.2, 16.2,16.0,13.8. Rf = 
0.33 (1:1 Hex:EtOAc; KMnO4). IR (NaCl, Thin Film) 3417, 2966, 2927, 1669, 1452, 1385,1175, 1002, 
867 cm-1. LRMS (ESI/APCI) m/z [C10H17IO2Na]
+ (M+Na) calcd 319.0, found 319.1. 
 
 tert-butyl 3-((2R,3R)-3-((E)-5-hydroxy-3-methylpent-3-en-1-yl)-2-
methyloxiran-2-yl)propanoate (S17). Procedure adapted from the 
literature.23 In a flame dried 500 ml round bottom flask, diisopropylamine 
(10.4 ml, 73.8 mmol, 3.1 equiv.) was dissolved in 150 ml THF under Ar. The solution was cooled to -78 
°C and n-butyllitium (49.2 ml, 71.4 mmol, 1.45 M in hexanes, 3.0 equiv.) was added. The reaction was 
stirred for 10 min and neat tert-butyl acetate (9.9 ml, 73.8 mmol, 3.1 equiv.; Chem-Impex International) 
was  added via syringe. The reaction was stirred for 1h and (E)-5-((2R,3S)-3-(iodomethyl)-3-
methyloxiran-2-yl)-3-methylpent-2-en-1-ol 139 (7.06 g, 23.8 mmol) in 15 ml THF was added. The 
reaction was stirred for 5 min and freshly distilled hexamethylphosphoramide (24.9 ml, 143 mmol, 6.0 
equiv.) was added. After stirring for 2 h at -78 °C, the reaction was quenched with 35 ml sat. NH4Cl. The 
cold bath was removed and the reaction was allowed to warm ~0°C. The reaction was transferred to a 
seperatory funnel and diluted with Et2O and D.I. H2O. The layers were separated and the aqueous was 
extracted with Et2O 2x. The organic layers were washed with sat. NaCl, dried with MgSO4, filtered, and 
concentrated. The crude reaction was purified via flash column chromatography to yield 5.28 g (78%) of 
tert-butyl 3-((2R,3R)-3-((E)-5-hydroxy-3-methylpent-3-en-1-yl)-2-methyloxiran-2-yl)propanoate as a 
clear oil. [α]20D =  +7.44, c = 0.0166 g/ml CH2Cl2. 
1H NMR (400 MHz, CDCl3) δ 5.44 (m, 1H), 4.14 (d, J 
= 6.8 Hz, 2H), 2.71 (t, J = 6.8 Hz, 1H), 2.28 (t, J = 7.2 Hz, 2H), 2.22-2.07 (m, 2H), 1.89-1.73 (m, 2H), 
1.69-1.62 (m, 2H), 1.67 (s, 3H), 1.59 (s, 1H), 1.42 (s, 9H), 1.23 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
172.4, 138.3, 124.1, 80.4, 62.8, 60.0, 59.2, 36.2, 33.1, 31.0, 28.0, 26.8, 16.7, 16.2. Rf = 0.23 (2:1 
Hex:EtOAc; KMnO4). IR (NaCl, Thin Film) 3435, 2976, 2931, 1730, 1456, 1368, 1255, 1152, 1009, 847 
cm-1. HRMS (DART) m/z [C16H32NO4]
+ (M+NH4) calcd 302.2326, found 302.2328. 
 
 tert-butyl 3-((2R,3R)-3-(2-((2R,3R)-3-(hydroxymethyl)-2-
methyloxiran-2-yl)ethyl)-2-methyloxiran-2-yl)propanoate (140). In a 
flame dried 300 ml round bottom flask, two scoops of 4 Å molecular 
sieves was suspended in 75 ml DCM under Ar. Titanium(IV) isopropoxide (2.07 ml, 7.01 mmol, 1.05 
equiv.) was added and the reaction was cooled to -35 °C. (-)-Diethyl D-tartrate (1.26 ml, 7.35 mmol, 1.1 
equiv.; Chem-Impex International or AK Scientific) and anhydrous tert-butyl hydrogen peroxide (4.5 ml, 
13.36 mmol, ~3.0M in DCM, 2.0 equiv.) was added and the reaction was allowed to stir for 45 min. tert-
butyl 3-((2R,3R)-3-((E)-5-hydroxy-3-methylpent-3-en-1-yl)-2-methyloxiran-2-yl)propanoate S17 (1.90 g, 
6.68 mmol) in 9 ml DCM was added slowly. The reaction was stirred at -30 °C for 6 h. At -20 °C, NaOH 
(5.3 ml, 26.72 mmol, aq. 5 M, 4 equiv.) was added and the reaction was stirred for 1h. The reaction was 
                                                            
22 Marshall, J. A.; Chobanian, H. R. Org. Lett. 2003, 5, 1931-1933. 












transferred to an 800 ml beaker. MgSO4 was added until the solution stopped bubbling. The solution was 
filtered through Celite and concentrated to form a milky oil. The crude reaction was purified via flash 
column chromatography to yield 1.298 g (65%) of tert-butyl 3-((2R,3R)-3-(2-((2R,3R)-3-
(hydroxymethyl)-2-methyloxiran-2-yl)ethyl)-2-methyloxiran-2-yl)propanoate as a clear oil. [α]20D =  
+11.7, c = 0.0093 g/ml CH2Cl2. 
1H NMR (400 MHz, CDCl3) δ 3.83-3.71 (m, 2H), 2.99 (t, J = 5.6 Hz, 
1H), 2.76 (m, 1H), 2.28 (dt, J = 7.6, 1.6 Hz, 2H), 1.90-1.76 (m, 4H), 1.66-1.58 (m, 3H), 1.44 (s, 9H), 1.33 
(s, 3H), 1.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 172.4, 80.5, 62.4, 62.3, 61.3, 60.5, 60.2, 35.0, 33.2, 
31.0, 28.1, 24.2, 16.9, 16.7. Rf = 0.18 (1:1 Hex:EtOAc; KMnO4). IR (NaCl, Thin Film) 3444, 2975, 2933, 
1730, 1458, 1255, 1036, 848 cm-1. HRMS (DART) m/z [C12H21O5]
+ (M-C4H9(tBu




bifuran]-5(2H)-one (S18). In an 100 ml round bottom flask, tert-butyl 3-
((2R,3R)-3-(2-((2R,3R)-3-(hydroxymethyl)-2-methyloxiran-2-yl)ethyl)-2-
methyloxiran-2-yl)propanoate 140 (1.368 g, 4.55 mmol) was dissolved in 20 ml DCM. Triphenyl 
phosphine (1.254 g, 4.78 mmol, 1.05 equiv.) and tetrabromomethane (1.585 g, 4.78 mmol, 1.05 equiv.) 
was added and the reaction was heated to reflux for 4h. The reaction mixture was cooled to 23 °C and dry 
p-toluenesulfonic acid24 (0.783 g, 4.55 mmol, 1.0 equiv.) was added. The reaction was stirred for 2 h and 
then quenched with sat. NaHCO3. The reaction was extracted with DCM 3x and the organic layer was 
dried with MgSO4, filtered, and concentrated. The crude was loaded onto Celite and purified via flash 
column chromatography to yield 1.11 g (71%) of (2S,2'R,5'S)-5'-((S)-2-bromo-1-hydroxyethyl)-2,5'-
dimethylhexahydro-[2,2'-bifuran]-5(2H)-one as a clear oil. [α]20D =  +6.9, c = 0.0076 g/ml CHCl3. 
1H 
NMR (400 MHz, CDCl3) δ 4.04 (m, 1H), 3.74 (m, 1H), 3.67 (dd, J = 10.0, 2.0 Hz, 1H), 3.35 (t, J = 10.0 
Hz, 1H), 2.60 (m, 2H), 2.50 (d, J = 3.0 Hz, 1H), 2.28-2.20 (m, 1H), 2.18-2.11 (m, 1H), 2.04-1.96 (m, 1H), 
1.93-1.85 (m, 1H), 1.76-1.68 (m, 2H), 1.38 (s, 3H), 1.18 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 176.5, 
86.9, 85.3, 82.7, 77.2, 36.5, 34.6, 29.2, 29.1, 26.8, 23.4, 21.0. Rf = 0.27 (1:1 Hex:EtOAc; CAM). IR 
(NaCl, Thin Film) 3459, 2975, 2878, 1768, 1454, 1381, 1081, 944 cm-1. HRMS (APCI) m/z 
[C12H20O4Br]




dimethylhexahydro-[2,2'-bifuran]-5(2H)-one S18 (1.79g, 5.82 mmol) was 
dissolved in 20 ml EtOAc. Pd/C (200 mg, 10% by wt.) and 11 ml triethyl amine were added to the 
reaction. The reaction flask was evacuated and backfilled with Ar 2x. The reaction was then evacuated 
and refilled with hydrogen 2x using a balloon. The reaction was stirred for 18 h and recharged with 
hydrogen. After stirring for another 18 h, the reaction was filtered through Celite. The crude reaction was 
purified via flash column chromatography to yield 0.962 g (72%) of (2S,2'R,5'S)-5'-((R)-1-hydroxyethyl)-
2,5'-dimethylhexahydro-[2,2'-bifuran]-5(2H)-one as a clear oil that solidified upon standing. Spectral data 
                                                            
24 Dry acid was obtained by the azeotropic removal of water from a benzene solution of p-toluenesulfonic acid 
monohydrate using a Dean-Stark apparatus. The dried acid was recrystallized from benzene. Use of the 












matches literature.25 [α]20D = +1.3, c = 0.0053 g/ml CH2Cl2. 
1H NMR (300 MHz, CDCl3) δ 4.02 (dd, J = 
8.4, 6.8 Hz, 1H), 3.75 (dq, J = 6.5, 2.6 Hz, 1H), 2.60 (m, 2H), 2.27-2.04 (m, 3H), 2.02-1.86 (m, 2H), 1.75-
1.60 (m, 1H), 1.57-1.50 (m, 1H), 1.40 (s, 3H), 1.14 (s, 3H), 1.13 (d, J = 6.3 Hz, 3H). Rf = 0.14 (1:1 
Hex:EtOAc; CAM). IR (NaCl, Thin Film) 3468, 2976, 2872, 1770, 1453, 1244, 1083, 943 cm-1. HRMS 
(APCI) m/z [C12H21O4]




hydroxyethyl)-2,5'-dimethylhexahydro-[2,2'-bifuran]-5(2H)-one 141 (0.962 g, 
4.20 mmol) was dissolved in 30 ml DCM, put under Ar, and cooled to -78 °C.26 Triethyl amine (2.0 ml, 
14.7 mmol, 3.5  equiv.) was added and then tert-butyldimethylsilyl trifluoromethanesulfonate (1.93 ml, 
8.4 mmol, 2.0 equiv.; Oakwood Chemical) was added slowly. The reaction was stirred at -78 °C for 4 h. 
The reaction was quenched with sat. NaHCO3 and warmed to 23 °C. The reaction was extracted with 
DCM 3x and the organic layer was dried with MgSO4, filtered, and concentrated. The crude reaction was 
purified via flash column chromatography to yield 1.325 g (92%) of (2S,2'R,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethylhexahydro-[2,2'-bifuran]-5(2H)-one as a clear oil that 
solidified upon standing. Spectral data matches literature.24  [α]20D = -9.5, c = 0.0107 g/ml CHCl3. 
1H 
NMR (300 MHz, CDCl3) δ 4.04-3.98 (m, 1 H) 3.58 (q, J = 6.3 Hz, 1H), 2.70-2.48 (m, 2H), 2.25 (ddd, J = 
12.8, 10.3, 5.9, 1H), 1.98-1.80 (m, 3H), 1.72-1.54 (m, 2H), 1.35 (s, 3H), 1.11 (d, J = 6.2 Hz, 3H), 1.10 (s, 
3H), 0.87 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H). Rf = 0.24 (4:1 Hex:EtOAc; CAM). 
 
 (2S,2'R,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-
dimethyloctahydro-[2,2'-bifuran]-5-yl benzoate (185). (2S,2'R,5'S)-5'-
((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethylhexahydro-[2,2'-
bifuran]-5(2H)-one 184 (97.8 mg, 0.286 mmol) was dissolved in 6 mL DCM and cooled to -78 °C. 
DIBAL (0.31 mL, 1M Hexanes, 1.1 equiv.) was added and the reaction was stirred for 1.5 h. 10 mL of 
sat. Rochelle's salt was added and the cold bath was removed. The reaction was stirred for 4 h. The 
reaction was extracted with DCM 3x, the resulting organic layer was washed with sat. brine 2x, dried with 
MgSO4, and concentrated to yield 92.8 mg (94%) of (2S,2'R,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-ol (S19) as clear oil. 1H NMR (300 
MHz, CDCl3) δ 5.36 (diastereomer a, dd, J = 4.4, 0.8 Hz, 0.37H), 5.33 (diastereomer b, dd, J = 4.4, 0.8 
Hz, 0.41 H), 4.50 (diastereomer b, s, 0.37 H), 4.46 (diastereomer a, s, 0.35H), 4.01 (diastereomer a, d, J = 
5.8 Hz, 0.34H), 3.98 (diastereomer b, d, J = 5.8 Hz, 0.43H), 3.64 (q, J = 6.2 Hz, 1H), 2.18-1.40 (m, 8H), 
1.18-1.12 (m, 8H), 0.87 (s, 9H), 0.07-0.03 (m, 6H). Crude (2S,2'R,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-ol S19 (93 mg, 0.270 mmol) was 
dissolved in 6 mL DCM. Benzoic anhydride (122 mg, 0.540 mmol, 2 equiv.), triethyl amine (0.11 mL, 
0.810 mmol, 3 equiv.), and 4-(dimethylamino)pyridine (23 mg, 0.188 mmol, 0.7 equiv.) was added and 
the reaction was stirred for 14 h. The entire reaction was loaded onto Celite and purified by flash column 
                                                            
25 Li, Y.; Cooksey, J. P.; Gao, Z.; Kocieński, P. J.; McAteer, S. M.; Snaddon, T. N. Synthesis, 2011, 104-108. 
26 Smaller scale reactions (0.37 mmol) can be done at 0 °C, but yields suffer at larger scales if the reaction is not 













chromatography to yield 93.2 mg (75%) of (2S,2'R,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-
2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl benzoate as a clear oil with slight benzoic anhydride 
contamination. Less polar diastereomer: 1H NMR (400 MHz, C6D6) δ 8.19-8.15 (m, 2H), 7.12-7.03 (m, 
3H), 6.72 (d, J = 4.1 Hz, 1H), 3.81 (dd, J = 7.9, 6.5 Hz, 1H), 3.67 (q, J = 6.2 Hz, 1H), 2.01-1.88 (m, 4H), 
1.73-1.61 (m, 2H), 1.59-1.48 (m, 2H), 1.37 (s, 3H), 1.23 (d, J = 6.2 Hz, 3H), 1.19 (s, 3H), 0.98 (s, 9H), 
0.07 (s, 6H). 13C NMR (100 MHz, C6D6) δ 165.4, 132.8, 129.9, 128.5, 100.7, 87.8, 85.6, 83.3, 74.0, 36.4, 
33.3, 32.0, 27.0, 26.1, 26.0, 24.7, 19.6, 18.7, 18.1, -3.8, -4.8. Rf = 0.33 (20:1 Hex:EtOAc). IR (ATR) 
2973, 2955, 2931, 2857, 1723, 1451, 1271, 1082 cm-1. LRMS (APCI+ESI) m/z [C18H35O3Si]
+ (M-OBz) 
calcd 327.2, found 327.2. More polar diastereomer: 1H NMR (400 MHz, C6D6) δ 8.20-8.16 (m, 2H), 7.12-
7.05 (m, 3H), 6.62 (dd, J = 3.6, 1.4 Hz, 1H), 4.04 (t, J = 6.6 Hz, 1H), 3.78 (q, J = 6.2 Hz, 1H), 2.02-1.91 
(m, 3H), 1.81-1.74 (m, 3H), 1.49-1.44 (m, 1H), 1.37 (m, 1H), 1.29 (d, J = 6.2 Hz, 3H), 1.20 (s, 3H), 1.17 
(s, 3H), 0.94 (s, 9H), 0.06 (s, 3H), 0.02 (s, 3H). 13C NMR (100 MHz, C6D6) δ 165.3, 132.9, 129.9, 128.5, 
100.0, 87.9, 85.9, 84.5, 73.7, 36.5, 32.6, 32.0, 26.6, 26.0, 22.4, 19.6, 18.7, 18.1, -3.9, -4.8. Rf = 0.27 (20:1 
Hex:EtOAc). 
 (S)-S-phenyl 4-((2R,5S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-
methyltetrahydrofuran-2-yl)-4-hydroxypentanethioate (120). Procedure 
adapted from the literature .27 Thiophenol (0.12 ml, 1.15 mmol, 2.0 equiv.) 
was dissolved into 2 ml DCM under Ar and cooled to 0 °C. Trimethyl aluminum (0.57  ml, 1.15 mmol, 
2.0 equiv., 2 M in PhMe) was added slowly over 5 min. After stirring the reaction for 10 min at 0 °C, the 
ice bath was removed and the reaction was stirred for another 10 min. The reaction was cooled back to 0 
°C and (2S,2'R,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethylhexahydro-[2,2'-bifuran]-
5(2H)-one 184 (196.2 mg, 0.573 mmol) in 3 ml DCM was added slowly. The reaction was stirred and 
allowed to warm to 23 °C over 12 h. The reaction was cooled to -78 °C and 10 ml Et2O was added. After 
stirring for 10 min, 3.5 ml 1 M HCl was added and the reaction was allowed to warm to ~0 °C. The 
reaction was extracted with EtOAc (the emulsion can be removed by addition of more 1 M HCl, ~ 2 ml) 
and the organic fractions were dried with MgSO4. The crude reaction was loaded onto Celite and purified 
via flash column chromatography to yield 92.8 mg (36%) of (S)-S-phenyl 4-((2R,5S)-5-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-5-methyltetrahydrofuran-2-yl)-4-hydroxypentanethioate as a clear oil and 
68.9 mg (35% rsm) of (2S,2'R,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethylhexahydro-
[2,2'-bifuran]-5(2H)-one. [α]20D =  +11.8, c = 0.0180 g/ml C6H6. 
1H NMR (400 MHz, C6D6) δ 7.40-7.36 
(m, 2H), 7.03-6.94 (m, 3H), 3.59 (q, J = 6.2 Hz, 1H), 3.51 (dd, J = 7.5, 7.1 Hz, 1H), 2.85 (ddd, J = 15.7, 
10.1, 5.5 Hz, 1H), 2.65 (ddd, J = 15.9, 10.2, 5.8 Hz, 1H), 1.97 (s, 1H), 1.96-1.84 (m, 2H), 1.68 (m, 1H), 
1.58 (m, 1H), 1.43 (m, 1H), 1.33 (m, 1H), 1.08-1.03 (m, 9H), 0.92 (s, 9H), 0.02 (s, 3H), 0.0 (s, 3H). 13C 
NMR (100 MHz, C6D6) δ 196.5, 134.8, 129.2, 129.2, 128.8, 85.6, 84.6, 73.5, 72.2, 38.6, 34.8, 33.0, 26.0, 
25.5, 23.8, 20.6, 19.0, 18.1, -4.0, -4.6. Rf = 0.19 (9:1 Hex:EtOAc; UV, CAM). IR (ATR) 3446, 2955, 
2930, 2856, 1710, 1371, 1255, 1096, 970, 832 cm-1. HRMS (APCI) m/z [C24H39O3SSi]
+ (M-H2O) calcd 


















borabicyclo[3.3.1]nonane (0.28 ml, 0.278 mmol, 1.36 
equiv., 1M in Hex) was dissolved in 1 ml DCM. The reaction was cooled to 0 °C and triethyl amine (0.04 
ml, 0.278 mmol, 1.36 equiv.) was added. The reaction went from pink to orange. After stirring for 5 min, 
(3R,5S)-3,5-dimethyl-7-((1-phenyl-1H-tetrazol-5-yl)sulfonyl)heptan-2-one 119a (71.7 mg, 0.205 mmol) 
was added in 1 ml DCM. After stirring for 5 min, the reaction was cooled to -78 °C and (4R,6S,8S)-ethyl 
4,6,8-trimethyl-9-oxononanoate 116 (59.6 mg, 0.246 mmol, 1.2 equiv.) was added in 1 ml DCM. After 
stirring for 1 h, the cold bath was removed and the reaction was stirred for 12 h. The reaction was 
quenched by the addition of 0.5 ml pH = 7.00 buffer, 2.0 ml MeOH, and 0.5 ml 30% H2O2. After 15 min, 
the reaction was extracted with Et2O 3x. The organic layers were washed with sat. NaHCO3 2x, dried 
with MgSO4, and concentrated. The crude reaction was purified via column chromatography to yield 70.2 
mg (56%) of (4R,6S,8S,12R,14S)-ethyl 9-hydroxy-4,6,8,12,14-pentamethyl-11-oxo-16-((1-phenyl-1H-
tetrazol-5-yl)sulfonyl)hexadecanoate. 1H NMR (400 MHz, CDCl3) δ 7.71-7.69 (m, 2H), 7.64-7.58 (m, 
3H), 4.12 (q, J = 7.1 Hz, 2H), 3.96 (m, 0.25H), 3.90 (m, 0.68H), 3.82-3.68 (m, 2H), 2.71-2.24 (m, 6H), 
1.98-1.48 (m, 10H), 1.33-1.07 (m, 2H), 1.32 (d, J = 6.3 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.11 (d, J = 7.1 
Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H), 0.97-0.84 (m, 2H), 0.89 (d, J = 6.9 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H). Rf 
= 0.24 (2:1 Hex:EtOAc; UV, CAM). IR (ATR) 2962, 2931, 2874, 1730, 1342, 1153 cm-1. LRMS 
(ESI/APCI) m/z [C30H49N4O6S]






pentamethyl-11-oxo-16-((1-phenyl-1H-tetrazol-5-yl)sulfonyl)hexadecanoate 161 (70.0 mg, 0.118 mmol) 
was dissolved into 10 ml EtOAc. 2-iodoxybenzoic acid (165 mg, 0.591 mmol, 5.0 equiv.) was added and 
the reaction was heated to 80 °C for 4h. The reaction was cooled to 23 °C, filtered through Celite, and 
purified via preparative thin layer chromatography to yield 31.0 mg (44%) (4R,6S,8S,12R,14S,Z)-ethyl 9-
hydroxy-4,6,8,12,14-pentamethyl-11-oxo-16-((1-phenyl-1H-tetrazol-5-yl)sulfonyl)hexadec-9-enoate and 
31.0 mg (44% rsm) of (4R,6S,8S,12R,14S)-ethyl 9-hydroxy-4,6,8,12,14-pentamethyl-11-oxo-16-((1-
phenyl-1H-tetrazol-5-yl)sulfonyl)hexadecanoate. [α]20D =  +18.0, c = 0.0105 g/ml CHCl3. 
1H NMR (400 
MHz, CDCl3) δ 7.70-7.68 (m, 2H), 7.63-7.57 (m, 3H), 5.48 (m, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.79-3.66 
(m, 2H), 2.51-2.17 (m, 5H), 1.91 (m, 1H), 1.83-1.32 (m, 10H), 1.25 (t, J = 7.1 Hz, 3H), 1.14 (d, J = 7.1 
Hz, 3H), 1.15-1.07 (m, 1H), 1.12 (d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.5 Hz, 3H), 0.92 (m, 1H), 0.86 (d, J = 
6.5 Hz, 3H), 0.82 (d, J = 6.5 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 198.7, 197.8, 174.0, 153.4, 133.0, 
131.4, 129.7, 125.0, 97.4, 60.2, 54.1, 44.9, 41.3, 40.3, 40.1, 40.0, 32.0, 31.8, 29.9, 29.5, 28.7, 27.9, 20.3, 



























1732, 1596, 1342, 1153 cm-1. HRMS (ESI/APCI) m/z [C30H47N4O6S]







dimethylundec-6-yn-5-one (240). Procedure adapted from the literature.28 In an oven dried 25 mL round 
bottom flask, [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium (II) (16.7 mg, 0.021 mmol, 10 
mol %), tri-(2-furyl)phosphine (11.9 mg, 0.051 mmol, 25 mol %), and copper(I) iodide (94.0 mg, 0.494 
mmol, 2.4 equiv.) was added in an inert air glove box. The reaction vessel was sealed, removed from the 
glove box, and 3.0 mL of DMF was added. In a vial, (((2R,3S,4S)-3-(benzyloxy)-2,4-dimethylhex-5-yn-
1-yl)oxy)(tert-butyl)diphenylsilane 239 (106.1 mg, 0.226 mmol, 1.1 equiv.), (S)-S-phenyl 4-((2R,5S)-5-
((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-methyltetrahydrofuran-2-yl)-4-hydroxypentanethioate 120 
(92.8 mg, 0.205 mmol), and N,N-diisopropylethylamine (36.9 mg, 0.286 mmol, 1.4 equiv.) was added to 
a vial and dissolved in 3.0 mL DMF. After adding this solution to the reaction, the reaction was heated to 
60 °C and stirred overnight. The reaction was cooled to 23 °C, Celite was added, and stirred for 30 min. 
Et2O and H2O was added and the solution was filtered through a pad of Celite. The filtrate was extracted 
with Et2O 3x. The organic layers were combined, washed with 10% LiCl 2x, dried with MgSO4, and 
concentrated. The residue was purified by flash column chromatography to yield 71.4 mg (43%) of 
(2S,8S,9S,10R)-9-(benzyloxy)-2-((2R,5S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-
methyltetrahydrofuran-2-yl)-11-((tert-butyldiphenylsilyl)oxy)-2-hydroxy-8,10-dimethylundec-6-yn-5-one 
as a clear oil. [α]20D =  +7.6, c = 0.0166 g/ml CH2Cl2. 
1H NMR (400 MHz, CDCl3) δ 7.64 (m, 4H), 7.44-
7.22 (m, 11H), 4.64 (d, J = 11.2 Hz, 1H), 4.57 (d, J = 11.2 Hz, 1H), 3.80-3.69 (m, 3H), 3.64 (q, J = 6.3 
Hz, 1H), 3.46 (dd, J = 7.3, 4.2 Hz, 1H), 3.01 (dq, J = 7.0, 4.3 Hz, 1H), 2.72 (ddd, J = 17.2, 9.9, 5.6 Hz, 
1H), 2.60 (ddd, J = 17.2, 9.9, 5.8 Hz, 1H). 2.16 (bs, 1H), 2.06 (m, 1H), 1.94 (m, 1H), 1.85-1.76 (m, 3H), 
1.64-1.53 (m, 2H), 1.30 (d, J = 7.0 Hz, 3H), 1.29 (m, 1H), 1.12-1.03 (m, 2H), 1.10 (s, 3H), 1.09 (s, 3H), 
1.07 (s, 9H), 1.04 (d, J = 6.9 Hz, 3H), 0.87 (m, 9H), 0.05 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 188.2, 
138.4, 135.7, 135.6, 133.6, 133.5, 129.6, 129.6, 128.2, 127.6, 127.6, 127.5, 127.4, 95.9, 85.6, 84.4, 82.8, 
82.1, 74.3, 73.0, 72.4, 65.3, 40.0, 38.7, 34.4, 30.9, 29.5, 27.0, 25.8, 25.4, 23.8, 20.4, 19.3, 18.8, 17.9, 17.2, 
14.6, -4.1, -4.6. Rf = 0.36 (9:1 Hex:EtOAc; UV/CAM). IR (ATR) 3467, 2957, 2932, 2858, 2210, 1673, 
1471, 1256, 1111, 832, 702 cm-1. HRMS (APCI) m/z [C49H72NaO6Si2]







































240 (29.1 mg, 0.036 mmol) was dissolved in 4 ml iPrOH and Ru(p-cymene)[(R,R)-Ts-DPEN]29 (2.2 mg, 
0.004 mmol, 10 mol %) was added. The reaction was stirred for 1.5 h and the reaction was homogenous 
and starting material was gone by thin layer chromatography. The reaction was loaded onto silica and 
purified via flash column chromatography to yield 20.0 mg (68%) of (2S,5R,8S,9S,10R)-9-(benzyloxy)-
2-((2R,5S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-methyltetrahydrofuran-2-yl)-11-((tert-
butyldiphenylsilyl)oxy)-8,10-dimethylundec-6-yne-2,5-diol as a light brown oil. [α]20D =  +10.8, c = 
0.0051 g/ml CHCl3. 
1H NMR (400 MHz, CDCl3) δ 7.68-7.63 (m, 4H), 7.43-7.21 (m, 11H), 4.65 (d, J = 
11.2 Hz, 1H), 4.54 (d, J = 11.2 Hz, 1H), 4.41 (bs, 1H), 3.81-3.69 (m, 3H), 3.66 (q, J = 6.2 Hz, 1H), 3.37 
(dd, J = 7.7, 4.1 Hz, 1H), 3.09 (bs, 1H), 2.85 (m, 1H), 2.57 (bs, 1H), 2.06 (m, 1H), 1.97-1.68 (m, 6H), 
1.51-1.35 (m, 2H), 1.26-1.16 (m, 2H), 1.24 (d, J = 7.1 Hz, 3H), 1.17 (s, 3H), 1.12-1.04 (m, 7H), 1.07 (s, 
9H), 0.88 (s, 9H), 0.07-0.04 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 138.8, 135.7, 135.7, 135.6, 133.8, 
133.7, 129.6, 129.5, 128.2, 127.6, 127.6, 127.6, 127.3, 86.1, 85.6, 84.5, 83.3, 82.6, 74.2, 73.0, 72.9, 65.5, 
62.4, 38.8, 33.7, 32.6, 31.8, 29.1, 27.0, 25.9, 25.2, 23.9, 21.0, 19.3, 19.0, 18.1, 18.0, 14.8, -4.2, -4.4. Rf = 
0.12 (9:1 Hex:EtOAc; UV, CAM). IR (ATR) 3404, 2957, 2930, 2857, 1257, 1111, 833, 701 cm-1. HRMS 
(APCI) m/z [C49H74NaO6Si2]








240 (44.0 mg, 0.054 mmol) was dissolved in 2 ml iPrOH and Ru(p-cymene)[(S,S)-Ts-DPEN] (3.3 mg, 
0.005 mmol, 10 mol %) was added. The reaction was stirred for 1.5 h and the reaction was homogenous 
and starting material was gone by thin layer chromatography. The reaction was loaded onto silica and 
purified via flash column chromatography to yield 21.7 mg (49%) of (2S,5S,8S,9S,10R)-9-(benzyloxy)-2-
((2R,5S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-methyltetrahydrofuran-2-yl)-11-((tert-
butyldiphenylsilyl)oxy)-8,10-dimethylundec-6-yne-2,5-diol as a light brown oil. 1H NMR (400 MHz, 
CDCl3) δ 7.70-7.64 (m, 4H), 7.43-7.21 (m, 11H), 4.64 (d, J = 11.3 Hz, 1H), 4.55 (d, J = 11.3 Hz, 1H), 
4.35 (m, 1H), 3.81-3.71 (m, 3H), 3.66 (q, J = 6.2 Hz, 1H), 3.38 (dd, J = 7.6, 4.2 Hz, 1H), 2.86 (m, 1H), 
2.41 (bs, 2H), 2.05 (m, 1H), 1.96 (m, 1H), 1.88-1.67 (m, 4H), 1.62-1.41 (m, 4H), 1.23 (d, J = 7.0 Hz, 3H), 
1.17 (s, 3H), 1.12-1.10 (m, 5H), 1.07 (s, 9H), 1.05 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.07 (s, 3H), 0.05 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 138.8, 135.7, 135.7, 135.5, 135.5, 133.8, 133.7, 129.6, 129.5, 128.2, 
127.6, 127.6, 127.5, 127.3, 87.0, 85.6, 84.2, 83.4, 82.7, 74.2, 73.0, 72.8, 65.4, 63.2, 38.8, 33.9, 33.7, 32.5, 
29.1, 27.0, 25.9, 25.2, 24.2, 20.8, 19.3, 19.0, 18.0, 18.0, 14.8, -4.2, -4.5. Rf = 0.10 (9:1 Hex:EtOAc; UV, 
CAM). 
                                                            
29 Ru(p-cymene)[(R,R)-Ts-DPEN] was obtained by deprotonation of commercially available RuCl(p-
cymene)[(R,R)-Ts-DPEN]. RuCl(p-cymene)[(R,R)-Ts-DPEN] (248 mg, 0.393 mmol) was dissolved in 10 ml DCM 
and flushed with Ar. Freshly powdered potassium hydroxide (228 mg, 3.93 mmol, 10 equiv.) was added and the 
reaction was stirred for 10 min. 10 ml H2O was added and the layers were separated. The dark purple DCM layer 
was dried with calcium hydride and filtered through glass wool into a vial. Concentration resulted in 212 mg (91%) 
of RuCl(p-cymene)[(R,R)-Ts-DPEN] as a purple solid. See: (a) Haack, K. J.; Hashiguchi, S.; Fujii, A.; Ikariya, T.; 























butyldiphenylsilyl)oxy)-8,10-dimethylundec-6-yne-2,5-diol 246 (20.3 mg, 0.025 mmol) was dissolved in 
2 ml DCM and cooled to 0 °C. An 8 ml solution of methanesulfonic anhydride (43.6 mg, 0.250 mmol, 
10.0 equiv.) and pyridine (19.8 mg, 0.250 mmol, 10.0 equiv.) was added and the reaction was stirred for 2 
h. At this time starting material had disappeared (Rf = 0.14 (4:1 Hex:EtOAc; CAM)) and a new spot (Rf = 
0.23 (4:1 Hex:EtOAc; CAM)) was present by TLC. The reaction was quenched by two drops of MeOH 
and then with sat. NaHCO3. The reaction was extracted with DCM 3x, dried with MgSO4, and 
concentrated onto silica. The reaction was purified to yield 11.8 mg (59%) of (((2R,3S,4S)-3-
(benzyloxy)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-
[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane as a clear oil. [α]20D = -19.3 
, c = 0.0066 g/ml CHCl3. 
1H NMR (400 MHz, CDCl3) δ 7.66-7.63 (m, 4H), 7.42-7.21 (m, 11H), 4.64 (d, J 
= 11.2 Hz, 1H), 4.64 (m, 1H), 4.54 (d, J = 11.3 Hz, 1H), 3.88 (dd, J = 8.2, 6.4 Hz, 1H), 3.77 (dd, J = 9.9, 
5.4 Hz, 1H), 3.72 (dd, J = 9.8, 4.0 Hz, 1H), 3.56 (q, J = 6.2 Hz, 1H), 3.36 (dd, J = 7.6, 4.2 Hz, 1H), 2.85 
(m, 1H), 2.13-1.82 (m, 5H), 1.71-1.55 (m, 4H), 1.21 (s, 3H), 1.21 (d, J = 7.0 Hz, 3H), 1.11 (d, J = 6.3 Hz, 
3H), 1.10 (s, 3H), 1.07 (s, 9H), 1.05 (d, J = 7.0 Hz, 3H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ 138.9, 135.7, 135.7, 134.8, 133.9, 133.8, 129.6, 129.5, 129.5, 128.1, 127.7, 127.6, 
127.6, 127.5, 127.2, 86.4, 85.5, 85.1, 84.0, 83.4, 82.3, 73.9, 73.2, 68.9, 65.5, 38.7, 35.9, 34.2, 33.0, 29.1, 
27.4, 27.0, 26.6, 25.8, 24.1, 19.5, 19.3, 18.3, 17.9, 17.7, 14.8, -3.9, -4.9. 1H NMR (500 MHz, C6D6) δ 
7.77-7.74 (m, 4H; Ph), 7.31-7.28 (m, 2H; Ph), 7.22-7.11 (m, 9H; Ph), 4.74 (m, 1H; C23-H), 4.62 (d, J = 
11.4 Hz, 1H; Bn), 4.49 (d, J = 11.4 Hz, 1H; Bn), 3.87-3.83 (m, 3H; C27-H, C17-H2), 3.68 (q, J = 6.2 Hz, 
1H; C31-H), 3.28 (dd, J = 7.5, 4.3 Hz, 1H; C19-H), 2.86 (m, 1H; C20-H), 2.23 (m, 1H; C18-H), 2.00-1.96 
(m, 2H; C24-H2), 1.94-1.87 (m, 2H; C25-H, C29-H), 1.70-1.64 (m, 2H; C25-H, C28-H), 1.62-1.58 (m, 
1H; C28-H), 1.54-1.48 (m, 1H; C29-H), 1.36 (s, 3H; C33-H3), 1.24 (d, J = 6.2 Hz, 3H; C32-H3), 1.22 (d, J 
= 7.0 Hz, 3H; C35-H3), 1.19 (s, 9H; TBDPS-Me3), 1.19 (s, 3H; C34-H3), 1.14 (d, J = 6.9 Hz, 3H; C36-
H3), 0.97 (s, 9H; TBS-Me3), 0.06 (s, 6H; TBS-Me2). Rf = 0.68 (4:1 Hex:EtOAc; CAM). IR (ATR) 2957, 
2930, 2856, 1471, 1371, 1257, 1112, 833, 702 cm-1. HRMS (ESI/APCI) m/z [C49H76NO5Si2]
+ (M+NH4) 








hydroxy-8,10-dimethylundec-6-yn-5-one 240 (47.0 mg, 0.058 mmol) was dissolved into 3 ml 















































and then dichloroacetic acid (22.4 mg, 0.174 mmol, 3.0 equiv.) in 3 ml trifluoroethanol was added. The 
reaction was stirred for 10 min and quenched with sat. NaHCO3. H2O and DCM were added to the 
reaction and the mixture was extracted with DCM 3x. The organic layer was dried with MgSO4, 
concentrated, and purified by preparative thin layer chromatography to yield 31.2 mg (68%) of 
(((2R,3S,4S)-3-(benzyloxy)-6-((2S,2'R,5R,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-
dimethyloctahydro-[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane as a 
clear oil. [α]20D =  +11.6, c = 0.0104 g/ml CHCl3. 
1H NMR (400 MHz, CDCl3) δ 7.65 (m, 4H), 7.42-7.31 
(m, 6H), 7.29-7.22 (m, 5H), 4.64 (d, J = 11.3 Hz, 1H), 4.64 (m, 1H), 4.54 (d, J = 11.3 Hz, 1H), 3.98 (m, 
1H), 3.78 (dd, J = 9.9, 5.3 Hz, 1H), 3.72 (dd, J = 9.9, 4.0 Hz, 1H), 3.60 (q, J = 6.2 Hz, 1H), 3.38 (dd, J = 
7.6, 4.3 Hz, 1H), 2.84 (m, 1H), 2.14 (m, 1H), 2.08-2.01 (m, 2H), 1.97-1.80 (m, 3H), 1.65-1.55 (m, 3H), 
1.22 (d, J = 7.0 Hz, 3H), 1.12 (d, J = 6.0 Hz, 3H), 1.12 (s, 3H), 1.07 (s, 9H), 1.07 (s, 3H), 1.06 (d, J = 6.9 
Hz, 3H), 0.87 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 138.8, 135.7, 135.6, 
133.8, 133.7, 129.5, 129.5, 128.2, 127.6, 127.6, 127.5, 127.2, 86.4, 85.5, 85.1, 83.6, 83.2, 82.0, 73.9, 73.2, 
68.5, 65.5, 38.7, 36.2, 35.2, 33.6, 29.0, 27.0, 26.4, 25.8, 22.0, 19.3, 19.1, 18.4, 17.9, 17.6, 14.7, -3.9, -4.9. 
1H NMR (400 MHz, C6D6) δ 7.78-7.75 (m, 4H; Ph), 7.30 (m, 2H; Ph), 7.22-7.09 (m, 9H; Ph), 4.64 (m, 
1H; C23-H), 4.62 (d, J = 12.0 Hz, 1H; Bn-H), 4.50 (d, J = 11.4 Hz, 1H; Bn-H), 4.09 (m, 1H; C27-H), 
3.94-3.87 (m, 2H; C17-H2), 3.78 (q, J = 6.2 Hz, 1H; C31-H), 3.30 (dd, J = 7.6, 4.4 Hz, 1H; C19-H), 2.87 
(m, 1H; C20-H), 2.24 (m, 1H; C18-H), 2.07-1.98 (m, 3H; C25-H, C28-H, C29-H), 1.98-1.83 (m, 3H; 
C24-H2, C28-H), 1.62-1.57 (m, 1H; C29-H), 1.43-1.38 (m, 1H; C25-H), 1.30 (d, J = 6.2 Hz, 3H; C32-H3), 
1.23 (d, J = 7.0 Hz, 3H; C35-H3), 1.22 (s, 3H; C34-H3), 1.20 (s, 9H; TBDPS-Me3), 1.18 (d, J = 7.1 Hz, 
3H; C36-H3), 1.17 (s, 3H; C33-H3), 0.98 (s, 9H; TBS-Me3), 0.09 (s, 3H; TBS-Me), 0.07 (s, 3H; TBS-Me). 
13C NMR (100 MHz, C6D6) δ 139.4, 136.1, 136.1, 134.2, 134.0, 129.9, 129.9, 128.5, 128.4, 128.1, 127.9, 
127.4, 86.4 (C21), 85.6 (C30), 85.0 (C22), 84.2 (C27), 83.8 (C19), 83.2 (C26), 74.3 (Bn), 74.0 (C31), 
68.8 (C23), 66.0 (C17), 39.3 (C18), 36.8 (C29), 35.9 (C25), 33.9 (C24), 29.6 (C20), 27.2 (TBDPS-Me3), 
26.7 (C28), 26.1 (TBS-Me3), 22.2 (C34), 19.6 (TBDPS-CMe3), 19.4 (C33), 18.8 (C32), 18.1 (TBS-
CMe3), 17.9 (C35), 15.1 (C36), -3.8 (TBS-Me), -4.7 (TBS-Me). Rf = 0.38 (9:1 Hex:EtOAc; UV, CAM). 
IR (ATR) 2958, 2930, 2857, 1461, 1256, 1105, 833, 739 cm-1. HRMS (APCI) m/z [C49H76NO5Si2]
+ 
(M+NH4) calcd 814.5257, found 814.5258. 
 (2S,5S,8S,9S,10R)-9-(benzyloxy)-2-((2R,5S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-
methyltetrahydrofuran-2-yl)-11-((tert-butyldiphenylsilyl)oxy)-8,10-dimethylundec-6-yne-2,5-diol 247 
(16.9 mg, 0.021 mmol) was dissolved in 2 ml DCM and cooled to 0 °C. An 8 ml solution of 
methanesulfonic anhydride (36.5 mg, 0.210 mmol, 10.0 equiv.) and pyridine (33.2 mg, 0.210 mmol, 20.0 
equiv.) was added and the reaction was stirred for 2 h. At this time starting material had disappeared (Rf = 
0.14 (4:1 Hex:EtOAc; CAM)) and a new spot (Rf = 0.23 (4:1 Hex:EtOAc; CAM)) was present by TLC. 
The reaction was quenched with sat. NaHCO3. The reaction was extracted with DCM 3x, dried with 
MgSO4, and concentrated onto silica. The reaction was purified to yield 6.2 mg (30%) of (((2R,3S,4S)-3-
(benzyloxy)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-








(249). Ammonium was condensed into a 250 ml three neck round 
bottom flask. Sodium metal was added until a deep blue color was 
produced. In a 50 ml three neck round bottom flask, (((2R,3S,4S)-3-
(benzyloxy)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-
yl)-2,4-dimethylhex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane 248 (90.9 mg, 0.114 mmol) was dissolved 
in 5 ml THF and 1 ml tBuOH. Ammonium was condensed into 50 ml round bottom flask from 250 ml 
round bottom flask and lithium metal was added until a blue color persisted. Lithium was added over two 
hours to maintain a blue solution. The reaction was quenched by addition of MeOH until the blue color 
disappeared. H2O was added and the reaction was allowed to warm to ~10 °C. The reaction was extracted 
with Et2O 3x, dried with MgSO4, and the crude material was purified via flash column chromatography to 
yield 52.3 mg (64%) of (2R,3S,4S)-1-((tert-butyldicyclohexenylsilyl)oxy)-6-((2S,2'R,5S,5'S)-5'-((R)-1-
((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-en-3-
ol as an oil. 1H NMR (300 MHz, CDCl3) δ 5.81-5.72 (m, 4H), 5.57-5.44 (m, 2H), 3.98-3.57 (m, 4H), 3.35 
(m, 1H), 2.73 (m, 2H), 2.34-0.80 (m, 57H), 0.05 (m, 6H). Rf = 0.32 (9:1 Hex:EtOAc; CAM). LRMS 
(ESI/APCI) m/z [C42H80NO5Si2]







yl)-2,4-dimethylhex-5-en-3-ol 249 (52.3 mg, 0.073 mmol) was dissolved 
in 5 ml THF. Tetrabutylammonium fluoride (0.15 ml, 0.146 mmol, 2.0 equiv., 1 M in THF)  was added. 
After 10 min., 4 drops of AcOH was added. The reaction was loaded onto silica and purified via flash 
column chromatography to yield 26.0 mg (76%) of (2R,3S,4S)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-ene-1,3-diol 
as a 1.5:1 E:Z ratio. 1H NMR (400 MHz, C6D6) δ 5.82-5.76 (m, 0.7H), 5.57-5.51 (m, 1.6H), 4.46 (m, 1H), 
3.96 (m, 1H), 3.77-3.54 (m, 3H), 3.42 (m, 1H), 3.18 (m, 1H), 2.38-2.11 (m, 3H), 2.05-1.86 (m, 3H), 1.74-
1.43 (m, 5H), 1.28 (m, 3H), 1.23 (m, 3H), 1.14 (m, 3H), 1.03 (m, 3H), 0.98-0.91 (m, 9H), 0.77-0.71 (m, 
3H), 0.07 (m, 6H). Rf = 0.16 (1:1 Hex:EtOAc; CAM). IR (ATR) 3342, 2958, 2930, 2858, 1462, 1371, 
1256, 1098 cm-1. LRMS (APCI) m/z [C26H54NO5Si]


























bifuran]-5-yl)-2,4-dimethylhex-5-ene-1,3-diol (S20). Ammonium was 
condensed into a 250 ml three neck round bottom flask. Sodium metal 
was added until a deep blue color was produced. In a 50 ml three neck 
round bottom flask, (((2R,3S,4S)-3-(benzyloxy)-6-((2S,2'R,5R,5'S)-5'-
((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-
[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane 245 (66.0 mg, 0.083 mmol) 
was dissolved in 5 ml THF and 1 ml tBuOH. Ammonium was condensed into 50 ml round bottom flask 
from 250 ml round bottom flask and lithium metal was added until a blue color persisted. Lithium was 
added over two hours to maintain a blue solution. The reaction was quenched by addition of MeOH until 
the blue color disappeared. H2O was added and the reaction was allowed to warm to ~10 °C. The reaction 
was extracted with Et2O 3x, dried with MgSO4, and the crude material was purified via flash column 
chromatography to yield 44.6 mg (75%) of (2R,3S,4S)-1-((tert-butyldicyclohexenylsilyl)oxy)-6-
((2S,2'R,5R,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-
yl)-2,4-dimethylhex-5-en-3-ol S21. 1H NMR (400 MHz, CDCl3) δ 5.79-5.44 (m, 6H), 4.38 (m, 1H), 3.95-
3.65 (m, 4H), 3.60 (q, J = 6.2 Hz, 1H), 3.36 (m, 1H), 2.73 (m, 2H), 2.34-0.82 (m, 55H), 0.05 (m, 6H).  
HRMS (APCI) m/z [C42H80NO5Si]
+ (M+NH4) calcd 734.5575, found 734.5555. (2R,3S,4S)-1-((tert-
butyldicyclohexenylsilyl)oxy)-6-((2S,2'R,5R,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-
dimethyloctahydro-[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-en-3-ol S21 (44.6 mg, 0.062 mmol) was 
dissolved in 5 ml THF. Tetrabutylammonium fluoride (0.16 ml, 0.156 mmol, 2.5 equiv., 1 M in THF)  
was added. After 10 min., 4 drops of AcOH was added. The reaction was loaded onto silica and purified 
via flash column chromatography to yield 18.7 mg (64%) of (2R,3S,4S)-6-((2S,2'R,5R,5'S)-5'-((R)-1-
((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-ene-
1,3-diol as a 2:1 E:Z ratio. 1H NMR (400 MHz, C6D6) δ 5.78 (dd, J = 15.6, 7.8/8.5 Hz, 1H; C21-H), 5.61 
(dd, J = 15.6, 6.7 Hz, 1H; C22-H), 4.33 (ddd, J = 13.6, 6.6, 6.6 Hz, 1H; C23-H), 3.95 (m, 1H; C27-H), 
3.75 (q, J = 6.3 Hz, 1H; C31-H), 3.58 (m, 1H; C17-HA), 3.46 (m, 1H; C17-HB), 3.18 (bs, 1H; OH), 3.16 
(m, 1H; C19-H), 2.24 (m; C20-H), 1.96 (m, 1H; C29-HA), 1.93 (m, 1H; C25-HA), 1.78 (m, 2H; C28-
HA/HB), 1.71 (m, 1H; C24-HA), 1.60 (m, 1H; C29-HB), 1.58 (m, 1H; C18-H), 1.57 (m, 1H; C24-HB), 
1.54 (bs, 1H; OH), 1.39 (m, 1H; C25-HB), 1.30 (d, J = 6.2 Hz, 3H; C32-H3), 1.19 (s, 3H; C34-H3), 1.17 
(s, 3H; C33-H3), 0.98 (s, 9H; TBS-tBu), 0.94 (m; C35-H3), 0.74 (d, J = 6.7/7.0 Hz, 3H; C36-H3), 0.09 (s, 
3H; TBS-Me), 0.08 (s, 3H; TBS-Me). Rf = 0.23 (1:1 Hex:EtOAc; CAM). HRMS (APCI) m/z 
[C26H51O5Si]







yl)-2,4-dimethylhex-5-ene-1,3-diol 250 (18.7 mg, 0.0397 mmol) was 
dissolved in 0.5 ml DMF. Imidazole (6.0 mg, 0.0873 mmol, 2.0 equiv.) and tertbutyldiphenyl 
silylchloride (0.01 ml, 0.0405 mmol, 1.02 equiv.) was added. The reaction was stirred for 12 h. EtOAc 










MgSO4, concentrated, and purified via preparative thin layer chromatography to yield 5.5 mg (20%) of 
(2R,3S,4S)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-
bifuran]-5-yl)-1-((tert-butyldiphenylsilyl)oxy)-2,4-dimethylhex-5-en-3-ol. Spectral data matches 
literature.30 1H NMR (300 MHz, CDCl3) δ 7.73-7.67 (m, 4H), 7.44-7.36 (m, 6H), 5.78 (dd, J = 15.5, 7.9 
Hz, 0.6 H), 5.54-5.45  (m, 1.4H), 4.41 (m, 0.6 H), 3.99 (m, 0.6 H), 3.84-3.58 (m, 3H), 3.40 (m, 1H), 2.36-
1.56 (m, 14H), 1.15-1.12 (m, 9H), 1.07 (s, 9H), 0.87 (s, 9H), 0.78 (d, J = 6.8 Hz, 3H), 0.06 (m, 6H). Rf = 
0.45 (4:1 Hex:EtOAc; UV, CAM). LRMS (APCI) m/z [C42H72NO5Si2]





5-yl)-2,4-dimethylhex-5-en-3-ol (S22). Sodium hydride (1.2 mg, 0.031 
mmol, 2.0 equiv., 60% in mineral oil) was added to 1 ml THF. To this 
(2R,3S,4S)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-
yl)-2,4-dimethylhex-5-ene-1,3-diol 250 (7.3 mg, 0.0156 mmol) was added in 1 ml THF. The reaction was 
cooled to 0 °C and stirred for 20 min. A solution of benzyl bromide in THF (2.7 mg, 0.0156 mmol, 1.0 
equiv.) was added and the reaction was stirred for 2 h. Starting material remained by TLC and 5 equiv. of 
sodium hydride and benzyl bromide were added and the reaction was stirred overnight. The reaction was 
quenched with sat. NH4Cl, extracted with EtOAc 3x, dried with MgSO4, and purified via flash column 
chromatography to yield 3.6 mg (41%) of (2R,3S,4S)-1-(benzyloxy)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-en-3-ol. 1H 
NMR (300 MHz, CDCl3) δ 7.34-7.27 (m, 5H), 5.72 (dd, J = 15.7, 8.2 Hz, 0.6 H), 5.54-5.42 (m, 1.6H), 
4.51 (s, 2H), 4.37 (m, 0.6H), 3.95 (m, 1H), 3.81 (m, 0.5H), 3.69-3.46 (m, 3H), 3.32 (m, 1H), 2.37-1.79 
(m, 8H), 1.69-1.52 (m, 5H), 1.19-1.10 (m, 9H), 1.06 (d, J = 6.9 Hz, 3H), 0.88-0.86 (m, 9H), 0.05 (m, 6H). 
Rf = 0.05 (9:1 Hex:EtOAc; CAM). HRMS (APCI) m/z [C33H60NO5Si]






yl)methyl)mercury(II) chloride (252). Procedure adapted from 
literature.31 (2R,3S,4S)-6-((2S,2'R,5S,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-
yl)-1-((tert-butyldiphenylsilyl)oxy)-2,4-dimethylhex-5-en-3-ol 251 (5.5 mg, 0.0078 mmol) was dissolved 
in 1 ml acetone. Chloromercury(II) acetate32 (6.0 mg, 0.0203 mmol, 2.6 equiv.) and ytterbium(III) 
trifluoromethane sulfonate (2.0 mg, 0.0032 mmol, 0.4 equiv.) were added at 0 °C. After stirring for 12 h, 
                                                            
30 Gao, Z.; Li, Y.; Cooksey, J. P.; Snaddon, T. N.; Schunk, S.; Viseux, E. M. E.; McAteer, S. M.; Kocienski, P. J. 
Angew. Chem. Int. Ed. 2009, 48, 5022-5025. 
31 Dreher, S. D.; Hornberger, K. R.; Sarraf, S. T.; Leighton, J. L. Org. Lett. 2000, 2, 3197-3199. 
























the reaction was quenched with sat. NaHCO3 and extracted with DCM. The organic layer was dried with 
MgSO4 and purified via flash column chromatography to yield 4.2 mg (54%) of (((2S,2'R,5S,5'S)-5'-((R)-
1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl)((4R,5R,6R)-6-((R)-1-
((tert-butyldiphenylsilyl)oxy)propan-2-yl)-2,2,5-trimethyl-1,3-dioxan-4-yl)methyl)mercury(II) chloride as 
a white powder. 1H NMR (400 MHz, CDCl3) δ 7.69-7.64 (m, 4H), 7.44-7.35 (m, 6H), 4.22-4.06 (m, 1H), 
3.97 (m, 1H), 3.75-3.38 (m, 3H), 2.03-1.77 (m, 6H), 1.66-1.50 (m, 4H), 1.54 (s, 3H), 1.26 (s, 3H), 1.15 
(d, J = 7.1 Hz, 3H), 1.12 (m, 9H), 1.05 (s, 9H), 0.98 (d, J = 7.0 Hz, 3H), 0.88-0.86 (m, 3H), 0.87 (s, 9H), 
0.06 (s, 3H), 0.04 (s, 3H). Rf = 0.30 (9:1 Hex:EtOAc; CAM). HRMS (APCI) m/z [C45H74ClHgO6Si2]
+ 





5-yl)methyl)mercury(II) chloride (S23). (2R,3S,4S)-1-(benzyloxy)-6-
((2S,2'R,5S,5'S)-5'-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-
dimethyloctahydro-[2,2'-bifuran]-5-yl)-2,4-dimethylhex-5-en-3-ol S22 
(3.0 mg, 0.0054 mmol) was dissolved in 1 ml acetone. Chloromercury(II) acetate (2.4 mg, 0.0081 mmol, 
1.5 equiv.) and ytterbium(III) trifluoromethane sulfonate (0.3 mg, 0.0005 mmol, 0.1 equiv.) were added at 
0 °C. After stirring for 12 h, the reaction was quenched with sat. NaHCO3 and extracted with DCM. The 
organic layer was dried with MgSO4 and purified via flash column chromatography to yield 0.8 mg (17%) 
of (((4R,5R,6R)-6-((R)-1-(benzyloxy)propan-2-yl)-2,2,5-trimethyl-1,3-dioxan-4-yl)((2S,2'R,5S,5'S)-5'-
((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl)methyl)mercury(II) 
chloride as a white powder. 1H NMR (400 MHz, CDCl3) δ 7.33 (m, 5H), 4.51 (m, 2H), 4.39 (m, 0.6H), 
4.12-3.29 (m, 7H), 2.06-0.76 (m, 39H), 0.06 (m, 6H). Rf = 0.30 (4:1 Hex:EtOAc; CAM). LRMS 
(ESI/APCI) m/z [C36H61HgO6Si]
+ (M-Cl) calcd 819.4, found 819.3. 
Model Reactions 
 
 2-(5-butyltetrahydrofuran-2-yl)-1-phenylethanone (197). Trimethyl((1-
phenylvinyl)oxy)silane 143 (38.5 mg, 0.20 mmol) and 5-butyltetrahydrofuran-2-yl 
benzoate 196 (49.7 mg, 0.20 mmol) were dissolved in 2 ml DCM and the reaction was 
cooled to -78 °C. Trifluoromethanesulfonimide (14.0 mg, 0.05 mmol, 0.25 equiv.) in 2 ml DCM was 
added and the reaction was stirred for 1 h. The reaction was quenched with sat. NaHCO3 and warmed to 
23 °C. The reaction was extracted with DCM 3x and the organic layer was dried with MgSO4, 
concentrated, and purified via flash column chromatography to yield 40.9 mg (83%, 1.3:1 dr) of 2-(5-
butyltetrahydrofuran-2-yl)-1-phenylethanone. Spectral data matches literature.33 1H NMR (300 MHz, 
CDCl3) δ 7.99-7.95 (m, 2H), 7.58-7.40 (m, 3H), 4.52 (m, 0.5H), 4.36 (m, 0.5H), 3.96 (m, 0.44H), 3.82 
(m, 0.52H), 3.42 (m, 1H), 3.03 (m, 1H), 2.27-1.94 (m, 2H), 1.63-1.25 (m, 8H), 0.89 (m, 3H). Rf = 0.29 
(9:1 Hex:EtOAc; UV, CAM). 
                                                            




















 Diethyl (2-(2,2-dimethylhydrazono)-2-phenylethyl)phosphonate (210). 1,1-
dimethyl-2-(1-phenylethylidene)hydrazine 20934 (108.8 mg, 0.68 mmol) was dissolved 
in THF. The reaction was cooled to -78 °C and nBuLi (0.42 ml, 0.68 mmol, 1.0 equiv., 
1.6 M in Hex) was added. After 10 min, diethyl chlorophosphate (0.1 ml, 0.68 mmol, 1.0 equiv.) was 
added. The reaction was allowed to stir and warm to 23 °C over 12 h. The reaction was quenched with 
H2O and extracted with EtOAc 3x. The organic layer was dried with MgSO4, concentrated, and purified 
via flash column chromatography to yield 127.2 mg (64%) of diethyl (2-(2,2-dimethylhydrazono)-2-
phenylethyl)phosphonate. 1H NMR (300 MHz, CDCl3) δ 7.54-7.51 (m, 2H), 7.32-7.26 (m, 3H), 5.34 (m, 
2H), 4.25-4.10 (m, 4H), 2.42 (s, 6H), 1.30 (m, 6H). 31P NMR (75 MHz, CDCl3) δ 4.36. Rf = 0.23 (EtOAc; 
KMnO4). LRMS (ESI/APCI) m/z [C14H24N2O3P]
+ (M+H) calcd 299.1, found 299.1. 
 
 Diethyl (2-(2,2-dimethylhydrazono)-3-methylbutyl)phosphonate (213). 1,1-
dimethyl-2-(3-methylbutan-2-ylidene)hydrazine 212 (127.2 mg, 1.0 mmol) was 
dissolved in THF. The reaction was cooled to -78 °C and nBuLi (0.63 ml, 1.0 mmol, 
1.0 equiv., 1.6 M in Hex) was added. After 10 min, diethyl chlorophosphate (0.15 ml, 1.0 mmol, 1.0 
equiv.) was added. The reaction was allowed to stir and warm to 23 °C over 12 h. The reaction was 
quenched with H2O and extracted with EtOAc 3x. The organic layer was dried with MgSO4, 
concentrated, and purified via flash column chromatography to yield 138.0 mg (53%) of diethyl (2-(2,2-
dimethylhydrazono)-3-methylbutyl)phosphonate. 1H NMR (300 MHz, CDCl3) δ 4.89 (m, 2H), 4.08 (m, 
4H), 2.67 (s, 6H), 2.42 (m, 1H), 1.32 (m, 6H), 1.12 (d, J = 6.8 Hz, 6H). 31P NMR (75 MHz, CDCl3) δ 
4.91. Rf = 0.16 (1:1 Hex:EtOAc; KMnO4). LRMS (ESI/APCI) m/z [C11H26N2O3P]




dimethyl hydroxylamine·HCl (2.61 g, 26.8 mmol, 2 equiv.) was suspended in 
DCM and cooled to 0 °C. Trimethyl aluminum (13.4 mL, 26.8 mmol, 2M in 
PhMe, 2 equiv.) was added very slowly. The reaction was  stirred for 20 min and resulted in a clear 
solution. γ-octalactone (2 mL, 13.4 mmol) was added slowly via syringe. After stirring for 1h, the 
reaction was quenched with 1M HCl and extracted with DCM 3x. The organic layer was dried with 
MgSO4 and concentrated. The residue was dissolved in DCM. Imidizole (2.28g, 33.5 mmol, 2.5 equiv.) 
was added and then chlorotrimethylsilane (2 mL, 16.9 mmol, 1.25 equiv.) was added slowly via syringe. 
After 5 min, a spatula tip of 4-(dimethylamino)pyridine was added and thre reaction was stirred. The 
reaction was quenched with water and the organic layer was seperated and dried with MgSO4. The 
residue was purified by flash column chromatography to yield 2.75 g of N-methoxy-N-methyl-4-
((trimethylsilyl)oxy)octanamide (74%) as a clear oil.  1H NMR (400 MHz, CDCl3) δ 3.70 (m, 1H), 3.68 
(s, 3H), 3.17 (s, 3H), 2.50 (m, 2H), 1.84 (m, 1H), 1.65 (m, 1H), 1.49-1.23 (6H), 0.89 (m, 3H), 0.11 (s, 
9H). Rf = 0.47 (2:1 Hex:EtOAc). IR (ATR) 2956, 2861, 1668, 1380, 1249, 1063, 999, 837 cm
-1. LRMS 
(APCI/ESI) m/z [C13H30NO3Si]
+ (M+H) calcd 276.2, found 276.2. 
                                                            
























one (235). Tert-butyl(hex-5-yn-1-yloxy)dimethylsilane (63.7 mg, 
0.300 mmol) was dissolved in 2 mL THF and cooled to -78 °C. 
n-BuLi (1.4 M, 0.22 mL, 0.315 mmol, 1.05 equiv) was added and the reaction was stirred for 30 min. A 
solution of BF3·OEt2 in THF (0.315 mmol, 1.05 equiv) was added and the reaction was stirred for 30 min. 
γ-octalactone (42.7 mg, 0.300 mmol) was dissolved in 2 mL THF and added to the reaction mixture. After 
stirring for 4 h, the reaction was quenched with sat NH4Cl, extracted with Et2O 2x, dried with MgSO4, 
and concentrated. The resulting residue was purified via column chromatography that resulted in 44.4 mg 
of 1-((tert-butyldimethylsilyl)oxy)-10-hydroxytetradec-5-yn-7-one (41%) as a clear oil. 1H NMR (400 
MHz, CDCl3) δ 3.63 (t, J = 5.8 Hz, 2H), 3.62 (s, 1H), 2.69 (m, 2H), 2.40 (t, J = 6.8 Hz, 2H), 1.86 (m, 
1H), 1.71 (m, 1H), 1.6 (m, 4H), 1.45 (m, 3H), 1.32 (m, 4H), 0.90 (m, 3H), 0.89 (s, 9H), 0.05 (s, 6H). 13C 
NMR (100 MHz, CDCl3) δ 188.4, 94.5, 81.0, 71.1, 62.4, 42.0, 37.3, 31.8, 31.2, 27.8, 25.9, 24.3, 22.7, 
18.8, 14.0, -5.3. Rf = 0.30 (4:1 Hex:EtOAc). IR (ATR) 3570, 2954, 2929, 2858, 1673, 1471, 1255, 1106, 
837, 776 cm-1. LRMS (APCI/ESI) m/z [C20H37O2Si]
+ (M-OH) calcd 337.2, found 337.2 and m/z 
[C21H41O3Si]
+ (M-OH+MeOH) calcd 369.3, found 369.3. 
 Tert-butyl((6-(5-butyltetrahydrofuran-2-yl)hex-5-yn-1-
yl)oxy)dimethylsilane (236). 1-((tert-butyldimethylsilyl)oxy)-10-
hydroxytetradec-5-yn-7-one 235 (44.0 mg, 0.124 mmol) was dissolved 
in 2mL DCM and cooled to -78 °C. Triethylsilane (0.05 mL, 0.590 
mmol, 4.7 equiv) was added and the reaction was stirred for 20 min. A solution of BF3·OEt2 in THF 
(0.372 mmol, 0.372 mmol, 3.0 equiv) was added and the reaction was warmed to 0 °C over 30 min. The 
reaction was quenched with sat NaHCO3 and extracted with DCM 2x. The organic layer was dried with 
MgSO4, concentrated, and purified via column chromatography to yield 7.1 mg of tert-butyl((6-(5-
butyltetrahydrofuran-2-yl)hex-5-yn-1-yl)oxy)dimethylsilane (17 %) as a clear oil. 1H NMR (400 MHz, 
CDCl3) δ 4.64 (diastereomer a, ddd, J = 6.4, 1.8, 1.8 Hz, 0.34 H), 4.47 (diastereomer b, ddd, J = 6.3, 1.9, 
1.9 Hz, 0.46 H), 4.05 (diastereomer a, m, 0.38 H), 3.79 (diastereomer b, m, 0.55 H), 3.61 (t, J = 6.1 Hz, 
2H), 2.22 (ddd, J = 6.9, 1.7, 1.7 Hz, 2H), 2.14-1.88 (m, 3H), 1.72-1.25 (m, 11H), 0.89 (s, 9H), 0.89 (m, 
3H), 0.04 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 84.9, 84.8, 80.6, 80.4, 80.1, 78.9, 68.2, 68.0, 62.7, 35.7, 
35.3, 33.8, 33.6, 32.0, 31.2, 31.1, 28.4, 28.3, 26.0, 25.1, 25.0, 22.8, 22.8, 18.6, 18.6, 18.3, 14.0, -5.3. Rf = 
0.21 (20:1 Hex:EtOAc). IR (ATR) 2954, 2929, 2858, 1463, 1255, 1106, 836, 776 cm-1. LRMS 
(APCI/ESI) m/z [C20H39O2Si]
+ (M+H) calcd 339.3, found 339.2. 
6-(5-butyltetrahydrofuran-2-yl)hex-5-yn-1-ol (237). Isolated from 
above reaction 5.8 mg (21 %) as a clear oil. 1H NMR (400 MHz, CDCl3) 
δ 4.63  (diastereomer a, ddd, J = 6.4, 1.9, 1.9 Hz, 0.48 H), 4.47 
(diastereomer b, ddd, J = 6.2, 1.8, 1.8 Hz, 0.48 H), 4.05 (diastereomer a, 
m, 0.53 H), 3.79 (diastereomer b, m, 0.60 H), 3.66 (t, J = 6.2 Hz, 2H), 2.25 (ddd, J = 6.9, 1.6, 1.6 Hz, 
2H), 2.18-1.88 (m, 3H), 1.71-1.25 (m, 12 H), 0.89 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 84.6, 84.5, 
80.8, 80.7, 80.1, 79.0, 68.1, 67.9, 62.4, 62.4, 35.7, 35.3, 33.8, 33.6, 31.8, 31.2, 31.1, 28.4, 28.3, 24.8, 24.8, 
22.8, 22.8, 18.6, 18.6, 14.0. Rf = 0.35 (1:1 Hex:EtOAc). IR (ATR) 3408, 2931, 2861, 1457, 1332, 1027, 
668 cm-1. LRMS (APCI/ESI) m/z [C14H25O2]













Dried cerium trichloride (12.9 mg, 0.0525 mmol, 1.4 equiv.) was added to an 
oven dried 10 mL round bottom flask in an inert air glovebox. After sealing and removing, the cerium 
trichloride was suspended in 1 mL THF and cooled to -78 °C. Phenyl lithium (0.03 mL, 0.0525 mmol, 
1.75 M in dibutyl ether, 1.4 equiv.) was added and stirred for 15 min. (2S,2'R,5'S)-5'-((R)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-2,5'-dimethylhexahydro-[2,2'-bifuran]-5(2H)-one 184 (13.1 mg, 0.038 
mmol) in 0.5 mL THF was added and the reaction was stirred for 30 min. The reaction was quenched at -
78 °C with sat. NH4Cl, allowed to warm, and extracted 3x with Et2O. The organic layers were combined, 
dried with MgSO4, filtered, and concentrated. The resultant residue was purified by flash column 
chromatography to yield 7.0 mg of mostly (S)-4-((2R,5S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-
methyltetrahydrofuran-2-yl)-4-hydroxy-1-phenylpentan-1-one (43%) as a clear oil. 1H NMR (300 MHz, 
CDCl3) δ 7.99 (m, 2H), 7.54 (m, 1H), 7.43 (m, 2H), 3.86 (t, J = 7.3 Hz, 1H), 3.87 (q, J = 6.3 Hz, 1H), 
3.24 (ddd, J = 17.2, 9.8, 5.3 Hz, 1H), 3.05 (ddd, J = 17.2, 9.9, 5.7 Hz, 1H), 2.33-1.00) (m, 5H), 1.21 (s, 
3H), 1.13 (m, 6H), 0.90-0.82 (m, 2H), 0.88 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H). Rf = 0.36 (4:1 Hex:EtOAc). 
HRMS (APCI/ESI) m/z [C24H39O3Si]
+ (M-H2O) calcd 403.2668, found 403.2668. 
 
 S-phenyl 4-hydroxyoctanethioate (243). Procedure adapted from literature.35 In an 
oven dried 100 mL flask, benzene thiol (0.88 mL, 8.6 mmol, 2.5 equiv.) was added to 20 
mL of DCM. The reaction flask was cooled to 0 °C and trimethyl aluminum (4.3 mL, 8.6 
mmol, 2 M in PhMe, 2.5 equiv.) was added very slowly. The reaction was stirred for 10 minutes at 0 °C, 
the ice bath was removed and the reaction was stirred for another 10 minutes, and then the reaction was 
cooled back to 0 °C. γ-octalactone (0.5 mL, 3.45 mmol) was added slowly and the reaction was stirred 
overnight and allwed to warm to 23 °C. The reaction mixture was cooled to -78 °C and diluted with 20 
mL of Et2O. 12 mL of 1 M HCl was added and the reaction was allowed to warm to 0 °C. The reaction 
was extracted with Et2O 3x, and the organic layer was washed with 1 M HCl 1x, sat. NaHCO3 1x, and sat. 
brine 1x. The organic layer was dried with MgSO4, filtered, loaded onto Celite and purified via flash 
column chromatography to yield 261 mg (28%) of S-phenyl 4-hydroxyoctanethioate as a clear oil. 
[Caution: this compound is acid sensitive and decomposes in CDCl3 over a few hours]. 
1H NMR (400 
MHz, C6D6) δ 7.43-7.40 (m, 2H), 7.08-6.99 (m, 3H), 3.26 (bs, 1H), 2.60 (m, 2H), 1.68 (m, 1H), 1.53 (m, 
1H), 1.23-1.05 (m, 7H), 0.85 (m, 3H). 13C NMR (100 MHz, C6D6) δ 196.5, 134.8, 129.3, 129.2, 128.7, 
70.5, 40.3, 37.5, 33.0, 28.0, 23.0, 14.2. Rf = 0.26 (4:1 Hex:EtOAc). IR (ATR) 3398, 2955, 2928, 2859, 
1705, 1441, 1023, 989, 745, 706 cm-1. LRMS (APCI/ESI) m/z [C14H19OS]



















hydroxy-2,4-dimethyltetradec-5-yn-7-one (244). Procedure 
adapted from literature.36 In a 10 mL round bottom flask, [1,1'-
Bis(diphenylphosphino)ferrocene]dichloropalladium (II) (2.4 mg, 
0.003 mmol, 10 mol %), tri-(2-furyl)phosphine (1.7 mg, 0.0075 mmol, 25 mol %), and copper(I) iodide 
(10.3 mg, 0.054 mmol, 2 equiv.) was added in an inert air glove box. The reaction vessel was sealed, 
removed from the glove box, and 1.5 mL of DMF was added. In a vial, (((2R,3S,4S)-3-(benzyloxy)-2,4-
dimethylhex-5-yn-1-yl)oxy)(tert-butyl)diphenylsilane 239 (12.7 mg, 0.027 mmol), S-phenyl 4-
hydroxyoctanethioate 243 (8.8 mg, 0.035 mmol, 1.3 equiv.), and N,N-diisopropylethylamine (6.9 mg, 
0.053mmol, 2 equiv.) was added to a vial and dissolved in 0.5 mL DMF. After adding this solution to the 
reaction, the reaction was heated to 60 °C and stirred overnight. The reaction was cooled to 23 °C, Celite 
was added, and stirred for 30 min. Et2O and H2O was added and the solution was filtered through a pad of 
Celite. The filtrate was extracted with Et2O 3x. The organic layers were combined, washed with 10% 
LiCl 2x, dried with MgSO4, and concentrated. The residue was purified by preparative thin layer 
chromatography to yield 2.8 mg of (2R,3S,4S)-3-(benzyloxy)-1-((tert-butyldiphenylsilyl)oxy)-10-
hydroxy-2,4-dimethyltetradec-5-yn-7-one (17%) as a clear oil. 1H NMR (300 MHz, C6D6) δ 7.76-7.72 (m, 
4H), 7.28-7.09 (m, 11H), 4.53 (d, J = 11.2 Hz, 1H), 4.46 (d, J = 11.4 Hz, 1H), 3.80 (m, 2H), 3.24 (m, 2H), 
2.81 (m, 1H), 2.53 (t, J = 7.4 Hz, 2H), 2.11 (m, 1H), 1.88-1.50 (m, 2H), 1.40-0.75 (m, 7H), 1.18 (s, 9H), 
1.12 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 7.0 Hz, 3H), 0.84 (m, 3H). Rf = 0.08 (9:1 Hex:EtOAc). IR (ATR) 
2957, 2929, 2857, 2210, 1775, 1671, 1456, 1185, 1112, 1069, 702 cm-1. HRMS (APCI/ESI) m/z 
[C39H56NO4Si]
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Crystal Structure Tables and Figures.  
 
Table A.4.1.  Crystal data and structure refinement for 1. 
Identification code  rovis176_0m 
Empirical formula  C7H10O3 
Formula weight  142.15 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 6.5932(3) Å = 90°. 
 b = 7.5104(4) Å = 91.980(3)°. 
 c = 14.0654(7) Å  = 90°. 
Volume 696.07(6) Å3 
Z 4 
Density (calculated) 1.356 Mg/m3 
Absorption coefficient 0.106 mm-1 
F(000) 304 
Crystal size 0.18 x 0.17 x 0.15 mm3 
Theta range for data collection 2.90 to 28.70°. 
Index ranges -8<=h<=8, -10<=k<=10, -18<=l<=18 
Reflections collected 16401 
Independent reflections 1801 [R(int) = 0.0392] 
Completeness to theta = 28.70° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9843 and 0.9810 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1801 / 0 / 93 
Goodness-of-fit on F2 1.034 
Final R indices [I>2sigma(I)] R1 = 0.0367, wR2 = 0.0871 
R indices (all data) R1 = 0.0507, wR2 = 0.0946 







Table A.4.2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 1.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 9703(2) 323(2) 3162(1) 20(1) 
C(2) 7443(2) 581(2) 3072(1) 17(1) 
C(3) 6554(2) 1056(2) 4025(1) 17(1) 
C(4) 7658(2) 2643(2) 4480(1) 18(1) 
C(5) 9895(2) 2252(2) 4588(1) 19(1) 
C(6) 6428(2) -1042(2) 2609(1) 25(1) 
C(7) 6819(2) 3164(2) 5437(1) 25(1) 
O(1) 10755(1) 1141(1) 3917(1) 22(1) 
O(2) 10706(1) -525(1) 2634(1) 30(1) 
O(3) 11032(1) 2800(1) 5200(1) 30(1) 
________________________________________________________________________________  
 
Table A.4.3.   Bond lengths [Å] and angles [°] for  1. 
_____________________________________________________  
C(1)-O(2)  1.1949(14) 
C(1)-O(1)  1.3917(14) 
C(1)-C(2)  1.5036(15) 
C(2)-C(3)  1.5225(15) 
C(2)-C(6)  1.5257(16) 
C(3)-C(4)  1.5259(15) 
C(4)-C(5)  1.5064(15) 
C(4)-C(7)  1.5242(16) 
C(5)-O(3)  1.1950(14) 



















Symmetry transformations used to generate equivalent atoms:  
  
 
Table A.4.4.   Anisotropic displacement parameters  (Å2x 103) for 1.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 20(1)  18(1) 21(1)  3(1) 4(1)  0(1) 
C(2) 16(1)  18(1) 18(1)  1(1) 2(1)  0(1) 
C(3) 13(1)  20(1) 18(1)  2(1) 2(1)  0(1) 
C(4) 17(1)  17(1) 18(1)  2(1) 2(1)  1(1) 
C(5) 19(1)  16(1) 22(1)  4(1) 1(1)  -2(1) 
C(6) 26(1)  25(1) 24(1)  -4(1) 3(1)  -5(1) 
C(7) 30(1)  24(1) 21(1)  -2(1) 6(1)  0(1) 
O(1) 13(1)  25(1) 27(1)  0(1) 2(1)  0(1) 
O(2) 26(1)  34(1) 31(1)  -3(1) 10(1)  7(1) 
O(3) 27(1)  29(1) 34(1)  -2(1) -9(1)  -4(1) 
______________________________________________________________________________  
 
Table A.4.5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 1. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 7188 1614 2636 20 
H(3A) 6669 18 4457 21 
H(3B) 5097 1344 3928 21 
H(4) 7481 3683 4040 21 
H(6A) 7020 -1265 1991 38 
H(6B) 4969 -821 2519 38 
H(6C) 6643 -2084 3020 38 
H(7A) 7029 2183 5889 37 
H(7B) 5364 3415 5358 37 
356 
 










Table A.4.6.  Crystal data and structure refinement for 170. 
Identification code  rovis163_0m 
Empirical formula  C16H20BrN3O 
Formula weight  350.26 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.5460(5) Å = 90°. 
 b = 14.5824(13) Å = 90°. 
 c = 20.209(2) Å  = 90°. 
Volume 1634.4(3) Å3 
Z 4 
Density (calculated) 1.423 Mg/m3 
Absorption coefficient 2.518 mm-1 
F(000) 720 
Crystal size 0.27 x 0.11 x 0.09 mm3 
Theta range for data collection 1.72 to 26.75°. 
Index ranges -7<=h<=7, -18<=k<=18, -24<=l<=25 
Reflections collected 30081 
Independent reflections 3464 [R(int) = 0.1170] 
Completeness to theta = 26.75° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8145 and 0.5551 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3464 / 0 / 194 
Goodness-of-fit on F2 1.032 
Final R indices [I>2sigma(I)] R1 = 0.0424, wR2 = 0.0577 
R indices (all data) R1 = 0.0836, wR2 = 0.0682 
Absolute structure parameter -0.001(11) 








Table A.4.7.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 170.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Br(1) 11527(1) 4720(1) -602(1) 26(1) 
C(1) 11284(7) 5683(2) 27(2) 15(1) 
C(2) 13107(7) 6314(3) 79(2) 16(1) 
C(3) 12909(6) 7021(2) 537(2) 15(1) 
C(4) 10900(6) 7096(3) 950(2) 14(1) 
C(5) 9091(6) 6437(3) 892(2) 15(1) 
C(6) 9257(6) 5734(3) 431(2) 19(1) 
C(7) 10671(7) 7850(3) 1421(2) 15(1) 
C(8) 8645(8) 8252(2) 1686(2) 15(1) 
C(9) 8097(7) 9566(3) 2494(2) 20(1) 
C(10) 6768(7) 9050(3) 3047(2) 20(1) 
C(11) 8495(8) 8526(3) 3508(2) 23(1) 
C(12) 7273(7) 7764(3) 3905(2) 26(1) 
C(13) 6326(9) 7038(3) 3441(2) 26(1) 
C(14) 8047(8) 6440(3) 3079(2) 38(1) 
C(15) 5228(6) 9737(3) 3427(2) 27(1) 
C(16) 9033(7) 7367(3) 4412(2) 37(1) 
N(1) 12623(5) 8328(2) 1646(2) 21(1) 
N(2) 11903(6) 8989(2) 2045(2) 23(1) 
N(3) 9453(5) 8940(2) 2067(2) 18(1) 
O(1) 4165(5) 6922(2) 3369(2) 41(1) 
________________________________________________________________________________  
 
Table A.4.8.   Bond lengths [Å] and angles [°] for  170. 
_____________________________________________________  
Br(1)-C(1)  1.899(4) 
C(1)-C(2)  1.371(5) 
C(1)-C(6)  1.391(5) 
C(2)-C(3)  1.392(5) 
C(3)-C(4)  1.396(5) 
C(4)-C(5)  1.393(5) 
C(4)-C(7)  1.460(5) 
C(5)-C(6)  1.389(5) 
C(7)-N(1)  1.366(5) 
C(7)-C(8)  1.376(5) 
C(8)-N(3)  1.342(5) 
C(9)-N(3)  1.464(5) 
359 
 
C(9)-C(10)  1.536(5) 
C(10)-C(15)  1.524(5) 
C(10)-C(11)  1.539(5) 
C(11)-C(12)  1.529(5) 
C(12)-C(13)  1.509(6) 
C(12)-C(16)  1.529(6) 
C(13)-O(1)  1.219(5) 
C(13)-C(14)  1.486(6) 
N(1)-N(2)  1.319(4) 



































Symmetry transformations used to generate equivalent atoms:  
  
 
Table A.4.9.   Anisotropic displacement parameters  (Å2x 103) for 170.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Br(1) 31(1)  22(1) 26(1)  -5(1) 5(1)  0(1) 
C(1) 19(2)  14(2) 12(2)  4(2) -2(2)  3(2) 
C(2) 10(2)  22(2) 16(2)  3(2) 8(2)  4(2) 
C(3) 8(2)  16(2) 22(2)  2(2) -2(2)  1(2) 
C(4) 10(2)  19(2) 14(2)  2(2) -2(2)  2(2) 
C(5) 9(2)  20(2) 17(2)  3(2) 4(2)  2(2) 
C(6) 15(2)  22(2) 21(3)  5(2) 0(2)  -3(2) 
C(7) 12(2)  21(2) 11(2)  3(2) -1(2)  -2(2) 
C(8) 12(2)  18(2) 14(2)  -2(2) 0(2)  -3(2) 
C(9) 18(2)  20(2) 22(2)  -2(2) 2(2)  2(2) 
C(10) 13(2)  31(2) 15(2)  -5(2) 1(2)  3(2) 
C(11) 19(2)  30(2) 19(2)  -6(2) 2(2)  3(2) 
C(12) 26(3)  29(3) 24(3)  6(2) 5(2)  8(2) 
C(13) 22(2)  32(3) 24(3)  11(2) -4(2)  -3(2) 
C(14) 32(3)  34(3) 48(4)  -14(3) 5(3)  0(3) 
C(15) 27(2)  34(3) 20(2)  -4(3) -2(2)  8(2) 
C(16) 36(3)  44(3) 30(3)  -4(3) -8(3)  11(2) 
N(1) 13(2)  27(2) 22(2)  -5(2) -1(2)  0(2) 
N(2) 16(2)  31(2) 22(2)  -7(2) 2(2)  -2(2) 
N(3) 14(2)  23(2) 16(2)  1(2) 2(2)  0(2) 









Table A.4.10.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 170. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 14492 6268 -196 19 
H(3) 14165 7462 570 18 
H(5) 7720 6470 1173 19 
H(6) 8003 5293 392 23 
H(8) 7015 8079 1614 18 
H(9A) 6911 9908 2223 25 
H(9B) 9218 10017 2693 25 
H(10) 5664 8594 2836 24 
H(11A) 9805 8255 3239 27 
H(11B) 9238 8967 3820 27 
H(12) 5876 8036 4149 32 
H(14A) 8028 5824 3273 57 
H(14B) 9675 6697 3112 57 
H(14C) 7573 6403 2612 57 
H(15A) 4397 9422 3790 41 
H(15B) 4035 10009 3128 41 
H(15C) 6262 10221 3608 41 
H(16A) 8330 6816 4612 55 
H(16B) 9348 7823 4757 55 










Table A.4.11.  Crystal data and structure refinement for 3b. 
Identification code  rovis172 
Empirical formula  C14H16O4 
Formula weight  248.27 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 14.1305(16) Å = 90°. 
 b = 5.0351(6) Å = 104.566(6)°. 
 c = 18.5891(18) Å  = 90°. 
Volume 1280.1(2) Å3 
Z 4 
Density (calculated) 1.288 Mg/m3 
Absorption coefficient 0.094 mm-1 
F(000) 528 
Crystal size 0.47 x 0.32 x 0.12 mm3 
Theta range for data collection 1.63 to 26.37°. 
Index ranges -17<=h<=17, -6<=k<=6, -23<=l<=23 
Reflections collected 17179 
Independent reflections 2605 [R(int) = 0.0492] 
Completeness to theta = 26.37° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9885 and 0.9572 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2605 / 0 / 165 
Goodness-of-fit on F2 1.123 
Final R indices [I>2sigma(I)] R1 = 0.0408, wR2 = 0.1059 
R indices (all data) R1 = 0.0605, wR2 = 0.1277 









Table A.4.12.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 3b.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 2217(1) 2961(3) 1709(1) 20(1) 
C(2) 2100(1) 346(3) 1306(1) 20(1) 
C(3) 2881(1) 65(3) 878(1) 18(1) 
C(4) 3893(1) 307(3) 1406(1) 20(1) 
C(5) 3986(1) 2946(3) 1791(1) 23(1) 
C(6) 1063(1) 5(4) 832(1) 33(1) 
C(7) 4730(1) -120(4) 1037(1) 34(1) 
C(8) 2678(1) 1248(4) -407(1) 29(1) 
C(9) 2307(1) 3467(3) -944(1) 22(1) 
C(10) 1318(1) 4086(4) -1139(1) 29(1) 
C(11) 958(1) 6065(4) -1655(1) 29(1) 
C(12) 1588(1) 7447(3) -1978(1) 24(1) 
C(13) 2574(1) 6851(3) -1790(1) 23(1) 
C(14) 2931(1) 4870(3) -1272(1) 21(1) 
O(1) 1580(1) 4227(2) 1865(1) 30(1) 
O(2) 3149(1) 4034(2) 1943(1) 22(1) 
O(3) 4714(1) 4232(3) 1982(1) 40(1) 
O(4) 2742(1) 2157(2) 338(1) 20(1) 
________________________________________________________________________________  
 
Table A.4.13.   Bond lengths [Å] and angles [°] for  3b. 
_____________________________________________________  
C(1)-O(1)  1.1962(19) 
C(1)-O(2)  1.389(2) 
C(1)-C(2)  1.503(2) 
C(2)-C(6)  1.518(2) 
C(2)-C(3)  1.520(2) 
C(3)-O(4)  1.4351(17) 
C(3)-C(4)  1.522(2) 
C(4)-C(5)  1.499(2) 
C(4)-C(7)  1.525(2) 
C(5)-O(3)  1.191(2) 
C(5)-O(2)  1.395(2) 
C(8)-O(4)  1.4393(18) 
C(8)-C(9)  1.501(2) 
C(9)-C(14)  1.385(2) 
C(9)-C(10)  1.388(2) 
C(10)-C(11)  1.388(2) 
C(11)-C(12)  1.380(2) 
C(12)-C(13)  1.382(2) 
365 
 





























Symmetry transformations used to generate equivalent atoms:  
  
Table A.4.14.   Anisotropic displacement parameters  (Å2x 103) for 3b.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 26(1)  17(1) 17(1)  4(1) 6(1)  -1(1) 
C(2) 25(1)  15(1) 19(1)  0(1) 5(1)  -3(1) 
C(3) 25(1)  12(1) 16(1)  1(1) 4(1)  0(1) 
C(4) 24(1)  16(1) 21(1)  2(1) 5(1)  1(1) 
C(5) 22(1)  19(1) 24(1)  3(1) 0(1)  1(1) 
C(6) 26(1)  35(1) 36(1)  -6(1) 6(1)  -8(1) 
C(7) 27(1)  38(1) 37(1)  0(1) 10(1)  5(1) 
C(8) 48(1)  22(1) 18(1)  -1(1) 10(1)  6(1) 
C(9) 32(1)  17(1) 15(1)  -3(1) 5(1)  2(1) 
C(10) 31(1)  31(1) 25(1)  0(1) 9(1)  -6(1) 
C(11) 22(1)  37(1) 26(1)  -4(1) 3(1)  3(1) 
C(12) 33(1)  23(1) 15(1)  0(1) 2(1)  6(1) 
C(13) 30(1)  21(1) 20(1)  -2(1) 8(1)  -1(1) 
C(14) 23(1)  22(1) 19(1)  -4(1) 4(1)  4(1) 
366 
 
O(1) 36(1)  22(1) 38(1)  -1(1) 18(1)  4(1) 
O(2) 28(1)  16(1) 23(1)  -4(1) 4(1)  -1(1) 
O(3) 26(1)  25(1) 62(1)  -6(1) -4(1)  -6(1) 
O(4) 33(1)  13(1) 15(1)  1(1) 5(1)  1(1) 
______________________________________________________________________________  
 
Table A.4.5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 3b. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 2218 -1085 1691 23 
H(3) 2815 -1698 623 22 
H(4) 3948 -1095 1795 24 
H(6A) 604 109 1149 49 
H(6B) 1000 -1729 585 49 
H(6C) 914 1414 457 49 
H(7A) 4731 1313 680 50 
H(7B) 4645 -1829 776 50 
H(7C) 5353 -118 1417 50 
H(8A) 2228 -288 -523 35 
H(8B) 3331 672 -452 35 
H(10) 882 3145 -917 34 
H(11) 280 6469 -1785 35 
H(12) 1343 8807 -2330 29 
H(13) 3007 7793 -2014 28 











Table A.4.16.  Crystal data and structure refinement for 137b. 
Identification code  rovis162 
Empirical formula  C22H25NO4S2 
Formula weight  431.55 
Temperature  115 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 12.0202(10) Å = 90°. 
 b = 8.2839(7) Å = 117.662(5)°. 
 c = 12.0687(10) Å  = 90°. 
Volume 1064.37(15) Å3 
Z 2 
Density (calculated) 1.347 Mg/m3 
Absorption coefficient 0.279 mm-1 
F(000) 456 
Crystal size 0.17 x 0.10 x 0.06 mm3 
Theta range for data collection 1.91 to 26.76°. 
Index ranges -15<=h<=15, -10<=k<=10, -14<=l<=15 
Reflections collected 20567 
Independent reflections 4461 [R(int) = 0.0774] 
Completeness to theta = 26.76° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9824 and 0.9547 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4461 / 1 / 266 
Goodness-of-fit on F2 1.001 
Final R indices [I>2sigma(I)] R1 = 0.0464, wR2 = 0.0781 
R indices (all data) R1 = 0.0799, wR2 = 0.0900 
Absolute structure parameter 0.03(7) 








Table A.4.17.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 137b.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 9753(3) 2667(4) 7275(3) 27(1) 
C(2) 10890(3) 1640(4) 8033(3) 19(1) 
C(3) 12042(3) 2357(4) 8783(3) 22(1) 
C(4) 13092(3) 1430(4) 9460(3) 25(1) 
C(5) 13022(3) -235(4) 9411(3) 26(1) 
C(6) 11873(3) -958(4) 8664(3) 26(1) 
C(7) 10814(3) -33(4) 7979(3) 19(1) 
C(8) 7678(3) 3179(4) 7031(3) 18(1) 
C(9) 7433(3) 4799(4) 7503(3) 22(1) 
C(10) 8490(3) 5970(4) 7698(3) 24(1) 
C(11) 9248(4) 6617(6) 9000(3) 68(2) 
C(12) 6776(3) 1817(4) 6956(3) 17(1) 
C(13) 6912(3) 350(4) 6260(3) 26(1) 
C(14) 6999(3) 1385(4) 8287(3) 20(1) 
C(15) 3366(3) 4015(4) 7099(3) 18(1) 
C(16) 2484(3) 3014(3) 6174(3) 15(1) 
C(17) 1302(3) 3571(4) 5327(3) 20(1) 
C(18) 1007(3) 5152(4) 5441(3) 23(1) 
C(19) 1882(3) 6177(4) 6353(3) 24(1) 
C(20) 3063(3) 5624(4) 7184(3) 24(1) 
C(21) 6177(3) 5540(4) 6598(3) 31(1) 
C(22) 4449(3) 1774(4) 7574(3) 15(1) 
N(1) 4495(2) 3271(3) 7894(2) 18(1) 
O(1) 8932(2) 2645(2) 7843(2) 19(1) 
O(2) 8700(2) 6363(3) 6856(2) 30(1) 
O(3) 6027(2) 435(3) 9695(2) 25(1) 
O(4) 5372(2) -1049(3) 7697(2) 27(1) 
S(1) 5728(1) 436(1) 8396(1) 20(1) 





Table A.4.18.   Bond lengths [Å] and angles [°] for  137b. 
_____________________________________________________  
C(1)-O(1)  1.440(4) 
C(1)-C(2)  1.506(4) 
C(2)-C(3)  1.388(4) 
C(2)-C(7)  1.388(4) 
C(3)-C(4)  1.377(4) 
C(4)-C(5)  1.382(5) 
C(5)-C(6)  1.387(5) 
C(6)-C(7)  1.383(4) 
C(8)-O(1)  1.434(3) 
C(8)-C(12)  1.538(4) 
C(8)-C(9)  1.538(4) 
C(9)-C(21)  1.523(4) 
C(9)-C(10)  1.527(4) 
C(10)-O(2)  1.201(3) 
C(10)-C(11)  1.502(4) 
C(12)-C(13)  1.528(4) 
C(12)-C(14)  1.544(4) 
C(14)-S(1)  1.776(3) 
C(15)-N(1)  1.390(4) 
C(15)-C(20)  1.398(4) 
C(15)-C(16)  1.400(4) 
C(16)-C(17)  1.389(4) 
C(16)-S(2)  1.737(3) 
C(17)-C(18)  1.380(4) 
C(18)-C(19)  1.401(4) 
C(19)-C(20)  1.382(4) 
C(22)-N(1)  1.292(4) 
C(22)-S(2)  1.730(3) 
C(22)-S(1)  1.778(3) 
O(3)-S(1)  1.437(2) 

















































Symmetry transformations used to generate equivalent atoms:  
  
 Table A.4.19.   Anisotropic displacement parameters  (Å2x 103) for 137b.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 22(2)  31(2) 32(2)  6(2) 17(2)  3(2) 
C(2) 18(2)  24(2) 18(2)  2(1) 12(2)  1(1) 
C(3) 29(2)  21(2) 24(2)  -3(1) 18(2)  -3(2) 
C(4) 16(2)  37(3) 22(2)  -7(2) 10(2)  -9(2) 
C(5) 25(2)  34(2) 21(2)  8(2) 13(2)  7(2) 
C(6) 35(2)  23(2) 26(2)  2(2) 20(2)  4(2) 
C(7) 18(2)  23(2) 18(2)  -1(1) 9(1)  -3(1) 
C(8) 18(2)  19(2) 16(2)  1(1) 8(1)  2(1) 
C(9) 31(2)  15(2) 26(2)  1(1) 19(2)  1(1) 
C(10) 29(2)  19(2) 25(2)  -2(2) 14(2)  2(2) 
C(11) 84(4)  92(4) 37(2)  -26(2) 35(3)  -56(3) 
C(12) 18(2)  14(2) 19(2)  0(1) 8(1)  1(1) 
C(13) 30(2)  22(2) 29(2)  -7(2) 18(2)  -2(2) 
C(14) 18(2)  18(2) 24(2)  4(1) 9(1)  5(1) 
C(15) 19(2)  20(2) 16(2)  3(1) 10(2)  2(1) 
C(16) 21(2)  10(2) 18(2)  0(1) 13(2)  -1(1) 
C(17) 20(2)  23(2) 21(2)  -2(1) 12(2)  -4(1) 
C(18) 21(2)  25(2) 23(2)  6(2) 10(2)  8(2) 
C(19) 29(2)  19(2) 24(2)  2(2) 11(2)  8(2) 
C(20) 26(2)  20(2) 20(2)  -4(1) 8(2)  0(2) 
C(21) 25(2)  20(2) 53(2)  7(2) 21(2)  6(2) 
C(22) 15(2)  15(2) 18(2)  2(1) 10(1)  1(1) 
N(1) 21(2)  16(2) 18(1)  2(1) 10(1)  2(1) 
O(1) 15(1)  26(1) 17(1)  1(1) 9(1)  2(1) 
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O(2) 39(1)  29(2) 29(1)  2(1) 21(1)  -8(1) 
O(3) 25(1)  27(1) 24(1)  10(1) 13(1)  7(1) 
O(4) 33(1)  13(1) 38(1)  1(1) 19(1)  0(1) 
S(1) 19(1)  14(1) 27(1)  5(1) 12(1)  3(1) 
S(2) 20(1)  14(1) 24(1)  -2(1) 9(1)  0(1) 
______________________________________________________________________________  
 
Table A.4.20.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 137b. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1A) 10012 3767 7238 32 
H(1B) 9313 2254 6427 32 
H(3) 12105 3477 8829 27 
H(4) 13858 1930 9956 30 
H(5) 13733 -860 9871 31 
H(6) 11813 -2078 8624 31 
H(7) 10049 -532 7480 23 
H(8) 7600 3346 6194 21 
H(9) 7439 4620 8308 26 
H(11A) 9865 7361 9011 102 
H(11B) 9661 5741 9563 102 
H(11C) 8702 7163 9258 102 
H(12) 5915 2223 6486 21 
H(13A) 7748 -75 6708 39 
H(13B) 6756 666 5435 39 
H(13C) 6318 -463 6201 39 
H(14A) 7207 2369 8780 24 
H(14B) 7724 678 8665 24 
H(17) 729 2902 4705 24 
H(18) 212 5545 4901 27 
H(19) 1665 7243 6400 29 
H(20) 3643 6307 7787 28 
H(21A) 6080 6563 6916 47 
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H(21B) 5509 4832 6509 47 
H(21C) 6151 5693 5797 47 
________________________________________________________________________________ 
  
 
 
